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As	  multiple	  myeloma	  (MM)	  progresses,	  Natural	  Killer	  (NK)	  cell	  responses	  decline	  against	  malignant	  
plasma	  cells.	  The	  immunomodulatory	  drug	  lenalidomide	  is	  widely	  used	  for	  the	  treatment	  of	  MM	  but	  
its	  influence	  on	  NK	  cell	  biology	  is	  unclear.	  Here,	  a	  combination	  of	  functional	  assays	  and	  microscopy	  
techniques	   were	   used	   to	   investigate	   how	   lenalidomide	   affects	   NK	   cell	   activation	   and	   effector	  
function.	  First,	  lenalidomide	  lowered	  the	  threshold	  for	  NK	  cell	  activation,	  causing	  a	  66%	  decrease	  in	  
the	  EC50	  for	  activation	  through	  CD16,	  and	  a	  38%	  decrease	  in	  the	  EC50	  for	  NKG2D-­‐mediated	  activation,	  
allowing	  NK	  cells	  to	  respond	  to	  lower	  doses	  of	   ligand.	  In	  addition,	   lenalidomide	  augmented	  NK	  cell	  
responses,	  causing	  a	  2-­‐fold	  increase	  in	  the	  proportion	  of	  primary	  NK	  cells	  producing	  IFN-­‐γ,	  and	  a	  20-­‐
fold	  increase	  in	  the	  amount	  of	  IFN-­‐γ	  produced	  per	  cell.	  Importantly,	  lenalidomide	  did	  not	  trigger	  IFN-­‐
γ	  production	  in	  unstimulated	  NK	  cells.	  Thus,	  lenalidomide	  enhances	  the	  NK	  cell	  arm	  of	  the	  immune	  
response,	  without	  activating	  NK	  cells	  inappropriately.	  Of	  particular	  clinical	  importance,	  lenalidomide	  
also	  allowed	  NK	  cells	  to	  be	  activated	  by	  lower	  doses	  of	  rituximab,	  an	  anti-­‐CD20	  mAb	  widely	  used	  to	  
treat	  B	  cell	  malignancies.	  This	  supports	  the	  combined	  use	  of	  lenalidomide	  and	  rituximab	  in	  a	  clinical	  
setting.	   Second,	   super	   resolution	   STED	   microscopy	   revealed	   that	   lenalidomide	   increased	   the	  
periodicity	   of	   cortical	   actin	   at	   immune	   synapses,	   resulting	   in	   an	   increase	   in	   the	   area	   of	   the	   actin	  
mesh	  predicted	  to	  be	  penetrable	  to	  vesicles	  containing	  IFN-­‐γ.	  Finally,	  lenalidomide	  augmented	  IFN-­‐γ	  
production	  and	  enhanced	  cortical	  actin	  rearrangements	  in	  NK	  cells	  from	  MM	  patients.	  Interestingly,	  
NK	   cells	   from	   relapsing	  MM	   patients	   showed	   defective	   F-­‐actin	   remodelling	   compared	   to	   NK	   cells	  
from	  MM	  patients	  in	  remission.	  This	  could	  be	  rescued	  with	  lenalidomide	  treatment.	  This	  establishes	  
that	   nanometre-­‐scale	   rearrangements	   in	   cortical	   actin,	   a	   recently	   discovered	   step	   in	   immune	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Chapter	  1	  -­‐ Introduction	  
	  
The	   immunomodulatory	   drug	   lenalidomide	   is	   a	   synthetic	   compound	   derived	   by	   modifying	   the	  
chemical	  structure	  of	  thalidomide	  to	  improve	  its	  potency	  and	  to	  reduce	  its	  side	  effects.	  Lenalidomide	  
is	   currently	   used	   for	   the	   treatment	   of	   multiple	   myeloma	   (MM),	   amongst	   other	   haematological	  
malignancies,	   and	   is	   being	   assessed	   as	   a	   potential	   treatment	   in	   multiple	   other	   disease	   settings.	  
Although	  the	  mechanism	  of	  action	  of	  lenalidomide	  is	  slowly	  becoming	  clearer,	  there	  is	  a	  long	  way	  to	  
go	  to	  fully	  understand	  the	  wide-­‐reaching	  effects	  of	  the	  drug	  and	  the	  mechanisms	  behind	  them.	  This	  
investigation	  focuses	  on	  the	  effect	  of	  lenalidomide	  on	  Natural	  Killer	  (NK)	  cells,	  on	  a	  cellular	  level	  and	  
a	  nanoscale	  level,	   in	  the	  context	  of	  MM.	  This	  first	  chapter	  will	  provide	  an	  overview	  of	  MM	  and	  the	  
development	   of	   lenalidomide,	   followed	   by	   a	   review	   of	   the	   effects	   of	   lenalidomide,	   as	   they	   are	  
understood	   at	   present.	   Then	  NK	   cell	   function	   and	   immune	   synapse	   formation	  will	   be	   introduced,	  
followed	   by	   an	   outline	   of	   super-­‐resolution	   microscopy	   techniques	   that	   allow	   imaging	   at	   the	  
nanoscale	  level.	  
	  
1.1 Multiple	  Myeloma	  
	  
MM	  is	  characterised	  by	  a	  clonal	  proliferation	  of	  plasma	  cells	   in	  the	  bone	  marrow.	  Cancer	  Research	  
UK	  estimates	  that	  MM	  represents	  1%	  of	  all	  cancer	  cases	  in	  the	  UK	  (4,792	  people	  diagnosed	  in	  2011)	  
and	  2%	  of	  all	  cancer	  deaths	  (2,742	  deaths	  from	  myeloma	  in	  2012)(Cancer	  Research	  UK,	  2012).	  MM	  
incidence	  rates	  have	  increased	  by	  11%	  over	  the	  last	  10	  years,	  although	  this	  may	  be	  largely	  explained	  
by	   improved	  diagnosis.	  MM	   is	   generally	   associated	  with	  older	   age	  –	   in	   the	  UK	  between	  2009	  and	  
2011,	  43%	  of	  cases	  occurred	  in	  people	  aged	  75	  years	  and	  over	  (incidence	  rates	  rise	  dramatically	   in	  
the	   age	   55-­‐59	   bracket,	  with	   very	   few	  diagnoses	   under	   the	   age	   of	   40)(Cancer	   Research	  UK,	   2012).	  
Although	  MM	  remains	  an	  incurable	  cancer,	  survival	  rates	  are	  improving	  and	  patients	  who	  are	  newly	  
diagnosed	  are	  now	  predicted	  to	  live	  for	  approximately	  5	  years	  (Bergsagel	  et	  al.,	  2013).	  	  
In	   most	   cases,	   MM	   arises	   from	   cases	   of	   monoclonal	   gammopathy	   of	   undetermined	   significance	  
(MGUS),	   which	   is	   an	   accumulation	   of	   bone	  marrow	   plasma	   cells	   derived	   from	   a	   single	   abnormal	  
clone	   (Mahindra	   et	   al.,	   2010).	   MGUS	   is	   considered	   benign	   and	   does	   not	   threaten	   the	   patient’s	  





health.	   Progression	   to	  MM	   happens	   in	   approximately	   1%	   of	   cases	   per	   year	   (Cancer	   Research	   UK	  
2012)	   and	   is	   associated	  with	   the	   development	   of	   pathogenic	   symptoms	   such	   as	   osteolytic	   lesions	  
(small	  areas	  of	  bone	  loss)	  along	  with	  anaemia	  and	  impaired	  renal	  function.	  	  
	  
1.1.1 Oncogenomics	  of	  myeloma	  
	  
Patients	  with	  MM	  can	  be	  divided	  into	  two	  sub-­‐groups	  based	  on	  the	  pattern	  of	  whole	  chromosome	  
gains	  and	  losses	  (Smadja	  et	  al.,	  1998).	  The	  first	  group,	  around	  55%	  of	  patients,	  have	  a	  hyperdiploid	  
karyotype	  (between	  48	  and	  74	  chromosomes)	  and	  all	  show	  trisomies	  (3	  chromosomes	  instead	  of	  2)	  
at	  various	  chromosomes,	  including	  3,5,7,9,11,15,19	  and	  21.	  The	  second	  group	  (the	  non-­‐hyperdiploid	  
group)	   includes	   patients	   who	   have	   hypodiploid	   (losses	   of	   chromosomes),	   pseudodiploid	   or	   near	  
tetraploid	  chromosome	  numbers	  (more	  than	  74	  chromosomes)(Smadja	  et	  al.,	  1998;	  Debes-­‐Marun	  et	  
al.,	   2003;	   Sáez	   et	   al.,	   2004).	   The	   mechanisms	   that	   underlie	   this	   cytogenetic	   pattern	   are	   not	  
understood,	   but	   patients	   with	   hyperdiploid	   MM	   tend	   to	   have	   a	   more	   favourable	   prognosis	   than	  
those	  with	  non-­‐hyperploid	  MM	  (Smadja	  et	  al.,	  1998;	  Smadja	  et	  al.,	  2001;	  Fassas	  et	  al.,	  2002).	  
In	   addition	   to	   these	   changes	   in	   chromosome	   numbers,	   gains	   or	   losses	   of	   specific	   chromosomal	  
regions	  also	  occur.	  These	  include	  loss	  of	  the	  short	  arm	  of	  chromosome	  17	  (17p)	  or	  the	  short	  arm	  of	  
chromosome	  1	  (1p),	  amplifications	  of	  the	  long	  arm	  of	  chromosome	  1,	  or	  chromosome	  13	  monosomy	  
(Debes-­‐Marun	  et	   al.,	   2003;	  Carrasco	  et	   al.,	   2006).	   	  Deletions	  of	   17p	  and	  1p,	   as	  well	   as	   the	   loss	  of	  
chromosome	  13,	  are	  linked	  to	  poor	  prognosis	  (Debes-­‐Marun	  et	  al.,	  2003;	  Stewart	  &	  Fonseca,	  2005).	  
It	  is	  clear	  that	  there	  is	  a	  great	  deal	  of	  genetic	  heterogeneity	  in	  MM	  that	  is	  likely	  to	  influence	  disease	  
progression.	  But	  another	  factor	  that	  appears	  to	  be	  equally	  important	  in	  myeloma	  pathogenesis	  is	  the	  
interaction	  between	  MM	  cells	  and	  the	  bone	  marrow	  microenvironment.	  
	  
1.1.2 MM	  and	  the	  bone	  marrow	  microenvironment	  
	  
Two	   factors	   have	   been	   identified	   as	   being	   important	   during	   MM	   progression:	   (i)	   the	   adhesion	  
molecules	   expressed	   on	   the	   surface	   of	   MM	   cells	   and	   how	   they	   interact	   with	   the	   bone	   marrow	  
microenvironment;	  and	  (ii)	  the	  effects	  of	  cytokines	  on	  MM	  cells.	  	  





The	  malignant	  plasma	  cells	  in	  MM	  are	  situated	  in	  close	  association	  with	  bone	  marrow	  stromal	  cells	  
(BMSCs),	  the	  connective	  tissue	  cells	  of	  the	  bone	  marrow.	  After	  the	  MM	  cells	  undergo	  class	  switching	  
in	   the	   lymph	   nodes,	   adhesion	   molecules	   on	   the	   surface	   of	   the	   MM	   cells	   (e.g.	   CD44,	   LFA-­‐1	   and	  
syndecan-­‐1)	  mediate	   the	   homing	   of	   the	  MM	   cells	   to	   the	   bone	  marrow	  where	   they	   interact	   with	  
BMSCs	   (Teoh	   &	   Anderson,	   1997;	   Ahsmann	   et	   al.,	   1992).	   Adhesion	   of	   the	   MM	   cells	   to	   BMSCs	  
activates	  many	  pathways,	  which	  upregulate	  cell	  cycle	  regulating	  proteins	  and	  anti-­‐apoptotic	  proteins	  
in	  the	  tumour	  cells	  (Yang	  et	  al.,	  2003).	  One	  such	  signalling	  pathway	  is	  the	  nuclear	  factor	  kappa-­‐light-­‐
chain-­‐enhancer	  of	  activated	  B	  cells	   (NF-­‐κB)	  pathway,	  which	  plays	  an	   important	   role	   in	   the	  survival	  
and	   proliferation	   of	   the	   MM	   cell	   (Ni	   et	   al.,	   2001).	   Specifically,	   NF-­‐κB	   signalling	   activates	   anti-­‐
apoptotic	  genes	  of	  the	  Bcl-­‐2	  family	  and	  promotes	  cell	  growth	  and	  differentiation	  by	  activating	  cyclin-­‐
D1	  expression	  (Guttridge	  et	  al.,	  1999;	  Karin	  &	  Lin,	  2002).	  	  The	  NF-­‐κB	  pathway	  has	  also	  been	  shown	  to	  
induce	  vascular	  endothelial	  growth	  factor	  (VEGF)	  expression,	  which	  stimulates	  angiogenesis	  (Huang	  
et	  al.,	  2001).	  
Cytokines	   produced	   by	   either	   the	   MM	   cells	   or	   the	   BMSCs	   as	   a	   result	   of	   direct	   intercellular	  
interactions	   have	   also	   been	   linked	   to	   disease	   progression.	   These	   include	   IL-­‐1β	   (Cozzolino	   et	   al.,	  
1989),	  IL-­‐3	  (Lee	  et	  al.,	  2004),	  IL-­‐6	  (Klein	  et	  al.,	  1989),	  Tumour	  Necrosis	  factor	  (TNF)-­‐α	  (Davies	  et	  al.,	  
2000)	   and	   VEGF	   (Ria	   et	   al.,	   2003).	   The	  most	   well-­‐documented	   example	   is	   IL-­‐6,	   which	   suppresses	  
apoptosis	  in	  myeloma	  cells	  and	  increases	  cell	  proliferation	  (Catlett-­‐Falcone	  et	  al.,	  1999;	  Osaki	  et	  al.,	  
2004).	   The	   increased	   understanding	   of	   how	   dependent	   MM	   cells	   are	   on	   the	   bone	   marrow	  
microenvironment	  is	  vital	  in	  the	  design	  of	  treatment	  strategies	  for	  MM.	  	  Various	  drugs	  used	  to	  treat	  
MM	  have	   been	   shown	   to	   counteract	   the	   supportive	   effect	   of	   the	   bone	  marrow	  milieu.	   One	   such	  
therapeutic	  agent	  is	  the	  immunomodulatory	  drug	  thalidomide.	  	  
	  
	  
1.2 Thalidomide	  and	  the	  development	  of	  its	  analogues	  
	  
Thalidomide	   (chemical	  name:	  α-­‐(N-­‐phthalimido)glutaramide)	   is	  a	  synthetic	  glutamic	  acid	  derivative	  
that	  was	  synthesised	  in	  1954	  in	  Germany	  by	  the	  pharmaceutical	  company	  Chemie	  Grunenthal.	  The	  
drug	  displayed	  sedative	  and	  anti-­‐emetic	  activity	  and	  appeared	  to	  be	  non-­‐toxic	  in	  human	  volunteers.	  
It	  quickly	  became	  popular	  as	  a	  morning	  sickness	  drug	  in	  Europe,	  Australia,	  Asia	  and	  South	  America	  
and	  was	  marketed	  as	   the	  safest	  available	  sedative	  of	   its	   time.	  Thalidomide	  was	  removed	  from	  the	  





market	   in	   the	   early	   1960s	   because	  of	   reports	   from	   clinicians	   that	   thalidomide	  use	  was	   associated	  
with	  birth	  defects	  (Hayman,	  1961;	  Ward,	  1962).	  Unfortunately,	  withdrawal	  of	  thalidomide	  came	  too	  
late	  to	  prevent	  the	  birth	  of	  at	  least	  8000	  babies	  with	  severe	  developmental	  deformities	  (Bartlett	  et	  
al.,	  2004).	  	  
We	   now	   understand	   that	   thalidomide	   has	   one	   chiral	   atom	   and	   so	   exists	   as	   S	   (-­‐)	   and	   R	   (+)	  
enantiomers	  that	  form	  a	  racemic	  mixture	  under	  physiological	  conditions.	  Only	  the	  S	  (-­‐)	  enantiomer	  is	  
responsible	   to	   the	   teratogenic	   effects	   of	   thalidomide	   (Bartlett	   et	   al.,	   2004).	   Specifically,	   in	   vivo	  
evidence	   suggests	   that	   the	   S	   (-­‐)	   enantiomer	   generates	   oxidative	   stress	   and	   subsequent	  
downregulation	  of	  Wnt	  and	  Akt	  survival	  pathways	  (reviewed	  in	  Knobloch	  &	  Rüther,	  2008).	  This	  leads	  
to	   the	   induction	   of	   apoptosis	   during	   early	   embryonic	   limb	   development,	   which	   leads	   to	   limb	  
truncations.	  
	  
1.2.1 Effects	  on	  the	  immune	  system	  
	  
In	   1965	   it	   was	   observed	   that	   thalidomide	   use	   improved	   the	   inflammatory	   lesions	   of	   erythema	  
nodosum	   leprosum	   (ENL)	   in	   a	   patient	   suffering	   from	   difficulty	   sleeping.	   ENL	   is	   an	   inflammatory	  
reaction	   that	   sometimes	   occurs	   in	   leprosy	   patients	   during	   treatment	   and	   is	  mediated	   by	   immune	  
complexes	  (clusters	  of	  interlocking	  antibodies	  and	  antigens).	  It	  constitutes	  a	  medical	  emergency	  with	  
the	   urgent	   requirement	   for	   anti-­‐inflammatory	   or	   immunomodulatory	   drugs	   to	   prevent	   chronic	  
disabilities.	   Subsequent	   research	   into	   the	   mechanism	   of	   action	   of	   thalidomide	   uncovered	   an	  
immunomodulatory	   effect	   of	   the	   drug	   which	   includes	   inhibition	   of	   new	   IgM	   antibody	   synthesis	  
(Shannon	  et	   al.,	   1981),	   decreased	   TNF-­‐α	   synthesis	   by	   activated	  monocytes	   (Sampaio	   et	   al.,	   1991),	  
increased	  T	  helper	  cell	  numbers	  in	  the	  blood	  of	  patients	  (Moncada	  et	  al.,	  1985)	  and	  the	  ability	  to	  co-­‐
stimulate	  T	  cells	  that	  have	  been	  partially	  activated	  by	  ligation	  of	  the	  T	  cell	  receptor	  (TCR)	  (Haslett	  et	  
al.,	  1998).	  	  	  
	  
1.2.2 Thalidomide	  inhibits	  angiogenesis	  
	  
One	   other	   important	   discovery	  was	   that	   thalidomide	   inhibits	   angiogenesis	   (the	   formation	   of	   new	  
blood	  vessels;	  a	  vital	  process	  in	  the	  growth	  and	  metastasis	  of	  solid	  tumours)	  (D’Amato	  et	  al.,	  1994).	  





It	  was	  this	  discovery	  that	   linked	  thalidomide	  and	  MM.	  Angiogenesis	  has	  been	  recognised	  as	  having	  
an	  important	  pathogenic	  role	  in	  MM,	  as	  noted	  by	  increased	  bone	  marrow	  microvascular	  density	  and	  
VEGF.	  Research	   into	  the	  effect	  of	  thalidomide	  on	  relapsed	  and	  refractory	  MM	  led	  to	  the	  discovery	  
that	  thalidomide	  elicits	  strong	  anti-­‐cancer	  activity	  (Singhal	  et	  al.,	  1999),	  prompting	  the	  clinical	  use	  of	  
thalidomide	  in	  newly	  diagnosed	  MM	  .	  
	  
1.2.3 The	  development	  of	  thalidomide	  analogues	  
	  
Despite	   the	   fact	   that	   thalidomide	   had	   been	   shown	   to	   possess	   potent	   anti-­‐cancer	   activity,	   the	  
negative	  effects	  of	  thalidomide	  could	  not	  be	  ignored.	  Along	  with	  its	  teratogenic	  properties	  that	  have	  
already	   been	   mentioned,	   thalidomide	   use	   also	   resulted	   in	   neuropathy	   (Chaudhry	   et	   al.,	   2002),	  
constipation,	  somnolence	  (Offidani	  et	  al.,	  2004)	  and	  an	  increased	  incidence	  of	  deep-­‐vein	  thrombosis	  
(Zangari	   et	   al.,	   2001;	   Cavo,	   2002).	   One	   study	   showed	   that	   nearly	   one	   quarter	   of	   patients	  
discontinued	  thalidomide	  use	  because	  they	  experienced	  toxic	  side	  effects	  (Offidani	  et	  al.,	  2004).	   In	  
order	   to	   search	   for	  anti-­‐cancer	  drugs	   that	  were	  both	  more	  potent	  and	   safer,	  Celgene	  Corporation	  
initiated	   a	   medicinal	   chemistry	   programme	   to	   systematically	   modify	   the	   chemical	   structure	   of	  
thalidomide.	  This	  programme	  yielded	  various	  thalidomide	  analogues,	  which	  were	  found	  to	  be	  up	  to	  
50,000	   fold	   more	   potent	   than	   thalidomide	   at	   inhibiting	   TNF-­‐α	   production,	   and	   also	   better	   than	  
thalidomide	  in	  their	  ability	  to	  co-­‐stimulate	  T	  cells	  (Muller	  et	  al.,	  1996;	  Corral	  et	  al.,	  1999).	  It	  was	  also	  
shown	   that	   these	   compounds	   displayed	   much	   less	   severe	   side-­‐effects	   than	   observed	   with	  
thalidomide	   treatment	   (Carrier	   et	   al.,	   2011).	   Two	   of	   these	   analogues	   –	   lenalidomide	   (CC-­‐5013;	  
IMiD3;	  Revlimid)	  and	  pomalidomide	  (CC-­‐4047;	  IMiD1;	  Actimid))	  –	  were	  derived	  by	  adding	  an	  amino	  
group	  to	  the	  fourth	  carbon	  of	  the	  phthaloyl	  ring	  of	  thalidomide	  (Figure	  1.1).	  The	  U.S.	  Food	  and	  Drug	  
Administration	  (FDA)	  have	  now	  approved	  both	  compounds	  for	  use	  in	  the	  treatment	  of	  patients	  with	  
MM.	  
	  






Figure	   1.1	   –	   Chemical	   structure	   of	   thalidomide,	   lenalidomide	   and	   pomalidomide.	   Lenalidomide	   and	  
pomalidomide	  are	  derived	  by	  adding	  an	  amino	  group	  to	  the	  fourth	  carbon	  of	  the	  phthaloyl	  ring	  of	  thalidomide.	  
Pomalidomide	  has	  a	  combined	  chemical	  structure	  of	  thalidomide	  and	  lenalidomide.	  
	  
1.3 The	  effect	  of	  lenalidomide	  in	  the	  treatment	  of	  MM	  
	  
Thalidomide,	   lenalidomide	  and	  pomalidomide	   represent	   a	  unique	   class	  of	  drug	  which	  Celgene	  has	  
termed	   IMiDs®	   (small	  molecule,	  orally	  available	  compounds	  which	  modulate	   the	   immune	  system).	  
These	   drugs	   display	   a	   dual	   mechanism	   of	   action,	   with	   both	   direct	   tumoricidal	   properties	   and	  
immunomodulatory	  activity.	  This	  section	  will	  review	  the	  large	  body	  of	  work	  that	  has	  looked	  at	  these	  
various	  mechanisms	  of	  action,	  mostly	   focusing	  on	   lenalidomide,	  and	  will	  highlight	   the	  most	   recent	  
findings	  in	  each	  area.	  	  
	  





1.3.1 Anti-­‐angiogenic	  activity	  
	  
As	  mentioned	  previously,	   the	   interaction	  between	  BMSCs	  and	  MM	  cells	   significantly	   increases	   the	  
levels	  of	  VEGF,	  which	  is	   involved	  in	  mediating	  the	  formation	  of	  new	  blood	  vessels.	   It	  was	  observed	  
that	  IMiDs	  decreased	  VEGF	  secretion	   in	  vitro	  thereby	  inhibiting	  new	  blood	  vessel	  formation	  (Gupta	  
et	   al.,	   2001).	   This	   was	   further	   demonstrated	   in	   vivo,	   where	   treatment	   with	   IMiDs	   resulted	   in	  
decreased	  microvessel	  density	   in	  B	  cell	  malignancy	  mouse	  models	   (Lentzsch	  et	  al.,	  2003;	  Reddy	  et	  
al.,	   2008).	   Notably,	   lenalidomide	   was	   shown	   to	   be	   a	   more	   potent	   inhibitor	   of	   angiogenesis	   than	  
thalidomide	  when	   assessed	   using	   both	   human	   and	   rat	   angiogenesis	   assay	   systems	   (Dredge	   et	   al.,	  
2002;	   Dredge	   et	   al.,	   2005).	   What	   causes	   the	   anti-­‐angiogenic	   activity	   of	   lenalidomide	   is	   not	  
understood,	  however	  it	  appears	  to	  correlate	  with	  a	  reduction	  in	  Akt	  phosphorylation	  in	  response	  to	  
VEGF	   (Dredge	   et	   al.,	   2005;	   Lu	   et	   al.,	   2009).	   This	   suggests	   that	   the	   mode	   of	   action	   could	   involve	  
interference	  of	  the	  phosphoinositide	  3-­‐kinase	  (PI3K)/Akt-­‐signalling	  pathway.	  	  
	  
1.3.2 Disruption	  of	  the	  interaction	  between	  MM	  cells	  and	  BMSCs	  
	  
In	   section	   1.1	   I	   explained	   how	   the	   interaction	   between	   MM	   cells	   and	   the	   bone	   marrow	  
microenvironment	   is	   vital	   for	   the	   survival	   of	   the	  MM	   cells.	   This	   includes	   cell-­‐cell	   contact	   through	  
various	  adhesion	  molecules	  and	  cytokine	  signalling	  through	  TNF-­‐α	  and	  IL-­‐6.	  Production	  of	  TNF-­‐α	  by	  
the	  MM	   cells	   facilitates	   the	   upregulation	   of	   adhesion	  molecules	   by	   the	   BMSCs	   (Hideshima	   et	   al.,	  
2001).	   Interestingly,	   treatment	   with	   IMiDs	   inhibited	   production	   of	   TNF-­‐α	   (Corral	   et	   al.,	   1999;	  
Sampaio	  et	  al.,	   1991;	  Rosinol	  et	   al.,	   2004),	   resulting	   in	  a	  decrease	   in	   IL-­‐6	  expression	   (Corral	   et	   al.,	  
1999;	  Gupta	  et	  al.,	  2001;	  Li	  et	  al.,	  2002).	  Thalidomide	  also	  downregulates	  the	  expression	  of	  ICAM-­‐1,	  
VCAM-­‐1,	   E-­‐selectin	   and	   LFA-­‐1	   (Geitz	   et	   al.,	   1996;	   Settles	   et	   al.,	   2001)	   as	   a	   result	   of	   the	  decreased	  
TNF-­‐α	  production.	  This	  leads	  to	  disrupted	  adhesion	  of	  MM	  cells	  to	  BMSCs	  (Figure	  1.2).	  Interestingly,	  
these	  cell	  adhesion	  molecules	  also	  contribute	  to	  cancer	  cell	  migration	  and	  metastasis.	  This	  suggests	  
that	  treatment	  with	  thalidomide	  or	  its	  analogues	  could	  also	  affect	  the	  metastatic	  process	  (Lin	  et	  al.,	  
2006).	  
	  






Figure	   1.2	   –	   Schematic	   diagram	   showing	   interactions	   between	  MM	   cells	   and	   BMSCs	   and	   the	   effects	   that	  
lenalidomide	  has	  on	  these	  interactions.	  MM	  plasma	  cells	  express	  adhesion	  molecules	  that	  mediate	  binding	  of	  
the	  plasma	  cells	  to	  bone	  marrow	  stromal	  cells	  (BMSCs).	  MM	  cells	  also	  express	  cytokines	  (e.g.	  IL-­‐3,	  IL-­‐1β,	  VEGF),	  
which	  activates	  the	  NF-­‐κB	  pathway	  in	  BMSCs.	  This	  results	  in	  expression	  of	  cytokines	  from	  the	  BMSCs	  (e.g.	  IL-­‐6),	  
which	  activate	  anti-­‐apoptotic	  genes	  in	  the	  MM	  cells	  and	  promotes	  survival	  and	  proliferation.	  In	  addition,	  they	  
secrete	  VEGF,	  which	  promotes	  angiogenesis.	   Lenalidomide	   treatment	  downregulates	  expression	  of	  adhesion	  
molecules	  and	  decreases	  cytokine	  production,	  which	  disrupts	  the	  interaction	  between	  BMSCs	  and	  MM	  cells.	  In	  
addition,	  lenalidomide	  displays	  anti-­‐angiogenic,	  anti-­‐proliferative	  and	  pro-­‐apoptotic	  activity.	  
	  
1.3.3 Direct	  tumoricidal	  effect	  of	  lenalidomide	  
	  
Apart	   from	   modulation	   of	   the	   bone	   marrow	   microenvironment,	   IMiDs	   also	   have	   a	   direct	   anti-­‐
proliferative	   effect	   on	   the	   MM	   cells	   via	   upregulation	   of	   tumour	   suppressor	   genes.	   In	   a	   study	  
published	   in	   2010,	   Gandhi	   and	   colleagues	   showed	   that	   lenalidomide	   treatment	   resulted	   in	   the	  
induction	  of	   cyclin-­‐dependent	   kinase	   (CDK)	   inhibitors	  p15,	   p16,	   p21	  and	  p27	   in	  MM	  cell	   lines	   and	  
MM	   patient	   cells	   (Gandhi	   et	   al.,	   2010).	   This	   results	   in	   inhibition	   of	   retinoblastoma	   protein	  
phosphorylation,	  G0/G1	  cell-­‐cycle	  arrest	  and	  apoptosis.	  When	  this	  was	  investigated	  in	  more	  detail,	  it	  





was	   found	   that	   lenalidomide	   regulates	   p21	   expression	   at	   the	   transcriptional	   level	   via	   the	  
transcription	  factors	  Egr1	  and	  Egr2.	  Lenalidomide	  reduces	  histone	  methylation	  and	  increases	  histone	  
acetylation	   at	   the	   p21	   promoter,	   thereby	   increasing	   transcription	   factor	   access	   to	   the	   DNA	  
(Escoubet-­‐Lozach	  et	  al.,	  2009).	  	  
In	  an	  earlier	  study,	  the	  effect	  of	  lenalidomide	  and	  pomalidomide	  on	  cellular	  proliferation	  had	  been	  
assessed.	  Verhelle	  et	  al.	  tested	  two	  myeloma	  cell	   lines	  compared	  to	  normal	  CD34+	  progenitor	  cells	  
(Verhelle	  et	  al.,	  2007).	  They	   found	  that	   IMiDs	   inhibited	  proliferation	   in	   the	  cancer	  cell	   lines,	  which	  
was	  associated	  with	  upregulation	  of	  p21	  and	  inhibition	  of	  CDK	  activity,	  leading	  to	  cell	  cycle	  arrest.	  In	  
contrast,	  treatment	  of	  normal	  CD34+	  cells	  with	  the	  IMiDs	  led	  to	  an	  upregulation	  of	  p21	  without	  CDK	  
inhibition,	   and	   they	   observed	   a	   significant	   expansion	   of	   the	   healthy	   cells	   (Verhelle	   et	   al.,	   2007).	  
These	  observations	  go	  some	  way	  to	  explain	  the	  different	  effects	  of	  lenalidomide	  on	  malignant	  cells	  
and	  their	  normal	  counterparts.	  In	  addition	  to	  triggering	  cell-­‐cycle	  arrest,	  IMiDs	  have	  also	  been	  shown	  
to	   activate	   caspases	   3,	   8	   and	   9,	   directly	   triggering	   tumour	   cell	   apoptosis	   (Gandhi	   et	   al.,	   2010;	  
Mitsiades	  et	  al.,	  2002).	  	  
	  
1.3.4 Immunomodulatory	  activities	  of	  lenalidomide	  
	  
Lenalidomide,	   along	   with	   the	   other	   IMiDs,	   has	   a	   strong	   capacity	   to	   augment	   both	   adaptive	   and	  
innate	  immune	  responses.	  For	  example,	  lenalidomide	  has	  been	  shown	  to	  be	  a	  potent	  co-­‐stimulator	  
of	   primary	   human	   T	   cells.	   T	   cell	   activation	   requires	   an	   antigen-­‐specific	   signal	   through	   the	   TCR	  
alongside	   a	   co-­‐stimulatory	   signal	   provided	   by	   antigen	   presenting	   cells	   (APCs).	   This	   co-­‐stimulatory	  
signal	  is	  mediated	  by	  interactions	  between	  CD80/86	  on	  APCs	  and	  the	  CD28	  co-­‐stimulatory	  molecule	  
expressed	  on	  the	  surface	  of	  T	  cells.	  It	  has	  been	  shown	  that	  thalidomide	  and	  its	  analogues	  abrogate	  
the	   requirement	   for	   the	   co-­‐stimulatory	   signal	   (Davies	   et	   al.,	   2001).	   It	   was	   later	   shown	   that	  
lenalidomide	  triggers	  tyrosine	  phosphorylation	  of	  CD28	  on	  T	  cells,	  followed	  by	  activation	  of	  NF-­‐κB	  (a	  
downstream	   target	   of	   CD28	   signalling),	   thus	   defining	   the	   co-­‐stimulatory	   mechanism	   whereby	  
lenalidomide	  activates	  T	   cells	   (LeBlanc	  et	  al.,	  2004).	  Treatment	  with	   IMiDs	   resulted	   in	  pronounced	  
proliferation	   of	   partially	   activated	   CD3+	   T	   cells	   (isolated	   from	   human	   PBMCs)	   and	   enhanced	   the	  
production	  of	  the	  Th1	  type	  cytokines	  IL-­‐2	  and	  Interferon-­‐γ	  (IFN-­‐γ)	  (Davies	  et	  al.,	  2001;	  Haslett	  et	  al.,	  
1998).	   Notably,	   CD8+	   and	   CD4+	   T	   cells	  were	   stimulated	   to	   equal	   degrees	   (Davies	   et	   al.,	   2001).	   In	  
comparison	   with	   thalidomide,	   lenalidomide	   is	   50−2000	   times	   more	   potent	   in	   inducing	   T	   cell	  
proliferation,	  and	  300−	  >1200	  times	  more	  potent	  in	  augmenting	  IL-­‐2	  and	  IFN-­‐γ	  production	  (Corral	  et	  





al.,	   1999;	   Davies	   et	   al.,	   2001).	   Interestingly,	   pomalidomide	   appears	   to	   be	   even	  more	   potent	   than	  
lenalidomide	  at	  co-­‐stimulating	  T	  cells	  and	  similarly	  increases	  Th1-­‐type	  cytokines	  (Schafer	  et	  al.,	  2003;	  
Dredge	  et	  al.,	  2002).	  
These	   T-­‐cell	   co-­‐stimulatory	   effects	   have	   also	   been	   confirmed	   in	   vivo	   (Dredge	   et	   al.,	   2002).	   In	   this	  
study,	   the	   authors	   found	   that	   treatment	   with	   pomalidomide	   prior	   to	   tumour	   cell	   vaccination	  
strongly	   enhanced	   anti-­‐tumour	   immunity.	   This	  was	   associated	  with	   tumour-­‐specific	   production	   of	  
IFN-­‐γ.	  In	  addition,	  isolated	  CD4+	  and	  CD8+	  splenocyte	  fractions	  from	  the	  treated	  individuals	  secreted	  
higher	   amounts	   of	   IFN-­‐γ	   and	   IL-­‐2	   in	   response	   to	   tumour	   cells	   in	   vitro.	   Also,	   treatment	   of	   the	  
splenocytes	  with	  pomalidomide	  in	  the	  presence	  of	  anti-­‐CD3	  monoclonal	  antibody	  (mAb)	  resulted	  in	  
the	  direct	  co-­‐stimulation	  of	  T	  cells	  and	  increased	  cytokine	  production.	  Protection	  was	  still	  observed	  
following	  a	  secondary	  live	  tumour	  cell	  challenge	  60	  days	  later,	  demonstrating	  a	  long-­‐lasting	  effect	  of	  
the	  IMiDs	  on	  the	  immune	  system	  (Dredge	  et	  al.,	  2002).	  	  
The	  augmentation	  of	  IL-­‐2	  production	  after	  lenalidomide	  treatment	  is	  mediated	  by	  an	  increase	  in	  the	  
transcriptional	   activity	   of	   activator	   protein-­‐1	   (AP-­‐1)	   (Schafer	   et	   al.,	   2003).	   AP-­‐1	   is	   a	   transcription	  
factor	  that	  regulates	  gene	  expression	  in	  response	  to	  various	  stimuli,	   including	  cytokines,	  stress	  and	  
infections.	  	  Lenalidomide	  treatment	  results	  in	  the	  nuclear	  translocation	  of	  AP-­‐1	  and	  nuclear	  factor	  of	  
activated	  T	  cells	  2	  (NFAT2)	  via	  PI3K	  signalling,	  resulting	  in	  increased	  IL-­‐2	  production	  (Hayashi	  et	  al.,	  
2005).	  	  
In	  addition,	  it	  has	  also	  been	  shown	  that	  lenalidomide	  and	  pomalidomide	  can	  inhibit	  regulatory	  T	  cell	  
(Treg)	  generation.	  Tregs	  are	  a	  component	  of	  the	  immune	  system	  that	  suppress	  the	  immune	  responses	  
of	  other	  cells,	  and	  are	  characterised	  by	   the	  expression	  of	   the	   transcription	   factor	   forkhead	  box	  p3	  
(FOXP3).	  In	  MM,	  it	  has	  been	  reported	  that	  Tregs	  were	  elevated	  in	  the	  blood	  of	  patients,	  leading	  to	  a	  
suppression	   of	   naïve	   T	   cells	   (Muthu	   Raja	   et	   al.,	   2011).	   It	   was	   observed	   that	   lenalidomide	   and	  
pomalidomide	  strongly	   inhibited	  Tregs	  proliferation	  via	  downregulation	  of	  FOXP3	  mRNA	  expression	  
(Galustian	  et	  al.,	  2009).	  However,	   treatment	  of	  newly	  diagnosed	  MM	  patients	  with	   thalidomide	  or	  
lenalidomide	  has	  been	  shown	  to	  increase	  the	  proportion	  of	  Tregs	  detected	  in	  the	  patients	  (Gupta	  et	  
al.,	  2011;	  Muthu	  Raja	  et	  al.,	  2012).	  It	  is	  possible	  that	  this	  discrepancy	  in	  the	  published	  results	  is	  due	  
to	   the	   increased	   complexity	   of	   treatment	   in	   vivo,	   for	   example	   the	   complex	   cytokine	  milieu	   in	   the	  
setting	  of	  the	  disease.	  Therefore,	  more	  work	  needs	  to	  be	  carried	  out	  in	  vivo	  to	  fully	  understand	  the	  
effect	  of	  lenalidomide	  on	  Tregs.	  
Lenalidomide	  has	  also	  been	  shown	  to	  increase	  NK	  cell	  proliferation	  and	  cytotoxicity	  against	  MM	  cell	  
lines	  and	  primary	   tumour	  cells	   (Davies	  et	  al.,	  2001;	  LeBlanc	  et	  al.,	  2004).	  Specifically,	   lenalidomide	  





increased	  NK	  cell-­‐mediated	   lysis	  against	   tumour	  cell	   lines	  and	  primary	   tumour	  cells,	  and	   increased	  
NK	  cell	  production	  of	  IFN-­‐γ	  (Wu	  et	  al.,	  2008;	  LeBlanc	  et	  al.,	  2004).	  However,	   it	   is	  not	  clear	  whether	  
the	  effect	  of	   lenalidomide	  on	  NK	   cells	   is	   direct	  or	  whether	   it	   is	   indirectly	   caused	  by	   the	   increased	  
production	  of	  IL-­‐2	  by	  T	  cells.	  The	  current	  understanding	  of	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  will	  
be	  discussed	  in	  more	  detail	  at	  the	  beginning	  of	  chapter	  3.	  	  
	  
1.4 Lenalidomide	  and	  cereblon	  
	  
Lenalidomide	  treatment	  has	  been	  shown	  to	  have	  a	  dramatic	  effect	  on	  the	  transcriptome	  of	  MM	  cells	  
–	  one	  study	  showed	  that	  1036	  genes	  were	  downregulated	  and	  1236	  genes	  were	  upregulated	  in	  MM	  
cells	  following	  lenalidomide	  treatment	  (Zhu	  et	  al.,	  2011).	  Until	  recently,	  however,	  the	  target	  protein	  
for	  lenalidomide	  and	  the	  molecular	  mechanism	  for	  lenalidomide-­‐mediated	  gene	  regulation	  were	  not	  
well	  understood.	  
In	  2010	  Ito	  and	  colleagues	  identified	  the	  target	  of	  thalidomide	  to	  be	  cereblon	  (CRBN)	  after	  pulling	  it	  
down	   using	   thalidomide-­‐conjugated	   beads	   (Ito	   et	   al.,	   2010).	   CRBN	   forms	   an	   E3	   ubiquitin	   ligase	  
complex	   with	   damaged	   DNA	   binding	   protein	   1	   (DDB1)	   and	   Cul4A,	   which	   is	   important	   in	   limb	  
outgrowth.	   They	   showed	   that	   thalidomide	   exerts	   its	   teratogenic	   effects	   by	   binding	   to	   CRBN	   and	  
inhibiting	   the	   ubiquitin	   ligase	   activity	   of	   the	   complex	   (Ito	   et	   al.,	   2010).	   In	   order	   to	   check	  whether	  
CRBN	   is	   also	   the	   primary	   target	   for	   lenalidomide,	   in	   terms	   of	   anti-­‐myeloma	   activity,	   Zhu	   et	   al.	  
depleted	  CRBN	   in	  human	  myeloma	  cells	  and	  showed	  that	  the	  resulting	  cells	  are	  highly	  resistant	  to	  
lenalidomide	  (Zhu	  et	  al.,	  2011).	  Furthermore,	  the	  gene	  expression	  changes	  induced	  by	  lenalidomide	  
mentioned	  above	  were	  highly	  suppressed	  when	  CRBN	  was	  depleted	  (Zhu	  et	  al.,	  2011).	  Another	  study	  
used	  thalidomide-­‐conjugated	  beads	  and	  pulled	  down	  CRBN	  from	  myeloma	  cell	  line	  extracts	  (Lopez-­‐
Girona	   et	   al.,	   2012).	   They	   then	   showed	   that	   pre-­‐treatment	   of	   the	   extracts	   with	   lenalidomide	   or	  
pomalidomide	  completely	  blocked	  the	  pulldown.	  
The	  DDB1-­‐CUL4a	  E3	  ubiquitin	  ligase	  complex	  has	  been	  shown	  to	  regulate	  various	  aspects	  of	  cellular	  
function,	  including	  DNA	  repair	  (Chen	  et	  al.,	  2001;	  Kapetanaki	  et	  al.,	  2006;	  Wang	  et	  al.,	  2006).	  CRBN	  
was	   identified	  as	  a	  potential	  DDB1-­‐Cul4-­‐associated	  factor	  which	  acts	  as	  a	  substrate	  receptor	   in	  the	  
complex	  (Angers	  et	  al.,	  2006).	  CRBN	  has	  also	  been	  associated	  with	  mammalian	  target	  of	  rapamycin	  
(mTOR)-­‐regulated	   protein	   synthesis	  which	   is	   essential	   for	   some	   forms	   of	   synaptic	   plasticity	   in	   the	  
brain	  (Lee	  et	  al.,	  2014),	  highlighting	  wide-­‐ranging	  roles	  for	  CRBN	  in	  the	  body.	  	  	  	  





The	   exact	   mechanism	   linking	   CRBN	   to	   the	   downstream	   effects	   of	   lenalidomide	   treatment	   is	   still	  
largely	  unknown.	  However,	  recent	  work	  has	  provided	  the	  first	  clues.	  In	  2014,	  Lu	  et	  al.	  and	  Krӧnke	  et	  
al.	   both	   demonstrated	   that	   lenalidomide-­‐bound	   CRBN	   is	   able	   to	   target	   two	   specific	   transcription	  
factors	   for	  proteasomal	  degradation	   –	   Ikaros	   family	   zinc	   finger	  proteins	  1	   and	  3	   (IKZF1	  and	   IKZF3,	  
also	   known	   as	   Ikaros	   and	   Aiolos)(Lu	   et	   al.,	   2014;	   Krönke	   et	   al.,	   2014).	   They	   showed	   that,	   under	  
normal	  conditions,	  Ikaros	  and	  Aiolos	  suppress	  expression	  of	  the	  gene	  encoding	  IL-­‐2	  in	  T	  cells.	  Down-­‐
regulation	  of	  Ikaros	  and	  Aiolos	  after	  lenalidomide	  treatment	  therefore	  directly	  causes	  the	  increase	  in	  
IL-­‐2	  production	  by	  T	  cells	  (Krönke	  et	  al.,	  2014).	  This	  work	  was	  corroborated	  by	  another	  study	  which	  
also	  showed	  that	   these	   two	  transcription	   factors	  are	   transcriptional	   suppressors	  of	   IL-­‐2	  expression	  
and	   that	   lenalidomide	   biding	   to	   CRBN	   results	   in	   degradation	   of	   the	   two	   proteins	   (Gandhi	   et	   al.,	  
2014).	  
This	   work	   has	   shown,	   for	   the	   first	   time,	   a	   direct	   mechanism	   for	   the	   therapeutic	   action	   of	  
lenalidomide.	  However,	   not	   all	   relapsed	   patients	   respond	   to	   lenalidomide	   and	   some	  patients	   lose	  
cereblon	   or	   find	   alternative	   pathways	   to	   become	   resistant	   to	   the	   IMiDs	   (Hideshima	   et	   al.,	   2008;	  
Gandhi	  et	  al.,	  2014).	  The	  reasons	  behind	  these	  existing	  issues	  represent	  important	  clinical	  dilemmas	  
that	  are	  still	  to	  be	  explained.	  	  
	  
1.5 Lenalidomide	  use	  for	  the	  treatment	  of	  other	  diseases	  
	  
In	  addition	  to	  MM,	  lenalidomide	  has	  also	  been	  shown	  to	  have	  clinical	  efficacy	  in	  a	  number	  of	  other	  
diseases.	  These	  include	  myelodysplastic	  syndromes	  (MDS),	  chronic	  lymphocytic	  leukaemia	  (CLL)	  and	  
Hodgkin’s	   lymphoma,	   amongst	   others.	   This	   section	   will	   provide	   a	   brief	   overview	   of	   the	   effect	   of	  
lenalidomide	  in	  these	  disease	  systems.	  
	  
1.5.1 Myelodysplastic	  syndromes	  (MDS)	  
	  
MDS	   are	   a	   heterogeneous	   group	   of	   haematological	   stem	   cell	   malignancies	   that	   display	   dysplasia	  
(ineffective	   production)	   of	   new	   blood	   cells	   in	   the	   bone	   marrow.	   The	   specific	   pathogenetic	  
mechanism	   of	   MDS	   is	   still	   not	   fully	   understood,	   but	   it	   is	   thought	   to	   arise	   from	   mutations	   in	  





hematopoietic	  stem	  cells.	  This	  results	  in	  impaired	  differentiation	  of	  blood	  precursor	  cells,	  leading	  to	  
production	  of	  abnormal	  cells,	  and	  increased	  apoptotic	  cell	  death	  in	  the	  bone	  marrow	  (Gañán-­‐Gómez	  
et	   al.,	   2015;	   Malcovati	   &	   Nimer,	   2008).	   Clonal	   expansion	   of	   the	   abnormal	   cells	   can	   also	   occur	  
resulting	  in	  progression	  to	  acute	  myeloid	  leukaemia	  (AML);	  this	  occurs	  in	  approximately	  1	  in	  3	  cases	  
of	  MDS.	  The	  most	  prevalent	  genetic	  abnormality	  is	  a	  partial	  deletion	  of	  the	  long	  arm	  of	  chromosome	  
5,	   del(5q),	   which	   is	   present	   in	   approximately	   15%	   of	   cases	   (Haase	   et	   al.,	   2007).	   In	   del(5q)	   MDS	  
patients,	   the	   genetic	   aberration	   seems	   to	   exert	   a	   proliferative	   advantage,	   as	   >99%	   of	   the	   CD34+	  
haematopoietic	   stem	   cells	   carry	   the	   abnormality	   (Jädersten,	   2010).	   	   Most	   patients	   with	   del(5q)	  
become	  red	  blood	  cell	  transfusion-­‐dependent	  over	  the	  course	  of	  the	  disease,	  which	  has	  an	  obvious	  
negative	  impact	  on	  both	  the	  quality	  of	  life	  and	  survival	  of	  the	  patient	  (Malcovati	  et	  al.,	  2006).	  One	  of	  
the	   major	   goals	   of	   the	   clinical	   management	   of	   del(5q)	  MDS	   is	   to	   make	   the	   patients	   transfusion-­‐
independent.	  	  
Lenalidomide	  has	  shown	  clear	  clinical	  efficacy	  in	  the	  treatment	  of	  MDS	  with	  the	  del(5q)	  cytogenetic	  
abnormality	   and	   has	   been	   FDA	   approved	   in	   the	   US	   for	   the	   treatment	   of	   transfusion-­‐dependent	  
del(5q)	  MDS	  patients.	   In	  clinical	  trial,	  67%	  of	  patients	  treated	  with	   lenalidomide	  became	  red	  blood	  
cell	   transfusion-­‐independent	   by	  week	  24	  of	   treatment	   (List	   et	   al.,	   2006).	   In	   a	   second	   trial,	   56%	  of	  
patients	  treated	  with	  lenalidomide	  achieved	  transfusion	  independence	  for	  ≥26	  weeks,	  which	  greatly	  
reduced	  the	  relative	  risk	  of	  progression	  to	  AML	  (Fenaux	  et	  al.,	  2011).	  	  
In	   MDS	   impaired	   immune	   function	   is	   thought	   to	   contribute	   to	   disease	   progression.	   Specifically	  
defective	   immune	  synapse	   interactions	  between	  APCs	  and	  T	   cells	  have	  been	  observed,	  along	  with	  
diminished	  NK	   cell	   activity	   and	  an	  altered	   cytokine	  milieu	   in	   the	  bone	  marrow	  microenvironment.	  
Experimental	   evidence	   has	   shown	   that	   lenalidomide	   corrects	   some	   of	   these	   immune	   defects	   in	  
patients	  with	  del(5q)	  MDS	  (Heise	  et	  al.,	  2010).	  For	  example,	   lenalidomide	  treatment	   increased	  the	  
proportion	  of	  activated	  peripheral	  blood	  T	  cells	  within	  the	  CD3+	  cell	  population	  of	  MDS	  patients	  who	  
were	   6	  months	   post-­‐treatment	   (Ximeri	   et	   al.,	   2010).	   	   Also	   the	   inhibition	   of	   IL-­‐6	   by	   lenalidomide,	  
along	  with	   the	  augmented	   immune	  synapse	   formation	  observed	   in	  other	  disease	  settings	   (such	  as	  
chronic	   lymphocytic	   leukaemia	   (CLL)),	   have	   been	   touted	   as	   possible	   mechanisms	   by	   which	  
lenalidomide	  restores	  immune	  function	  in	  MDS	  patients	  (Heise	  et	  al.,	  2010).	  	  
	  
	  





1.5.2 Chronic	  lymphocytic	  leukaemia	  (CLL)	  
	  
CLL,	  which	  is	  the	  most	  common	  type	  of	  leukaemia,	  affects	  B	  cell	  differentiation	  in	  the	  bone	  marrow.	  
A	   single	   B	   cell,	   which	   has	   been	   arrested	   during	   differentiation,	   clonally	   proliferates	   in	   the	   bone	  
marrow	  leading	  to	  a	  clonal	  population	  consisting	  of	  large	  numbers	  of	  abnormal	  B	  cells	  in	  the	  blood,	  
bone	  marrow	   or	   tissues.	   	   Most	   patients	   display	   some	   type	   of	   genetic	   abnormality	   and	   the	   most	  
common	  is	  deletion	  of	  the	  long	  arm	  of	  chromosome	  13,	  known	  as	  del(13q),	  found	  in	  approximately	  
50%	  of	  patients.	  The	  gene	  affected	  by	  this	  deletion	  is	  a	  segment	  that	  codes	  for	  the	  microRNAs	  miR-­‐
15a	  and	  miR-­‐16-­‐1.	  It	  has	  been	  found	  that	  these	  microRNAs	  are	  part	  of	  a	  cluster	  which	  function	  as	  a	  
tumour	  suppressor	   (Mraz	  et	  al.,	  2009).	  These	  patients	  actually	  have	   the	  best	  prognosis.	  The	  worst	  
prognosis	  is	  given	  to	  the	  5-­‐10%	  of	  patients	  who	  have	  a	  deletion	  of	  the	  short	  arm	  of	  chromosome	  17	  
(del(17p)),	  which	  contains	  the	  cell	  cycle	  regulating	  protein	  p53	  (Chang	  et	  al.,	  2010;	  Van	  Dyke	  et	  al.,	  
2010).	  	  
Clinical	   activity	   of	   lenalidomide	   in	   CLL	  was	   first	   demonstrated	   in	   a	   phase	   II	   study	   of	   patients	  with	  
relapsed	   or	   refractory	   CLL,	   where	   the	   overall	   response	   rate	  was	   47%	   (Chanan-­‐Khan	   et	   al.,	   2006).	  
However,	   this	   study	   and	   others	   showed	   a	   high	   percentage	   of	   patients	   who	   had	   a	   tumour	   flare	  
reaction	  (which	  is	  characterised	  by	  painful	  swelling	  of	  the	  lymph	  nodes)	  (Chanan-­‐Khan	  et	  al.,	  2006;	  
Chen	  et	  al.,	  2011).	  These	  tumour	  response	   flares	  are	  a	  CLL-­‐specific	   reaction	  to	   lenalidomide	  and	   it	  
been	   suggested	   that	   a	   slow-­‐dose	   escalation	   strategy	   may	   reduce	   the	   intensity	   of	   the	   reactions	  
(Chanan-­‐Khan	  et	  al.,	  2011).	  	  
One	   reason	   behind	   the	   clinical	   efficacy	   of	   lenalidomide	   in	   CLL	   is	   that	   it	   has	   been	   shown	   to	  
significantly	  inhibit	  CLL	  cell	  proliferation.	  This	  effect	  was	  shown	  to	  be	  dependent	  on	  CRBN	  and	  p21,	  
but	   independent	   of	   p53	   (Fecteau	   et	   al.,	   2014).	   However,	   this	   is	   one	   of	   the	   few	   direct	   effects	   of	  
lenalidomide	  observed	   in	  CLL	  cells	  so	   far.	  Unlike	  MM	  cells	   lenalidomide	   is	  not	  directly	  cytotoxic	   to	  
CLL	   cells	   in	   vitro	   (Riches	  et	  al.,	   2012;	  Chanan-­‐Khan	  et	  al.,	   2011)	  and	   so	   the	  majority	  of	   the	   clinical	  
effects	  of	   lenalidomide,	  observed	   in	  CLL	  patients,	  are	  thought	  to	  be	  due	  to	   its	   immunomodulatory	  
activity.	  For	  example,	  CLL	  cells	  depend	  on	  stimuli	  provided	  by	  cells	  in	  the	  tumour	  microenvironment	  
for	   their	   survival.	   One	   study	   showed	   that	   14	   day	   treatment	   with	   lenalidomide	   reduced	   the	  
expression	   of	   human	   leukocyte	   antigen	   (HLA)-­‐DR	   and	   increased	   IL-­‐10	   levels	   in	   these	   nearby	   cells,	  
which	  impaired	  the	  migration	  capability	  of	  the	  CLL	  cells	  (Schulz	  et	  al.,	  2013).	  	  
In	  addition	   to	   this,	   lenalidomide	  can	   reverse	   functional	  defects	  of	   follicular	  T	   cells	   in	  patients	  with	  
CLL	   (Görgün	   et	   al.,	   2005;	   Ramsay	   et	   al.,	   2008;	   Ramsay	   et	   al.,	   2012;	   Ramsay	   et	   al.,	   2013).	   Using	  





primary	  patients’	  T	  cells	  in	  conjugate	  with	  CLL	  cells,	  Ramsay	  and	  colleagues	  showed	  that	  CLL	  T	  cells	  
exhibited	  defective	  F-­‐actin	  polymerisation	  at	   the	   immune	  synapse.	   In	  addition,	   these	  cells	   showed	  
reduced	   recruitment	   of	   signalling	   proteins	   to	   the	   immune	   synapse,	   including	   tyrosine-­‐
phosphorylated	  proteins	   involved	  in	  early	  T	  cell	  signalling	  (Ramsay	  et	  al.,	  2008).	  Treatment	  of	  both	  
CLL	  cells	  and	  autologous	  T	  cells	  with	  lenalidomide	  restored	  formation	  of	  the	  T	  cell	  immune	  synapse	  
and	  subsequent	  T	  cell	  signalling	  (Ramsay	  et	  al.,	  2008).	  In	  a	  later	  study,	  the	  same	  group	  showed	  that	  
this	  impaired	  immune	  synapse	  formation	  was	  due	  to	  the	  upregulation	  of	  multiple	  inhibitory	  ligands	  
on	   the	   surface	   of	   the	  CLL	   cells	   and	   that	   lenalidomide	   treatment	   downregulated	   the	   expression	  of	  
these	  inhibitory	  ligands,	  thereby	  restoring	  activating	  immune	  synapse	  formation	  between	  T	  cells	  and	  
CLL	  cells	  (Ramsay	  et	  al.,	  2012).	  Most	  recently	  Ramsay	  and	  colleagues	  have	  shown	  that	  T	  cells	  which	  
come	   into	   direct	   contact	   with	   the	   CLL	   cells	   display	   impaired	   leukocyte	   functional	   antigen	   (LFA)-­‐1	  
mediated	  migration;	  it	  was	  demonstrated	  that	  this	  is	  due	  to	  altered	  Rho	  GTPase	  activation	  signalling	  
(Ramsay	   et	   al.,	   2013).	   Normal	   Rho	   GTPase	   signalling	   was	   restored	   with	   lenalidomide	   treatment,	  
thereby	   rescuing	   the	   adhesion	   and	  motility	   function	   of	   T	   cells	   (Ramsay	   et	   al.,	   2013).	   This	  work	   is	  
corroborated	  by	  other	   studies,	  which	  have	   shown	   that	   lenalidomide	   can	   induce	   the	   expression	  of	  
stimulatory	  molecules	  such	  as	  CD80,	  CD86	  and	  CD40L	  on	  CLL	  cells	  in	  vitro,	  thereby	  enhancing	  T	  cell	  
engagement	  (Aue	  et	  al.,	  2009;	  Lapalombella	  et	  al.,	  2010)	  
Treatment	  of	  NK	  cells	  with	  lenalidomide	   in	  vitro	  has	  also	  been	  shown	  to	  enhance	  NK	  cell-­‐mediated	  
antibody-­‐dependent	   cellular	   cytotoxicity	   (ADCC)	   of	   rituximab-­‐treated	   primary	   CLL	   cells	   (Wu	   et	   al.,	  
2008;	   Lapalombella	  et	  al.,	  2008),	   suggesting	   that	   the	  combined	  use	  of	   rituximab	  and	   lenalidomide	  
could	   be	   beneficial	   in	   the	   context	   of	   CLL.	   However,	   it	   was	   also	   shown	   that	   lenalidomide	  
downregulated	  CD20	  on	  CLL	  cells,	  resulting	  in	  a	  reduction	  in	  NK-­‐cell	  mediated	  ADCC	  (Lapalombella	  et	  
al.,	  2008).	  This	  suggests	  that	  the	  combined	  use	  of	  the	  two	  drugs	  would	  have	  to	  be	  optimised	  in	  order	  
to	   effectively	   enhance	   anti-­‐CLL	   responses.	   In	   clinical	   trials,	   however,	   the	   combined	   treatment	   of	  
rituximab	  and	  lenalidomide	  showed	  a	  64%	  overall	  response	  rate	  in	  patients	  with	  CLL	  (Badoux	  et	  al.,	  
2013).	   Recently,	   results	   from	   a	   further	   trial	   have	   been	   published	  which	   showed	   a	   >78%	   response	  
rate	  across	  two	  different	  age	  ranges	  (James	  et	  al.,	  2014).	  This	  data	  is	  promising	  and	  the	  efficacy	  of	  
lenalidomide	  in	  the	  treatment	  of	  CLL	  continues	  to	  be	  investigated.	  
The	   studies	   published	   on	   lenalidomide,	   in	   the	   context	   of	   CLL,	   are	   important	   for	   this	   investigation	  
because	   they	   highlight	   two	   important	   effects	   of	   lenalidomide	   that	   could	   be	   important	   for	  NK	   cell	  
effector	  function:	  the	  effect	  on	  immune	  synapse	  formation	  and	  the	  increase	  in	  ADCC	  via	  rituximab.	  It	  
is	   possible	   that	   lenalidomide	   affects	   F-­‐actin	   reorganisation	   during	   NK	   cell	   synapse	   formation	   in	   a	  
similar	  manner	  to	  that	  observed	  in	  follicular	  T	  cell,	  although	  this	  remains	  to	  be	  investigated.	  	  	  





1.5.3 Other	  diseases	  
	  
Lenalidomide	  is	  also	  approved	  for	  the	  treatment	  of	  non-­‐Hodgkin’s	  lymphoma,	  including	  mantle	  cell	  
lymphoma	  where	  it	  showed	  a	  response	  rate	  of	  >50%	  in	  clinical	  trials	  (Habermann	  et	  al.,	  2009;	  Witzig	  
et	   al.,	   2015).	   Lenalidomide	   has	   also	   been	   assessed	   for	   the	   treatment	   of	   classical	   Hodgkin’s	  
lymphoma	  and	  has	  shown	  positive	  results	  (Fehniger	  et	  al.,	  2011;	  Mandac	  &	  Kolonic,	  2010).	  	  
A	   recent	   study	   has	   shown	   that	   lenalidomide	   is	   effective	   in	   the	   context	   of	   neuroblastoma.	   Xu	   and	  
colleagues	  showed	  that	  co-­‐cultures	  of	  neuroblastoma	  cells	  and	  monocytes	  (which	  are	  present	  in	  the	  
microenvironment	   of	   neuroblastoma	   tumours	   in	   vivo)	   produce	   IL-­‐6	   and	   TGFβ1	   (Xu	   et	   al.,	   2013).	  
These	   cytokines	   suppress	   NK	   cell	   cytotoxicity	   and	   IFN-­‐γ	   production	   via	   activation	   of	   the	   Signal	  
transducers	  and	  activators	  of	  the	  transcription	  3	  (STAT3)	  pathway.	  Lenalidomide	  prevents	  activation	  
of	  these	  pathways	  by	  IL-­‐6	  and	  TGFβ1	  thereby	  inhibiting	  NK	  cell	  suppression	  in	  this	  system	  (Xu	  et	  al.,	  
2013).	   This	   suggests	   that	   lenalidomide	   may	   improve	   current	   immunotherapy	   for	   neuroblastoma.	  
Importantly,	  this	  work	  provides	  an	  key	  link	  between	  lenalidomide	  and	  NK	  cell	  IFN-­‐γ	  production,	  and	  
suggests	   that	   lenalidomide	   increases	   IFN-­‐γ	   production	   indirectly	   in	   the	   context	   of	   neuroblastoma.	  
Whether	  the	  effect	  of	  lenalidomide	  on	  NK	  cell	  IFN-­‐γ	  production	  in	  the	  context	  of	  MM	  is	  also	  indirect,	  
or	  whether	  it	  occurs	  via	  a	  distinct	  mechanism,	  remains	  to	  be	  understood.	  
	  
1.5.4 Conclusions	  and	  aims	  
	  
In	   conclusion,	   the	   immunomodulatory	   activity	   of	   lenalidomide	   has	   a	   wide-­‐ranging	   effect	   on	   the	  
immune	  system	  and	  therefore	  has	  the	  potential	  to	  be	  of	  clinical	  use	  in	  a	  variety	  of	  different	  diseases.	  
In	  MM	  lenalidomide	  modulates	  the	  immune	  response	  resulting	  in	  increased	  anti-­‐tumour	  activity	  of	  
various	   components	   of	   the	   immune	   system,	   including	   T	   cells	   and	   NK	   cells.	   Although	   increased	  
numbers	  of	  NK	  cells	  have	  been	  detected	  in	  the	  peripheral	  blood	  of	  MM	  patients,	  it	  is	  not	  yet	  known	  
whether	   lenalidomide	   directly	   affects	   the	   activity	   of	   NK	   cells.	   The	   work	   presented	   in	   this	   thesis	  
focuses	  on	  the	  effect	  of	  lenalidomide	  on	  NK	  cell	  function.	  	  
	  





1.6 Natural	  Killer	  Cells	  
	  
NK	   cells	   are	   large	   granular	   lymphocytes	   that	   account	   for	   5−15%	  of	   peripheral	   blood	   lymphocytes.	  
They	   contribute	   to	   an	   early	   defence	   against	   pathogen	   infections	   and	   tumours	   by	   detecting	   and	  
eliminating	  “stressed”	   (abnormal)	  and	  diseased	  cells.	  Human	  NK	  cells	  are	  distinguished	  from	  other	  
lymphocytes	  by	  being	  CD3-­‐CD56+	  (they	  do	  not	  express	  CD3,	  which	  distinguishes	  them	  from	  T	  cells,	  
but	  they	  do	  express	  CD56)	  (Robertson	  &	  Ritz,	  1990;	  Cooper	  et	  al.,	  2001).	  In	  addition,	  the	  activating	  
receptor	   NKp46	  was	  more	   recently	   identified	   as	   a	   conserved	  marker	   for	   NK	   cells	   across	   different	  
species	  (Walzer	  et	  al.,	  2007).	  	  
	  
1.6.1 NK	  cell	  effector	  functions	  
	  
NK	  cells	  eliminate	  diseased	  or	  stressed	  cells	  via	   the	  directed	  secretion	  of	   lytic	  granules,	  containing	  
perforin	  and	  granzymes,	  at	  the	   intercellular	  contact	  between	  the	  NK	  cell	  and	   its	  target	  (Kägi	  et	  al.,	  
1994).	  Once	  the	  proteins	  have	  been	  released	  into	  the	  intercellular	  space,	  perforin	  binds	  to	  the	  target	  
cell	   membrane	   through	   a	   calcium-­‐dependent	  mechanism	   (Voskoboinik	   et	   al.,	   2005).	   The	   perforin	  
monomers	  then	  oligomerise	  to	  form	  pores	  within	  the	  membrane	  of	  the	  target	  cell	  (Liu	  et	  al.,	  1995).	  
These	  pores	  are	  up	  to	  20	  nm	  in	  diameter	  and	  allow	  the	  passage	  of	  granzymes	  into	  the	  cytoplasm	  of	  
the	  cell	  where	   they	   initiate	  apoptosis	   (Law	  et	  al.,	  2010).	  NK	  cells	   can	  also	   induce	   target	   cell	  death	  
through	  perforin-­‐independent	  pathways.	  These	  pathways	  include	  other	  factors	  such	  as	  TNF-­‐α,	  TNF-­‐
related	   apoptosis-­‐inducing	   ligand	   (TRAIL)	   and	   Fas	   ligand	   (FasL)(Kashii	   et	   al.,	   1999;	   Screpanti	   et	   al.,	  
2001).	  These	  factors	  bind	  to	  associated	  receptors	  on	  the	  surface	  of	  target	  cells	  and	  induce	  death	  by	  
apoptosis	  or	  necrosis.	  
As	  well	  as	  cytolytic	  activity	  against	  target	  cells,	  NK	  cells	  secrete	  soluble	  pro-­‐inflammatory	  cytokines	  
such	  as	  IFN-­‐γ.	  IFN-­‐γ	  has	  a	  diverse	  array	  of	  roles	  in	  the	  immune	  system,	  including	  pro-­‐inflammatory,	  
anti-­‐proliferative,	  anti-­‐angiogenic	  and	  pro-­‐apoptotic	  activity	  in	  the	  tumour	  microenvironment	  (Chin	  
et	  al.,	  1996;	  Beatty	  &	  Paterson,	  2001;	  Chawla-­‐Sarkar	  et	  al.,	  2003).	  In	  addition,	  IFN-­‐γ	  directly	  activates	  
macrophages	   and	   induces	   the	   production	   of	   chemokines	  which	   recruit	   other	   effector	   cells	   to	   the	  
sites	   of	   inflammation	   (Hu	   et	   al.,	   2008).	   IFN-­‐γ	   also	   upregulates	   major	   histocompatibility	   complex	  
(MHC)	  class	  I	  molecules	  on	  the	  surface	  of	  potential	  target	  cells,	  therefore	  aiding	  in	  the	  priming	  and	  





presentation	   of	   antigens	   to	   professional	   APCs	   (Seliger	   et	   al.,	   2008).	   NK	   cells	   also	   produce	   TNF-­‐α	  
which	   initiates	  a	  cytokine	  cascade	  during	  an	   inflammatory	   response	  and	  can	  directly	   induce	  target	  
cell	  death	  (Waters	  et	  al.,	  2013).	  	  
Cytokine	   secretion	   and	   cytotoxicity	   have	   generally	   been	   regarded	   as	   two	   distinct	   functions	   of	   NK	  
cells.	  Interestingly,	  however,	  a	  recent	  study	  has	  shown	  that	  IFN-­‐γ	  and	  TNF-­‐α	  synergistically	  enhance	  
NK	  cell	  cytotoxicity	  through	  upregulation	  of	  ICAM-­‐1	  expression	  in	  target	  cells,	  thus	  promoting	  NK	  cell	  
conjugate	  formation	  (Wang	  et	  al.,	  2012).	  
NK	   cell	   effector	   functions	   are	   regulated	   by	   direct	   interactions	  with	   other	   immune	   cells,	   such	   as	   T	  
cells,	   dendritic	   cells	   (DCs)	   and	   macrophages	   or	   by	   the	   cytokine	   milieu	   in	   the	   NK	   cell	  
microenvironment	   (Lucas	   et	   al.,	   2007;	   Long,	   2007;	   Vivier	   et	   al.,	   2008).	   	   Numerous	   cytokines	   have	  
been	   shown	   to	   promote	   NK	   cell	   effector	   functions,	   including	   IFN-­‐α	   and	   –β,	   IL-­‐12,	   IL-­‐18	   and	   IL-­‐15	  
(Walzer	   et	   al.,	   2005).	   The	   cytokine	   with	   the	   most	   pronounced	   effect	   on	   NK	   cells	   is	   IL-­‐2,	   which	  
stimulates	   NK	   cell	   proliferation,	   cytokine	   secretion	   and	   cytotoxic	   activity	   (Henney	   et	   al.,	   1981;	  
Trinchieri,	  1989).	  
	  
1.6.2 Bridging	  the	  gap	  between	  innate	  and	  adaptive	  immune	  responses	  
	  
The	  adaptive	   immune	  response	  has	  high	  specificity	   to	   foreign	  peptide	  sequences,	  which	   is	  derived	  
from	  somatic	  recombination.	  Adaptive	  immunity	  requires	  priming	  by	  cytokines	  or	  direct	  intercellular	  
contact	   and	   is	   additionally	   characterised	   by	   long-­‐term	   ‘memory’	   capabilities.	   In	   contrast,	   innate	  
immune	   responses	   are	   fast	   acting	   and	   rely	   on	   a	   limited	   selection	   of	   germline-­‐encoded	   receptors	  
(Janeway	  &	  Medzhitov,	   2002).	   NK	   cells	   were	   initially	   considered	   to	   be	   components	   of	   the	   innate	  
immune	  system	  as	  they	  are	  not	  ‘antigen-­‐specific’	  and	  do	  not	  have	  to	  be	  primed	  in	  order	  to	  react	  to	  
pathogen	   infection	   or	   the	   presence	   of	   tumours	   (Vivier	   et	   al.,	   2011).	   However,	   some	   studies	   have	  
shown	  that	  NK	  cells	  can	  also	  regulate	  the	  adaptive	  immune	  system	  by	  directly	  interacting	  with	  and	  
co-­‐stimulating	   CD4+	   T	   cells	   (Zingoni	   et	   al.,	   2004),	   macrophages	   (Nedvetzki	   et	   al.,	   2007)	   and	   DCs	  
(Gerosa	  et	  al.,	  2002).	  	  
In	  addition,	  studies	  have	  revealed	  that	  NK	  cells	  exhibit	  signs	  of	  ‘immunological	  memory.’	  Specifically,	  
NK	  cells	  undergo	  clonal	  expansion,	  persistence	  and	  a	  secondary	  response	  to	  a	  particular	  antigen	  (Sun	  
et	  al.,	  2009;	  Cooper	  et	  al.,	  2009;	  Keppel	  et	  al.,	  2013).	  These	  ‘memory-­‐like’	  NK	  cells	  have	  been	  shown	  





to	   persist	   in	  mice	   for	   several	  months	   after	   initial	   infection,	   suggesting	   a	   long-­‐term	  memory	   effect	  
that	  was	  previously	  only	  associated	  with	  T	  and	  B	  cells	  (Sun	  et	  al.,	  2009;	  Keppel	  et	  al.,	  2013).	  
	  
1.6.3 NK	  cell	  recognition	  
	  
NK	   cell	   effector	   functions	   involve	   recognition	   of	   potential	   target	   cells	   via	   germ-­‐line	   encoded	  
receptors.	   Ligation	  of	   these	   receptors	   results	   in	  either	  activating	  or	   inhibitory	   signalling	  within	   the	  
NK	  cell,	  depending	  on	  the	  receptors	  and	  ligands	  involved	  in	  the	  interaction.	  The	  dynamic	  equilibrium	  
that	   occurs	   between	   simultaneous	   signals	   from	   activating	   and	   inhibitory	   cell	   surfaces	   receptors	   is	  
crucial	  for	  determining	  the	  end	  functional	  outcome	  for	  NK	  cells	  (Lanier,	  2003;	  Vivier	  et	  al.,	  2004).	  NK	  
cells	   express	   a	   large	   repertoire	   of	   invariant	   receptors.	   Using	   this	   large	   collection	   of	   receptors,	   NK	  
cells	   can	   discriminate	   between	   healthy	   and	   abnormal	   cells	   using	   different	   strategies,	   such	   as	  
‘induced-­‐self’	  and	  ‘missing-­‐self’	  recognition	  (Figure	  1.3).	  
	  
Activating	  receptors	  and	  ‘induced-­‐self’	  recognition	  
NK	   cells	   express	   a	   variety	   of	   structurally	   distinct	   activating	   receptors	   on	   their	   surfaces	   that	   allow	  
them	   to	   recognise	   non-­‐self	   ligands	   (such	   as	   viral	   ligands)	   or	   stress-­‐induced	   self-­‐ligands.	   NK	   cell	  
activation	  often	   arises	   from	   the	   combined	  action	  of	  multiple	   surface	  proteins,	   including	   activating	  
receptors,	  cytokine	  receptors	  and	  adhesion	  molecules	  (Bryceson	  et	  al.,	  2005).	  In	  order	  to	  dissect	  the	  
requirements	   for	   NK	   cell	   activation,	   Eric	   Long	   and	   colleagues	   transfected	   insect	   cells	   to	   express	  
various	  combinations	  of	  activating	  receptor	  ligands	  and	  adhesion	  molecules.	  The	  results	  showed	  that	  
some	   activating	   receptors	   on	   human	   NK	   cells	   require	   simultaneous	   stimulation	   through	   other	  
receptors,	  or	  through	  adhesion	  molecules,	  and	  are	  not	  sufficient	  to	  trigger	  activation	  if	  ligated	  alone	  
(Bryceson	  et	  al.,	  2005;	  Bryceson	  et	  al.,	  2006a).	  	  






Figure	  1.3	  –	  Recognition	  of	  target	  cells	  by	  NK	  cells.	  (A)	  Upon	  interaction	  with	  a	  healthy	  target	  cell,	  an	  NK	  cell	  
might	   receive	   activating	   signals;	   however,	   due	   to	   expression	   of	   appropriate	   self-­‐MHC	   class	   I	   alleles	   on	   the	  
target	  cell,	  the	  NK	  cell	  receives	  inhibitory	  signals	  and	  does	  not	  lyse	  the	  cell.	  (B)	  ‘Missing-­‐self’:	  if	  the	  target	  cell	  
loses	   its	   expression	   of	  MHC	   class	   I	   molecules,	   the	   inhibitory	   receptor	   on	   the	   NK	   cell	   is	   not	   engaged	   so	   no	  
inhibitory	   signals	   are	   received.	   Activating	   signals	   therefore	   dominate	   and	   the	   NK	   cell	   lyses	   the	   target.	   (C)	  
‘Induced-­‐self’:	  if	  the	  target	  cell	  upregulates	  stress	  ligands	  on	  its	  surface,	  then	  activating	  signals	  dominate	  and	  









One	  of	   the	  best-­‐characterised	  NK	  cell	   activating	   receptors	   is	  NK	  group	  2	  member	  D	   (NKG2D),	  a	  C-­‐
type	   lectin-­‐like	   type	   II	   transmembrane	   receptor	   (Houchins	   et	   al.,	   1991).	   The	   ligands	   for	  NKG2D	   in	  
humans	  include	  MICA	  and	  MICB,	  two	  proteins	  encoded	  by	  the	  MHC	  class	  I	  chain	  related	  (MIC)	  genes,	  
and	   UL-­‐16	   binding	   proteins	   (ULBP)	   1−6	   (Bahram	   et	   al.,	   1996;	   Bahram	   &	   Spies,	   1996;	  
Carayannopoulos	  et	  al.,	  2002;	  Cosman	  et	  al.,	  2001;	  Eagle	  et	  al.,	  2009).	   	  These	   ligands	  are	  generally	  
not	  present	  on	  healthy	  cells	  but	  are	  often	  upregulated	  when	  the	  cells	  are	  transformed,	  stressed	  or	  
virally	  infected.	  Because	  of	  this,	  NKG2D	  is	  considered	  to	  elicit	  natural	  cytotoxicity	  via	  recognition	  of	  
‘induced-­‐self’.	   In	  other	  words	  NKG2D	  recognises	  host	  proteins	  whose	  expression	  has	  been	  induced	  
on	   the	   surface	  of	   cells	   that	  need	   to	  be	  eliminated.	  Crucially,	  NKG2D-­‐mediated	   signalling	   is	   able	   to	  
override	   inhibitory	  signals	   induced	  by	  the	  presence	  of	  MHC	  class	   I	  molecules	  on	  the	  surface	  of	  the	  
target	  cell	  (Bauer	  et	  al.,	  1999;	  Cerwenka	  et	  al.,	  2001;	  Diefenbach	  et	  al.,	  2001).	  However,	  ligation	  of	  
NKG2D	  alone	   is	  not	   sufficient	   to	   fully	  activate	  NK	  cells;	   co-­‐ligation	  of	   LFA-­‐1	   is	   required	   in	  order	   to	  
elicit	  NK	  cell	  effector	  functions	  (Bryceson	  et	  al.,	  2009).	  The	  exception	  to	  this	  is	  synergistic	  activation	  
through	  multiple	  activating	  receptors,	  which	  will	  be	  discussed	  later.	  
Another	   type	   of	   activating	   receptor	   is	   the	   family	   of	   Natural	   Cytotoxicity	   Receptors	   (NCRs),	   which	  
include	   NKp30,	   NKp44	   and	   NKp46	   (Pende	   et	   al.,	   1999;	   Vitale	   et	   al.,	   1998;	   Cantoni	   et	   al.,	   1999;	  
Pessino	   et	   al.,	   1998).	   The	   search	   for	   ligands	   for	   NCRs	   is	   on-­‐going.	   B7-­‐H6,	   which	   is	   expressed	   on	  
human	  tumour	  cells	  (including	  T	  and	  B	  cell	   lymphomas	  and	  melanomas),	  was	  shown	  to	  be	  a	  ligand	  
for	  NKp30	  (Brandt	  et	  al.,	  2009).	  B7-­‐H6	  was	  not	  expressed	  on	  healthy	  cells,	   thus	   indicating	  another	  
example	  of	  ‘induced-­‐self’	  recognition.	  Although	  a	  ligand	  for	  NKp44	  (known	  as	  NKp44L)	  was	  identified	  
recently	  on	  the	  surface	  of	  tumour	  cells	  (Rajagopalan	  &	  Long,	  2013;	  Baychelier	  et	  al.,	  2013),	  no	  host	  
ligands	  have	  been	  identified	  for	  NKp46.	  Interestingly,	  some	  in	  vitro	  studies	  have	  shown	  that	  NKp44	  
and	  NKp46	  can	  recognise	  haemagglutinins	  of	   influenza	  virus	  particles,	   leading	  to	  NK	  cell	  activation	  
(Arnon	  et	  al.,	  2001;	  Mandelboim	  et	  al.,	  2001).	  In	  a	  later	  study	  it	  was	  shown	  that	  NKp46	  requires	  co-­‐
ligation	  of	   LFA-­‐1	   in	  order	   to	  activate	  NK	  cells	   (as	   shown	  by	  cortical	  actin	   rearrangements)	  and	   the	  
authors	   suggest	   that	   LFA-­‐1	   ligation	   of	   ICAM-­‐1	   could	   be	   required	   to	   differentiate	   between	   virally	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NKp44L,	  viral	  haemagglutinins	  
Viral	  haemagglutinins	  
	  
(Pende	  et	  al.,	  1999)	  
(Cantoni	  et	  al.,	  1999)	  
(Pessino	  et	  al.,	  1998)	  
CD16	   CD3ζ	   Fc	  portion	  of	  antibodies	   (Lanier	  et	  al.,	  1985)	  (Perussia,	  1998)	  
2B4	   SAP	   CD48	   (Eissmann	  et	  al.,	  2005)	  
DNAM-­‐1	   -­‐	   PVR	  (CD155)	  Nectin-­‐2	  (CD226)	   (Bottino	  et	  al.,	  2003)	  
CD2	   CD2BP1	   CD58	   (Siliciano	  et	  al.,	  1985)	  (Dustin	  et	  al.,	  1987)	  
CD44	   SAP	   Hyaluronate	   (Galandrini	  et	  al.,	  1994)	  
BY55	  
(CD169)	   DAP10	   HLA-­‐C	   (Le	  Bouteiller	  et	  al.,	  2002)	  
CD28	   -­‐	   B7	  ligands	  (CD80	  and	  CD86)	  
(Galea-­‐Lauri	  et	  al.,	  1999)	  
(Wilson	  et	  al.,	  1999)	  
Table	  1.1	  –	  NK	  cell	  activating	  receptors.	  DAP10/12,	  DNAX	  activating	  protein	  of	  10	  or	  12	  kDa;	  DNAM-­‐1,	  DNAX	  
accessory	  molecule	  1;	  PVR,	  polio	  virus	  receptor;	  CD2BP1,	  CD2	  cytoplasmic	  tail-­‐binding	  protein;	  SAP,	  signalling	  
lymphocyte	  activation	  protein.	  
	  
CD16	  (or	  FcγRIIIA)	  is	  a	  different	  kind	  of	  activating	  receptor,	  which	  binds	  the	  Fc	  portion	  of	  antibodies	  
and	  triggers	  a	  process	  called	  Antibody-­‐Dependent	  Cellular	  Cytotoxicity	   (ADCC),	  where	  NK	  cells	   lyse	  
antibody-­‐coated	   target	   cells	   (Lanier	  et	   al.,	   1985;	  Perussia,	   1998).	  CD16	  does	  not	   require	   LFA-­‐1	   co-­‐
ligation	   in	   order	   to	   elicit	   full	   NK	   cell	   activation	   (Bryceson	   et	   al.,	   2009).	   NK	   cells	   express	   other	  
activating	   receptors	   that	   recognise	   non-­‐self	   proteins	   or	   stress-­‐inducible	   ligands,	   as	   summarised	   in	  
Table	   1.1.	   These	   include	  2B4,	  which	  binds	  CD48,	   a	   protein	  widely	   expressed	   in	   the	  hematopoietic	  
system	  (Tangye	  et	  al.,	  1999;	  Eissmann	  et	  al.,	  2005).	  
	  
	  





Synergistic	  NK	  cell	  activation	  
It	  has	  been	  shown	  that	  simultaneous	  ligation	  of	  combinations	  of	  activating	  receptors	  also	  triggers	  NK	  
cell	   activation	   (Bryceson	   et	   al.,	   2006b).	   Using	   a	   redirected	   lysis	   cytotoxicity	   assay,	   Bryceson	   and	  
colleagues	  showed	  that	  no	  single	  receptor,	  with	  the	  exception	  of	  CD16,	  was	  sufficient	  to	  stimulate	  
substantial	  cytotoxicity	  or	  cytokine	  secretion	  (Bryceson	  et	  al.,	  2006b).	  However,	  each	  receptor	  does	  
contribute	   a	   signal	   because	   specific	   pair-­‐wise	   combinations	   of	   activating	   receptors	   resulted	   in	  
synergistic	   activation	  of	  NK	   cells	   (Bryceson	  et	   al.,	   2006b).	   Some	   receptors,	   e.g.	  NKG2D,	   synergised	  
with	  multiple	  other	  activating	  receptors	  (NKp46	  and	  2B4).	  CD2,	  however,	  only	  synergised	  with	  one	  
receptor	   (NKp46).	  NKp46	  was	   able	   to	   synergise	  with	   all	   four	   receptors	   that	  were	  assessed	   (Figure	  
1.4).	  These	  specific	  patterns	  of	  synergy	  resulted	  in	  strong	  NK	  cell	  activation,	  suggesting	  that	  receptor	  
synergy	  might	  play	  a	  role	  in	  overriding	  the	  balance	  between	  activation	  and	  inhibition.	  
	  
Figure	   1.4	   –	   Schematic	   representation	   of	   activating	   receptor	   synergies	   in	   resting	   NK	   cells.	   Black	   lines	  
represent	  strong	  synergies	  between	  pairs	  of	  receptors.	  Figure	  adapted	  from	  Figure	  7,	  Bryceson	  et	  al,	  2006b.	  
	  
Activating	  receptor	  signalling	  
Following	   activating	   receptor	   ligation,	   complex	   downstream	   signalling	   events	   lead	   to	   NK	   cell	  
activation.	  Activating	  receptors	   lack	  their	  own	  cytoplasmic	  signalling	  domains	  and	  so	  are	  unable	  to	  
intrinsically	   initiate	   signalling.	   Instead	   they	   couple	   with	   adaptor	   proteins	   that	   are	   responsible	   for	  
triggering	   signalling	   after	   activating	   receptor	   ligation.	   The	  majority	   of	  NK	   cell	   activating	   receptors,	  
including	  the	  NCRs	  and	  CD16,	  mediate	  signalling	  through	  adaptor	  proteins	  such	  as	  CD3ζ	  and	  DAP12	  
(Table	  1.1)(Wirthmueller	  et	  al.,	  1992;	  Moretta	  et	  al.,	  2001).	  These	  adaptor	  proteins	  contain	  one	  or	  
more	   common	   immunoreceptor	   tyrosine-­‐based	   activation	   motifs	   (ITAMs),	   which	   include	   the	  





consensus	   sequence	   YxxL(x)6-­‐8YxxL	   (amino	   acid	   letter	   code,	   where	   x	   stands	   for	   any	   amino	   acid)	  
(Reth,	  1989;	  Lanier,	  2003).	  Signalling	   through	   ITAM-­‐bearing	  adaptors	   leads	   to	   the	   recruitment	  and	  
activation	  of	   the	  tyrosine	  kinases	  Lyk	   (Ting	  et	  al.,	  1995),	  Syk	   (Ståhls	  et	  al.,	  1994;	  Brumbaugh	  et	  al.,	  
1997)	  and	  the	  zeta-­‐chain-­‐associated	  protein	  kinase	  of	  70	  kDa	  (ZAP70)	  (Vivier	  et	  al.,	  1993).	  Signalling	  
events	  downstream	  of	   this	   include	  phosphorylation	   (or	   activation)	  of	   linker	   for	   activation	  of	   T	   cell	  
(LAT)	  (Jevremovic	  et	  al.,	  1999),	  phospholipase	  C-­‐γ	  (PLC-­‐γ)	  (Ting	  et	  al.,	  1992),	  growth	  factor	  receptor-­‐
bound	   protein	   2	   (Grb2)	   (Cerboni	   et	   al.,	   1998),	   phosphoinositol	   3-­‐kinase	   (PI3K)	   (Kanakaraj	   et	   al.,	  
1994)	  and	  Vav	  proteins	  (Xu	  &	  Chong,	  1996;	  Galandrini	  et	  al.,	  1999)(Figure	  1.5).	  	  
	  
Figure	  1.5	  –	  NK	  effector	  signalling	  pathways.	  NK	  cells	  express	  activating	  receptors	  that	  recognise	  upregulated	  
stress-­‐induced	  ligands	  as	  well	  as	  those	  that	  can	  bind	  the	  Fc	  portion	  of	  an	  IgG	  antibody.	  As	  described	  in	  the	  text,	  
ligation	   of	   activating	   receptors	   to	   their	   ligands	   results	   in	   activation	   through	   their	   adaptor	   proteins.	   These	  
kinase	   cascades	   are	   initially	   different	   for	   NKG2D	   and	   CD16	   but	   then	   converge	   later	   on	   resulting	   in	   actin	  
rearrangements,	  cytotoxicity	  and	  cytokine	  secretion.	  	  





NKG2D,	   however,	   mediates	   NK	   cell	   activation	   through	   an	   ITAM-­‐independent	   pathway.	   NKG2D	   in	  
humans	   couples	   with	   the	   adaptor	   signalling	   molecule	   DAP10	   via	   a	   charged	   residue	   in	   its	  
transmembrane	  domain	  (Wu	  et	  al.,	  1999).	  Ligation	  of	  NKG2D	  results	  in	  phosphorylation	  of	  the	  ITAM-­‐
like	  PI3K-­‐binding	  motif	  (YxxM)	  in	  the	  cytoplasmic	  tail	  of	  DAP10	  by	  the	  Src-­‐kinase	  Lyk	  (Billadeau	  et	  al.,	  
2003).	  This	   is	   reminiscent	  of	  signalling	  through	  the	  T	  cell	  co-­‐stimulatory	  molecule	  CD28	  (Wu	  et	  al.,	  
2000).	  Lyk-­‐mediated	  phosphorylation	  of	  DAP10	   leads	  to	  recruitment	  of	  PI3K	  and	  Grb2,	  resulting	   in	  
signalling	  via	  Akt	  and	  Vav	  proteins	  (Chang	  et	  al.,	  1999;	  Wu	  et	  al.,	  2000).	  	  	  
Both	   ITAM-­‐dependent	  and	  DAP10-­‐mediated	  signalling	  pathways	  converge	  on	  a	  common	  activation	  
pathway,	  which	   involves	   the	  activation	  of	  Rho	  and	  Rac	  GTPases,	  mitogen-­‐activated	  protein	   kinase	  
(MAPK)	  and	  extracellular	  activating-­‐regulated	  kinase	  (ERK)	  (Vivier	  et	  al.,	  2004)(Figure	  1.5).	  This	  leads	  
to	   common	   the	   outcomes	   of	   NK	   cell	   activation:	   F-­‐actin	   polymerisation	   and	   reorganisation,	  
polarisation	  of	  the	  microtubule-­‐organising	  centre	  (MTOC),	  cytotoxicity	  and	  cytokine	  secretion.	  
	  
Inhibitory	  receptors	  and	  ‘missing-­‐self’	  recognition	  
NK	  cells	  also	  express	  a	  repertoire	  of	  inhibitory	  receptors,	  which	  prevent	  NK	  cells	  from	  killing	  healthy	  
cells.	   These	   inhibitory	   receptors	   recognise	   self	  MHC	   class	   I	   molecules	   as	  markers	   of	   healthy	   cells	  
(Karlhofer	  et	  al.,	  1992;	  Moretta	  et	  al.,	  1993).	  MHC	  class	  I	  molecules	  are	  expressed	  by	  the	  majority	  of	  
human	  cells	  and	  their	  role	  is	  to	  present	  cell-­‐derived	  antigens	  to	  T	  cells.	  This	  allows	  T	  cells	  to	  survey	  
other	  cells	  for	  signs	  of	  intracellular	  infections	  or	  transformation.	  As	  an	  immune	  avoidance	  technique	  
many	  viruses	  and	  tumour	  transformations	  have	  evolved	  to	  downregulate	  MHC	  class	  I	  proteins	  from	  
the	   cell	   surface,	   thus	   rendering	   them	   ‘invisible’	   to	   T	   cells	   (Früh	   et	   al.,	   1999).	   In	   the	   ‘missing-­‐self’	  
model	  of	  recognition	  NK	  cells	  eliminate	  target	  cells	  that	  have	  downregulated	  MHC	  molecules	  (Kärre	  
et	  al.,	  2005;	  Ljunggren	  &	  Kärre,	  1985).	  This	  happens	  because	  the	  inhibitory	  receptors	  are	  no	  longer	  
able	  to	  recognise	  ligands	  on	  potential	  target	  cells;	  activating	  signals	  therefore	  dominate	  and	  the	  cell	  










Receptor	   Ligand	   References	  
KIR	   HLA-­‐A,	  -­‐B,	  -­‐C	   (Colonna	  &	  Samaridis,	  1995)	  (Wagtmann	  et	  al.,	  1995)	  
CD94/NKG2A	   HLA-­‐E	   (Braud	  et	  al.,	  1998)	  (Vance	  et	  al.,	  1998)	  
LIRs	   Broad	  range	  of	  MHC	  class	  I	  ligands	  
(Samaridis	  &	  Colonna,	  1997)	  
(Cosman	  et	  al.,	  1997)	  
CD66	  	  
(CEACAM-­‐1)	   Non-­‐MHC	  ligands	   (Markel	  et	  al.,	  2002)	  
TIGIT	   PVR	  PVR	  ligand	  2	   (Stanietsky	  et	  al.,	  2009)	  
KLRG1	   Cadherins	   (Ito	  et	  al.,	  2006)	  
LAIR-­‐1	   Collagen	   (Meyaard	  et	  al.,	  1997)	  
NKR-­‐P1A/	  
CD161	   LLT-­‐1	   (Lanier	  et	  al.,	  1994)	  
	  
Table	  1.2	  –	  Inhibitory	  receptors	  expressed	  by	  human	  NK	  cells.	  LILR,	  leukocyte	  immunoglobulin-­‐like	  receptors;	  
CEACAM-­‐1,	   carcinoembryonic	   antigen-­‐related	   cell	   adhesion	   molecule;	   TIGIT,	   T	   cell	   immunoreceptor	   with	  
immunoglobulin	   and	   ITIM	   domains;	   KLRG1,	   killer	   cell	   lectin-­‐like	   receptor	   G1;	   LAIR-­‐1,	   leukocyte	   associated	  
immunoglobulin-­‐like	  receptor	  1;	  NKR-­‐P1A,	  NK	  cell	  receptor	  protein	  1A;	  LLT-­‐1,	  lectin-­‐like	  transcript	  1	  
	  
The	   range	  of	   inhibitory	   receptors	   expressed	  by	  human	  NK	   cells	   is	   summarised	   in	   Table	   1.2.	   These	  
include	  human	  killer	  immunoglobulin-­‐like	  receptors	  (KIRs),	  which	  recognise	  the	  classical	  MHC	  class	  I	  
proteins	  HLA-­‐A,	  -­‐B	  and	  -­‐C	  (Colonna	  &	  Samaridis,	  1995;	  Wagtmann	  et	  al.,	  1995).	  In	  addition	  there	  are	  
the	  CD94/NKG2	  receptors,	  which	  recognise	  the	  non-­‐classical	  MHC	  class	  I	  protein	  HLA-­‐E	  (Braud	  et	  al.,	  
1998;	  Vance	  et	  al.,	  1998),	  and	  the	  leukocyte	  immunoglobulin-­‐like	  receptors	  (LILR),	  which	  recognise	  a	  
broad	   range	   of	   classical	   and	   non-­‐classical	   MHC	   class	   I	   molecules	   (Samaridis	   &	   Colonna,	   1997;	  
Cosman	   et	   al.,	   1997;	   Vitale	   et	   al.,	   1999).	   KIRs	   and	   LILRs	   are	   both	   immunoglobulin-­‐like	   type	   I	  
transmembrane	   receptors	   and	   so	   are	   structurally	   quite	   similar.	   In	   contrast,	   CD94/NKG2	   receptors	  
are	   C-­‐type	   lectin-­‐like	   type	   II	   transmembrane	   heterodimers.	   Other	   inhibitory	   receptors	   also	   exist	  
which	   recognise	   non-­‐MHC	   class	   I	   ligands	   (Table	   1.2).	   Inhibitory	   NK	   cell	   receptors	   are	   very	  
heterogeneous	  and	  the	  KIR	  receptor	  family	  displays	  large	  haplotype	  and	  allelic	  variability.	  This	  leads	  
to	  each	  individual	  carrying	  distinct	  NK	  cell	  inhibitory	  receptor	  repertoires	  (Parham,	  2005).	  





Inhibitory	  receptor	  signalling	  
The	   majority	   of	   NK	   cell	   inhibitory	   receptors	   have	   a	   common	   immunoreceptor	   tyrosine-­‐based	  
inhibition	   motif	   (ITIM)	   in	   their	   cytoplasmic	   domains.	   This	   contains	   the	   consensus	   sequence	  
I/V/LxYxxL/V	   (amino	  acid	   letter	  code,	  where	  x	   stands	   for	  any	  amino	  acid)	   (Wagtmann	  et	  al.,	  1995;	  
Burshtyn	  et	  al.,	  1996).	  After	   inhibitory	  receptors	  are	   ligated,	   the	  tyrosine	  residues	   in	   the	   ITIMs	  are	  
phosphorylated	   by	   Src	   kinases	   and	   then	   Src	   homology	   2	   (SH2)	   domain-­‐containing	   tyrosine	  
phosphatases	  SHP-­‐1	  and	  SHP-­‐2	  or	  SH2	  domain-­‐containing	  inositol	  phosphatase	  (SHIP)	  are	  recruited	  
(Binstadt	   et	   al.,	   1996).	   These	   phosphatases	   initiate	   a	   signalling	   cascade	   that	   results	   in	  
dephosphorylation	  (and	  therefore	  inactivation)	  of	  components	  of	  the	  activating	  signalling	  pathway,	  
such	  as	  ZAP70	  (Binstadt	  et	  al.,	  1996),	  PLC-­‐γ	  (Valiante	  et	  al.,	  1996)	  and	  Vav-­‐1	  (Stebbins	  et	  al.,	  2003).	  	  
It	   is	   thought	   that	  NK	   cell	   inhibitory	   signalling	   results	   in	   a	   block	   at	   an	   early	   stage	   of	   the	   activation	  
signalling	  pathway,	   because	   it	   has	  been	   shown	   that	   engagement	  of	   inhibitory	   receptors	   represses	  
actin	   cytoskeletal	   rearrangements	   (Krzewski	   et	   al.,	   2006;	   Masilamani	   et	   al.,	   2006).	   Inhibitory	  
receptor	   ligation	   also	   blocks	   the	   tyrosine	   phosphorylation	   of	   the	   activating	   receptors	   NKG2D	   and	  
2B4	  (Watzl	  et	  al.,	  2000)	  and	  prevents	  their	  recruitment	  to	  GM1-­‐rich	  membrane	  domains	  (Endt	  et	  al.,	  
2007;	   Watzl	   &	   Long,	   2003).	   The	   exact	   way	   in	   which	   these	   inhibitory	   and	   activating	   signals	   are	  
integrated	  at	  the	  molecular	  level,	  however,	  is	  still	  poorly	  understood.	  
	  
1.6.4 The	  immune	  synapse	  
	  
A	  major	  new	  challenge	  in	  the	  field	  of	  NK	  cell	   immunology	  is	  to	  understand	  the	  spatial	  organisation	  
and	   dynamics	   of	   receptors	   and	   adaptor	   molecules	   within	   the	   cell	   membrane,	   in	   order	   to	   better	  
understand	  how	  activating	   and	   inhibitory	   signalling	   is	   integrated.	   This	   is	   currently	   an	   area	   of	   very	  
active	   research	   due	   to	   the	   emergence	   of	   new	   microscopy	   techniques,	   which	   enable	   protein	  
localisation	  and	  cytoskeletal	  mapping	  on	  a	  nanometre	  scale.	  Over	  20	  years	  ago	  visualisation	  of	  NK	  
cells	  using	  fluorescence	  microscopy	  led	  to	  the	  discovery	  of	  a	  polarised	  intercellular	  contact	  between	  
immune	   cells	   and	   their	   target	   cells	   (Kupfer	   et	   al.,	   1983).	   The	   formation	   and	   distinct	   spatial	  
organisation	   of	   this	   intercellular	   contact,	   termed	   the	   immune	   synapse,	  was	   observed	   by	   confocal	  
microscopy	   16−17	   years	   ago	   (Monks	   et	   al.,	   1998;	   Grakoui	   et	   al.,	   1999;	   Davis	   et	   al.,	   1999).	   A	   vast	  
amount	  of	  work	  has	  been	  carried	  out	  since	  then	  and	  this	  has	  shown	  that	  immune	  synapses	  are	  key	  
for	  intercellular	  communication	  and	  eliciting	  immune	  effector	  responses	  (Stinchcombe	  et	  al.,	  2001;	  





McCann	  et	  al.,	  2003;	  Lee	  et	  al.,	  2003;	  Varma	  et	  al.,	  2006;	  Culley	  et	  al.,	  2009).	  The	  complex	  and	  highly	  
regulated	   nature	   of	   the	   immune	   synapse	   is	   necessary	   in	   order	   to	   control	   immune	   responses	   and	  
prevent	  NK	  cells	  from	  killing	  healthy	  cells.	  
	  
The	  NK	  cell	  immune	  synapse	  
Although	   immune	  synapses	  were	   first	  discovered	   in	  T	  cells,	   they	  also	  have	  a	  crucial	   role	   in	  NK	  cell	  
function	   (Davis	   et	   al.,	   1999;	  McCann	  et	   al.,	   2003).	   It	   has	  become	   increasing	   clear	   that	   the	  protein	  
interactions	   that	   take	   place	   at	   the	   NK	   cell	   immune	   synapse	   determine	   the	   outcome	   of	   the	  
intercellular	  contact.	  When	  inhibitory	  signals	  dominate,	  as	  is	  the	  case	  when	  an	  NK	  cell	  encounters	  a	  
healthy	   cell,	   an	   inhibitory	   synapse	   forms	   (Eissmann	   &	   Davis,	   2010).	   However,	   when	   an	   NK	   cell	  
encounters	   a	   diseased	   or	   stressed	   cell,	   activating	   signals	   will	   dominate	   the	   interaction	   and	   an	  
activating	   synapse	   forms	   (Orange,	   2008).	   The	   activating	   immune	   synapse	   allows	   the	   effector	  
response	   to	  be	   initiated	   locally	   at	   the	   site	  of	   specific	   activating	   signalling,	   and	   inhibitory	   signalling	  
can	   occur	   locally	   at	   a	   different	   immune	   synapse	   simultaneously	   (Eriksson	   et	   al.,	   1999).	   Effector	  
responses	  can	  therefore	  be	  directionally	  secreted	  towards	  the	  target	  cell	  that	  is	  expressing	  activating	  
ligands,	  without	  harming	  healthy	  cells	  that	  may	  also	  be	  in	  contact	  with	  the	  NK	  cell.	  	  
	  
The	  activating	  NK	  cell	  immune	  synapse	  
The	  end	  outcome	  of	  an	  activating	  NK	  cell	  immune	  synapse	  is	  direct	  cytolysis	  of	  the	  target	  cell	  and/or	  
cytokine	  secretion.	  Activation	  of	  NK	  cells	  halts	  NK	  cell	  migration,	  and	  induced	  symmetrical	  spreading	  
of	  the	  NK	  cell,	  leading	  to	  the	  formation	  of	  a	  stable	  NK	  cell	  immune	  synapse	  (Culley	  et	  al.,	  2009).	  This	  
is	  followed	  by	  a	  tightly	  controlled	  series	  of	  events	  including	  cytoskeletal	  rearrangement,	  MTOC	  and	  
lytic	   granule	   polarisation	   and	   granule	   exocytosis	   (Orange	   et	   al.,	   2003;	   Davis,	   2002;	   Orange,	   2008;	  
Krzewski	  &	  Strominger,	  2008;	  Mace	  et	  al.,	  2014).	  In	  the	  most	  recent	  review	  (at	  the	  time	  of	  writing),	  
Emily	  Mace	  and	  colleagues	  redefine	  the	  regulated	  steps	  in	  NK	  cell	  cytotoxicity	  and	  identify	  48	  steps	  
and	  potential	  checkpoints	  before	  reaching	  cytolytic	  function	  (Mace	  et	  al.,	  2014).	  These	  steps	  fall	  into	  
three	  distinct	  stages:	  recognition,	  effector	  and	  termination.	  
The	  first	  stage	  in	  immune	  synapse	  formation	  is	  recognition	  of	  the	  target	  cell.	  Receptors	  and	  adhesion	  
molecules	  (such	  as	  LFA-­‐1)	  are	  engaged	  on	  the	  NK	  cell	  and	  these	  proteins	  laterally	  translocate	  to	  (and	  
accumulate	  at)	  the	  immune	  synapse.	  This	  is	  followed	  by	  receptor	  organisation.	  Protein	  microclusters	  
have	   been	   observed	   in	   NK	   cells	   and	   these	   were	   initially	   considered	   to	   be	   a	   basic	   unit	   of	   signal	  





transduction	   (Abeyweera	   et	   al.,	   2011;	   Liu	   et	   al.,	   2009).	   Classically,	   upon	   receptor	   ligation,	   the	  
microclusters	   were	   thought	   to	   segregate	   into	   a	   peripheral	   supramolecular	   activation	   complex	  
(pSMAC)	  containing	  adhesion	  molecules	  and	  a	  central	  SMAC	  (cSMAC)	  containing	  activating	  receptors	  
(Vyas	  et	  al.,	  2001;	  Vyas	  et	  al.,	  2002).	  NKG2D	  has	  been	  shown	  to	  form	  discrete	  microclusters	  at	  the	  
periphery	  of	  the	   immune	  synapse	  which	  traffic	  centripetally	  after	  NKG2D	  engagement	  (Abeyweera	  
et	  al.,	  2011;	  Liu	  et	  al.,	  2009).	  However,	  instead	  of	  fusing	  into	  a	  central	  cSMAC,	  NKG2D	  microclusters	  
assembled	   into	   a	   ring-­‐shaped	   structure	   surrounding	   a	   central	   domain	   where	   lytic	   granules	   dock	  
(Brown	  et	  al.,	  2011).	  In	  addition,	  formation	  of	  both	  NKG2D	  microclusters	  and	  CD16	  microclusters	  are	  
dependent	  on	  actin	  polymerisation	  (Abeyweera	  et	  al.,	  2011;	  Liu	  et	  al.,	  2012).	  However,	  how	  protein	  
microclusters	   link	  with	  the	  actin	  cytoskeleton	  is	  currently	  unknown.	  What	  is	  clear,	  however,	   is	  that	  
receptor	   clustering	   is	   vital	   for	   robust	   signalling	  within	   the	  NK	   cell	   after	   activation	   (Giurisato	  et	   al.,	  
2007).	  
In	   addition,	   during	   this	   initial	   synapse	   rearrangement,	   lytic	   granules	   rapidly	   polarise	   to	   the	  MTOC	  
(Mentlik	  et	  al.,	  2010).	  This	  phenomenon	  is	  independent	  of	  actin	  and	  microtubule	  reorganisation,	  and	  
is	  considered	  to	  be	  a	  priming	  step	  to	  ready	  the	  cell	  for	  potential	  degranulation	  (Mentlik	  et	  al.,	  2010).	  
	  
Figure	   1.6	   –	   Activating	   NK	   cell	   immune	   synapse.	  Activating	   receptors	   and	   their	   ligands	   accumulate	   at	   the	  
synapse,	   whereas	   inhibitory	   receptors	   and	   MHC	   class	   I	   molecules	   do	   not.	   F-­‐actin	   also	   accumulates	   at	   the	  
synapse	  at	  the	  MTOC	  and	  associated	  lytic	  granules	  polarise	  to	  the	  intercellular	  contact	  point.	  	  





After	  NK	  cell	  activating	  receptors	  have	  been	  ligated,	  downstream	  signalling	  molecules	  are	  recruited	  
to	  the	  immune	  synapse,	  such	  as	  LAT,	  ZAP-­‐70,	  PLC-­‐γ	  and	  Vav-­‐1	  (depending	  on	  the	  activating	  receptor	  
involved)	  and	  this	   triggers	  polymerisation	  and	  reorganisation	  of	  F-­‐actin.	  This	   rearrangement	  of	   the	  
actin	  cytoskeleton	  has	  been	  shown	  to	  be	  vital	  for	  the	  end	  effector	  function,	  as	  the	  presence	  of	  actin	  
inhibitors	   results	   in	   less	  actin	  accumulation	  and	   impaired	  NK	  cell	   cytotoxicity	   (Orange	  et	  al.,	  2002;	  
Orange	  et	  al.,	  2003).	  Rearrangements	  of	  the	  actin	  cytoskeleton	  is	  also	  important	  for	  the	  recruitment	  
and	   organisation	   of	   activating	   receptors	   at	   the	   NK	   cell	   synapse	   (Orange	   et	   al.,	   2003).	   Sustained	  
receptor	   signalling	   leads	   to	   the	   polarisation	   of	   the	  MTOC	   to	   the	   synapse,	   together	   with	   the	   lytic	  
granules	   that	   remain	   clustered	   around	   the	   structure	   as	   it	  moves	   (Vyas	   et	   al.,	   2001;	  Orange	  et	   al.,	  
2003;	   Stinchcombe	   et	   al.,	   2006;	   Banerjee	   et	   al.,	   2007;	  Mentlik	   et	   al.,	   2010)(Figure	   1.6).	   Once	   the	  
MTOC	  has	  docked	  at	  the	  synapse	  lytic	  granules	  move	  to	  the	  site	  of	  secretion.	  The	  whole	  polarisation	  
process,	   from	   lytic	   granule	   convergence	   to	   the	   MTOC	   all	   the	   way	   to	   lytic	   granule	   exocytosis,	   is	  
heavily	   reliant	   on	   the	   actin	   and	   microtubule	   cytoskeleton	   and	   associated	   proteins	   (reviewed	   in	  
Lagrue	  et	  al.,	  2013).	  	  
The	   final	   step	   in	   lytic	   granule	   exocytosis	   involves	   the	   granules	   penetrating	   the	   actin	   meshwork.	  
Recent	  studies	  using	  super-­‐resolution	  microscopy	  techniques	  have	  shown	  that	  the	  actin	  meshwork	  
opens	   up	   in	   specific	   regions	   across	   the	   NK	   cell	   synapse,	   creating	   regions	   large	   enough	   for	   lytic	  
granules	  to	  traverse	  (Brown	  et	  al.,	  2011;	  Rak	  et	  al.,	  2011;	  Brown	  et	  al.,	  2012).	  This	  will	  be	  explained	  
in	  more	  detail	  at	  the	  beginning	  of	  Chapter	  4.	  	  
	  
The	  inhibitory	  NK	  cell	  synapse	  
Resting	  NK	  cells	  contains	  pre-­‐formed	  stores	  of	  lytic	  granules	  so	  that	  they	  are	  armed	  to	  kill	  target	  cells	  
at	  all	  times.	  The	  role	  of	  the	  inhibitory	  synapse	  is	  therefore	  to	  prevent	  the	  lysis	  of	  the	  target	  cell	  with	  
which	  the	  NK	  cell	   is	   in	  contact.	  After	   inhibitory	  receptors	  have	  been	  engaged	  the	  receptors	  rapidly	  
cluster	  at	  the	  intercellular	  contact.	  Unlike	  the	  process	  for	  activating	  synapses,	  this	  process	  does	  not	  
require	  engagement	  of	  adhesion	  molecules	  or	  downstream	  signalling	  (Fassett	  et	  al.,	  2001;	  Faure	  et	  
al.,	   2003).	   It	   is	   also	  not	  dependent	  on	  any	  ATP-­‐driven	  process,	   such	  as	   reorganisation	  of	   the	  actin	  
cytoskeleton	  (Davis	  et	  al.,	  1999;	  Standeven	  et	  al.,	  2004;	  Almeida	  &	  Davis,	  2006).	  Instead	  it	  is	  thought	  
to	  be	  driven	  by	  thermodynamic	  processes	  (Davis	  et	  al.,	  1999;	  Vyas	  et	  al.,	  2002;	  Fassett	  et	  al.,	  2001;	  
Faure	  et	  al.,	  2003;	  Almeida	  &	  Davis,	  2006).	  	  The	  inhibitory	  synapse	  differs	  in	  terms	  of	  organisation	  in	  
that	  it	  excludes	  lipid	  raft	  membrane	  domains	  (Lou	  et	  al.,	  2000;	  Fassett	  et	  al.,	  2001;	  Sanni	  et	  al.,	  2004;	  
Vyas	  et	  al.,	  2004),	  does	  not	  include	  large	  amounts	  of	  polymerised	  F-­‐actin	  (McCann	  et	  al.,	  2003)	  and	  





contains	   inhibitory	   phosphatases	   such	   as	   SHP1	   (Vyas	   et	   al.,	   2001;	   Vyas	   et	   al.,	   2002;	   Faure	   et	   al.,	  
2003;	   Vyas	   et	   al.,	   2004)(Figure	   1.7).	   The	   spatial	   organisation	   of	   SHP-­‐1	   between	   cytolytic	   and	  
inhibitory	  synapses	  is	  very	  different;	  SHP-­‐1	  clusters	  in	  the	  periphery	  of	  activating	  synapses	  within	  the	  
first	  minute	  of	  conjugation	  whereas	  it	  clusters	  in	  the	  centre	  of	  inhibitory	  synapses	  (Vyas	  et	  al.,	  2002).	  
	  
Figure	  1.7	  –	  Inhibitory	  NK	  cell	  immune	  synapse.	  Inhibitory	  receptors	  and	  MHC	  class	  I	  molecules	  accumulate	  at	  
the	  inhibitory	  synapse.	  F-­‐actin	  does	  not	  accumulate	  at	  the	  synapse	  and	  the	  MTOC	  does	  not	  polarise.	  
	  
SHP-­‐1	   has	   been	   shown	   to	   dephosphorylate	   key	   components	   in	   the	   activatory	   signalling	   pathway,	  
such	  as	  Vav1	  (Stebbins	  et	  al.,	  2003).	  Local	  dephosphorylation	  events	  such	  as	  this	  are	  responsible	  for	  
inhibiting	   NK	   cell	   activation	   at	   specific	   intercellular	   contacts.	   One	   example	   of	   local	   inhibitory	  
signalling	   events	   is	   that	   of	   KIR2DL1	   (a	  member	  of	   the	  KIR	   family),	  which	  has	  been	   shown	   to	   form	  
microclusters	  within	   the	   inhibitory	   synapse	   (Oddos	  et	  al.,	  2008).	  However,	  only	  a	   small	   fraction	  of	  
KIR2DL1	   microclusters	   become	   phosphorylated	   and	   this	   is	   restricted	   to	   discrete	   microdomains	  
within	  the	  inhibitory	  synapse	  (Treanor	  et	  al.,	  2006).	  This	  would	  result	  in	  the	  local	  dephosphorylation	  
of	  activating	  signalling	  molecules	  but	  would	  not	  interfere	  with	  activating	  signalling	  elsewhere	  in	  the	  
cell.	  
	  





1.6.5 Distinct	  thresholds	  for	  NK	  cell	  activation	  
	  
The	  balance	  between	   activating	   and	   inhibitory	   signalling	   at	   the	  NK	   cell	   synapse	   results	   in	   the	   end	  
outcome	  being	  determined	  by	  the	  amount	  of	  each	  type	  of	  signalling	  that	  occurs	  at	  each	  intercellular	  
contact.	   This	   leads	   to	   distinct	   thresholds	   for	   NK	   cell	   activation.	   Previous	   studies	   have	   shown	   that	  
there	  is	  a	  threshold	  concentration	  of	  MICA	  needed	  to	  trigger	  a	  ‘stop’	  signal	  in	  migrating	  NK	  cells,	  and	  
to	   form	   a	   symmetrical	   synapse	   characterised	   by	   a	   dense	   ring	   of	   F-­‐actin	   at	   the	   synapse	   periphery	  
(Culley	   et	   al.,	   2009;	   Gruda	   et	   al.,	   2012).	   	   Functionally,	   a	   threshold	   concentration	   of	  MICA	   is	   also	  
required	  for	  NKG2D-­‐mediated	  cytolysis	  of	  target	  cells	  (Chauveau	  et	  al.,	  2010).	  A	  similar	  threshold	  for	  
activation	  has	  been	  observed	  for	  activation	  through	  CD16	  ligation,	  where	  a	  certain	  concentration	  of	  
anti-­‐CD16	  antibody	  was	  needed	  to	  stimulate	  the	  cells	   to	  form	  rings	  of	  F-­‐actin	   (Gruda	  et	  al.,	  2012).	  
This	  means	  that	  a	  specific	  amount	  of	  activating	  ligand	  is	  required	  in	  order	  to	  overcome	  the	  inhibitory	  
signals	  from	  the	  target	  cell.	  
In	   a	   similar	   manner,	   a	   threshold	   concentration	   of	   MHC	   molecules	   is	   required	   in	   order	   to	   block	  
activatory	   signals,	   creating	   a	   threshold	   for	   inhibition	   (Almeida	   &	   Davis,	   2006).	   Almeida	   and	   Davis	  
observed	   that	   above	   a	   specific	   concentration	   of	   cell	   surface	   MHC	   Class	   I	   proteins,	   there	   was	   a	  
dramatic	  reduction	  in	  NK	  cell-­‐mediated	  target	  cell	  lysis	  (Almeida	  &	  Davis,	  2006).	  	  
The	  presence	  of	   these	   thresholds	  paints	  an	   interesting	  picture	  of	  what	   is	  happening	  at	   the	  NK	  cell	  
synapse.	  It	   is	  clear	  that	  the	  strength	  of	  the	  signal	  from	  inhibitory	  and	  activating	  receptors	  is	  crucial	  
for	  determining	  the	  end	  outcome.	  However,	  the	  signalling	  molecules	  for	  the	  two	  different	  types	  of	  
receptors	   would	   need	   to	   be	   close	   together	   in	   order	   for	   phosphorylation	   and	   dephosphorylation	  
events	   to	   compete	   in	   the	   way	   that	   has	   been	   described	   in	   previous	   studies	   (Vyas	   et	   al.,	   2002).	  
Understanding	  the	  nanoscale	  organisation	  of	   receptors	  and	  their	  associated	  signalling	  molecules	   is	  
therefore	  crucial	  in	  order	  to	  further	  elucidate	  the	  way	  in	  which	  activating	  and	  inhibitory	  signals	  are	  
integrated.	  	  
	  
1.6.6 A	  nanoscale	  view	  of	  the	  immune	  synapse	  
	  
The	  advent	  of	  super-­‐resolution	  microscopy	  techniques	  has	  allowed	  the	  immune	  synapse	  in	  NK	  cells	  
and	   T	   cells	   to	   be	   imaged	   at	   an	   unprecedented	   resolution.	   This	   has	   led	   to	   some	   interesting	  





observations	   about	   the	   organisation	  of	   receptors	   in	   resting	   and	   activating	   cells.	   For	   example,	   in	   T	  
cells,	   TCR	   and	   LAT	   have	   been	   shown	   to	   be	   pre-­‐clustered	   in	   nanometre-­‐scale	   domains	   in	   the	  
membrane	  of	  resting	  T	  cells	  (Lillemeier	  et	  al.,	  2010;	  Sherman	  et	  al.,	  2011).	  In	  a	  similar	  way	  the	  first	  
evidence	  has	  recently	  emerged	  that	  NK	  cell	  receptors	  are	  organised	  into	  nanometre-­‐scale	  clusters	  at	  
the	   surface	   of	   cells	   (Pageon	   et	   al.,	   2013).	   Specifically,	   Pageon	   and	   colleagues	   showed	   that	   the	  
inhibitory	  receptor	  KIR2DL1	  forms	  clusters	  in	  the	  membrane	  of	  resting	  NK	  cells	  (Pageon	  et	  al.,	  2013).	  
Interestingly	   the	   authors	   showed	   that	   ligation	   of	   the	   NKG2D	   changed	   the	   nanometre-­‐scale	  
organisation	   of	   KIR2DL1,	   resulting	   in	   clusters	   that	  were	   smaller	   and	   denser	   (Pageon	   et	   al.,	   2013).	  
These	  changes	  in	  the	  nanoclusters	  were	  abolished	  when	  the	  actin	  cytoskeleton	  was	  disrupted	  with	  
drugs,	  suggesting	  a	  key	  role	  for	  the	  cytoskeleton	  in	  signalling-­‐induced	  nanocluster	  re-­‐arrangements	  
at	  the	  NK	  cell	  synapse	  (Pageon	  et	  al.,	  2013).	  	  
One	   example	   of	   the	   importance	   of	   actin-­‐controlled	   receptor	   clustering	  was	   shown	   by	  Guia	   et	   al.,	  
who	  compared	  the	  nanoscale	  organisation	  of	   inhibitory	  and	  activating	  receptors	  in	  hyporesponsive	  
(less	   active)	  NK	   cells	   compared	   to	   ‘educated’	  NK	   cells	   (Guia	  et	   al.,	   2011).	  Hyporesponsive	  NK	   cells	  
lack	   inhibitory	   receptors	   specific	   to	   self-­‐MHC	   class	   I	   molecules	   whereas	   ‘educated’	   NK	   cells	   have	  
gained	  detection	  of	   self-­‐MHC	   class	   I	  molecules	   due	   to	   expressing	   appropriate	   inhibitory	   receptors	  
(Kim	  et	  al.,	  2005;	  Anfossi	  et	  al.,	  2006;	  Brodin	  et	  al.,	  2009).	  The	  authors	  determined	  whether	  specific	  
receptors	   are	   confined	   within	   the	   actin	   mesh	   or	   are	   in	   domains	   not	   constrained	   by	   actin,	   and	  
showed	   that	   both	   inhibitory	   and	   activating	   receptors	   were	   confined	   within	   the	   actin	   mesh	   in	  
hyporesponsive	   NK	   cells	   (Guia	   et	   al.,	   2011).	   In	   contrast	   activating	   receptors	   in	   educated	   NK	   cells	  
were	  found	  in	  domains	  not	  confined	  by	  actin	  (Guia	  et	  al.,	  2011).	  It	   is	  possible	  that	  the	  proximity	  of	  
activating	   and	   inhibitory	   receptors	   when	   they	   are	   localised	   together	   in	   the	   same	   meshwork	   is	  
important	  for	  understanding	  why	  these	  hyporesponsive	  NK	  cells	  respond	  less	  well.	  
There	  are	  at	  least	  three	  models	  to	  account	  for	  the	  way	  in	  which	  nanoclustering	  is	  achieved	  and	  for	  
determining	  the	  role	  that	  the	  actin	  cytoskeleton	  has	  to	  play	   in	  this	  assembly.	  These	  models	  are:	  (i)	  
the	  lipid	  raft	  model,	  (ii)	  the	  picket	  fence	  model	  and	  (iii)	  the	  protein	  island	  model	  (Figure	  1.8).	  In	  the	  
lipid	  raft	  model,	  subsets	  of	  proteins	  cluster	  into	  lipid	  rafts,	  which	  are	  domains	  within	  the	  membrane	  
that	  are	  cholesterol	  rich	  (Simons	  &	  Ikonen,	  1997;	  Simons	  &	  Sampaio,	  2011).	  Lipid	  raft	  dynamics	  are	  
dependent	  on	   the	  actin	   cytoskeleton	   (Jordan	  &	  Rodgers,	  2003),	   and	   several	  actin-­‐binding	  proteins	  
link	   lipid	   rafts	   to	   the	   cytoskeleton	   (Gupta	   et	   al.,	   2006).	   In	   this	   model,	   receptor	   clustering	   is	  
determined	   by	   whether	   the	   proteins	   exist	   within	   or	   outside	   these	   dynamic	   membrane	  
compartments.	   In	   the	   picket	   fence	   model,	   the	   cortical	   actin	   filaments	   act	   as	   a	   fence	   and	  
transmembrane	  receptors	  act	  as	  pickets	  (Kusumi	  et	  al.,	  2005).	  	  






Figure	  1.8	  –	  Models	   for	  receptor	  clustering	  at	  the	  cell	  surface.	  Schematics	  of	  the	  mechanisms	  by	  which	  the	  
actin	   cytoskeleton	   can	   influence	   the	   nanoscale	   organisation	   of	   proteins	   at	   the	   cell	  membrane.	  Upper	   panel	  
shows	  lipid	  raft	  model,	  where	  specific	  chemical	  features	  of	  the	  membrane	  allow	  subsets	  of	  proteins	  to	  cluster	  
into	   lipid	   rafts,	  which	   are	   rich	   in	   actin,	  whilst	   other	   proteins	   sit	   outside	   these	   structures.	   The	  middle	   panel	  
shows	   the	   picket	   fence	   model,	   which	   suggests	   that	   the	   actin	   mesh	   is	   anchored	   to	   the	   membrane	   by	  
transmembrane	  receptors	  (the	  pickets)	  and	  the	  F-­‐actin	  filaments	  (the	  fences)	  create	  regions	  that	  prevent	  free	  
diffusion	  of	  cell	  surface	  proteins	  (red	  path	  and	  arrow).	  The	  lower	  panel	  shows	  the	  protein	  island	  model,	  where	  
the	  membrane	  proteins	  are	  sorted	  by	  type	  into	  ‘islands’.	  Figure	  from	  Lagrue	  et	  al,	  2013.	  
	  





This	  creates	  small	  domains	  within	  the	  cell	  membrane	  in	  which	  all	  membrane	  components	  reside.	  In	  
this	  model,	  reorganisation	  of	  the	  actin	  cytoskeleton	  would	  then	  directly	  affect	  the	  size	  and	  spacing	  
between	  these	  domains,	  thus	  changing	  receptor	  clustering.	  
The	  final	  model	  suggests	  that	  receptors	  and	  other	  membrane	  proteins	  are	  segregated	  into	  ‘protein	  
islands’	  (Lillemeier	  et	  al.,	  2010).	  These	  protein	  islands	  are	  membrane	  domains	  rich	  in	  cholesterol	  and	  
are	   associated	  with	   the	   actin	   cytoskeleton,	  which	   controls	   their	   distribution	  and	   their	   interactions	  
(Lillemeier	  et	  al.,	  2006;	  Lillemeier	  et	  al.,	  2010).	  	  
More	  research	  must	  be	  done	  to	  determine	  whether	  any	  of	  these	  models	  accurately	  reflect	  the	  way	  
in	  which	   nanoclusters	   assemble	   and	   interact.	   However,	   one	   important	   lesson	   to	   draw	   from	   these	  
models	   is	  the	  potential	   importance	  of	  the	  actin	  cytoskeleton	  in	  controlling	  cluster	  rearrangements.	  
Further	  work	  on	  the	  link	  between	  actin	  and	  receptor	  dynamics	  is	  needed	  to	  better	  understand	  how	  
receptor	  clustering	  influences	  signal	  integration	  at	  the	  NK	  cell	  synapse.	  
	  
1.7 Super-­‐resolution	  microscopy	  
	  
Fluorescence	  microscopy	  is	  now	  an	  important	  and	  widely	  used	  tool	  for	  the	  study	  of	  cellular	  events	  in	  
live	  and	  fixed	  cells.	  Most	  of	  the	  major	  breakthroughs	   in	  the	  study	  of	  the	  dynamics	  and	  function	  of	  
the	  immune	  synapse	  have	  been	  made	  using	  fluorescence	  microscopy.	  The	  need	  to	  visualise	  events	  
with	  a	  greater	  resolution	  has	  driven	  the	  development	  of	  new	  fluorescence	  microscopy	  techniques,	  
which	  have	  the	  power	  to	  take	  our	  knowledge	  and	  understanding	  of	  the	  immune	  synapse	  to	  the	  next	  
level.	  
	  
1.7.1 The	  basic	  principles	  of	  confocal	  microscopy	  
	  
In	  a	  conventional	  wide-­‐field	  fluorescence	  microscope	  the	  entire	  sample	  is	  uniformly	  illuminated	  and	  
all	  the	  excited	  photons	  are	  collected	  at	  the	  same	  time	  to	  create	  an	  image	  from	  the	  localisation	  of	  the	  
fluorophores.	   	   The	   collected	   fluorescence,	   however,	   includes	   a	   substantial	   amount	   of	   background	  
noise	   from	   the	  out-­‐of-­‐focus	  planes	  of	   the	   sample.	   This	   issue	  was	   resolved	  by	   the	  development	  of	  
laser-­‐scanning	  confocal	  microscopy.	  This	  technique	  uses	  point	  illumination	  (a	  focussed	  laser	  source)	  





that	  is	  scanned	  across	  the	  sample,	  and	  the	  fluorescence	  signal	  is	  detected	  using	  a	  pinhole	  in	  front	  of	  
the	   detector.	   The	   combination	   of	   selective	   illumination	   and	   point	   detection	   prevents	   out-­‐of-­‐focus	  
light	  from	  reaching	  the	  detection	  device.	   In	  this	  way	  only	  photons	  emitted	  close	  to	  the	  focal	  plane	  
can	   be	   detected,	   which	   improves	   the	   resolution	   of	   the	   microscope	   compared	   to	   widefield	  
techniques	   (Figure	  1.9).	  This	  method	  allows	   the	   imaging	  of	   thin	  confocal	  planes	  and,	   if	   images	  are	  
collected	  at	  multiple	  confocal	  planes,	  then	  a	  3D	  image	  of	  the	  sample	  can	  be	  reconstructed.	  However,	  
as	  a	  lot	  of	  the	  photons	  from	  the	  sample	  are	  blocked	  by	  the	  pinhole,	  the	  signal	  intensity	  of	  the	  sample	  
is	  decreased.	  This	  means	  that	  the	  detection	  devices	  used	  have	  to	  be	  as	  sensitive	  as	  possible.	  	  
	  
Figure	   1.9	   –	   Schematic	   representation	   of	   a	   fluorescence	   confocal	  microscope.	   The	   excitation	   beam	   (grey)	  
originates	  from	  a	  laser	  source	  and	  is	  focussed	  onto	  the	  sample	  to	  create	  an	  excitation	  spot.	  The	  fluorescence	  
emitted	  by	  this	  spot	  (red)	  is	  collected	  on	  a	  point	  detector	  through	  a	  confocal	  pinhole.	  The	  combination	  of	  point	  
excitation	  and	  point	  detection	  rejects	  signal	  coming	  from	  out-­‐of-­‐focus	  planes	   (green	  and	  blue)	  ensuring	  that	  
only	  light	  from	  the	  focal	  plane	  is	  collected.	  
	  





There	  are	  three	  types	  of	  detectors	  commonly	  used	   in	  confocal	  microscopes:	  photomultiplier	   tubes	  
(PMTs),	  avalanche	  photodiodes	  (APD)	  and	  Hybrid	  detectors	  (HyD),	  which	  are	  a	  combination	  of	  both	  
(Borlinghaus	   et	   al.,	   2012).	   A	   PMT	   detectors	   is	   a	   vacuum	   phototube	   that	   detects	   low	   amounts	   of	  
photons	  and	  converts	  the	  signal	  into	  an	  analogue	  electron	  flow.	  The	  PMT	  then	  multiplies	  the	  current	  
in	  multiple	  stages,	  resulting	  in	  a	  multiplication	  factor	  of	  as	  much	  as	  100	  million	  times.	  The	  electrons	  
are	   then	   collected	   at	   the	   anode.	   Large	   gain	   and	   low	   noise	  make	   PMTs	   an	   attractive	   detector	   for	  
many	   applications	   including	   confocal	  microscopy.	  APD	  detectors	   are	   an	   alternative	   to	   PMTs.	   They	  
are	   so	   called	   because	   they	   use	   a	   method	   of	   amplification	   called	   avalanche	   multiplication,	   which	  
creates	  gain	  by	  multiplying	  electron	  pairs	  in	  electric	  fields	  by	  impact	  ionisation.	  APD	  detectors	  have	  
small	   amounts	   of	   circuitry	   to	   limit	   noise,	   and	   provide	   better	   sensitivity	   at	   red	   wavelengths.	   HyD	  
detectors	  are	  a	  combination	  of	   the	   two	   types	  of	  detectors,	  allowing	  precise	  measurements	  over	  a	  
wide	  dynamic	   range	   (Borlinghaus	  et	   al.,	   2012).	   These	  detectors	  use	  PMT	   technology	   to	   accelerate	  
the	  electrons	  and	  then	  APD	  technology	  to	  amplify	  the	  electron	  signal.	  This	  type	  of	  detector	   is	  now	  
used	  in	  commercially	  available	  microscopes	  and	  is	  considered	  the	  most	  sensitive	  type	  of	  detector	  for	  
use	  in	  microscopes.	  
	  
Optical	  resolution	  and	  the	  diffraction	  barrier	  
The	  current	   limited	  optical	   resolution	  capability	  of	  confocal	  microscopy,	  despite	  being	  a	  significant	  
improvement	   over	   previous	   imaging	   techniques,	   is	   a	   significant	   constraint	   for	   biologists	   who	   are	  
trying	   to	   observe	   the	   intracellular	   environment.	   Optical	   resolution	   is	   defined	   as	   the	   minimum	  
distance	  between	  two	  fluorophores	  where	   they	  can	  still	  be	  discriminated	  as	   two	  separate	  objects.	  
The	  lower	  limit	  in	  confocal	  microscopy	  is	  approximately	  200	  nm.	  This	  resolution	  is	  dependent	  on	  the	  
signal-­‐to-­‐noise	   ratio	   (SNR)	  and	   the	  point	   spread	   function	   (PSF)	  of	   the	  microscope.	  The	  SNR,	  as	   the	  
name	  suggests,	  is	  the	  ratio	  at	  which	  the	  signal	  strength	  from	  the	  sample	  can	  be	  measured	  over	  the	  
‘noise’	   (the	   background	   level	   of	   fluorescence).	   This	   ratio	   can	   be	   affected	   by	   the	   brightness	   of	   the	  
fluorophore,	   the	  density	  of	  molecules	   that	   are	  being	   imaged	  and	   the	   specificity	  of	   staining.	   These	  
variations	  mean	   that	   the	  SNR	  can	  vary	  between	  different	   samples	  and	  acquisitions.	  The	  PSF	   is	   the	  
smallest	  representation	  of	  a	  single	  object	  that	  the	  imaging	  system	  can	  form	  and	  it	  is	  determined	  by	  
the	  microscope	  itself.	   If	  there	  is	  sufficient	  overlap	  of	  the	  PSFs	  of	  two	  fluorophores,	  the	  microscope	  
will	  be	  unable	  to	  distinguish	  them	  as	  separate	  objects.	  This	  is	  known	  as	  the	  diffraction	  limit	  of	  optical	  
microscopy,	  as	  it	  caused	  by	  the	  diffraction	  of	  light	  as	  it	  travels	  through	  the	  physical	  environment	  of	  
the	   sample.	   This	   is	   an	   important	  barrier,	  which	   limits	   the	   resolution	  of	   a	   fluorescence	  microscope	  
and	   has	   significantly	   restricted	   the	   level	   of	   detail	   that	   can	   be	   observed	   in	   cellular	   structures.	  	  





However,	   the	  development	  of	  new	   imaging	  techniques	  has	  broken	  through	  this	  diffraction	  barrier,	  
using	  various	  approaches,	  and	  the	  resolution	  that	  can	  be	  achieved	  has	  significantly	  improved.	  
	  
1.7.2 Resolution	  improvement	  with	  Total	  Internal	  Reflection	  Fluorescence	  Microscopy	  
	  
Total	   internal	   reflection	   fluorescence	   (TIRF)	  microscopy	   is	  based	  on	  classical	  widefield	  microscopy;	  
fluorophores	  are	   selectively	  excited	  near	   the	   coverslip	   (and	   therefore	  near	   the	   cell	   surface)	  whilst	  
fluorescence	  emanating	  from	  deeper	  inside	  the	  cell	  is	  minimised	  (Axelrod,	  1981;	  Axelrod,	  2001).	  TIRF	  
microscopy	   is	   achieved	   by	   utilising	   the	   critical	   angle	   of	   light,	   which	   results	   in	   all	   the	   light	   being	  
reflected	   at	   the	   coverslip-­‐sample	   interface.	   This	   creates	   an	   evanescent	   wave	   (a	   near	   field	   wave	  
which	  decays	  exponentially),	  which	  is	  only	  able	  to	  penetrate	  approximately	  100	  nm	  into	  the	  sample	  
(Figure	   1.10).	   Only	   fluorophores	   that	   are	   within	   this	   wave	   become	   excited	   resulting	   in	   less	  
background	   fluorescence.	   This	   technique	   also	   provides	   better	   sectioning	   depth	   than	   a	   confocal	  
microscope.	  To	  achieve	  optimal	  TIRF,	  all	  the	  light	  should	  reach	  the	  interface	  at	  a	  uniform	  angle.	  This	  
requires	   careful	   focusing	   of	   the	   laser	   beam	   for	   each	   sample,	   as	   the	   critical	   angle	   will	   change	  
depending	  on	  the	  refractive	  index	  of	  the	  sample.	  
TIRF	   microscopy	   works	   well	   with	   both	   fixed	   and	   live	   cell	   samples.	   It	   allows	   the	   imaging	   of	  
membrane-­‐proximal	   events	   at	   an	   improved	   resolution	   whilst	   removing	   interference	   from	  
fluorescence	  within	  the	  cell.	  Examples	  of	  ways	  in	  which	  it	  has	  been	  used	  in	  biological	  studies	  include	  
investigating	  microtubule	  dynamics	  (Schmoranzer	  &	  Simon,	  2003;	  Krylyshkina	  et	  al.,	  2003;	  Grigoriev	  
&	  Akhmanova,	  2010),	  actin	  dynamics	  (Kuhn	  &	  Pollard,	  2005;	  Breitsprecher	  et	  al.,	  2009),	  endocytosis	  
(Rappoport,	  2008;	  Julliė	  et	  al.,	  2011),	  exocytosis	  (Schmoranzer	  et	  al.,	  2000;	  Allersma	  et	  al.,	  2006)	  and	  
membrane-­‐proximal	  signalling	  (Haugh	  et	  al.,	  2000;	  Dyachok	  et	  al.,	  2006;	  Purbhoo	  et	  al.,	  2010).	  	  
Thus	   it	   can	   be	   seen	   that	   TIRF	   microscopy	   is	   a	   powerful	   tool	   for	   imaging	   membrane-­‐proximal	  
structures	  and	  events	  and	  has	  been	  utilised	   for	   the	  study	  of	   the	  dynamics	  of	   the	   immune	  synapse	  
(Purbhoo	  et	  al.,	  2010).	  TIRF	  has	  also	  been	  used	  for	  super-­‐resolution	  imaging,	  which	  will	  be	  described	  
in	  detail	  below.	  
	  






Figure	  1.10	  –	  Schematic	  representation	  of	  TIRF	  illumination.	  The	  excitation	  beam	  travels	  from	  the	  left	  at	  an	  
incidence	  angle,	  which	  is	  greater	  than	  the	  critical	  angle	  (dashed	  line).	  The	  excitation	  beam	  is	  reflected	  off	  the	  
coverslip-­‐sample	   interface,	   generating	   an	   evanescent	  wave	   of	   the	   opposite	   side	   of	   the	   interface	  within	   the	  
sample.	  Only	  fluorophores	  than	  are	  within	  the	  evanescent	  field	  are	  excited	  (as	  indicated	  in	  green).	  	  
	  
1.7.3 Super-­‐resolution	  imaging	  techniques	  
	  
Developments	   in	   super-­‐resolution	   fluorescence	   microscopy	   techniques	   have	   broken	   through	   the	  
diffraction	  barrier	  using	  different	  approaches.	  These	  techniques	  can	  be,	  broadly	  speaking,	  grouped	  
into	   two	   main	   classes:	   ensemble	   techniques	   (where	   the	   improvement	   in	   resolution	   comes	   from	  
minimising	   the	  size	  of	   the	  PSF	  during	   image	  acquisition)	  and	  single-­‐particle	   localisation	   techniques	  










Ensemble	  super-­‐resolution	  microscopy	  techniques	  improve	  the	  resolution	  of	  images	  by	  reducing	  the	  
size	  of	   the	  PSF	   as	   the	   images	   are	  being	   acquired,	   resulting	   in	   end	   images	  with	   increased	   levels	   of	  
detail.	  Two	  of	  the	  main	  ensemble	  techniques	  used	  are	  Structured	  illumination	  microscopy	  (SIM)	  and	  
Stimulated	  emission	  depletion	  (STED)	  microscopy.	  	  
SIM	  uses	   full-­‐field	   illumination	  of	   the	   sample,	  with	  patterned	   lines	  of	   light	   that	  are	   translated	  and	  
rotated,	   generating	   a	   series	   of	   images	   with	   high	   spatial	   frequency	   information.	   By	   imaging	   the	  
sample	   with	   structured	   light	   patterns	   in	   different	   orientations,	   the	   images	   can	   be	   combined	   and	  
reconstructed	  using	  computer	  algorithms	  to	  obtain	  a	  high-­‐resolution	   image.	  The	  pattern	  of	   light	   is	  
made	   by	   passing	   the	   laser	   beam	   through	   optical	   grating	   before	   projecting	   it	   onto	   the	   image	  
(Heintzmann	  &	  Cremer,	  1999;	  Gustafsson,	  2000;	  Gustafsson,	  2005).	  Theoretically	  this	  approach	  can	  
result	  in	  a	  two-­‐fold	  improvement	  in	  lateral	  resolution	  (Gustafsson,	  2000).	  	  
SIM	  uses	  standard	  dyes	  and	  staining	  protocols,	  provided	  the	  dyes	  are	  sufficiently	  photostable,	  which	  
makes	   it	   an	   attractive	   choice	   for	   cell	   biology	   applications.	   SIM	   has	   been	   used	   in	   many	   studies,	  
including	   an	   investigation	   of	   the	  way	   in	  which	   the	   actin	   cytoskeletal	  mesh	   underlying	   the	  NK	   cell	  
synapse	   is	   remodelled	   to	   allow	   the	   passage	   of	   lytic	   granules	   into	   the	   synaptic	   cleft	   (Brown	   et	   al.,	  
2011).	  It	  has	  also	  been	  used	  to	  observe	  mitochondria,	  tubulin	  filaments	  and	  kinesin	  dynamics	  in	  live	  
cells	  (Hirvonen	  et	  al.,	  2009;	  Kner	  et	  al.,	  2009).	  	  
In	   STED	  microscopy	   the	   PSF	   is	  manipulated	   using	   a	   different	   approach,	   involving	   de-­‐excitation	   of	  
previously	  excited	  fluorophores.	  	  The	  sample	  is	  illuminated	  with	  a	  laser	  at	  a	  focal	  spot,	  in	  the	  same	  
way	  as	  in	  confocal	  microscopy,	  but	  this	  focal	  spot	  is	  surrounded	  by	  a	  doughnut-­‐shaped	  beam	  formed	  
by	  a	  laser	  of	  a	  longer	  wavelength	  (called	  the	  STED	  beam).	  This	  doughnut-­‐shaped	  beam	  depletes	  the	  
fluorophores	  surrounding	  the	  central	  part	  of	  the	  focal	  spot	  back	  to	  the	  ground	  state.	  This	  results	  in	  
only	  the	  fluorescence	  from	  the	  central	  region	  being	  detected.	  This	  focal	  spot	   is	  scanned	  across	  the	  
sample	  resulting	  in	  a	  super-­‐resolution	  sub-­‐diffraction	  image	  being	  generated.	  Stefan	  Hell,	  who	  first	  
developed	   and	   successfully	   implemented	   the	   technique,	   reported	   that	   a	   resolution	   of	   30-­‐80	   nm	  
could	  be	  achieved	  using	  this	  approach	  (Hell	  &	  Wichmann,	  1994;	  Dyba	  &	  Hell,	  2002).	  	  
One	   key	   consideration	   when	   designing	   a	   STED	   microscopy	   experiment	   is	   the	   choice	   of	   dye;	   the	  
wavelength	  of	  the	  depletion	  laser	  cannot	  overlap	  with	  the	  excitation	  range	  of	  the	  dye	  otherwise	  the	  
whole	  sample	  will	  be	  bleached.	  Examples	  of	  studies	  that	  have	  successfully	  applied	  STED	  microscopy	  
include	  an	  observation	  of	  the	  distribution	  of	  proteins	  at	  neuronal	  synapses	  (Willig	  et	  al.,	  2006)	  and	  
additional	  studies	  on	  the	  actin	  mesh	  in	  NK	  cells	  (Rak	  et	  al.,	  2011;	  Mace	  &	  Orange,	  2012).	  





Single	  particle	  localisation	  techniques	  
A	   radically	   different	   approach	   to	   improving	   the	   resolution	   of	   an	   image	   is	   to	   localise	   single	  
fluorophores	   and	   then	   reconstruct	   a	   super-­‐resolution	   image	   from	   multiple	   frames.	   This	   is	   the	  
method	   used	   in	   single-­‐molecule	   localisation	   microscopy.	   Two	   different	   techniques	   that	   use	   this	  
approach	   are	   photoactivated	   localisation	  microscopy	   (PALM)	   and	   stochastic	   optical	   reconstruction	  
microscopy	  (STORM).	  Both	  techniques	  were	  developed	  using	  the	  concept	  that	  a	  single	  fluorophore	  
could	  be	  precisely	  localised	  by	  calculating	  the	  centroid	  of	  the	  PSF,	  as	  long	  as	  it	  is	  isolated	  at	  the	  time	  
of	  detection.	  In	  order	  to	  excite	  fluorophores	  in	  isolation	  the	  image	  is	   illuminated	  with	  a	  low	  power	  
laser.	  This	  results	  in	  fluorophores	  being	  activated	  stochastically,	  meaning	  that	  only	  a	  selection	  of	  all	  
fluorophores	   in	  a	  given	  image	  are	  excited	  in	  each	  frame.	  These	  fluorophores	  are	   imaged	  until	  they	  
are	   bleached	   and	   the	   cycle	   is	   repeated	   as	   more	   and	   more	   frames	   are	   collected.	   Therefore	   by	  
acquiring	  a	  large	  number	  of	  frames,	  and	  then	  localising	  the	  centroid	  of	  the	  PSF	  of	  each	  fluorescent	  
spot	  detected	  within	  each	  frame,	  a	  full	  super-­‐resolution	  image	  can	  be	  reconstructed.	  So	  rather	  than	  
altering	  the	  PSF	  during	  acquisition,	  as	  in	  STED	  microscopy,	  these	  techniques	  achieve	  sub-­‐diffraction	  
level	  resolution	  by	  extensive	  post-­‐acquisition	  image	  processing.	  	  
PALM	   and	   STORM	   differ	   in	   their	   use	   of	   fluorophores.	   PALM	   uses	   photoswitchable	   and	  
photoactivatable	  fluorescent	  proteins.	  In	  the	  case	  of	  both	  of	  these	  types	  of	  fluorophores	  exposure	  to	  
a	   specific	   wavelength	   causes	   the	   fluorophore	   to	   alter	   its	   emission	   spectra,	   either	   from	   a	   non-­‐
fluorescent	   to	   fluorescent	   state	   (photoactivatable)	   or	   from	   one	   fluorescent	   state	   to	   another	  
(photoswitchable).	   The	  advantage	  of	   this	   technique	   is	   that	   the	   fluorophores	   can	  be	   tagged	  onto	  a	  
protein	  of	  interest,	  resulting	  in	  high	  specificity,	  and	  is	  compatible	  with	  live	  imaging.	  STORM	  is	  mainly	  
implemented	  using	  photoswitchable	  fluorescent	  dyes	  coupled	  to	  antibodies.	  This	  means	  it	  is	  largely	  
limited	  to	  fixed	  cell	  imaging.	  Direct	  STORM	  (dSTORM)	  is	  a	  variant	  of	  STORM	  that	  uses	  the	  reversible	  
photoswitching	  of	  conventional	  fluorophores	  into	  a	  long-­‐lived	  ‘dark	  state’	  (an	  energy	  level	  where	  the	  
molecule	   cannot	   emit	   photons).	   This	   allows	   the	   technique	   to	   use	   readily	   available	   dyes	   such	   as	  
AlexaFluor488	   and	   647,	   which	   makes	   experiment	   design	   easier.	   Although	   there	   is	   likely	   to	   be	   a	  
higher	  amount	  of	  background	  fluorescence	  due	  to	  free	  dye	  or	  non-­‐specific	  staining.	  	  
There	   are	  multiple	   examples	   of	   studies	   that	   have	   successfully	   used	   PALM	   and	   STORM	   imaging	   to	  
reveal	   new	   aspects	   cellular	   function	   at	   an	   unprecedented	   resolution.	   These	   include	   a	   number	   of	  
studies	   focusing	   on	   the	   immune	   synapse.	   For	   example,	   PALM	   has	   been	   used	   to	   study	   protein	  
microclusters	  at	   the	  T	  cell	   synapse	   (Lillemeier	  et	  al.,	  2010;	  Williamson	  et	  al.,	  2011;	  Sherman	  et	  al.,	  
2011).	   The	   results	   showed	   that	   signalling	  molecules	   such	   as	   TCR	   and	   LAT	   co-­‐localised	   during	   the	  
early	  stages	  of	  T	  cell	  activation.	  In	  addition	  recent	  work	  has	  showed,	  for	  the	  first	  time,	  that	  NK	  cell	  





receptors	  pre-­‐exist	   in	  clusters	  at	   the	  NK	  cell	   immune	  synapse	  and	  that	   these	  clusters	  change	  after	  
activating	  receptor	  ligation	  (Pageon	  et	  al.,	  2013).	  
In	  summary	  previous	  studies	  have,	  for	  the	  most	  part,	  used	  TIRF	  microscopy	  to	  image	  events	  at	  the	  
immune	  synapse	  in	  high	  resolution.	  However,	  the	  advent	  of	  super-­‐resolution	  imaging	  techniques	  has	  
shed	  new	  light	  on	  the	  intricacies	  of	  the	  immune	  synapse	  in	  T	  cells	  and	  NK	  cells.	  Not	  only	  has	  super-­‐
resolution	  microscopy	   revealed	   important	   information	  about	   the	  nanoscale	  clustering	  of	   receptors	  
at	   the	   synapse,	  but	   it	  has	  also	  provided	  an	   important	  new	   insight	   into	   the	  way	   in	  which	   the	  actin	  
cytoskeleton	   reorganises	   after	   activating	   receptor	   ligation	   (Brown	   et	   al.,	   2011;	   Rak	   et	   al.,	   2011;	  
Brown	  et	  al.,	  2012).	  This	  has	  provided	  us	  with	  new	  tools	  to	  study	  the	  immune	  synapse,	  and	  to	  probe	  
the	   ways	   in	   which	   exogenous	   compounds	   may	   manipulate	   the	   nanoscale	   organisation	   of	   the	  
synapse.	  For	  example,	   there	   is	  some	  evidence	  that	   lenalidomide	  can	  affect	  actin	  polymerisation	  at	  
the	  T	  cell	  synapse,	  however	  the	  exact	  effect	  of	   lenalidomide	  on	  F-­‐actin	  is	  unknown.	  To	  understand	  
this,	  super-­‐resolution	  microscopy	  techniques	  can	  be	  used	  to	  image	  the	  effect	  of	  lenalidomide	  on	  F-­‐




The	   immunomodulatory	   drug	   lenalidomide	   has	   the	   potential	   to	   be	   clinically	   useful	   in	   a	   variety	   of	  
diseases	   due	   to	   its	   ability	   to	   activate	   different	   arms	   of	   the	   immune	   system.	   The	   effect	   of	  
lenalidomide	   on	   T	   cells	   has	   been	  well-­‐studied	   but	   it	   is	   still	   not	   clear	   whether	   lenalidomide	   has	   a	  
direct	  effect	  on	  NK	  cells.	  	  NK	  cells	  exert	  their	  effector	  functions	  following	  the	  formation	  of	  dynamic	  
intercellular	  contacts	  called	  immune	  synapses.	  Recent	  advances	  in	  imaging	  techniques	  have	  revealed	  
that	  the	  dynamics	  of	  the	  actin	  cytoskeleton	  play	  a	  key	  role	  in	  the	  function	  of	  the	  immune	  synapse.	  
The	  nanoscale	  organisation	  of	  the	  synapse	  may	  also	  play	  a	  role	  in	  controlling	  receptor	  clustering,	  and	  
therefore	  the	  way	  in	  which	  signals	  are	  integrated	  at	  the	  synapse	  to	  determine	  the	  end	  outcome	  of	  
the	  intercellular	  contact.	  A	  major	  gap	  in	  current	  knowledge	  exists	  when	  considering	  the	  way	  in	  which	  
lenalidomide	  affects	  NK	  cells	  on	  a	  population	  level	  and	  on	  a	  single	  cell	   level.	  The	  main	  aims	  of	  this	  
thesis	  were	  to	  investigate	  the	  effect	  of	  lenalidomide	  on	  NK	  cell	  effector	  function	  and	  to	  observe	  how	  
lenalidomide	  alters	   the	  actin	   cytoskeleton	  at	   the	  NK	   cell	   activating	   synapse	  using	   super-­‐resolution	  
microscopy.	  
The	  specific	  objectives	  of	  this	  thesis	  were	  as	  follows:	  





• To	   investigate	   the	  effect	  of	   lenalidomide	  on	  NK	  cell	  activation	  and	  effector	   functions,	  on	  a	  
population	  level	  and	  a	  single	  cell	  level	  (Chapter	  3).	  
	  
• To	   image	   the	   nanoscale	   organisation	   of	   cortical	   actin	   during	   NK	   cell	   activation	   after	  
lenalidomide	  treatment	  (Chapter	  4).	  
	  
• To	  assess	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  from	  multiple	  myeloma	  patients	  (Chapter	  5).	  
	  
A	  panel	  of	  techniques	  was	  used	  to	  address	  these	  aims,	  including	  super-­‐resolution	  STED	  microscopy,	  
confocal	  microscopy,	  flow	  cytometry	  and	  other	  assays	  to	  assess	  NK	  cell	  function.	  The	  results	  of	  this	  
study	  are	  discussed	  in	  chapters	  3-­‐5	  of	  this	  thesis,	  and	  significant	  portions	  of	  this	  research	  were	  also	  
published	  in	  Blood	  earlier	  this	  year	  (Lagrue	  et	  al.,	  2015).	  
	  





Chapter	  2	  -­‐ Materials	  and	  Methods	  
	  
2.1 Cells	  and	  cell	  culture	  
	  
2.1.1 Primary	  NK	  cells	  
	  
Peripheral	   blood	   mononuclear	   cells	   (PBMCs)	   from	   normal	   healthy	   donors	   were	   obtained	   by	  
separation	   on	   a	   Ficoll-­‐paque	   gradient.	   Primary	   NK	   cells	   were	   isolated	   from	   PBMCs	   by	   negative	  
selection	   using	   an	  NK	   cell	   isolation	   kit	   (Miltenyi	   Biotec,	   Bergisch	  Gladbach,	  Germany).	   Primary	  NK	  
cells	  were	  maintained	  in	  DMEM	  (GIBCO),	  supplemented	  with	  10%	  human	  serum,	  2	  mM	  L-­‐glutamine,	  
1	  mM	   sodium	   pyruvate,	   1	  mM	   penicillin/streptomycin,	   1	  mM	   non-­‐essential	   amino	   acids	   and	   150	  
U/ml	  IL-­‐2	  (Roche).	  Cells	  were	  then	  used	  in	  experiments	  6	  days	  later.	  
NK	  cells	   from	  multiple	  myeloma	  patients	  were	   isolated	  by	  negative	  magnetic	  selection	   from	  40	  ml	  
peripheral	   blood	   taken	   from	   9	   MM	   patients	   (MCRC	   Biobank	   Research	   Tissue	   Bank	   Ethics	   (ref:	  
07/H1003/161+5))	   in	  accordance	  with	   the	  Declaration	  of	  Helsinki.	  NK	  cells	  were	  used	   immediately	  
after	  isolation.	  
	  
2.1.2 Immortalised	  cell	  lines	  
	  
Table	  2.1	  –	  Target	  cell	  lines.	  	  The	  cell	  lines	  listed	  above	  are	  B	  cell	  lines	  used	  as	  target	  cells	  in	  this	  thesis.	  
	  
	  
Various	   immortalised	   B	   cell	   lymphoma	   cell	   lines	   were	   used	   in	   this	   study	   as	   target	   cells	   for	   the	  
Cell	  Line	   Derived	  from	   Source	   References	  
Daudi	   Burkitt’s	  lymphoma	   ATCC	   (Klein	  et	  al.,	  1968)	  
Daudi-­‐CD20-­‐GFP	   Daudi	   Previously	  transfected	  in	  the	  lab	   (Rudnicka	  et	  al.,	  2013)	  
Raji	   Burkitt’s	  lymphoma	   ATCC	   (Epstein	  et	  al.,	  1966;	  Karpova	  et	  al.,	  2005)	  
JeKo	   Mantle	  cell	  lymphoma	   Gift	  from	  Celgene	   (Wu	  et	  al.,	  2008)	  





primary	  NK	  cells	  (Table	  2.1).	  These	  cell	  lines	  were	  maintained	  in	  R10	  culture	  medium,	  which	  consists	  
of	   RPMI-­‐1640	   (Sigma-­‐Aldrich)	   supplemented	   with	   10%	   heat-­‐inactivated	   foetal	   calf	   serum	   (FCS;	  
Gibco),	  2	  mM	  L-­‐glutamine	  (Gibco),	  and	  1	  mM	  penicillin/streptomycin	  (Sigma-­‐Aldrich)	  at	  37°C	  in	  a	  5%	  
CO2	  atmosphere.	  	  	  
	  
2.1.3 Primary	  T	  cells	  
Primary	  human	  T	  cells	  were	   isolated	   from	  PBMCs	  by	  negative	  magnetic	   selection	   (Miltenyi	  Biotec)	  
and	  cultured	  in	  the	  same	  media	  as	  NK	  cells.	  The	  T	  cells	  were	  used	  3	  days	  after	  isolation.	  	  
	  
2.2 Antibodies	  and	  recombinant	  proteins	  
	  
2.2.1 Antibodies	  
Various	  antibodies	  were	  used	   for	   flow	  cytometry,	  ELISA	  and	   imaging	  experiments.	  Flow	  cytometry	  
experiments	  were	  performed	  using	  primary	  antibodies	  directly	  conjugated	  to	  different	  fluorophores	  
and	  isotype	  matched	  controls	  were	  also	  used	  (Table	  2.2).	  
Table	  2.2	  –	  Antibodies	  used	  to	  assess	  protein	  surface	  expression.	   	  The	  antibodies	  listed	  above	  were	  used	  to	  
stain	  the	  surface	  of	  cells	  for	  analysis	  by	  flow	  cytometry,	  as	  described	  in	  section	  2.4.3.	  All	  antibodies	  are	  mouse	  
monoclonal.	  All	  the	  antibodies	  were	  diluted	  in	  FACS	  buffer	  at	  the	  specified	  concentrations.	  
	  
For	   imaging	   experiments	   and	   ELISAs,	   antibodies	   were	   used	   to	   coat	   surfaces	   (glass	   slides	   or	  
polystyrene-­‐coated	  wells,	  respectively)	  to	  ligate	  specific	  proteins	  (Table	  2.3).	  
Antigen	   Clone	   Isotype	   Conjugate	   Source	  
Isotype	  control	   MOPC-­‐21	   IgG1	   AlexaFluor	  647	   BD	  Pharmingen	  
Isotype	  control	   MOPC-­‐21	   IgG1	   PE	   BD	  Pharmingen	  
Isotype	  control	   G18-­‐145	   IgG1	   FITC	   BD	  Pharmingen	  
CD56	   HCD56	   IgG1	   BV421	   Biolegend	  
CD16	   3G8	   IgG1	   AlexaFluor	  647	   Biolegend	  
NKG2D	   1D11	   IgG1	   PE	   BD	  Pharmingen	  
LFA-­‐1	   HI111	   IgG1	   FITC	   BD	  Pharmingen	  
2B4	   C1.7	   IgG1	   PE	   Biolegend	  





Intracellular	  IFN-­‐γ	  was	  detected	  by	  flow	  cytometry	  and	  by	  microscopy	  using	  two	  antibodies:	  anti-­‐IFN-­‐
γ-­‐AlexaFluor488	  and	  anti-­‐IFN-­‐γ-­‐AlexaFluor647	  (BD	  Biosciences,	  Clone	  B27).	  
The	  antibodies	  used	  in	  the	  detection	  of	  IFN-­‐γ	  in	  the	  sandwich	  ELISA	  are	  detailed	  in	  Table	  2.4.	  
Table	  2.3	  –	  Antibodies	  used	  to	  coat	  slides	  for	  microscopy	  and	  ELISAs.	  	  The	  antibodies	  listed	  above	  were	  used	  
to	  coat	  the	  surface	  of	  ELISA	  plates,	  as	  described	  in	  section	  2.4.2,	  or	  Labtek	  slides,	  as	  described	  in	  section	  2.5.	  
All	  antibodies	  are	  mouse	  monoclonal.	  The	  antibodies	  were	  diluted	  in	  PBS	  at	  the	  specified	  concentrations.	  
	  
In	  addition	  to	  these	  antibodies,	  slides	  were	  also	  coated	  with	  the	  humanised	  anti-­‐CD20	  monoclonal	  
antibody	   Rituximab	   (Invivogen),	   which	   is	   known	   to	   stimulate	   NK	   cells	   through	   CD16	   ligation.	  
Rituximab	  was	  used	  at	  1	  µg/ml	  for	  microscopy	  and	  at	  0.0001-­‐100	  µg/ml	  for	  ELISAs.	  
	  
2.2.2 Recombinant	  proteins	  
In	  addition	  to	  antibodies,	  recombinant	  human	  proteins	  were	  used	  to	  ligate	  NK	  cell	  surface	  receptors.	  
These	  proteins	  were	  used	  to	  coat	  surfaces	  for	  ELISA	  and	  imaging	  experiments	  (Table	  2.5).	  
Table	  2.5	  –	  Recombinant	  proteins	  used	  to	  coat	  surfaces	  for	  ELISA	  and	  microscopy	  experiments.	  	  The	  proteins	  
listed	  above	  were	  used	  to	  coat	  the	  surface	  of	  ELISA	  plates,	  as	  described	   in	  section	  2.4.2,	  or	  Labtek	  slides,	  as	  
described	  in	  section	  2.5.	  All	  the	  proteins	  were	  diluted	  in	  PBS	  at	  the	  specified	  concentrations.	  
	  
Antigen	   Clone	   Isotype	   Concentration	   Source	  
Isotype	  control	   MOPC-­‐21	   IgG1k	   1-­‐3	  µg/ml	   BD	  Biosciences	  
CD16	   3G8	   IgG1k	   1	  µg/ml	  (ELISA);	  	  
3	  µg/ml	  (microscopy)	  
BD	  Biosciences	  
NKG2D	   149810	   IgG1k	   3	  µg/ml	   R&D	  Systems	  
2B4	   2-­‐69	   IgG1k	   3	  µg/ml	   BD	  Biosciences	  
Table	  2.4	  –	  Antibodies	  used	  in	  the	  detection	  of	  IFN-­‐γ .	  The	  antibodies	  listed	  above	  were	  used	  to	  detect	  IFN-­‐γ	  
in	   flow	  cytometry	  and	  microscopy	  experiments.	  Both	  antibodies	  are	  monoclonal	  and	  were	  diluted	   in	  PBS	  at	  
the	  specified	  concentrations.	  
Antigen	   Conjugate	   Type	   Clone	   Concentration	   Source	  
IFN-­‐γ	   -­‐	   Capture	   NIB42	   1µg/ml	   BD	  Biosciences	  
IFN-­‐γ	   Biotin	   Detection	   4S.B3	   1µg/ml	   BD	  Biosciences	  
Protein	   Concentration	   Source	  
MICA-­‐Fc	   0.1-­‐10	  µg/ml	   R&D	  Systems	  
ICAM-­‐1	   2.5	  µg/ml	   R&D	  Systems	  	  
Human	  IgG	   1-­‐500	  µg/ml	   Sigma-­‐Aldrich	  





Although	   it	   is	   not	   an	   antibody	   or	   a	   recombinant	   protein,	   phalloidin	   (conjugated	   to	   either	   the	  
fluorescent	   dye	   Atto-­‐590	   or	   Alexa-­‐488)	   were	   used	   to	   stain	   cells	   to	   detect	   filamentous	   actin	   in	  




Lenalidomide	   was	   provided	   by	   Celgene	   Corporation	   in	   powder	   form.	   Lenalidomide	   was	   then	  
dissolved	  in	  DMSO	  and	  aliquoted	  at	  a	  stock	  concentration	  of	  30	  mM.	  Aliquots	  were	  stored	  at	  -­‐80°C	  
and	  each	  aliquot	  was	  used	  within	  7	  days	  of	  thawing.	  	  
To	  treat	  NK	  cells,	  lenalidomide	  was	  diluted	  in	  media	  at	  0.001-­‐10	  µM	  (as	  specified).	  Generally,	  0.87	  µl	  
of	   lenalidomide	   stock	   was	   added	   to	   2.5	   ml	   media	   to	   make	   a	   10	   µM	   solution	   and	   then	   each	  
subsequent	  concentration	  was	  obtained	  by	  1	   in	  10	  serial	  dilutions.	  For	  the	  DMSO	  control	  samples,	  
DMSO	  was	  added	  to	  media	  to	  match	  the	  maximum	  amount	  added	  in	  the	  lenalidomide	  samples:	  0.87	  
µl	  DMSO	  in	  2.5	  ml	  media	   if	  10	  µM	  lenalidomide	   is	  being	  used	   in	  the	  experiment,	  10	  fold	   less	  than	  
that	  if	  the	  maximum	  concentration	  of	  lenalidomide	  being	  used	  is	  1	  µM.	  	  
	  
2.4 Functional	  assays	  
	  
2.4.1 Cytotoxicity	  assay	  
	  
The	  susceptibility	  of	  target	  cells	  to	  NK	  cell	  cytotoxicity	  was	  assessed	  using	  a	  5-­‐hour	  [35S]-­‐methionine	  
release	  assay.	  NK	  cells	  were	  treated	  with	  0.001-­‐10	  µM	  lenalidomide	  or	  DMSO,	  with	  and	  without	  150	  
U/ml	  IL-­‐2	  (Roche)	  and	  plated	  in	  V-­‐bottomed	  96-­‐well	  plates	  (2.5	  x	  105	  cells/well)	  in	  a	  volume	  of	  50	  µl.	  
Target	  cells	  were	  incubated	  overnight	  with	  [35S]-­‐labelled	  methionine.	  Target	  cells	  were	  washed	  three	  
times	  and	  resuspended	  in	  R10	  medium	  at	  a	  final	  concentration	  of	  105	  cells	  per	  ml	  and	  then	  50	  µl	  of	  
target	  cells	  were	  added	  to	  the	  NK	  cells.	  The	  assay	  was	  incubated	  at	  37°C	  for	  5	  hours	  and	  [35S]	  release	  
was	  measured	   in	   a	   scintillation	   counter	   (TopCount	   NXT,	   Perkin	   Elmer).	  Maximal	   [35S]	   release	  was	  
determined	  by	   lysing	  target	  cells	   in	  0.1	  M	  sodium	  hydroxide	   (NaOH)	  and	  spontaneous	  release	  was	  





measured	  by	  incubating	  target	  cells	  in	  medium	  alone.	  Spontaneous	  release	  was	  20%	  of	  the	  maximal	  




2.4.2 Enzyme	  linked	  immunosorbent	  assay	  (ELISA)	  
	  
IFN-­‐γ	  release	  from	  NK	  cells	  was	  assessed	  using	  an	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  NK	  
cells	  were	  treated	  with	  0.001-­‐10	  μM	  lenalidomide	  or	  DMSO	  plus	  150	  U/ml	  human	  recombinant	  IL-­‐2	  
(Roche),	  and	  were	  plated	   in	  antibody-­‐	  or	  protein-­‐coated	  96-­‐well	  V-­‐bottomed	  plates	   in	   triplicate	  at	  
1.5	  x	  105	  cells	  per	  well.	  Cells	  were	  then	  incubated	  at	  37°C	  overnight.	  The	  supernatant	  was	  collected	  
after	   centrifuging	   the	   plates	   for	   10	  minutes	   at	   200g	   and	   samples	   were	   stored	   at	   -­‐20°C	   until	   use.	  
ELISA	  plates	  (Maxisorb,	  NUNC)	  were	  incubated	  overnight	  at	  4°C	  with	  50	  µl/well	  of	  anti-­‐IFN-­‐γ	  capture	  
antibody	   (1	   µg/ml)	   in	   binding	   solution	   (Carbonate	   bicarbonate,	   Sigma).	   Plates	   were	   washed	   with	  
PBS/0.05%	   Tween	   20	   and	   blocked	   with	   blocking	   buffer	   (PBS/1%	   BSA/0.05%	   Tween	   20).	   Samples	  
were	   diluted	   in	   blocking	   buffer	   and	   purified	   human	   IFN-­‐γ	   (R&D	   systems)	   was	   serially	   diluted	   in	  
blocking	  buffer	  to	  determine	  a	  standard	  curve.	  Standards	  and	  samples	  were	  plated	  in	  triplicate	  and	  
incubated	   at	   room	   temperature	   for	   1	   hour.	   After	  washing,	   plates	  were	   incubated	  with	   50	   µl/well	  
biotinylated	   anti-­‐IFN-­‐γ	   detection	   antibody	   (1	   µg/ml)	   for	   1	   hour	   at	   room	   temperature.	   Plates	  were	  
then	   washed	   and	   incubated	   for	   30	   minutes	   with	   50	   µl/well	   streptavidin-­‐HRP	   diluted	   in	   blocking	  
buffer.	   Plates	   were	   then	   washed	   again	   and	   50	   µl/well	   TMB	   ELISA	   substrate	   (Sigma-­‐Aldrich)	   was	  
added.	  The	  reaction	  was	  halted	  after	  10	  minutes	  with	  100	  µl/well	  1N	  H2SO4.	  Plates	  were	  read	  on	  an	  
ELISA	  plate	  reader	  at	  450	  nm.	  
	  
2.4.3 Flow	  cytometry	  
	  
Primary	  NK	  cells	  from	  healthy	  patients	  were	  analysed	  for	  surface	  expression	  of	  various	  receptors	  and	  
the	   intracellular	   expression	   of	   IFN-­‐γ	  with	   and	  without	   lenalidomide	   treatment.	  NK	   cells	   from	  MM	  
Specific!lysis! % = ! (experimental!release− spontaneous!release)(maximal!release− spontaneous!release !×!100!





patients	   were	   analysed	   for	   the	   surface	   expression	   of	   activating	   receptors	   compared	   to	   healthy	  
controls.	  
Briefly,	  NK	  cells	  were	  treated	  with	  1	  µM	  lenalidomide	  or	  DMSO	  and	  stimulated	  on	  slides	  coated	  with	  
anti-­‐CD16	  mAb	  or	  murine	  isotype	  control.	  For	  experiments	  measuring	  intracellular	  IFN-­‐γ,	  cells	  were	  
additionally	   treated	  with	   1	  µM	  monensin,	   to	   prevent	   IFN-­‐γ	   from	  being	   released	   during	   the	   assay.	  	  
Cells	  were	   then	   removed	   and	   loaded	   into	   flow	   cytometry	   tubes.	   Cells	  were	  washed	   once	   in	   2	  ml	  
FACS	  buffer	  (PBS	  containing	  1%	  FCS)	  and	  then	  blocked	  with	  100	  µl	  2%	  human	  serum	  for	  15	  min	  at	  
4°C.	  Cells	  were	  then	  stained	  with	  antibodies	  at	  specified	  concentrations	  in	  100	  µL	  FACS	  buffer	  for	  20	  
min	  at	  4°C.	  Samples	  were	  washed	  twice	  in	  2	  mL	  FACS	  buffer	  and	  then	  fixed	  in	  2%	  PFA.	  To	  measure	  
IFN-­‐γ	  production,	  cells	  were	  fixed	  with	  4%	  paraformaldehyde	  and	  permeabilised	  with	  0.1%	  Triton-­‐X-­‐
100	  before	  staining	  with	  AlexaFluor	  647-­‐conjugated	  anti-­‐IFN-­‐γ	  mAb	  (BD	  Biosciences).	  	  
In	  the	  case	  of	  NK	  cells	  from	  MM	  patients,	  the	  cells	  were	  loaded	  straight	   into	  flow	  cytometry	  tubes	  
(without	  stimulation	  or	  lenalidomide	  treatment)	  and	  then	  stained	  as	  described	  above.	  
In	  general,	  100,000	  cells,	  as	  determined	  in	  the	  forward	  scatter/side	  scatter	  plots,	  were	  collected	  for	  
each	   condition	   on	   a	   FACS	   Calibur	   machine.	   Data	   analysis	   was	   performed	   using	   FlowJo	   software	  
version	  10	  (TreeStar).	  
	  
2.4.4 Quantitative	  RT-­‐PCR	  	  
	  
Cells	  were	   treated	  with	  1	  µM	   lenalidomide	  or	  DMSO	  plus	  150	  U/ml	   IL-­‐2	  and	  were	  plated	  on	  glass	  
slides	   coated	   with	   0.01%	   poly-­‐L-­‐lysine	   (PLL)	   and	   then	  mAb	   or	   recombinant	   proteins	   in	   PBS	   for	   4	  
hours	   at	   37°C.	   Cells	   were	   then	   lysed	   and	   RNA	   extracted	   using	   an	   RNeasy	   kit	   (Qiagen).	   RNA	   was	  
reverse	   transcribed,	   and	   subjected	   to	   qPCR	   (Applied	   biosystems,	   CA,	   USA)	   using	   Sybr	   Green	  
detection	   for	   IFN-­‐γ	   using	   the	   following	   primer	   pair:	   Forward	   primer	   −	   5'-­‐	  
AAAAATAATGCAGAGCCAAATTG	   -­‐3';	   Reverse	   primer	   −	   5'-­‐	   TAGCTGCTGGCGACAGTTCA	   -­‐3'.	   Data	  
analysed	   by	   δδCT	  method	   (Livak	   and	   Schmittgen	   402-­‐08);	   gene	   expression	  was	   normalised	   to	   the	  
housekeeping	  gene	  GAPDH	  ,	  which	  was	  detected	  using	  the	  following	  primer	  pair:	  Forward	  primer	  −	  
5'-­‐	  GAAGGTGAAGGTCGGAGT	  -­‐3';	  Reverse	  primer	  −	  5'-­‐	  CATGGGTGGAATCATATTGGAA	  -­‐	  3'.	  
	  





2.4.5 Immunoblot	  analysis	  
	  
Cells	  were	   treated	  with	  1	  µM	   lenalidomide	  or	  DMSO	  plus	  150	  U/ml	   IL-­‐2	  and	  were	  plated	  on	  glass	  
slides	  coated	  with	  0.01%	  PLL	  and	  then	  anti-­‐CD16	  mAb	  in	  PBS	  for	  10	  min	  or	  30	  min	  at	  37°C.	  Cells	  were	  
then	  lysed	  in	  RIPA	  buffer	  (50	  mM	  TrisCl	  pH7.4,	  1	  %	  NP40	  (Igepal),	  0.25	  %	  Na-­‐deoxycholate	  150	  mM	  
NaCl,	  1	  mM	  EDTA)	  containing	  protease	  (Calbiochem)	  and	  phosphatase	  inhibitors	  (Sigma),	  and	  10	  µg	  
protein	  was	  electrophoresed	  on	  Bolt	  Bis/Tris	  4-­‐12	  %	  gels	  (Novex,	  Life	  Technologies)	  and	  transferred	  
to	  0.2	  micron	  PVDF	  membranes	  (GE	  Healthcare)	  	  for	  1hr	  at	  room	  temperature.	  	  
Membranes	  were	  blocked	  for	  2	  hours	  (NaCl	  0.15	  M,	  2	  %	  dried	  milk,	  0.1	  %	  Tween	  20)	  and	  incubated	  
with	  primary	  antibodies	  (diluted	  in	  blocking	  buffer)	  overnight	  at	  4	  ˚C.	  After	  three	  10	  minute	  washes	  
(88	  mM	  Tris	  pH	  7.8,	  0.25	  %	  dried	  milk,	  0.1	  %	  Tween	  20),	  membranes	  were	  incubated	  with	  a	  species-­‐
specific	  horseradish	  peroxidase-­‐conjugated	  secondary	  antibody	  (diluted	  in	  wash	  buffer)	  for	  1	  hour	  at	  
room	   temperature,	   and	   washed	   a	   further	   three	   times,	   each	   for	   10	   minutes.	   Immunoreactive	  
proteins	   were	   visualised	   using	   enhanced	   chemiluminescence	   (SuperSignal	   West	   Dura	   Extended	  
Duration	  Substrate;	  Thermo	  Scientific,	   Life	  Technologies).	  Blots	  were	   read	  on	  a	  ChemiDoc	   imaging	  
system	   (Bio-­‐Rad).	   Densitometric	   analysis	   (raw	   densitometric	   values	   normalised	   to	   α-­‐tubulin)	   was	  
carried	  out	  in	  an	  image	  analysis	  program	  (ImageJ;	  National	  Institute	  of	  Health).	  	  
Antibodies	   used	  were:	   anti-­‐phospho-­‐(Y142)-­‐CD247	   (BD	   Biosciences);	   anti-­‐phospho-­‐(S3)-­‐Cofilin	   and	  
anti-­‐phospho-­‐(S473)-­‐Akt	   (Cell	   Signalling	   Technology);	   anti-­‐α-­‐Tubulin	   (DM1A	   clone;	   Sigma);	  




2.5.1 Confocal	  microscopy	  
	  
Sample	  preparation	  
Eight-­‐well	   chambered	   borosilicate	   coverglass	   (Lab-­‐Tek®,	   Nunc)	   was	   coated	   with	   filter-­‐sterilised	  
0.01%	  PLL	   for	   20	  min	   and	   then	   dried.	   For	   samples	  with	   antibody-­‐	   or	   protein-­‐coated	   surfaces,	   the	  
slides	   were	   coated	   with	   antibody	   or	   recombinant	   protein	   at	   specific	   concentrations	   by	   overnight	  





incubation	  at	  4°C	  with	  200	  µl	  of	  antibody	  or	  protein	  solution	  (diluted	  in	  PBS).	  The	  slides	  were	  then	  
washed	  three	  times	  and	  blocked	  with	  PBS/2%	  BSA	  for	  30	  min.	  	  
IL-­‐2	   cultured	   primary	  NK	   cells	  were	   treated	  with	   0.1-­‐10	   µM	   lenalidomide	   or	   DMSO	   and	   added	   to	  
antibody-­‐	  or	  protein-­‐coated	  slides.	  Slides	  were	   incubated	  at	  37°C	   for	  2	  hours,	  90	  min	  or	  6	  min,	  as	  
indicated.	   For	   the	   IFN-­‐γ	   production	   time	   course	   experiments,	   the	   incubation	   time	   varied	   as	  
indicated.	  For	  the	  6	  min	  experiments,	  cells	  were	  pre-­‐treated	  with	  lenalidomide	  or	  DMSO	  for	  1	  hour.	  
For	   experiments	  with	  brefeldin	  A	   (Sigma-­‐Aldrich),	   5	  µg/ml	  brefeldin	  was	  added	   to	   the	   cells	   at	   the	  
start	  of	  the	  experiment.	  
For	   conjugate	   formation,	   primary	   NK	   cells	   and	   Daudi-­‐CD20-­‐GFP	   (green	   fluorescent	   protein)	   cells	  
were	   pre-­‐treated	   with	   DMSO	   or	   10	   µM	   lenalidomide	   for	   24	   hours	   at	   37°C.	   The	   cells	   were	   then	  
washed	   twice	   and	   co-­‐cultured	   for	   30	  min	   in	   at	   a	   1:1	   ratio	   (100,000	   cells	   each	  per	   condition).	   The	  
conditions	   analysed	  were:	   both	   cell	   types	   treated	  with	  DMSO;	  NK	   cells	   treated	  with	   lenalidomide	  
and	  targets	  treated	  with	  DMSO;	  NK	  cells	  treated	  with	  DMSO	  and	  targets	  treated	  with	  lenalidomide;	  
both	  cell	  types	  treated	  with	  lenalidomide.	  Co-­‐cultures	  were	  then	  gently	  transferred	  to	  poly-­‐L-­‐lysine	  
coated	  Lab-­‐Teks	  and	  left	  for	  10	  min	  at	  RT	  to	  settle.	  	  
For	   T	   cell	   stimulation,	   the	   three-­‐day	   rested	  primary	  human	  T	   cells	  were	   stimulated	   for	   10	  min	  on	  
glass	  slides	  coated	  with	  0.01%	  PLL	  and	  then	  anti-­‐CD3	  mAb	  (Clone	  OKT3,	  eBioscience)	  and	  anti-­‐CD28	  
mAb	  (Clone	  CD28.8,	  BD	  Pharmingen)	  in	  PBS.	  
	  
Immunostaining	  for	  fixed	  cell	  imaging	  
After	  the	  incubation	  time,	  the	  cells	  were	  fixed	  in	  200	  µl	  4%	  paraformaldehyde	  (PFA)	  in	  PBS	  at	  room	  
temperature	  for	  20	  min.	  Cells	  were	  then	  gently	  washed	  once	  in	  PBS	  and	  permeabilised	  with	  200	  µl	  	  
0.1%	  TritonX-­‐100	  (Sigma)	  in	  PBS	  for	  10	  min.	  Cells	  were	  then	  washed	  again	  in	  PBS	  and	  then	  blocked	  
with	   blocking	   buffer	   (PBS/2%	   BSA)	   for	   30	  min	   at	   room	   temperature.	   Samples	   were	   labelled	   with	  
primary	  antibody	  at	  a	  specified	  concentration	  in	  PBS	  overnight	  at	  4°C.	  Samples	  were	  then	  washed	  3	  
times	   and	   stained	   with	   phalloidin-­‐Atto590	   (Sigma)	   to	   visualise	   F-­‐actin.	   	   Nucleus	   staining	   was	  
obtained	  by	   incubating	  the	  samples	  with	  NucBlue	  (Invitrogen)	  for	  20-­‐25	  min	  at	  room	  temperature.	  
Samples	  were	  then	  washed	  a	  final	  3	  times,	  covered	  with	  200	  µl	  cold	  PBS	  and	  stored	  in	  the	  dark	  at	  
4°C	  until	  imaged.	  	  
	  






Samples	   were	   imaged	   by	   laser-­‐scanning	   confocal	   microscopy	   (SP8	   resonant	   inverted	   microscope,	  
Leica)	   with	   a	   100x	   oil	   immersion	   objective	   (NA	   =	   1.4).	   Brightfield	   and	   fluorescence	   images	   were	  
obtained.	  35-­‐40	  optical	  slices	  were	  collected	  at	  0.2	  µm	  intervals.	  Simultaneous	   imaging	  of	  multiple	  
fluorophores	   was	   achieved	   by	   sequential	   line	   scanning.	   Large	   numbers	   of	   frames	   were	   acquired	  
using	   the	   tile-­‐scanning	   function	   of	   the	   Leica	   Application	   Suite,	   Advanced	   Fluorescence	   (LAS	   AF)	  
software.	  9	  frames	  (3x3)	  were	  acquired	  per	  condition.	  Images	  were	  acquired	  with	  a	  line	  average	  of	  
16.	  	  
	  
2.5.2 STED	  microscopy	  
	  




Samples	  were	  imaged	  through	  a	  100x	  oil	  immersion	  objective	  (NA	  =	  1.4)	  on	  a	  Leica	  TCS	  SP8	  STED	  CW	  
system	  controlled	  by	  Leica	  AS	  AF	  software.	  Cells	  were	  imaged	  0.5-­‐1	  µm	  above	  the	  plane	  of	  the	  glass.	  
AlexaFluor	   488	   was	   excited	   using	   a	   white	   light	   laser	   (set	   to	   480	   nm)	   and	   STED	   depletion	   was	  
achieved	  using	  a	  592	  nm	  continuous	  wave	  fiber	  laser.	  IFN-­‐γ	  was	  co-­‐stained	  using	  an	  AlexaFluor	  647	  
directly	   labelled	   IFN-­‐γ	   antibody;	  AlexaFluor	  647	  was	  excited	  using	   the	  white	   light	   laser	   (set	   to	  647	  
nm)	   and	   imaged	   using	   the	   laser	   scanning	   confocal	   modality	   of	   the	   system.	   Fluorescence	   was	  
detected	  with	  HyD	  detectors	  (Leica).	  Images	  were	  acquired	  with	  a	  line	  average	  of	  16,	  and	  the	  first	  1	  










2.6 Data	  analysis	  
	  
2.6.1 Confocal	  imaging	  data	  analysis	  
	  
Confocal	   microscopy	   images	   were	   analysed	   using	   specific	   software	   (LAS	   AF,	   Leica,	   and	   FIJI,	   US	  
National	  Institutes	  of	  Health,	  Bethesda,	  MA).	  	  
	  
Imaris	  analysis	  
A	  schematic	  of	  the	  sample	  used	  for	   IFN-­‐γ	   imaging	   is	  shown	  in	  Figure	  2.1.	   In	  order	  to	  automatically	  




Figure	  2.1	  –	  Schematic	  drawing	  of	  sample	  used	  for	  IFN-­‐γ 	  imaging.	  NK	  cells	  were	  plated	  on	  glass	  slides	  coated	  
with	   anti-­‐CD16	  mAb	   to	   ligate	   CD16.	   IFN-­‐γ	   was	   stained	   with	   anti-­‐IFN-­‐γ	   mAb	   conjugated	   with	   Alexa488.	   The	  
nucleus	  was	  stained	  with	  NucBlue	  and	  F-­‐actin	  was	  visualised	  with	  phalloidin	  conjugated	  with	  Atto590.	  
	  
For	  the	  single	  cell	  IFN-­‐γ	  analysis,	  merged	  tilescan	  confocal	  images	  (9	  frames	  merged	  together)	  were	  
imported	  into	  Imaris	  software	  (BitPlane,	  Zurich).	  Individual	  cells	  were	  segmented	  based	  on	  cell	  body	  
staining	   (phalloidin)	   and	   nucleus	   staining.	   IFN-­‐γ	   vesicles	  were	   identified	   based	   on	   AlexaFluor	   488-­‐





conjugated	   IFN-­‐γ	  mAb	   staining	  within	  each	   cell.	  Different	   vesicle	   statistics	  were	  exported	   for	  each	  
image:	  number	  of	  cells	  containing	  IFN-­‐γ,	  number	  of	  vesicles	  per	  cell	  and	  sum	  vesicle	  fluorescence	  per	  
cell	  (Figure	  2.2).	  
	  
Cell	  area	  measurements	  
	  
Figure	  2.2	  –	  Flow-­‐chart	  of	  cell	  and	  vesicle	  detection	  using	   Imaris.	   Images	   in	   (A)	   representing	  corresponding	  
steps	   in	   the	   flow-­‐chart	   (B),	   labelled	  with	   the	  same	   inset	   letter.	  First,	   the	  confocal	   image	  stack	  was	   imported	  
into	  Imaris	  (a).	  Then,	  the	  nucleus	  of	  each	  cell	  was	  detected	  based	  on	  NucBlue	  staining	  (b).	  The	  outline	  of	  each	  
cell	  was	   then	   identified	  based	  on	  Atto590-­‐conjugated	  phalloidin	   staining	   (c).	   Finally,	   the	   IFN-­‐γ	   vesicles	  were	  
identified	  using	  Alexa488	   fluorescence.	   Images	  were	  checked	  at	  each	  stage	   to	  ensure	   that	   cells	  and	  vesicles	  
were	  correctly	  identified.	  
	  
To	  measure	  the	  area	  of	  NK	  cells	  that	  are	  in	  contact	  with	  the	  slide,	  the	  confocal	  microscopy	  images	  
were	   imported	   into	   ImageJ.	   The	   threshold	  was	   adjusted	   to	   remove	   background	   fluorescence	   and	  
then	   the	   image	   was	   converted	   to	   binary.	   The	   contact	   area	   was	   filled	   in	   completely	   to	   create	   a	  
silhouette	   of	   each	   cell	   (ImageJ,	   ‘Fill	   Holes’	   function).	   In	   some	   cases,	   cells	   were	   too	   close	   to	   each	  
A	   B	  





other	   and	   therefore	   appeared	   as	   one	   cell	   after	   the	   holes	   were	   filled.	   To	   separate	   them,	   the	  
‘Watershed’	  function	  was	  used.	  Then,	  all	   the	  cells	  that	  were	  correctly	   identified	  were	  selected	  and	  
then	   the	   individual	   cell	   areas	   were	   measured	   (ImageJ,	   ‘Analyse	   Particles’	   function)	   (Figure	   2.3).	  	  
Brightness	  and	  contrast	  levels	  of	  images	  were	  adjusted	  in	  Photoshop	  (Adobe)	  to	  improve	  depiction	  




Figure	  2.3	  –	  Flow-­‐chart	  of	  cell	  detection	  and	  measurement	  in	  ImageJ.	  Images	  were	  thresholded,	  converted	  to	  
binary	  and	  then	  watershedded	  to	  correctly	  identify	  individual	  cells,	  before	  measuring	  cell	  areas.	  
	  
	  
Actin	  ring	  measurements	  
To	  assess	  the	  proportion	  of	  NK	  cells	  with	  actin	  rings,	  the	  confocal	  microscopy	  images	  were	  imported	  
into	   ImageJ.	   Within	   each	   image,	   both	   the	   number	   of	   NK	   cells	   displaying	   a	   dense	   ring	   of	   F-­‐actin	  
around	  the	  periphery	  and	  the	  total	  number	  of	  NK	  cells	  were	  counted,	  as	  previously	  described	  (Culley	  
et	  al.,	  2009).	  This	  was	  repeated	  for	  each	  image	  and	  then	  the	  data	  was	  pooled	  for	  each	  donor.	  
	  





Conjugate	  image	  analysis	  
To	  measure	   the	   frequency	  of	   immune	   synapse	   formation	   in	   co-­‐cultures	  between	  primary	  NK	   cells	  
and	  Daudi-­‐CD20-­‐GFP	  cells,	  images	  were	  imported	  into	  ImageJ.	  For	  each	  image,	  the	  total	  number	  of	  
target	   cells	   was	   counted	   (based	   on	   GFP	   fluorescence).	   Next	   the	   total	   number	   of	   conjugates	   was	  
counted	   (identified	   by	   NK	   cells	   in	   contact	   with	   a	   target	   cell).	   For	   each	   conjugate,	   the	   integrated	  
fluorescence	  intensity	  was	  measured	  along	  a	  line	  at	  the	  contact	  point	  between	  cells	  and	  then	  on	  the	  
opposite	   side	   of	   the	   NK	   cell	   (Figure	   2.4).	   The	   ratio	   between	   the	   two	   measurements	   was	   then	  
calculated.	   If	   the	   ratio	   exceeded	   1.5	   then	   the	   conjugate	  was	   considered	   to	   be	   an	   active	   immune	  
synapse.	  
	  
Figure	  2.4	  –	  Representative	  microscopy	  image	  showing	  conjugate	  formation	  between	  primary	  NK	  cell	  and	  
Daudi-­‐CD20-­‐GFP	  cell	  (green).	  Integrated	  fluorescence	  intensity	  was	  measured	  at	  the	  point	  of	  contact	  (1)	  and	  
an	  area	  on	  the	  opposite	  part	  of	  the	  cell	  (2).	  The	  ratio	  between	  the	  two	  areas	  determined	  whether	  a	  conjugate	  
was	  an	  active	  immune	  synapse	  or	  not.	  
	  
	  
Cell	  morphology	  analysis	  
Cell	   symmetry	  was	  determined	  using	  a	  custom	  programme	  written	   in	  G	   (Labview	  software)	  as	  has	  
been	  previously	  described	  (Culley	  et	  al.,	  2009).	  The	  perimeter	  of	   the	  cell	  was	  defined	  according	  to	  
the	  fluorescence	  intensity	  of	  phalloidin	  staining	  and	  then	  the	  centroid	  of	  the	  cell	  was	  located.	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Figure	   2.5	   –	   Cell	   morphology	   analysis.	   Representative	   microscopy	   image	   and	   schematic	   showing	   cell	  
morphology	  analysis.	  First,	  the	  centroid	  of	  the	  cell	  is	  located	  (red)	  and	  then	  the	  distance	  from	  the	  centroid	  to	  
the	  perimeter	  was	  measured	  along	  360	  evenly	  spaced	  radii	  (blue	  arrows	  show	  examples).	  
	  
The	  distance	  from	  the	  centroid	  to	  the	  perimeter	  was	  then	  measured	  along	  360	  evenly	  spaced	  radii	  
(Figure	  2.5).	  The	  standard	  deviation	  (SD)	  of	  these	  distances	  was	  used	  to	  determine	  cell	  symmetry	  –	  
the	  larger	  the	  SD	  for	  each	  cell,	  the	  more	  asymmetric	  the	  cell	  is.	  
	  
2.6.2 STED	  imaging	  data	  analysis	  
	  
Two	   different	   techniques	   were	   used	   to	   quantify	   the	   size	   of	   holes	   in	   the	   actin	   mesh	   –	   a	   manual	  
technique	   using	   FIJI	   and	   a	   custom	   written	   MatLab	   program	   (Mathworks)	   that	   has	   been	   used	  
previously	  (Brown	  et	  al.,	  2011;	  Brown	  et	  al.,	  2012).	  	  
	  
Manual	  detection	  of	  the	  holes	  within	  the	  meshwork	  
The	  manual	   analysis	   technique	   used	   here	  was	   adapted	   from	   the	   analysis	   previously	   described	   by	  
Jordan	  Orange’s	  lab	  (Rak	  et	  al.,	  2011).	  Briefly,	  STED	  microscopy	  images	  of	  the	  actin	  meshwork	  were	  
imported	   into	  FIJI.	   The	  background	  of	   the	   image	  was	   subtracted	  using	   the	  Rolling	  Ball	   Subtraction	  
algorithm	  with	   the	   radius	   set	   to	   150	   pixels	   and	   then	   the	   pixel	   intensities	  were	  multiplied	   by	   3.	   A	  
region	   of	   interest	  was	   drawn	   around	   the	   interior	   of	   the	   cell	   (inside	   the	   actin	   perimeter)	   and	   this	  
region	   was	   thresholded	   using	   the	   default	   autothreshold	   with	   ‘dark	   background’	   unchecked.	   The	  





areas	  of	  the	  holes	  within	  the	  meshwork	  were	  then	  identified	  using	  the	  ‘analyse	  particles’	   function,	  
with	  a	  detection	  limit	  of	  25	  nm	  minimum	  (as	  this	  is	  the	  detection	  limit	  of	  the	  microscope).	  	  
	  
Actin	  mesh	  MatLab	  program	  
STED	  images	  were	  also	  analysed	  using	  a	  custom-­‐written	  MatLab	  program	  that	  was	  originally	  written	  
to	   analyse	   structured	   illumination	   images.	   Images	  were	   imported	   into	   the	   program	   as	   8-­‐bit	   TIFFs	  
with	  each	  image	  containing	  one	  cell	  of	  interest.	  First,	  an	  empty	  region	  of	  background	  was	  selected	  to	  
evaluate	   the	   background	   intensity	   characteristics.	   The	   mean	   background	   intensity	   was	   then	  
subtracted	  from	  the	  image.	  The	  borders	  of	  the	  cell	  and	  the	  central	  synaptic	  zone	  (inside	  the	  dense	  
peripheral	   actin	   ring)	   were	   found	   using	   Chunming	   Li’s	   region	   scalable	   fitting	   energy	  minimization	  
algorithm	  (Li	  et	  al.,	  2008).	  The	  cell	  border	  and	  central	  zone	  detection	  was	  then	  corrected	  manually	  if	  
necessary.	   In	   order	   to	   detect	   the	   narrow	   actin	   filaments	   within	   the	   mesh,	   thresholding	   with	  
extensive	   pre-­‐processing	  was	   used.	   First,	   an	   ordinance	   filter	   in	   a	   5-­‐by-­‐5	   pixel	   neighbourhood	  was	  
used	   to	   find	   the	   local	   minimum	   intensity.	   In	   order	   to	   avoid	   pixelation	   of	   the	   image,	   the	   local	  
minimum	   image	  was	   convolved	  with	   a	   Gaussian	   function	   (σ	   =	   5	   pixels)	   using	   a	   fifteen	   pixel	  wide	  
kernel.	   The	   convolved	  minimum	   intensity	   image	  was	   then	   subtracted	   from	   the	  unmodified	   image.	  
The	   resulting	   image	   was	   rescaled	   and	   the	   borders	   were	   de-­‐blurred	   by	   deconvolution	   using	   a	  
Gaussian	   function	   (σ	   =	   0.8	   pixels	   and	   kernel	   width	   =	   5	   pixels).	   Otsu’s	   method	   was	   then	   used	   to	  
estimate	  the	  grey	  level	  threshold.	  The	  multiplier	  for	  the	  threshold	  was	  then	  modified	  manually	  while	  
comparing	   the	   threshold	   image	   to	   the	  original	   image.	  After	   thresholding,	   the	   sizes	  of	   holes	   in	   the	  
actin	  mesh	  were	  calculated	  in	  the	  image.	  A	  distance	  transform	  was	  used	  to	  calculate	  the	  minimum	  
distance	   to	   an	   actin-­‐positive	   pixel	   for	   all	   pixels	  within	   the	   cell.	   This	   distance	   transform	   image	  was	  
then	   used	   to	   generate	   the	   penetrable	   area	   image.	   It	   was	   also	   used	   to	   calculate	   the	   percentage	  
penetrable	  area	  for	  the	  selected	  vesicle	  size	  by	  selecting	  pixels	  whose	  distance	  to	  the	  closest	  actin-­‐
positive	  pixel	  was	  more	  than	  half	  the	  vesicle	  diameter.	  	  
	  
2.6.3 Statistical	  analysis	  
	  
Mean	  values	  and	  standard	  error	  of	  the	  mean	  (SEM)	  was	  shown.	  Most	  data	  was	  analysed	  by	  one-­‐way	  
ANOVA	  and	  Tukey’s	  post-­‐test	  although	  Students	  t-­‐test	  was	  also	  used	  when	  stated	  (Prism	  version	  6;	  
GraphPad).	  In	  the	  statistical	  analysis,	  differences	  were	  defined	  as	  non-­‐significant	  (ns)	  where	  p	  ≥	  0.05	  





and	  statistically	  significant	  where	  p	  <	  0.05	  (indicated	  by	  a	  single	  asterisk	  *),	  p	  <	  0.01	  (**),	  p	  <	  0.001	  
(***)	  and	  p	  <	  0.0001	  (****).	  All	  graphs	  were	  prepared	  and	  statistically	  analysed	  using	  Prism.	  	  
For	   threshold	   analysis,	   IFN-­‐γ	   production	   was	   normalised	   to	   the	   maximum	   value	   seen	   with	   each	  
receptor	  and	  EC50	  was	  determined	  by	  nonlinear	  regression	  (Prism	  version	  6;	  GraphPad).	  





Chapter	  3	  -­‐ Effect	  of	  lenalidomide	  on	  NK	  cell	  
effector	  functions	  	  
	  
3.1 Introduction	  
Lenalidomide	   is	  a	  clinically	  relevant	  derivative	  of	  thalidomide	  that	   is	  used	  to	  treat	  MM	  and	  MGUS.	  
Preclinical	  research,	  combined	  with	  clinical	  observations,	  has	  suggested	  that	  lenalidomide	  treatment	  
affects	  both	  the	  phenotype	  and	  function	  of	  NK	  cells.	   In	  this	  chapter,	  the	  focus	   is	  on	  understanding	  
the	  effect	  of	  lenalidomide	  on	  NK	  cell	  effector	  functions.	  
	  
3.1.1 Lenalidomide	  and	  NK	  cell	  cytotoxicity	  
Several	   studies	  have	  established	   that	   lenalidomide	   treatment	   enhances	  NK	   cell-­‐mediated	  ADCC	  of	  
tumour	   cells.	   Overnight	   pre-­‐treatment	   of	   primary	   NK	   cells	   with	   lenalidomide	   dose-­‐dependently	  
increased	   the	   NK	   cell-­‐specific	   lysis	   of	   rituximab-­‐coated	   non-­‐Hodgkin’s	   lymphoma	   cell	   lines	   and	  
primary	   B	   cells	   from	   CLL	   patients	   in	   vitro	   (Wu	   et	   al.,	   2008).	   In	   another	   study,	   PBMCs	   were	   pre-­‐
treated	   with	   1	   µM	   lenalidomide	   for	   14	   days	   prior	   to	   co-­‐culture	   with	   rituximab-­‐coated	   CLL	   cells	  
(Acebes-­‐Huerta	  et	  al.,	  2014).	  Cytotoxicity	  was	  measured	  using	  a	  CD107a	  flow	  cytometry	  assay,	  and	  
the	  effect	  of	  NK	  cells	  was	  assessed	  by	  gating	  on	  CD56+	  cells.	  The	  results	  showed	  a	  1.5-­‐fold	  increase	  
in	   cytotoxic	   activity	   of	   NK	   cells	   after	   lenalidomide	   treatment	   (Acebes-­‐Huerta	   et	   al.,	   2014).	   These	  
results	  have	  been	  confirmed	  by	  other	  studies	  using	  alternative	  antibodies	  to	  trigger	  ADCC,	  such	  as	  
the	  humanised	  anti-­‐CD40	  mAb	  SGN-­‐40	  (Tai	  et	  al.,	  2005;	  Lapalombella	  et	  al.,	  2009;	  Wu	  et	  al.,	  2011).	  	  
This	  significant	  enhancement	  in	  ADCC	  with	  lenalidomide	  treatment	  correlates	  with	  a	  reported	  2-­‐fold	  
increase	  in	  the	  number	  of	  primary	  NK	  cells	  expressing	  CD16	  after	  treatment	  with	  lenalidomide	  (Tai	  
et	   al.,	   2005).	   Another	   study,	   however,	   reported	   no	   change	   in	   CD16	   expression	   after	   lenalidomide	  
treatment,	  along	  with	  no	  change	  in	  the	  expression	  of	  NKG2D,	  NKp30,	  NKp44	  or	  NKG2A	  (Dauguet	  et	  
al.,	  2010).	  	  	  	  
It	  is	  not	  clear	  whether	  lenalidomide	  has	  an	  enhancing	  effect	  on	  NK	  cell	  cytotoxicity	  in	  the	  absence	  of	  
antibodies	  to	  trigger	  ADCC,	  as	  the	  published	  data	  shows	  contradictory	  results.	  It	  has	  been	  reported	  
that	  enhancement	  of	  primary	  NK	  cell-­‐mediated	  lysis	  of	  K562	  cells	  with	  lenalidomide	  treatment	  (from	  





57%	  lysis	  without	  lenalidomide	  to	  70%	  lysis	  with	  lenalidomide)	  was	  only	  seen	  when	  the	  primary	  NK	  
cells	  were	  co-­‐cultured	  with	  CD4+	  T	  cells	  during	  drug	  treatment.	  This	  effect	  is	  IL-­‐2	  dependent,	  as	  pre-­‐
treating	  the	  NK	  cells	  with	  anti-­‐IL-­‐2	  receptor-­‐α-­‐blocking	  antibodies	  abolished	  the	  observed	  increase	  in	  
lysis	   (Hsu	   et	   al.,	   2011).	   These	   results	   were	   supported	   by	   a	   recent	   study,	   which	   also	   showed	   that	  
depletion	  of	  T	  cells	  or	  blockade	  of	  IL-­‐2	  production	  abrogated	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  
(Acebes-­‐Huerta	  et	  al.,	  2014).	  
Another	   study	   reported	   that	   IMiDs	  do	  not	   directly	   activate	  NK	   cells	   by	   showing	   that	   lenalidomide	  
treatment	   does	   not	   result	   in	   the	   increased	   phosphorylation	   of	   PKCζ,	   PKCδ,	   Akt,	   ERK	   or	   p38	  MAP	  
kinase,	   all	   of	   which	   have	   been	   described	   as	   being	   involved	   in	   NK	   cell	   cytotoxicity	   (Hayashi	   et	   al.,	  
2005).	  This	  study	  concluded	  that	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  is	  an	  indirect	  effect	  caused	  by	  
an	   increase	   in	   IL-­‐2	  production	  by	  T	  cells	   (Hayashi	  et	  al.,	  2005).	   In	  contrast	   to	   this,	   it	  has	  also	  been	  
shown	  that	  lenalidomide	  treatment	  of	  primary	  NK	  cells	  alone	  is	  sufficient	  to	  significantly	  increase	  NK	  
cell-­‐mediated	   lysis	   of	   Namalwa	   cells	   (from	   7%	   lysis	   without	   lenalidomide	   to	   19%	   lysis	   with	  
lenalidomide)	  in	  the	  absence	  of	  rituximab	  (Wu	  et	  al.,	  2008).	   In	  addition,	   lenalidomide	  treatment	  of	  
primary	   NK	   cells	   alone,	   in	   the	   presence	   of	   immobilised	   IgG	   and	   IL-­‐2,	   increased	   the	   production	   of	  
Granzyme	  B	  by	  NK	  cells	  but	  had	  no	  effect	  on	  perforin	  production	  (Wu	  et	  al.,	  2008).	  More	  recently,	  
this	   was	   confirmed	   by	   the	   observation	   that	   14-­‐day	   treatment	   with	   lenalidomide	   enhanced	   the	  
natural	  cytotoxic	  activity	  of	  primary	  NK	  cells	  towards	  CLL	  cells	  (Acebes-­‐Huerta	  et	  al.,	  2014).	  
It	   is	   clear,	   therefore,	   that	   lenalidomide	   treatment	   affects	   NK	   cells,	   but	   the	   details	   remain	   poorly	  
defined.	  It	  has	  been	  suggested	  that	  the	  increase	  in	  cytotoxicity	  can	  be	  accounted	  for	  by	  a	  change	  in	  
the	  ratio	  of	  CD56bright	   to	  CD56dim	  NK	  cells.	  CD56brightCD16dim	  NK	  cells	  mediate	   low	  or	  no	  cytotoxicity	  
and	   produce	   high	   levels	   of	   inflammatory	   cytokines.	   In	   contrast,	   CD56dimCD16bright	   cells	   are	   potent	  
mediators	  of	  cytotoxicity	   (Cooper	  et	  al.,	  2001).	  Tai	  and	  colleagues	  showed	  that	   lenalidomide	  has	  a	  
direct	   effect	   on	  NK	   cell	   function	   by	   altering	   the	   ratio	   of	   CD56bright	   to	   CD56dim	  NK	   cells	   resulting	   in	  
more	   CD56dimCD16bright	   cells	   (Tai	   et	   al.,	   2005)	   and	   the	   authors	   suggest	   that	   this	   could	   be	   partially	  
responsible	  for	  the	  increased	  NK	  cell	  cytotoxicity	  that	  they	  observe.	  However,	  culturing	  NK	  cells	  in	  IL-­‐
2	  prior	  to	  use	  also	  results	  in	  the	  majority	  of	  the	  cells	  becoming	  CD56bright	  (Tai	  et	  al.,	  2005)	  suggesting	  
that	  this	  is	  not	  the	  explanation	  behind	  the	  effects	  of	  lenalidomide	  in	  the	  majority	  of	  studies	  carried	  
out	  in	  vitro.	  	  
Of	   note,	   Carbone	   and	   colleagues	   showed	   that	   expression	   of	   NCRs	   and	   NKG2D	   is	   necessary	   for	  
myeloma	   cell	   recognition	   (Carbone	   et	   al.,	   2005),	   and	   another	   study	   showed	   that	   blocking	  NKG2D	  
abrogated	   the	   effect	   of	   lenalidomide	   in	   solid	   tumours	   (Wu	   et	   al.,	   2011).	   This	   suggests	   that	  
lenalidomide	  may	  have	  an	  effect	  on	  NKG2D-­‐mediated	  effector	  function	  as	  well	  as	  through	  CD16.	  	  	  





3.1.2 Lenalidomide	  and	  NK	  cell	  cytokine	  production	  
	  
The	  effect	  of	  lenalidomide	  on	  NK	  cell	  cytokine	  production	  is	  also	  unclear.	  One	  study	  showed	  that	  the	  
addition	  of	  lenalidomide	  to	  primary	  NK	  cells	  incubated	  with	  IL-­‐2,	  in	  the	  presence	  of	  immobilised	  IgG,	  
resulted	  in	  an	  8-­‐fold	  increase	  in	  IFN-­‐γ	  production	  This	  effect	  was	  not	  seen	  with	  IL-­‐2	  or	  IgG	  alone	  (Wu	  
et	   al.,	   2008).	   The	  dependence	  of	   the	   increase	   in	   IFN-­‐γ	   production	  on	   IgG	   suggests	   that	   ligation	  of	  
CD16	  on	  NK	   cells	   is	   required	   for	   lenalidomide	   to	  have	  an	  effect.	   It	   is	   not	   clear,	  however,	  whether	  
ligation	  of	  other	  activating	  receptors	  on	  NK	  cells	  can	  result	  in	  a	  similar	  increase	  in	  IFN-­‐γ	  production	  
with	   lenalidomide	   treatment,	   or	   whether	   CD16	   is	   unique	   in	   this	   respect.	   Conflicting	   results	   have	  
since	   been	   reported	   showing	   that	   lenalidomide	   treatment	   inhibits	   the	   production	   of	   IFN-­‐γ	   by	  
primary	  NK	  cells,	  but	  has	  no	  effect	  on	  the	  number	  of	  cells	  expressing	  IFN-­‐γ	  (Dauguet	  et	  al.,	  2010).	  	  
Interestingly,	   in	   a	   recent	   study,	   prolonged	   treatment	   with	   lenalidomide	   increased	   the	   levels	   of	  
CD107a	   and	   IFN-­‐γ	   in	   primary	   NK	   cells.	   This	   effect	   correlated	   with	   increased	   TRAIL	   expression,	  
suggesting	   a	   functional	   role	   for	   the	   TRAIL	   system	   in	   NK	   cell-­‐mediated	   activity	   against	   MM	   cells	  
(Jungkunz-­‐Stier	  et	  al.,	  2014).	  
This	   overall	   discrepancy	   in	   published	   data	   will	   be	   investigated	   in	   this	   study	   by	   assessing	   IFN-­‐γ	  




The	  discrepancy	   in	  the	   literature	  has	  resulted	   in	  a	  major	  gap	   in	  knowledge	   in	  the	  specific	  effect	  of	  
lenalidomide	  on	  NK	  cell	  effector	   functions.	  The	  main	  goal	  of	   this	   investigation	  was	   to	  clear	  up	   the	  
conflict	  in	  the	  literature	  and	  establish	  how	  lenalidomide	  affects	  NK	  cells	  on	  a	  population	  level	  and	  a	  
single	  cell	  level.	  IFN-­‐γ	  production	  after	  lenalidomide	  treatment	  was	  assessed	  in	  detail	  under	  different	  
conditions.	  	  In	  addition,	  the	  effect	  of	  lenalidomide	  on	  immune	  synapse	  formation	  was	  observed.	  The	  
specific	  aims	  of	  this	  study	  were	  as	  follows:	  
(i) To	   assess	   the	   effect	   of	   lenalidomide	   on	  NK	   cell	   cytotoxicity	   and	   IFN-­‐γ	   production	   on	   a	  
population	  level	  in	  primary	  NK	  cells	  in	  conjugate	  with	  target	  cells.	  





(ii) To	  determine	  whether	  lenalidomide	  affects	  NK	  cell	  cytokine	  production	  through	  multiple	  
triggers	  for	  NK	  cell	  activation.	  
(iii) To	  investigate	  IFN-­‐γ	  production	  on	  a	  single	  cell	  level	  after	  lenalidomide	  treatment.	  
(iv) To	  investigate	  the	  effect	  of	  lenalidomide	  on	  immune	  synapse	  formation.	  
(v) To	  investigate	  the	  effect	  of	  lenalidomide	  on	  the	  threshold	  for	  NK	  cell	  activation.	  





3.2.1 Lenalidomide	  enhances	  primary	  NK	  cell	  effector	  functions.	  
	  
As	   described	   above,	   it	   is	   not	   clear	  whether	   lenalidomide	   has	   a	   direct	   effect	   on	   NK	   cells,	   nor	   is	   it	  
apparent	  how	  large	  a	  role	  IL-­‐2	  stimulation	  plays	  in	  this	  process.	  In	  order	  to	  investigate	  this,	  NK	  cell	  
	  
Figure	   3.1	   –	   Lenalidomide	   increases	   primary	  NK	   cell	   cytotoxicity.	   Healthy	   donor	   primary	  NK	   cells	   and	   (A)	  
Daudi	  cells	  or	   (B)	   JeKo-­‐1	  cells	  were	  pre-­‐treated	  with	   lenalidomide	  (0.001-­‐10	  µM)	  for	  24	  hours	  and	  then	  the	  
target	  cells	  were	  tested	  for	  susceptibility	  to	  NK	  cell-­‐mediated	  lysis.	  Data	  from	  3	  independent	  experiments.	  E:T	  
ratio	  was	  10:1	  in	  all	  experiments.	  One-­‐way	  ANOVA	  was	  used	  to	  test	  if	  observed	  differences	  were	  statistically	  
significant.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001.	  
	  





cytotoxicity	  was	  first	  studied.	  To	  assess	  the	  effect	  of	  lenalidomide	  on	  primary	  NK	  cell	  cytotoxicity,	  NK	  
cell-­‐mediated	  lysis	  of	  Daudi	  target	  cells	  (a	  well	  characterised	  B	  cell	  lymphoma	  line	  susceptible	  to	  NK	  
cell-­‐mediated	  cytotoxicity)	  was	  measured.	  Daudi	  cells	  and	  healthy	  donor	  primary	  NK	  cells	  were	  pre-­‐
treated	   with	   0.001-­‐10	   μM	   lenalidomide	   or	   vehicle	   control	   (DMSO)	   for	   24	   hours	   prior	   to	   co-­‐
incubation.	  24	  hours	  is	  a	  clinically	  relevant	  time	  point	  as	  lenalidomide	  is	  given	  daily	  during	  treatment	  
for	   multiple	   myeloma.	   Daudi	   cell	   lysis	   was	   significantly	   enhanced	   with	   10	   μM	   lenalidomide	  
treatment	   (from	  13%	   lysis	  ±	  2%	  without	   lenalidomide	  to	  30%	   lysis	  ±	  1%	  with	  10	  μM	   lenalidomide)	  
when	   primary	   NK	   cells	   had	   been	   treated	   in	   the	   presence	   of	   exogenous	   IL-­‐2	   (Figure	   3.1A).	   In	   the	  
absence	   of	   IL-­‐2	   stimulation,	   no	   increase	   in	   Daudi	   cell	   lysis	   was	   observed	   with	   any	   tested	  
concentration	  of	  lenalidomide	  (Figure	  3.1A).	  	  
In	  order	  to	  test	  this	  in	  another	  cell	  line,	  JeKo-­‐1	  cells	  (a	  mantle	  cell	  lymphoma	  cell	  line)	  were	  used	  as	  
target	  cells.	  Without	  IL-­‐2,	  JeKo-­‐1	  cell	  lysis	  remained	  <8%	  and	  showed	  no	  increase	  with	  lenalidomide	  
treatment	   (Figure	   3.1B).	   As	   observed	  with	  Daudi	   cells,	   JeKo-­‐1	   cell	   lysis	  was	   significantly	   enhanced	  
with	  10	  µM	  lenalidomide	  treatment	  (from	  27%	  lysis	  ±	  5%	  without	  lenalidomide	  to	  36%	  ±	  4%	  with	  10	  
µM	  lenalidomide)	  in	  the	  presence	  of	  IL-­‐2	  (Figure	  3.1B).	  	  
These	   results	   are	   consistent	   with	   the	   data	   presented	   by	   Wu	   and	   colleagues,	   and	   shows	   that	  
lenalidomide	   does	   have	   an	   enhancing	   effect	   on	   NK	   cell	   cytotoxicity	   in	   the	   absence	   of	   exogenous	  
	  
Figure	  3.2	  –	  Lenalidomide	  increases	  primary	  NK	  cell	  IFN-­‐γ 	  secretion.	  Healthy	  donor	  primary	  NK	  cells	  and	  (A)	  
Daudi	   cells	   or	   (B)	   Raji	   cells	   were	   pre-­‐treated	   with	   lenalidomide	   (0.001-­‐10	   µM)	   for	   24	   hours	   and	   then	   the	  
supernatant	  was	  assessed	  BY	  ELISA	   for	   IFN-­‐γ	   secretion.	  Data	   from	  3	   independent	  experiments.	  Graph	  shows	  
mean	  ±	  SEM.	  E:T	  ratio	  was	  10:1	  in	  all	  experiments.	  One-­‐way	  ANOVA	  was	  used	  to	  test	  if	  observed	  differences	  
were	  statistically	  significant.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001.	  
	  
	  





antibodies	  to	  trigger	  ADCC	  (Wu	  et	  al.,	  2008).	  The	  effect	  of	  lenalidomide	  does	  seem	  to	  require	  IL-­‐2,	  as	  
suggested	  by	   various	  different	   studies	   (Hsu	  et	   al.,	   2011;	  Acebes-­‐Huerta	  et	   al.,	   2014),	  however	  our	  
results	  show	  that	   it	   is	  not	  solely	  due	  to	  the	  presence	  of	   IL-­‐2.	  This	  suggests	  that	   lenalidomide	  has	  a	  
direct	  effect	  on	  NK	  cell	  cytotoxicity	  and	  is	  not	  dependent	  on	  the	  presence	  of	  T	  helper	  cells.	  	  
Secretion	   of	   inflammatory	   cytokines,	   such	   as	   IFN-­‐γ,	   is	   another	   important	   outcome	   of	   NK	   cell	  
activation.	  Here,	  production	  of	  IFN-­‐γ	  by	  NK	  cells	  in	  conjugate	  with	  Daudi	  cells	  increased	  3-­‐fold	  in	  the	  
presence	  of	  1	  µM	  lenalidomide	  (from	  215	  ±	  30	  pg/ml	  without	  lenalidomide	  to	  640	  ±	  50	  pg/ml	  with	  1	  
µM	   lenalidomide;	  p<0.001;	   Figure	  3.2A).	   This	   increase	   in	   IFN-­‐γ	   secretion	  was	  only	  observed	   in	   the	  
presence	  of	  IL-­‐2.	  Similarly,	  IFN-­‐γ	  production	  by	  NK	  cells	  in	  conjugate	  with	  the	  EBV-­‐transformed	  B	  cell	  
line	   Raji	   increased	   2.5-­‐fold	   in	   the	   presence	   of	   1	  µM	   lenalidomide	   and	   IL-­‐2	   (from	   245	   ±	   40	   pg/ml	  
without	  lenalidomide	  to	  650	  ±	  50	  pg/ml	  with	  1	  µM	  lenalidomide;	  p<0.01;	  Figure	  3.2B).	  	  
	  
Figure	  3.3	  –	  Surface	  expression	  of	  CD16	  on	  primary	  NK	  cells.	  NK	  cells	  from	  3	  donors	  were	  analysed	  by	  flow	  










These	  results	  clarify	  that	  treatment	  of	  primary	  NK	  cells	  with	  1	  µM	  lenalidomide,	  in	  the	  presence	  of	  
exogenous	  IL-­‐2,	  has	  a	  direct	  and	  enhancing	  effect	  on	  NK	  cell	  cytotoxicity	  and	  IFN-­‐γ	  secretion.	  	  
	  
3.2.2 Lenalidomide	  enhances	  IFN-­‐γ 	  secretion	  from	  primary	  NK	  cells	  	  
	  
It	  is	  therefore	  clear	  that	  lenalidomide	  treatment	  directly	  increases	  NK	  cell	  effector	  functions,	  either	  
by	  affecting	  the	  NK	  cells	  or	  the	  tumour	  cells.	  Next,	  the	  system	  was	  reduced	  in	  order	  to	  more	  directly	  
test	  the	  effect	  of	  lenalidomide	  of	  NK	  cells	  alone	  after	  engagement	  of	  specific	  activating	  receptors.	  	  	  
CD16	  is	  an	  activating	  receptor	  that	  recognises	  the	  Fc	  portion	  of	  antibodies.	  Ligation	  of	  CD16	  on	  NK	  
cells	   leads	  to	  killing	  of	  the	  target	  cell	  by	  ADCC.	  The	  surface	  expression	  of	  CD16	  on	  primary	  NK	  cells	  
from	  three	  different	  donors	  was	  checked	  by	  flow	  cytometry	  (Figure	  3.3).	  These	  results	  confirm	  that	  
50-­‐60%	  of	  primary	  NK	  cells	  from	  each	  donor	  express	  CD16	  on	  their	  surface,	  and	  that	  this	  does	  not	  
fluctuate	   significantly	  between	  donors	   (Figure	  3.3).	   In	  order	   to	  observe	   IFN-­‐γ	   secretion	  after	  CD16	  
ligation,	  NK	  cells	  were	  stimulated	  on	  surfaces	  coated	  with	  anti-­‐CD16	  mAb	   (to	  directly	   ligate	  CD16)	  
for	  24	  hours.	  NK	  cells	  were	  treated	  with	  exogenous	  IL-­‐2	  and	  0.1-­‐10	  µM	  lenalidomide	  or	  DMSO	  as	  a	  
vehicle	   control.	   Supernatants	   were	   then	   analysed	   by	   ELISA	   for	   the	   presence	   of	   IFN-­‐γ.	   NK	   cells	  
stimulated	   on	   control	   surfaces	   (blank	   or	  wells	   coated	  with	   isotype-­‐matched	   control	  mAb)	   did	   not	  
secrete	   IFN-­‐γ	   (411	   ±	   183	   pg/ml	   on	   isotype	   control)	   and	   this	   did	   not	   change	   with	   lenalidomide	  
	  
Figure	   3.4	   –	   Lenalidomide	   enhances	   NK	   cell	   IFN-­‐γ 	   secretion	   after	   ligation	   of	   CD16.	   Primary	   NK	   cells	   were	  
treated	  with	  DMSO	  or	  0.1-­‐10	  µM	  lenalidomide	  either	  with	  (A)	  or	  without	  (B)	  150	  U/ml	  IL-­‐2	  for	  24	  hours	  in	  wells	  
coated	  with	  anti-­‐CD16	  mAb	  or	   isotype-­‐matched	  control	  mAb.	  IFN-­‐γ	  release	  was	  assessed	  by	  ELISA.	  Data	  shows	  
mean	  ±	  SEM	  from	  3	  donors.	  *	  =	  p	  <0.05,	  **	  =	  p<0.01,	  ns	  =	  non-­‐significant,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐
test.	  





treatment	  (706	  ±	  355	  pg/ml;	  p	  =	  0.92;	  Figure	  3.4A).	  DMSO-­‐treated	  NK	  cells	  that	  were	  stimulated	  on	  
anti-­‐CD16	  mAb	   showed	   a	   robust	   release	   of	   IFN-­‐γ	   as	   expected	   (from	   411	   ±	   183	   pg/ml	   on	   isotype-­‐
matched	   control	   surfaces	   to	   3700	   pg/ml	   ±	   420	   pg/ml	   on	   anti-­‐CD16;	   Figure	   3.4A).	   Treatment	  with	  
lenalidomide	  resulted	  in	  a	  further	  two-­‐fold	  increase	  in	  the	  amount	  of	  IFN-­‐γ	  secreted	  by	  primary	  NK	  
cells	  after	  ligation	  of	  CD16	  (from	  3700	  ±	  420	  pg/ml	  without	  lenalidomide	  to	  8320	  ±	  370	  pg/ml	  with	  
1.0	  µM	  lenalidomide;	  p	  =	  0.002;	  Figure	  3.4A).	  This	  demonstrates	   that	   IFN-­‐γ	  production	  after	  CD16	  
ligation	  is	  augmented	  by	  lenalidomide	  treatment.	  	  
In	  order	   to	   see	  whether	   IL-­‐2	   is	   required	   for	   this	   increase	   in	   IFN-­‐γ	   production,	   the	  experiment	  was	  
also	  carried	  out	   in	  the	  absence	  of	   IL-­‐2.	  Much	  less	   IFN-­‐γ	  was	  secreted	  after	  CD16	  ligation	  when	  IL-­‐2	  
was	  not	  present	  (341	  pg/ml;	  Figure	  3.4B).	  This	  is	  to	  be	  expected,	  as	  IL-­‐2	  is	  a	  potent	  activator	  of	  NK	  
cells	  (Trinchieri,	  1989).	  Also,	  no	  increase	  in	  IFN-­‐γ	  was	  observed	  when	  NK	  cells	  were	  treated	  with	  0.1-­‐
10	   µM	   lenalidomide	   (340	   ±	   90	   pg/ml	   without	   lenalidomide	   to	   601	   ±	   254	   pg/ml	   with	   10	   µM	  
lenalidomide;	  p	  =	  0.414;	  Figure	  3.4B).	  This	  suggests	  that	  both	  CD16	  ligation	  and	  the	  presence	  of	  IL-­‐2	  
are	  required	  for	  lenalidomide	  treatment	  to	  augment	  IFN-­‐γ	  secretion.	  
	  
Figure	   3.5	   –	   Surface	   expression	   of	   LFA-­‐1	   and	   NKG2D	   on	   primary	   NK	   cells.	   NK	   cells	   from	   2	   donors	   were	  
analysed	   by	   flow	   cytometry	   for	   surface	   expression	   of	   (A)	   LFA-­‐1	   and	   (B)	   NKG2D.	   Specific	   staining	   (blue)	   is	  
compared	  to	  isotype	  control	  (grey).	  





To	   test	   whether	   this	   is	   true	   of	   other	   activating	   receptors,	   NKG2D-­‐induced	   NK	   cell	   activation	   was	  
assessed.	  NKG2D	  is	  a	  stress-­‐inducible	  activating	  receptor,	  which	  requires	  co-­‐ligation	  of	  the	   integrin	  
LFA-­‐1	   to	   elicit	   full	   NK	   cell	   responses.	   Primary	   NK	   cells	   were	   analysed	   by	   flow	   cytometry	   for	   the	  
surface	   expression	  of	  NKG2D	  and	   LFA-­‐1	   (Figure	   3.5).	   Both	  NKG2D	  and	   LFA-­‐1	  were	  present	   on	   the	  
surface	   of	   primary	   NK	   cells,	   as	   expected,	   and	   this	   was	   true	   for	   NK	   cells	   from	   multiple	   different	  
donors	  (Figure	  3.5).	  NK	  cells	  were	  then	  activated	  on	  surfaces	  coated	  with	  anti-­‐NKG2D	  mAb	  or	  MICA-­‐
Fc	  (to	  ligate	  NKG2D)	  and	  ICAM-­‐1	  (to	  ligate	  LFA-­‐1).	  Both	  anti-­‐NKG2D	  mAb	  and	  recombinant	  MICA	  (the	  
ligand	   for	   NKG2D)	   are	   able	   to	   ligate	   NKG2D	   on	   the	   surface	   of	   NK	   cells.	   Ligation	   of	   LFA-­‐1	   alone	  
triggers	  the	  NK	  cells	  to	  migrate	  but	  does	  not	  activate	  the	  cells	  (Culley	  et	  al.,	  2009).	  Ligation	  of	  NKG2D	  
alone	  partially	  stimulates	  the	  NK	  cells,	  but	  does	  not	  induce	  full	  NK	  cell	  effector	  functions	  (Culley	  et	  
al.,	   2009;	  Bryceson	  et	  al.,	   2009).	   This	   is	   clearly	   seen	   in	  Figure	  3.6A,	  where	   the	  DMSO-­‐treated	  cells	  
secreted	  very	   little	   IFN-­‐γ	  when	   LFA-­‐1	  or	  NKG2D	  were	   ligated	  alone	   (262	  ±	  89	  pg/ml	  and	  271	  ±	  53	  
pg/ml	   respectively).	   Co-­‐ligation	   of	   NKG2D	   and	   LFA-­‐1	   (through	   anti-­‐NKG2D	  mAb	   and	   recombinant	  
ICAM-­‐1)	   resulted	   in	   a	   substantial	   induction	   of	   IFN-­‐γ	   and	   this	   was	   significantly	   enhanced	   with	  
lenalidomide	  treatment	  (from	  1730	  ±	  224	  pg/ml	  without	   lenalidomide	  to	  2850	  ±	  213	  pg/ml	  with	  1	  
µM	   lenalidomide;	   p	   =	   0.038;	   Figure	   3.6A).	   This	   suggests	   that	   full	  NK	   cell	   activation	   is	   required	   for	  
lenalidomide	  to	  have	  an	  effect.	  	  
When	  MICA-­‐Fc	  was	  used	   to	   ligate	  NKG2D	   instead	  of	   a	  monoclonal	   antibody,	   the	   results	   show	   the	  
same	   trend.	   ICAM-­‐1	   alone	  was	   not	   sufficient	   to	   induce	   IFN-­‐γ	   secretion	   from	  primary	  NK	   cells	   and	  
	  
Figure	  3.6	  –	  Lenalidomide	  enhances	  NK	  cell	   IFN-­‐γ 	   secretion	  after	   ligation	  of	  NKG2D	  and	  LFA-­‐1.	  Primary	  NK	  
cells	  were	  treated	  with	  DMSO	  or	  0.1-­‐10	  µM	  lenalidomide	  (+150	  U/ml	  IL-­‐2)	  for	  24	  hours	  in	  wells	  coated	  with	  (A)	  
anti-­‐NKG2D	  mAb,	  recombinant	  ICAM-­‐1	  or	  both	  (B)	  recombinant	  MICA-­‐Fc,	  recombinant	  ICAM-­‐1	  or	  both.	  IFN-­‐γ	  
release	  was	  assessed	  by	  ELISA.	  Data	  shows	  mean	  ±	  SEM	  from	  3	  donors.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ns	  =	  non-­‐
significant,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  
	  





lenalidomide	   treatment	   did	   not	   change	   this	   (Figure	   3.6B).	   The	   combination	   of	   recombinant	  MICA	  
and	  recombinant	  ICAM-­‐1	  activated	  the	  NK	  cells	  and	  led	  to	  a	  strong	  induction	  of	  IFN-­‐γ	  (from	  262	  ±	  89	  
pg/ml	  on	  ICAM-­‐1	  alone	  to	  3180	  ±	  318	  pg/ml	  on	  MICA-­‐FC	  +	  ICAM-­‐1;	  Figure	  3.6B).	  Treatment	  with	  0.1	  
µM	   lenalidomide	  was	   enough	   to	   augment	   IFN-­‐γ	   secretion	   (from	  3180	   ±	   318	   pg/ml	   to	   4230	   ±	   509	  
pg/ml;	  p	  =	  0.026;	  Figure	  3.6B).	  1	  µM	  lenalidomide	  treatment	  further	  augmented	  IFN-­‐γ	  secretion	  to	  -­‐
5100	  ±	  630	  pg/ml	  (p	  =	  0.0013),	  although	  this	  was	  significantly	  decreased	  with	  10	  µM	  lenalidomide	  
treatment	   (Figure	   3.6B).	   Interestingly,	   NK	   cells	   stimulated	   on	   surfaces	   coated	   with	   MICA	   alone	  
showed	  an	   increase	   in	   IFN-­‐γ	   secretion	  compared	  to	   ICAM-­‐1	  alone	   (262	  ±	  89	  pg/ml	  with	   ICAM-­‐1	  to	  
1740	   ±	   144	   pg/ml	   with	   MICA;	   Figure	   3.6B).	   However	   this	   was	   not	   significantly	   affected	   by	   any	  
concentration	  of	  lenalidomide	  tested	  (2840	  ±	  279	  pg/ml	  with	  0.1	  µM	  lenalidomide;	  p	  =	  0.578;	  Figure	  
3.6B).	  Again,	  this	  demonstrates	  that	  full	  NK	  cell	  activation	  through	  the	  co-­‐ligation	  of	  NKG2D	  and	  LFA-­‐
1	  is	  required	  in	  this	  case	  to	  observe	  an	  effect	  with	  lenalidomide	  treatment.	  
Combinations	   of	   activating	   receptors	   have	   been	   shown	   to	   act	   synergistically	   to	   activate	   NK	   cells	  
without	  the	  need	  for	  LFA-­‐1	  co-­‐ligation	  (Bryceson	  et	  al.,	  2006b).	  One	  such	  combination	  is	  NKG2D	  and	  
	  
Figure	  3.7	  –	  Lenalidomide	  enhances	  synergistic	  NK	  cell	  activation	  through	  NKG2D	  and	  2B4	  ligation.	  (A)	  NK	  
cells	  from	  2	  donors	  were	  analysed	  by	  flow	  cytometry	  for	  surface	  expression	  of	  2B4.	  Specific	  staining	  (blue)	  is	  
compared	  to	  isotype	  control	  (grey).	  (B)	  Primary	  NK	  cells	  were	  treated	  with	  DMSO	  or	  0.1-­‐10	  µM	  lenalidomide	  
(+	  150	  U/ml	  IL-­‐2)	  for	  24	  hours	  in	  wells	  coated	  with	  anti-­‐NKG2D	  mAb,	  anti-­‐2B4	  mAb	  or	  both.	  IFN-­‐γ	  release	  was	  
assessed	  by	  ELISA.	  Data	  shows	  mean	  ±	  SEM	  from	  3	  donors.	  *	  =	  p	  <0.05,	  Two	  way	  ANOVA	  with	  Tukey’s	  post	  
test.	  
	  





2B4,	  a	  member	  of	  the	  SLAM-­‐related	  receptor	  family.	  Surface	  expression	  of	  2B4	  on	  primary	  NK	  cells	  
was	   confirmed	   by	   flow	   cytometry	   (Figure	   3.7A).	   To	   test	   whether	   lenalidomide	   enhances	   NK	   cell	  
responses	  following	  NK	  cell	  activation	  through	  NKG2D	  and	  2B4,	  primary	  NK	  cells	  were	  treated	  with	  
0.1-­‐10	   µM	   lenalidomide	   in	   the	   presence	   of	   immobilised	   anti-­‐NKG2D	   and	   anti-­‐2B4	   mAbs.	   As	  
expected,	  IFN-­‐γ	  secretion	  was	  negligible	  when	  either	  receptor	  was	  ligated	  separately;	  IFN-­‐γ	  secretion	  
was	  less	  than	  390	  pg/ml	  in	  all	  conditions	  and	  this	  was	  not	  enhanced	  with	  lenalidomide	  treatment.	  In	  
contrast,	  co-­‐ligation	  of	  both	  receptors	  led	  to	  a	  robust	  release	  of	  IFN-­‐γ	  (2-­‐fold	  greater	  than	  co-­‐ligation	  
of	  NKG2D	  and	  LFA-­‐1).	  Notably,	  IFN-­‐γ	  release	  was	  further	  increased	  in	  the	  presence	  of	  lenalidomide	  
(6610	   ±	   620	   pg/ml	  without	   lenalidomide	   to	   10740	   ±	   380	   pg/ml	  with	   1	  µM	   lenalidomide;	   p<0.05;	  
Figure	  3.7B).	  	  
Together,	  this	  establishes	  that	  lenalidomide	  increases	  IFN-­‐γ	  secretion	  irrespective	  of	  which	  activating	  
receptor	   (or	   synergistic	   combination	   thereof)	   is	   ligated.	   Importantly,	   this	   effect	   is	   only	   observed	  
when	  NK	  cells	  are	  appropriately	  activated	  and	  in	  the	  presence	  of	  IL-­‐2.	  Lenalidomide	  is	  not	  sufficient	  
to	  activate	  NK	  cells	  alone.	  The	  fact	  that	  lenalidomide	  does	  not	  elicit	  NK	  cell	  effector	  functions	  in	  the	  
absence	  of	  activating	  receptor	   ligation	  indicates	  that	  NK	  cells	  retain	  their	  specificity	  and	  would	  not	  
activate	  without	  appropriate	  triggers	  in	  the	  presence	  of	  the	  drug.	  	  	  
	  
	  
Figure	  3.8	  –	  Lenalidomide	  does	  not	  affect	  IFN-­‐γ 	  mRNA	  induction.	  Primary	  NK	  cells	  were	  treated	  with	  DMSO	  
or	   1.0	  µM	   lenalidomide	   (+	   150	   U/ml	   IL-­‐2)	   for	   4	   hours	   in	   wells	   coated	  with	   (A)	   anti-­‐CD16	  mAb	   or	   isotype-­‐
matched	   control	   mAb,	   or	   (B)	   recombinant	   ICAM-­‐1	   or	   recombinant	  MICA-­‐Fc	   and	   ICAM-­‐1.	   IFN-­‐γ	   mRNA	   was	  
assessed	   by	   qRT-­‐PCR	   and	   is	   normalised	   to	  GAPDH.	   Data	   shows	   triplicate	   data	   from	   (A)	   3	   donors	   and	   (B)	   2	  
donors.	  Data	  points	  for	  each	  donor	  are	  shaded	  the	  same.	  Red	  line	  shows	  the	  mean.	  ***	  =	  p	  <0001,	  ns	  =	  non-­‐
significant,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  
	  





3.2.3 Lenalidomide	   does	   not	   affect	   IFN-­‐γ 	   mRNA	   transcription	   or	   activating	   receptor	   surface	  
expression	  	  	  
	  
To	  test	  whether	  this	  enhancement	  in	  IFN-­‐γ	  secretion	  is	  due	  to	  increased	  transcription	  of	  IFN-­‐γ	  mRNA,	  
primary	   NK	   cells	   were	   activated	   on	   surfaces	   coated	   with	   either	   anti-­‐CD16	   mAb	   or	   MICA-­‐Fc	   and	  
ICAM-­‐1.	  Cells	  were	  then	  lysed	  and	  RNA	  was	  extracted.	  Both	  stimulatory	  conditions	  elicited	  a	  strong	  
induction	   of	   IFN-­‐γ	   mRNA	   compared	   to	   the	   respective	   non-­‐stimulatory	   conditions,	   as	   expected	  
(Figure	  3.8).	  On	  anti-­‐CD16	  mAb,	  two	  of	  the	  donors	  showed	  an	  approximately	  10-­‐fold	  increase	  in	  IFN-­‐
γ	  mRNA	   compared	   to	  unstimulated	   conditions	   (Figure	  3.8A).	  One	  of	   the	  donors	   showed	  a	   greater	  
than	   20-­‐fold	   increase	   in	   IFN-­‐γ	   mRNA	   upon	   stimulation,	   although	   this	   can	   be	   explained	   by	   donor	  
	  
Figure	  3.9	  –	  No	  change	  in	  cell	  surface	  expression	  of	  receptors	  after	  lenalidomide	  treatment.	  Representative	  
histograms	  of	  LFA-­‐1,	  NKG2D	  and	  CD16	  expression	  on	  (A)	  unstimulated	  cultured	  primary	  NK	  cells	  treated	  with	  
DMSO	   (blue)	   or	   1	  µM	   lenalidomide	   (red)	   for	   2	   hours	   and	   (B)	   NK	   cells	   treated	   with	   DMSO	   (blue)	   or	   1	   µM	  
lenalidomide	  (red)	  and	  stimulated	  on	  immobilised	  anti-­‐CD16	  mAb	  for	  2	  hours.	  Cells	  were	  stained	  with	  isotype-­‐
matched	  control	  mAb	  (grey)	  or	  mAbs	  against	  LFA-­‐1,	  NKG2D	  and	  CD16.	  Representative	  of	  3	  separate	  donors.	  





variability	   (Figure	  3.8A).	  However,	  no	   further	   increase	   in	   IFN-­‐γ	  mRNA	   induction	  was	  observed	  with	  
lenalidomide	   treatment	   in	   NK	   cells	   from	   any	   of	   the	   three	   donors	   (Figure	   3.8A).	   The	   same	   was	  
observed	   after	   stimulation	  with	  MICA	   and	   ICAM-­‐1.	   One	   donor	   showed	   an	   approximately	   3.5-­‐fold	  
increase	  in	  IFN-­‐γ	  mRNA	  production	  after	  stimulation	  and	  the	  other	  donor	  showed	  an	  approximately	  
12.5-­‐fold	   increase	   (Figure	  3.8B).	  Again,	  no	   further	   increase	   in	   IFN-­‐γ	  mRNA	   induction	  was	  observed	  
with	   1	   µM	   lenalidomide	   treatment	   (Figure	   3.8B).	   Also,	   it	   is	   worth	   noting	   that	   the	   donor	   that	  
responded	  more	  strongly	   than	   the	  others	   in	  each	  experiment	  was	  not	   the	  same	  donor.	   	  Thus,	   the	  
increase	   in	   IFN-­‐γ	   secretion	   observed	   after	   ligation	   of	   multiple	   different	   activating	   receptors	  
separately	  is	  not	  due	  to	  an	  increase	  in	  IFN-­‐γ	  mRNA	  production.	  	  	  
The	  results	  shown	  so	  far	  could	  also	  be	  an	  outcome	  of	  an	  increase	  in	  the	  cell	  surface	  expression	  of	  NK	  
cell	  activating	  receptors.	  To	  assess	  whether	  this	   is	  the	  case,	  NK	  cells	  were	  treated	  with	  DMSO	  or	  1	  
µM	  lenalidomide	  and	   incubated	  on	   isotype-­‐matched	  control	  surfaces	  or	  surfaces	  coated	  with	  anti-­‐
CD16	  mAb.	  The	  surface	  expression	  of	  LFA-­‐1,	  NKG2D	  and	  CD16	  was	  then	  checked	  by	  flow	  cytometry	  
(Figure	   3.9).	   Cell	   surface	   expression	   of	   all	   three	   receptors	   remained	   similar	   after	   lenalidomide	  
treatment	   in	   unstimulated	   cells	   (Figure	   3.9A).	   When	   cells	   were	   stimulated	   with	   anti-­‐CD16	   mAb,	  
expression	  of	  CD16	  was	  markedly	  reduced	  compared	  to	  unstimulated	  cells,	  as	  expected,	  consistent	  
with	  CD16	  being	  shed	  from	  the	  surface.	  However,	  there	  was	  again	  no	  difference	  in	  NK	  cells	  that	  had	  
been	  treated	  with	  1	  µM	  lenalidomide	  (Figure	  3.9B).	  Thus,	  an	   increase	   in	   IFN-­‐γ	   secretion	  caused	  by	  
lenalidomide	  is	  not	  due	  to	  a	  higher	  surface	  expression	  of	  CD16,	  NKG2D	  or	  LFA-­‐1,	  and	  is	  not	  the	  result	  
of	  increased	  mRNA	  production.	  
	  
3.2.4 Lenalidomide	   increases	   the	   proportion	   of	   cells	   secreting	   IFN-­‐γ 	   as	   well	   as	   the	   amount	   of	  
cytokine	  produced	  per	  cell	  
	  
The	  enhancement	   in	   IFN-­‐γ	   secretion	  with	   lenalidomide	   treatment	   could	   involve	  an	   increase	   in	   the	  
number	  of	  NK	  cells	  secreting	   IFN-­‐γ	  and/or	  an	   increase	   in	  each	   individual	  cell’s	  production	  of	   IFN-­‐γ.	  
This	  distinction	   is	   important	   for	  understanding	   the	  effect	  of	   lenalidomide	  on	  a	   single	   cell	   level.	   To	  
test	   this	   initially,	   primary	   NK	   cells	   were	   stimulated	   on	   immobilised	   anti-­‐CD16	   mAb	   or	   isotype-­‐
matched	  control	  mAb	   in	   the	  presence	  of	  DMSO	  or	  1	  µM	  lenalidomide	  and	   then	   fixed	  and	   stained	  
with	   fluorescently	   labelled	   anti-­‐IFN-­‐γ	   mAb.	   Expression	   of	   intracellular	   IFN-­‐γ	   was	   then	   checked	   by	  
flow	  cytometry	  (Figure	  3.10).	  	  





The	   dot	   plot,	   representative	   of	   2	   separate	   donors,	   shows	   that	   lenalidomide	   treatment	   does	   not	  
change	   the	  percentage	  of	   cells	  expressing	   IFN-­‐γ	   in	  unstimulated	  conditions.	  This	   is	   consistent	  with	  
the	   ELISA	   results	   (Figure	   3.4).	  When	   the	   cells	  were	   stimulated	  with	   anti-­‐CD16	  mAb,	   there	  was	   an	  
increase	   in	   the	   number	   of	   cells	   expressing	   IFN-­‐γ.	   Visual	   inspection	   of	   the	   dot	   plots	   suggests	   that	  
more	  cells	  have	  higher	  fluorescence	  intensities	  in	  the	  lenalidomide-­‐treated	  sample	  (Figure	  3.10A).	  To	  
quantify	   this,	   the	   geometric	   mean	   fluorescence	   intensity	   (gMFI)	   per	   sample	   was	   calculated.	   The	  
results	   show	   that	   lenalidomide	   treatment	   does	   indeed	   significantly	   increase	   the	   gMFI	   after	  
stimulation	  with	  anti-­‐CD16	  mAb,	  indicating	  that	  more	  IFN-­‐γ	  is	  being	  produced	  per	  cell	  (Figure	  3.10B).	  	  	  
In	   order	   to	   confirm	   these	   results	   and	   investigate	   this	   further,	   IFN-­‐γ	   production	   was	   assessed	   by	  
confocal	  microscopy.	  Primary	  NK	  cells	  were	  incubated	  on	  glass	  slides	  coated	  with	  anti-­‐CD16	  mAb	  in	  
the	   presence	   of	   0.1-­‐10	   µM	   lenalidomide.	   Cells	   were	   then	   fixed	   and	   stained	   with	   Alexa488-­‐	  
conjugated	  anti-­‐IFN-­‐γ	  mAb,	  and	  with	  Atto590-­‐conjugated	  phalloidin	  to	  visualise	  F-­‐actin,	  and	  imaged	  
by	   confocal	  microscopy	   (Figure	   3.11).	   In	   the	   absence	   of	   lenalidomide,	   expression	   of	   IFN-­‐γ	   protein	  
could	  be	  detected	  within	  30	  min	  in	  a	  small	  proportion	  of	  primary	  NK	  cells	  (2.5	  ±	  1.5%)	  and	  peaked	  
120	  min	  after	  stimulation,	  when	  22	  ±	  2%	  of	  NK	  cells	  expressed	  IFN-­‐γ	  (Figure	  3.12A).	  
	  
Figure	  3.10	  –	  Lenalidomide	  treatment	  increases	  IFN-­‐γ 	  production	  by	  NK	  cells.	  	  (A)	  Representative	  example	  of	  
IFN-­‐γ	   staining	   in	  NK	  cells	   treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	   for	  2	  hours	  on	  either	  anti-­‐CD16	  mAb	  or	  
isotype-­‐matched	  control	  mAb.	  Representative	  of	  2	  donors.	  (B)	  The	  geometric	  fluorescence	  intensity	  (gMFI)	  of	  
IFN-­‐γ	  fluorescence	  in	  the	  CD56+/IFN-­‐γ+	  population	  in	  cells	  treated	  as	  in	  (A).	  Graph	  shows	  mean	  ±	  SEM	  from	  2	  
donors.	  
	  





The	  percentage	  of	  NK	  cells	  expressing	   IFN-­‐γ	  decreased	  by	  240	  min	  suggesting	   that	   the	  majority	  of	  
IFN-­‐γ	  had	  been	  secreted	  by	  this	  time	  (Figure	  3.12A,	  white	  bars).	  The	  effect	  of	  1	  µM	  lenalidomide	  also	  
peaked	  120	  min	  after	  stimulation,	  almost	  doubling	  the	  proportion	  of	  NK	  cells	  expressing	  IFN-­‐γ	  from	  
22	  ±	  2%	  to	  41	  ±	  5%	  (Figure	  3.12A,	  striped	  bars).	  Lenalidomide	  had	  no	  impact	  on	  the	  proportion	  of	  NK	  
cells	  expressing	  IFN-­‐γ	  at	  either	  30	  or	  60	  min	  stimulation.	  A	  caveat	  to	  this	  is	  that,	  in	  this	  experiment,	  
the	  cells	  with	  120	  and	  240	  min	  stimulation	  were	  exposed	  to	  lenalidomide	  for	  a	  longer	  length	  of	  time	  
than	  earlier	  time	  points.	  To	  correct	  for	  this,	  in	  a	  separate	  experiment,	  cells	  were	  treated	  at	  the	  start	  
of	  the	  experiment	  and	  added	  to	  anti-­‐CD16	  mAb	  coated-­‐surfaces	  in	  reverse	  order	  for	  the	  time	  course	  
	  
Figure	  3.11–	  Representative	  confocal	  microscopy	   images	  of	  NK	  cell	   IFN-­‐γ 	  production.	   Images	  show	  F-­‐actin	  
(red)	  and	  IFN-­‐γ	  (shown	  in	  greyscale	  in	  middle	  column,	  and	  green	  in	  merged	  image)	  in	  pNK	  cells	  stimulated	  for	  
120	  mn	  on	  surfaces	  coated	  with	  IgG1	  isotype	  control	  mAb	  or	  anti-­‐CD16	  mAb	  in	  the	  presence	  of	  DMSO	  or	  1	  
µM	  lenalidomide	  (+	  150	  U/ml	  IL-­‐2).	  Scale	  bars:	  10	  µm.	  





(Figure	  3.12B).	  	  
This	  meant,	  for	  example,	  that	  cells	  undergoing	  30	  min	  stimulation	  with	  anti-­‐CD16	  mAb	  had	  120	  min	  
incubation	  with	  lenalidomide	  prior	  to	  plating	  (Figure	  3.12B).	  This	  experiment	  showed	  similar	  results;	  
the	   effect	   of	   lenalidomide	   peaked	   after	   120	   min	   stimulation	   (increasing	   the	   proportion	   of	   cells	  
expressing	   IFN-­‐γ	   from	   43%	   without	   lenalidomide	   to	   64%	   with	   1	   µM	   lenalidomide;	   Figure	   3.12B).	  
Interestingly,	   there	  was	   still	   no	   effect	   of	   lenalidomide	  at	   30	  or	   60	  min	   stimulation	  with	   anti-­‐CD16	  
mAb.	  This	  confirmed	  that	  the	  effect	  of	  lenalidomide	  on	  primary	  NK	  cell	  IFN-­‐γ	  production	  only	  occurs	  
after	  the	  NK	  cells	  have	  been	  stimulated	  with	  anti-­‐CD16	  mAb	  for	  a	  minimum	  of	  90	  min.	  	  	  
To	  investigate	  this	  further,	  lenalidomide	  was	  used	  at	  a	  range	  of	  concentrations	  (0.1-­‐10	  µM)	  and	  NK	  
cells	  were	  stimulated	  for	  120	  min,	  as	  this	  was	  the	  peak	  time	  for	  IFN-­‐γ	  production.	  1	  µM	  and	  10	  µM	  
lenalidomide	  increased	  the	  proportion	  of	  cells	  expressing	  IFN-­‐γ	  from	  19	  ±	  3%	  to	  35	  ±	  2%	  or	  33	  ±	  2%	  
respectively	   (Figure	   3.13).	   Lenalidomide	   treatment	   did	   not	   significantly	   increase	   the	   proportion	  of	  
cells	   expressing	   IFN-­‐γ	   on	   isotype-­‐matched	   control	   mAb-­‐coated	   slides.	   This	   establishes	   that	   the	  
increase	   in	   total	   IFN-­‐γ	   secreted	   from	   anti-­‐CD16-­‐stimulated	   NK	   cells	   caused	   by	   lenalidomide	   is,	   at	  
least	  to	  some	  extent,	  due	  to	  an	  increase	  in	  the	  proportion	  of	  primary	  NK	  cells	  producing	  IFN-­‐γ.	  	  
	  
Figure	  3.12	  –	  Timecourse	  for	  IFN-­‐γ 	  production	  with	  CD16	  stimulation.	  (A)	  The	  proportion	  of	  cells	  expressing	  
IFN-­‐γ	  after	  stimulation	  on	  anti-­‐CD16	  mAb-­‐coated	  surfaces	  in	  the	  presence	  of	  DMSO	  or	  1	  µM	  lenalidomide	  (+	  
150	  U/ml	   IL-­‐2)	   for	  30-­‐240	  min.	  Graph	   shows	  mean	  ±	   SD,	  n	  >200	   from	  3	  donors.	   (B)	  The	  proportion	  of	   cells	  
expressing	   IFN-­‐γ	   after	   stimulation	   on	   anti-­‐CD16	   mAb-­‐coated	   surfaces	   in	   the	   presence	   of	   DMSO	   or	   1	   µM	  
lenalidomide	  (+	  150	  U/ml	  IL-­‐2)	  for	  30-­‐240	  min.	  All	  cells	  treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  for	  240	  min	  
total	  and	  added	   to	  surfaces	   in	   reverse	  order	   for	   the	   time	  course	   (e.g.	   for	  30	  min	  stimulation,	  NK	  cells	  were	  
treated	   for	  210	  min	  before	  plating).	  Graph	   shows	  mean	  ±	   SEM,	  n	  >100	   from	  2	  donors.	   *	  =	  p	  <0.05,	   **	  =	  p	  
<0.01,	  ***	  =	  p	  <0.001,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  





To	  test	  whether	  the	  amount	  of	  IFN-­‐γ	  produced	  by	  each	  cell	  is	  influenced	  by	  lenalidomide	  treatment	  
(as	  suggested	  by	  the	  flow	  cytometry	  data	  in	  Figure	  3.10),	  the	  number	  of	  IFN-­‐γ	  vesicles	  per	  cell	  was	  
quantified.	   The	   average	   number	   of	   vesicles	   per	   cell	   significantly	   increased	   with	   1.0	   and	   10	   µM	  
lenalidomide	  treatment	  (from	  14	  ±	  2	  without	   lenalidomide	  to	  35	  ±	  4	  or	  37	  ±	  4	  respectively;	  Figure	  
3.14A).	   In	   addition,	   the	   total	   fluorescence	   intensity	   per	   cell	   increased	   20-­‐fold	   with	   lenalidomide	  
treatment	  (from	  1930	  ±	  310	  (AU)	  without	  lenalidomide	  to	  39100	  ±	  5900	  with	  10	  µM	  lenalidomide;	  
Figure	  3.14B).	  Both	  of	  these	  results	  suggest	  that	  lenalidomide	  treatment	  substantially	  increases	  the	  
amount	  of	  IFN-­‐γ	  produced	  by	  each	  primary	  NK	  cell.	  	  	  
	  
Figure	  3.13	  –	  Lenalidomide	  increases	  the	  proportion	  of	  primary	  NK	  cells	  expressing	  IFN-­‐γ .	  Graph	  shows	  the	  
proportion	  of	   cells	   expressing	   IFN-­‐γ	   after	   stimulation	  on	   anti-­‐CD16	  mAb-­‐coated	   surfaces	   in	   the	  presence	  of	  
0.1-­‐10	   lenalidomide	   (+	   150	  U/ml	   IL-­‐2).	   Graph	   shows	  mean	  ±	   SEM,	   n	   >100	   per	   donor	   from	   3	   donors.	   *	   =	   p	  




Figure	  3.14	  –	  Lenalidomide	   increases	  the	  amount	  of	   IFN-­‐γ 	  produced	  per	  cell.	   (A)	  Number	  of	   IFN-­‐γ	  detected	  
per	   cell	   after	   stimulation	   on	   anti-­‐CD16	  mAb-­‐coated	   surfaces	   in	   the	   presence	   of	   0.1-­‐10	   lenalidomide	   (+	   150	  
U/ml	  IL-­‐2).	  (B)	  Sum	  IFN-­‐γ	  fluorescence	  per	  cell	  in	  same	  cells	  as	  in	  (A).	  	  Each	  data	  point	  represents	  a	  single	  cell	  
and	  red	  line	  shows	  the	  mean.	  	  n	  =	  75-­‐111	  from	  3	  donors.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001,	  one	  way	  
ANOVA	  with	  Tukey’s	  post-­‐test.	  
	  





Together,	  these	  data	  establish	  a	  dual	  effect	  of	  lenalidomide	  on	  IFN-­‐γ	  production	  in	  primary	  NK	  cells.	  
Lenalidomide	  treatment	  (i)	  influences	  the	  NK	  cell	  population	  –	  almost	  doubling	  the	  proportion	  of	  NK	  
cells	  expressing	   IFN-­‐γ	  –	  and	  (ii)	  affects	  NK	  cells	  on	  a	  single	  cell	   level,	  with	  a	  20-­‐fold	   increase	   in	  the	  
amount	  of	  cytokine	  produced	  per	  cell.	  
	  
3.2.5 Lenalidomide	  and	  immune	  synapse	  formation	  
	  
The	  next	  aim	  was	  to	  determine	  whether	  lenalidomide	  treatment	  affected	  the	  formation	  of	  immune	  
synapses,	  as	  this	  could	  explain	  why	  a	  higher	  proportion	  of	  NK	  cells	  produced	  IFN-­‐γ.	  NK	  cell	  activating	  
immune	   synapse	   formation	   occurs	   in	   a	   number	   of	   stages,	   including	   initial	   recognition,	   conjugate	  
formation,	   cell	   spreading	   and	   F-­‐actin	   polymerisation	   (Orange,	   2008).	   To	   visualise	   these	   steps,	  
primary	   NK	   cells	   were	   imaged	   on	   glass	   slides,	   or	   in	   conjugate	   with	   target	   cells,	   by	   confocal	  
microscopy.	   First,	   conjugate	   formation	   was	   observed.	   Daudi	   cells	   that	   had	   been	   previously	  
transfected	  to	  express	  CD20	  tagged	  to	  GFP	  (Daudi-­‐CD20-­‐GFP)	  were	  used	  as	  target	  cells	  (so	  that	  they	  
could	  be	  distinguished	   from	  NK	  cells	   in	   the	  microscopy	   images).	  Primary	  NK	  cells	  and	  Daudi-­‐CD20-­‐
GFP	  cells	  were	  pre-­‐treated	  with	  DMSO	  or	  10	  µM	  lenalidomide	  for	  24	  hours	  prior	  to	  co-­‐incubation.	  
The	  cells	  were	  co-­‐cultured	  for	  30	  min	  before	  fixation	  and	  were	  stained	  with	  phalloidin	  (conjugated	  to	  
	  
Figure	   3.15	   –	   Representative	   microscopy	   images	   of	   conjugate	   formation	   after	   lenalidomide	   treatment.	  	  
Daudi-­‐CD20-­‐GFP	  (green)	  and	  primary	  NK	  cells	  were	  treated	  with	  DMSO	  or	  10	  µM	  lenalidomide	  for	  24	  hours	  
prior	   to	   co-­‐culture	   for	   30	   min	   in	   different	   combinations.	   White	   arrows	   show	   conjugates	   that	   are	   not	  
considered	  immune	  synapses.	  Yellow	  arrows	  show	  activating	  immune	  synapses.	  Scale	  bars	  =	  10	  µm	  





Atto647)	  to	  visualise	  F-­‐actin	  (Figure	  3.15).	  Visual	  inspection	  of	  the	  images	  suggested	  that	  the	  fewest	  
immune	   synapses	  were	   found	   in	   the	   samples	  where	   both	   the	  NK	   cells	   and	   target	   cells	  were	   pre-­‐
treated	  with	  DMSO.	  In	  contrast,	  the	  highest	  frequency	  of	  synapses	  appeared	  to	  occur	  in	  the	  samples	  
where	  both	  cell	  types	  were	  pre-­‐treated	  with	  10	  µM	  lenalidomide	  (Figure	  3.15).	  In	  order	  to	  quantify	  
this,	  the	  total	  number	  of	  conjugates	  (white	  arrows;	  Figure	  3.15)	  was	  measured	  for	  each	  image	  and	  
activating	   immune	   synapses	   (yellow	   arrows;	   Figure	   3.15)	  were	   identified	   based	   on	   the	   level	   of	   F-­‐
actin	  polymerisation	  at	  the	  contact	  point	  between	  cells.	   	  The	  results	  show	  a	  substantial	   increase	  in	  
the	  proportion	  of	  target	  cells	  that	  are	  part	  of	  activating	   immune	  synapses	  with	  NK	  cells,	   from	  20%	  
when	   both	   cell	   types	   were	   treated	   with	   DMSO	   to	   47%	  when	   both	   cells	   types	   were	   treated	   with	  
lenalidomide	  (Figure	  3.16).	  This	  increase	  was	  only	  observed	  when	  both	  cell	  types	  were	  treated	  with	  
lenalidomide,	  and	  not	  when	  either	  targets	  or	  NK	  cells	  were	  treated	  alone	  (Figure	  3.16).	  These	  results	  
suggest	   that	   lenalidomide	   treatment	   increases	   the	   probability	   that	   NK	   cells	   will	   form	   activating	  
synapses	  when	  they	  contact	  potential	  target	  cells.	  	  
To	   see	   whether	   this	   increase	   in	   immune	   synapse	   formation	   is	   due	   to	   more	   NK	   cells	   becoming	  
activated,	   NK	   cells	   were	   plated	   on	   various	   activating	   conditions	   (and	   appropriate	   controls)	   and	  
incubated	  for	  6	  min	  before	  fixation.	  The	  cells	  were	  then	  stained	  with	  phalloidin	  to	  visualise	  F-­‐actin	  
and	  imaged	  by	  confocal	  microscopy.	  
	  
Figure	  3.16	  –	  Lenalidomide	  increases	  the	  probability	  of	  NK	  cell	  activating	  immune	  synapse	  formation.	  Graph	  
shows	  number	  of	  conjugates	  (grey)	  overlaid	  with	  number	  of	  immune	  synapses	  (white)	  as	  a	  proportion	  of	  total	  
target	  cells.	  n	  =	  100	  from	  2	  donors.	  





The	  activating	  surfaces	  used	  were	  slides	  coated	  with	  anti-­‐CD16	  mAb	  (3	  µg/ml),	  anti-­‐NKG2D	  mAb	  (3	  
µg/ml)	   and	   anti-­‐NKG2D	  mAb	  plus	   ICAM-­‐1	   (2.5	  µg/ml).	  On	   the	   activating	   surfaces,	   the	   primary	  NK	  
cells	  exhibited	  a	  spreading	  phenotype	  typical	  of	  activated	  NK	  cells	  and	  a	  dense	  ring	  of	  F-­‐actin	  could	  
be	  observed	  at	   the	  periphery	  of	   the	  cell	   (Figure	  3.17A,	  white	  arrows).	  The	  cells	  did	  not	  undergo	  a	  
spreading	  response	  on	  slides	  coated	  with	  isotype-­‐matched	  control	  antibody	  or	  recombinant	  ICAM-­‐1	  
(Figure	   3.17A).	   	   However,	   there	   did	   not	   appear	   to	   be	   any	   difference	   between	   cells	   treated	   with	  
	  
Figure	  3.17	  –	  Lenalidomide	  does	  not	  change	  the	  proportion	  of	  NK	  cells	  with	  actin	  rings.	  (A)	  Representative	  
microscopy	   images	  of	  primary	  NK	  cells	  pre-­‐treated	  with	  either	  DMSO	  or	  1	  µM	   lenalidomide	   for	  1	  hour	  and	  
then	  plated	  on	  various	  activating	  conditions	  (anti-­‐CD16	  mAb,	  anti-­‐NKG2D	  mAb	  and	  anti-­‐NKG2D	  plus	  ICAM-­‐1)	  
and	  appropriate	  controls	  (IgG1	  isotype	  control	  mAb	  and	  ICAM-­‐1).	  Cells	  were	  fixed	  and	  permeabilised	  after	  6	  
min	  incubation	  on	  surfaces	  and	  then	  stained	  with	  phalloidin-­‐Atto647	  to	  visualise	  F-­‐actin.	  Actin	  rings	  are	  shown	  
with	  white	  arrows.	  Scale	  bars	  =	  10	  µm.	  (B)	  Proportion	  of	  total	  NK	  cells	  displaying	  an	  actin	  ring	  (dense	  ring	  of	  F-­‐
actin	  around	  periphery	  of	  contact	  area).	  Graph	  shows	  mean	  ±	  SEM,	  n	  >	  120	  from	  3	  independent	  donors.	  





DMSO	  and	  cells	  treated	  with	  1	  µM	  lenalidomide.	  To	  quantify	  this,	  the	  proportion	  of	  cells	  displaying	  
dense	  rings	  of	  F-­‐actin	  was	  assessed	  across	  large	  numbers	  of	  images	  (Figure	  3.17B).	  
The	  results	  show	  that	  the	  proportion	  of	  activated	  NK	  cells	  increases	  dramatically	  when	  the	  NK	  cells	  
are	   stimulated	  on	  anti-­‐CD16	  mAb,	  anti-­‐NKG2D	  mAb	  or	  anti-­‐NKG2D	  mAb	  plus	   ICAM-­‐1,	  as	  expected	  
(from	  approximately	   10%	  actin	   rings	  on	  unstimulated	   surfaces	   to	   approximately	   60%	  on	  activated	  
surfaces,	  Figure	  3.17B).	  However,	  treatment	  with	  1	  µM	  lenalidomide	  did	  not	  change	  the	  proportion	  
of	   NK	   cells	   with	   actin	   rings	   on	   any	   of	   the	   activating	   surfaces	   tested	   (Figure	   3.17B).	   These	   results	  
suggest	   that	   lenalidomide	   does	   not	   affect	   the	   proportion	   of	   NK	   cells	   that	   activate	   under	   these	  
specific	  stimulatory	  conditions.	  	  
In	   order	   to	   test	   whether	   lenalidomide	   treatment	   affected	   the	   size	   of	   primary	   NK	   cells	   during	  
activation,	  the	  cell	  areas	  were	  quantified	  in	  the	  images.	  The	  cell	  periphery	  was	  defined	  by	  phalloidin	  
staining.	  The	  mean	  cell	  area	  was	  significantly	  increased	  in	  lenalidomide-­‐treated	  primary	  NK	  cells	  that	  
had	   been	   stimulated	  with	   anti-­‐NKG2D	  mAb	   and	   ICAM-­‐1	   (from	   219	   ±	   6	  µm2	  without	   lenalidomide	  
treatment	   to	   242	   ±	   5	   µm2	   with	   1	   µM	   lenalidomide;	   Figure	   3.18).	   The	   mean	   cell	   area	   was	   also	  
significantly	   increased	  in	  NK	  cells	  that	  had	  been	  stimulated	  with	  anti-­‐CD16	  mAb	  after	   lenalidomide	  
treatment	  (from	  138	  ±	  3	  µm2	  without	  lenalidomide	  to	  156	  ±	  4	  µm2	  with	  1	  µM	  lenalidomide;	  Figure	  
3.18).	   This	   significant	   enhancement	   in	   cell	   spreading	   area	   was	   not	   seen	   when	   the	   cells	   were	  
	  
Figure	  3.18	  –	  Lenalidomide	  increases	  primary	  NK	  cell	  area	  after	  activation.	  The	  mean	  area	  of	  NK	  cells	  from	  the	  
same	   images	   as	   shown	   in	   Figure	   3.17.	   Graph	   shows	   mean	   ±	   SEM,	   n	   >120	   per	   donor	   from	   3	   independent	  
donors.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ns	  =	  not	  significant.	  One	  way	  ANOVA	  with	  Turkey’s	  post-­‐test	  





incubated	   on	   slides	   coated	   with	   anti-­‐NKG2D	  mAb	   alone	   or	   isotype-­‐matched	   control	   mAb	   (Figure	  
3.18).	  Interestingly,	  when	  LFA-­‐1	  alone	  was	  ligated	  on	  NK	  cells	  (with	  recombinant	  ICAM-­‐1),	  the	  mean	  
cell	   area	   significantly	   increased	   with	   lenalidomide	   treatment	   (from	   131	   ±	   2	   µm2	   without	  
lenalidomide	   to	   148	   ±	   2	   µm2	   with	   1	   µM	   lenalidomide;	   Figure	   3.18).	   These	   results	   suggest	   that	  
lenalidomide	  has	   a	   slight	   enhancing	   effect	   on	   cell	   spreading	   areas	   after	   full	  NK	   cell	   activation	   (via	  
ligation	  of	  CD16	  or	  NKG2D	  +	  ICAM-­‐1)	  and	  after	  ligation	  of	  LFA-­‐1	  alone	  (via	  ICAM-­‐1).	  	  
When	   observing	   the	   images,	   lenalidomide	   treatment	   appeared	   to	   result	   in	   an	   increase	   in	   the	  
proportion	   of	   NK	   cells	   with	   a	   more	   asymmetric	   shape	   compared	   to	   vehicle	   control-­‐treated	   cells.	  
Analysis	  of	  cell	  morphology	   revealed	   that	  1	  µM	  lenalidomide	   treatment	  significantly	   increased	   the	  
mean	  standard	  deviation	  (SD)	  of	  radii	  in	  primary	  NK	  cells	  stimulated	  with	  anti-­‐CD16	  mAb	  (from	  2.7	  ±	  
0.2	  µm	  without	  lenalidomide	  to	  3.6	  ±	  0.2	  µm	  with	  1	  µM	  lenalidomide;	  Figure	  3.19A).	  The	  same	  effect	  
was	   observed	   after	   stimulation	   with	   anti-­‐NKG2D	   mAb	   and	   ICAM-­‐1	   (from	   3.0	   ±	   0.1	   µm	   without	  
lenalidomide	  to	  3.7	  ±	  0.2	  µm	  with	  1	  µM	  lenalidomide;	  Figure	  3.19E).	  No	  effect	  on	  cell	  morphology	  
was	   observed	  when	   cells	  were	   on	   isotype-­‐matched	   control	   surfaces	   (Figure	   3.19B)	   or	   anti-­‐NKG2D	  
mAb	  alone	  (Figure	  3.19D),	  although	  an	  increase	  was	  observed	  in	  cells	  that	  had	  been	  stimulated	  on	  
ICAM-­‐1	  alone	  (Figure	  3.19C).	  Together,	  this	  suggests	  that	  lenalidomide	  treatment	  results	   in	  a	  more	  
asymmetric	  morphology	   in	  NK	   cells,	  which	   could	   explain	   the	   slight	   increase	   in	   cell	   spreading	   area	  
that	  was	  observed.	  
Overall,	   lenalidomide	  treatment	  increases	  the	  probability	  of	  NK	  cell	  activation	  when	  NK	  cells	  are	  in	  
contact	  with	  target	  cells.	  Small	  changes	  in	  NK	  cell	  morphology	  were	  observed,	  however	  lenalidomide	  
does	   not	   increase	   the	   proportion	   of	  NK	   cells	   that	   become	   activated	   on	   surfaces	   coated	  with	   high	  
amounts	   of	   stimulatory	   ligands.	   The	   next	   objective	  was	   therefore	   to	   assess	  whether	   lenalidomide	  
treatment	  has	  an	  effect	  on	  NK	  cell	  activation	  on	  lower	  concentrations	  of	  stimulatory	  ligands.	  






Figure	   3.19	   –	   Lenalidomide	   promotes	   asymmetric	   morphology	   in	   NK	   cells	   after	   activation.	  NK	   cells	   were	  
stimulated	   for	  6	  min	  on	   surfaces	   coated	  with	   (A)	  anti-­‐CD16	  mAb	   (3	  µg/ml),	   (B)	   IgG1	   isotype	  control	  mAb	   (3	  
µg/ml),	  (C)	  recombinant	  ICAM-­‐1	  (2.5	  µg/ml),	  (D)	  anti-­‐NKG2D	  mAb	  (3	  µg/ml)	  and	  (E)	  anti-­‐NKG2D	  mAb	  +	  ICAM-­‐1	  
in	   the	   presence	   of	   DMSO	   or	   1	   µM	   lenalidomide.	   The	   symmetry	   of	   primary	   NK	   cells	   is	   represented	   as	   the	  
standard	  deviation	  of	  the	  radii	  for	  n	  >70	  cells	  from	  3	  donors.	  Each	  data	  point	  represents	  a	  single	  cell	  and	  bars	  
shows	  mean	  ±	  SEM.	  Students	  t-­‐test	  was	  used	  to	  test	  significance.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  <0.001,	  ns	  =	  
not	  significant.	  
	  





3.2.6 Lenalidomide	  lowers	  the	  threshold	  for	  NK	  cell	  activation	  	  
	  
It	  was	  previously	  reported	  that	  there	  is	  a	  threshold	  concentration	  of	  MICA	  needed	  to	  trigger	  a	  ‘stop’	  
signal	   in	  migrating	  NK	  cells,	  and	  to	  form	  a	  symmetrical	  synapse	  characterised	  by	  a	  dense	  ring	  of	  F-­‐
actin	   at	   the	   synapse	   periphery	   (Culley	   et	   al.,	   2009;	   Gruda	   et	   al.,	   2012).	   	   Functionally,	   a	   threshold	  
concentration	  of	  MICA	  is	  also	  required	  for	  NKG2D-­‐mediated	  cytolysis	  of	  target	  cells	  (Chauveau	  et	  al.,	  
2010).	   With	   this	   in	   mind,	   the	   effect	   of	   lenalidomide	   on	   the	   threshold	   density	   of	   MICA	   proteins	  
needed	  to	  activate	  primary	  NK	  cells	  was	  then	  assessed.	  	  
To	  do	  this,	  the	  range	  of	  MICA	  concentrations	  that	  would	  give	  a	  threshold	  curve	  for	  NK	  cell	  activation,	  
using	  IFN-­‐γ	  production	  as	  readout,	  needed	  to	  be	  established.	  In	  the	  study	  by	  Gruda	  and	  colleagues,	  
0-­‐2.5	  µg/ml	  MICA	  was	   used	   to	   observe	   a	   threshold	   in	   the	   formation	   of	   actin	   rings	   (Gruda	   et	   al.,	  
2012).	  In	  order	  to	  make	  sure	  that	  the	  full	  threshold	  curve	  can	  be	  seen,	  an	  increased	  range	  of	  MICA	  
concentrations	   (0.5-­‐20	  µg/ml	  MICA)	   was	   chosen	   for	   this	   experiment.	   It	   is	   important	   to	   note	   that	  
there	  was	  always	  2.5	  µg/ml	  immobilised	  ICAM-­‐1	  present	  on	  the	  slides	  in	  order	  to	  ligate	  LFA-­‐1.	  This	  is	  
because	  co-­‐ligation	  of	  NKG2D	  and	  LFA-­‐1	  is	  required	  to	  elicit	  full	  NK	  cell	  responses.	  When	  cells	  were	  
stimulated	  on	  0.5-­‐20	  µg/ml	  MICA,	  an	  increase	  in	  IFN-­‐γ	  production	  was	  observed	  between	  0.5	  and	  5	  
µg/ml	  MICA	  and	  this	  levelled	  off	  above	  5	  µg/ml	  MICA	  (Figure	  3.20A).	  This	  indicates	  that	  0.5-­‐10µg/ml	  
MICA	  is	  satisfactory	  to	  observe	  an	  activation	  threshold	  for	  primary	  NK	  cell	  IFN-­‐γ	  production.	  	  
	  
Figure	   3.20	   –	   Lenalidomide	   lowers	   the	   threshold	   for	   activation	   through	  NKG2D.	   (A)	   Primary	  NK	   cells	  were	  
treated	  with	  DMSO	  and	  stimulated	  on	  surfaces	  coated	  with	  0-­‐20	  µg/ml	  MICA-­‐Fc	  plus	  a	  constant	  concentration	  
of	   ICAM-­‐1	   (2.5	  µg/ml).	  Supernatants	  were	  harvested	  24	  hours	   later	  and	   tested	  by	  ELISA	   for	   the	  presence	  of	  
IFN-­‐γ.	   Bars	   show	   the	   mean	   ±	   SEM	   from	   three	   donors.	   (B)	   NK	   cells	   were	   treated	   with	   DMSO	   or	   1	   µM	  
lenalidomide	   and	   stimulated	   as	   in	   (A).	   Non-­‐linear	   regression	   fit	   was	   applied	   to	   data.	   EC50	   values	   were	  
calculated	  as:	  2.09	  µg/mll	  (MICA	  DMSO;	  R2	  =	  0.98)	  and	  1.32	  µg/ml	  (MICA	  1	  µg/ml	  Len;	  R2	  =	  0.96).	  





To	  test	  the	  effect	  of	  lenalidomide	  on	  the	  threshold	  for	  IFN-­‐γ	  production,	  NK	  cells	  were	  incubated	  on	  
surfaces	  coated	  with	  0.5-­‐10	  µg/ml	  MICA	  with	  2.5	  µg/ml	  ICAM-­‐1,	  in	  the	  presence	  or	  absence	  of	  1	  µM	  
lenalidomide.	  The	  data	  showed	  a	  clear	  increase	  in	  IFN-­‐γ	  production	  after	  lenalidomide	  treatment	  at	  
lower	  concentrations	  of	  MICA,	  suggesting	  a	  shift	  in	  the	  threshold	  for	  activation.	  In	  order	  to	  quantify	  
this	  change,	  the	  effective	  concentration	  of	  activating	  receptor	  that	  elicited	  half-­‐maximal	  responses	  
(EC50)	   was	   determined	   for	   each	   condition	   using	   non-­‐linear	   regression	   analysis	   (Figure	   3.20B).	  	  
Lenalidomide	  treatment	  resulted	  in	  a	  33%	  decrease	  in	  the	  EC50,	  from	  2.1	  µg/ml	  without	  lenalidomide	  
to	  1.4	  µg/ml	  with	  lenalidomide	  (Figure	  3.20B).	  The	  coefficient	  of	  determination	  R2,	  which	  quantifies	  
the	  “goodness	  of	   fit”	  of	   the	  curve,	  had	  a	  value	  of	  0.98	  for	  the	  DMSO	  curve	  and	  0.96	  for	  the	  1	  µM	  
lenalidomide	   curve.	   This	   indicates	   that	   the	   experimental	   data	   and	   the	  non-­‐linear	   regression	   curve	  
were	  well	  correlated.	  	  This	  establishes	  that	  lenalidomide	  treatment	  induced	  an	  increased	  sensitivity	  
to	  stress-­‐inducible	  ligands,	  resulting	  in	  NK	  cell	  activation	  at	  lower	  concentrations	  of	  MICA.	  
A	  threshold	  in	  the	  level	  of	  CD16	  ligation	  needed	  to	  activate	  NK	  cells	  has	  also	  been	  observed	  (Gruda	  
et	  al.,	  2012).	   	  Gruda	  and	  colleagues	   titrated	  anti-­‐CD16	  mAb	  to	  generate	  a	   threshold	   in	   the	  NK	  cell	  
response	  (Gruda	  et	  al.,	  2012).	  Here,	  the	  ligand	  for	  CD16	  (human	  IgG;	  hIgG)	  was	  used	  instead	  as	  it	  is	  
more	   physiologically	   relevant.	   To	   generate	   a	   threshold	   IFN-­‐γ	   response,	   primary	   NK	   cells	   were	  
stimulated	  on	  surfaces	  coated	  with	  1-­‐100	  µg/ml	  hIgG	  overnight.	  The	  supernatants	  were	  then	  tested	  
by	  ELISA	  for	  the	  presence	  of	  IFN-­‐γ.	  A	  distinct	  threshold	  for	  NK	  cell	  activation	  was	  observed	  using	  this	  
range	  of	  hIgG	  concentrations	   (Figure	  3.21A).	  When	  NK	  cells	  were	  treated	  with	  1	  µM	  lenalidomide,	  
	  
Figure	   3.21	   –	   Lenalidomide	   lowers	   the	   threshold	   for	   activation	   through	   CD16.	   (A)	   Primary	   NK	   cells	   were	  
treated	  with	  DMSO	  and	  stimulated	  on	  surfaces	  coated	  with	  0-­‐500	  µg/ml	  hIgG.	  Supernatants	  were	  harvested	  
24	  hours	  later	  and	  tested	  by	  ELISA	  for	  the	  presence	  of	  IFN-­‐γ.	  Bars	  show	  the	  mean	  ±	  SEM	  from	  three	  donors.	  (B)	  
NK	  cells	  were	  treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	  stimulated	  as	  in	  (A).	  Non-­‐linear	  regression	  fit	  was	  
applied	   to	  data.	  EC50	  values	  were	  calculated	  as:	  61.64	  µg/ml	   (hIgG	  DMSO;	  R
2	  =	  0.93)	  and	  21.41	  µg/ml	   (hIgG	  
µg/ml	  Len;	  R2	  =	  0.92).	  





the	   threshold	   curve	   shifted	   to	   the	   left	   (Figure	   3.21B).	   The	   curves	   were	   fitted	   using	   nonlinear	  
regression	  analysis	  and	  the	  EC50	  was	  calculated.	  	  Lenalidomide	  treatment	  caused	  a	  66%	  decrease	  in	  
the	  EC50	  from	  62	  µg/ml	  without	  lenalidomide	  to	  21	  µg/ml	  with	  lenalidomide	  (Figure	  3.21B).	  The	  R2	  
values	  were	  0.93	  for	  the	  DMSO	  curve	  and	  0.92	  for	  the	  1	  µM	  lenalidomide	  curve.	  Again,	  this	  indicates	  
that	   the	   curves	   correlate	   well	   with	   the	   experimental	   data.	   Together,	   these	   data	   establish	   that	  
lenalidomide	  lowers	  the	  threshold	  for	  NK	  cell	  activation,	  even	  when	  NK	  cells	  are	  triggered	  through	  
distinct	  activating	  receptors.	  	  
In	   order	   to	   investigate	   whether	   activating	   ligand	   concentration	   is	   important	   for	   the	   effect	   of	  
lenalidomide	  at	   the	  single	  cell	   level,	  NK	  cells	  were	   imaged	  by	  confocal	  microscopy.	  First,	   the	   initial	  
activation	   of	   NK	   cells	   was	   visualised.	   To	   do	   this,	   NK	   cells	   were	   treated	   with	   DMSO	   or	   1	   µM	  
lenalidomide	   for	   1	   hour	   and	   then	   stimulated	   for	   6	   min	   on	   glass	   slides	   coated	   with	   increasing	  
concentrations	  of	  MICA-­‐Fc	   (0-­‐2.5	  μg/ml)	  plus	  a	  constant	  concentration	  of	   ICAM-­‐1	   (2.5	  µg/ml).	  The	  
cells	  were	  then	  fixed	  and	  stained	  with	  phalloidin	  (conjugated	  to	  Alexa488)	  to	  visualise	  F-­‐actin	  (Figure	  
3.22).	  Cells	  were	  said	  to	  have	  an	  ‘actin	  ring’	  –	  and	  therefore	  be	  activated	  –	  if	  they	  had	  a	  dense	  ring	  of	  
polymerised	  F-­‐actin	  around	  the	  periphery	  of	  the	  cell	  (Figure	  3.22,	  white	  arrows).	  There	  was	  a	  clear	  
increase	  in	  the	  proportion	  of	  cells	  with	  actin	  rings	  between	  0	  µg/ml	  MICA	  and	  2	  µg/ml	  MICA,	  which	  
then	  plateaus	  between	  2	  µg/ml	  and	  2.5	  µg/ml	  (Figure	  3.23).	  When	  NK	  cells	  were	  treated	  with	  1	  µM	  
lenalidomide,	   there	  was	  a	  significant	   increase	   in	   the	  percentage	  of	  activated	  cells	  compared	  to	  NK	  
	  
Figure	  3.22	  –	  Representative	  microscopy	  images	  of	  NK	  cell	  activation	  on	  increasing	  concentrations	  of	  MICA.	  
NK	  cells	  were	   treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	   for	  1	  hour	  and	   then	   stimulated	  on	   surfaces	   coated	  
with	  0-­‐2.5	  µg/ml	  MICA	  plus	  a2.5	  µg/ml	  ICAM-­‐1.	  Cells	  were	  then	  fixed	  and	  stained	  with	  Phalloidin-­‐Alexa488	  to	  
visualise	  F-­‐actin.	  White	  arrows	  show	  actin	  rings.	  Scale	  bars	  =	  10	  µm.	  	  
	  





cells	  that	  were	  treated	  with	  DMSO	  (from	  24%	  without	  lenalidomide	  to	  48%	  with	  lenalidomide	  on	  0.5	  
µg/ml	   MICA;	   p	   =	   0.0043;	   Figure	   3.23).	   There	   was	   also	   a	   significant	   increase	   in	   the	   number	   of	  
activated	  cells	  on	  1	  µg/ml	  MICA,	  from	  32%	  without	  lenalidomide	  to	  54%	  with	  1	  µM	  lenalidomide	  (p	  =	  
0.012;	  Figure	  3.23).	  This	  suggests	  that	  1-­‐hour	  pre-­‐treatment	  with	  lenalidomide	  is	  enough	  to	  allow	  NK	  
cells	  to	  activate	  at	  lower	  concentrations	  of	  MICA.	  	  
To	   assess	   the	   effect	   of	   lenalidomide	   on	   IFN-­‐γ	   production	   at	   the	   single	   cell	   level,	   primary	  NK	   cells	  
were	  treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	  stimulated	  for	  90	  min	  on	  glass	  slides	  coated	  with	  
increasing	  concentrations	  of	  MICA-­‐Fc	  (1-­‐5	  µg/ml)	  plus	  2.5	  µg/ml	  ICAM-­‐1.	  Cells	  were	  then	  fixed	  and	  
stained	  with	  anti-­‐IFN-­‐γ	  mAb	   (labelled	  with	  Alexa488;	  green)	  and	  phalloidin	   (labelled	  with	  Atto590;	  
red)	  to	  visualise	  F-­‐actin,	  and	  imaged	  by	  confocal	  microscopy	  (Figure	  3.24).	  The	  proportion	  of	  NK	  cells	  
expressing	   IFN-­‐γ	   was	   then	   assessed.	   On	   2.5	   µg/ml	   MICA,	   lenalidomide	   treatment	   significantly	  
increased	   the	   percentage	   of	   cells	   that	   stained	   positive	   for	   IFN-­‐γ	   (from	   33	   ±	   1.7%	   without	  
lenalidomide	  to	  55	  ±	  2.6%	  with	  lenalidomide;	  Figure	  3.25A).	  However,	  no	  change	  in	  the	  proportion	  
of	  IFN-­‐γ-­‐positive	  cells	  was	  observed	  with	  lenalidomide	  treatment	  when	  the	  cells	  were	  stimulated	  on	  
1	  µg/ml	  MICA	  (Figure	  3.25A).	  At	  5	  µg/ml	  MICA,	  both	  conditions	  showed	  a	  similar,	  high	  proportion	  of	  
NK	  cells	  with	  IFN-­‐γ	  protein	  expression	  (Figure	  3.25A).	  These	  results	  suggest	  that	  there	  is	  a	  threshold	  
concentration	   of	   MICA	   above	   which	   lenalidomide	   treatment	   increases	   the	   proportion	   of	   cells	  
expressing	  IFN-­‐γ.	  	  
	  
Figure	   3.23	   –	   Lenalidomide	   increases	   the	   proportion	   of	   NK	   cells	  with	   actin	   rings	   at	   low	   concentrations	   of	  
MICA.	  Graph	  shows	  the	  proportion	  of	  cells	  displaying	  dense	  rings	  of	  F-­‐actin	  at	  the	  periphery	  of	  the	  cells	  for	  the	  
images	  described	  in	  Figure	  3.22.	  Graph	  shows	  mean	  ±	  SEM,	  n	  >130	  per	  donor	  from	  3	  independent	  donors.	  One	  
way	  ANOVA	  with	  Tukey’s	  post-­‐test	  was	  used	  to	  test	  if	  observed	  differences	  were	  statistically	  significant.	  *	  =	  p	  
<0.05,	  **	  =	  p	  <0.01.	  
	  





The	  amount	  of	   IFN-­‐γ	  per	  cell	  was	   then	  quantified	  by	  assessing	   the	  sum	  Alexa488	   fluorescence	  per	  
cell.	   Strikingly,	   lenalidomide	   treatment	   resulted	   in	   a	   significant	   increase	   in	   the	   sum	   IFN-­‐γ	  
fluorescence	  per	  cell	  in	  all	  concentrations	  of	  MICA	  tested	  (Figure	  3.25B).	  These	  results	  establish	  that	  
at	  any	  level	  of	  NK	  cell	  stimulation,	  lenalidomide	  increases	  the	  amount	  of	  IFN-­‐γ	  produced	  per	  cell.	  	  
	  
	  
Figure	   3.24	   –	  Representative	  microscopy	   images	  of	   IFN-­‐γ 	   production	   in	  NK	   cells	   stimulated	  with	  different	  
concentrations	  of	  MICA.	  	  F-­‐actin	  (red)	  and	  IFN-­‐γ	   (grey)	   in	  primary	  NK	  cells	  stimulated	  for	  90	  min	  on	  surfaces	  
coated	   with	   1	   µg/ml	   or	   2.5	   µg/ml	   MICA-­‐Fc	   (+2.5	   µg/ml	   ICAM-­‐1)	   in	   the	   presence	   of	   DMSO	   or	   1	   µM	  
lenalidomide.	  Scale	  bars	  =	  10	  µm.	  
	  





Overall,	   this	   establishes	   that	   lenalidomide	   has	   two	   effects	   on	   NK	   cells:	   at	   any	   level	   of	   NK	   cell	  
stimulation,	   lenalidomide	   increases	   the	   amount	   of	   IFN-­‐γ	   produced	   per	   cell	   and,	   in	   addition,	  
lenalidomide	  lowers	  the	  threshold	  for	  activation	  so	  that	  a	  greater	  proportion	  of	  NK	  cells	  are	  involved	  
in	  the	  response.	  
	  
3.2.7 Lenalidomide	  lowers	  the	  threshold	  for	  activation	  through	  rituximab	  
Lenalidomide	  in	  combination	  with	  rituximab,	  a	  human	  anti-­‐CD20	  mAb	  that	  triggers	  ADCC-­‐mediated	  
lysis	  of	  tumour	  B	  cells,	  is	  currently	  in	  clinical	  trials	  for	  the	  treatment	  of	  some	  lymphomas	  (Badoux	  et	  
al.,	   2013;	   M.	   Wang	   et	   al.,	   2012).	   Since	   the	   results	   shown	   here	   demonstrate	   that	   lenalidomide	  
treatment	  augments	  NK	  cell	  responses	  after	  CD16	  ligation,	  the	  effect	  of	  lenalidomide	  treatment	  on	  
rituximab-­‐activated	  NK	  cells	  was	  next	  investigated.	  	  
To	  test	  whether	   lenalidomide	   influenced	  the	  threshold	   for	  NK	  cell	  activation	  by	  rituximab,	  primary	  
NK	  cells	  were	  incubated	  on	  surfaces	  coated	  with	  increasing	  concentrations	  of	  immobilised	  rituximab	  
(0.0001-­‐100	   µg/ml).	   This	   range	   was	   chosen	   as	   it	   was	   previously	   identified	   in	   our	   laboratory	   as	  
sufficient	  to	  observe	  a	  threshold	   in	  the	   level	  of	  NK	  cell	  cytotoxicity	  against	  rituximab-­‐coated	  target	  
cells	   (D.	   Rudnicka,	   personal	   communication).	   In	   this	   experiment,	   NK	   cells	   were	   treated	   in	   the	  
	  
Figure	  3.25	  –	  Differential	  effects	  of	  lenalidomide	  on	  the	  proportion	  of	  cells	  expressing	  IFN-­‐γ 	  and	  the	  amount	  
produced	  per	  cell.	   	  (A)	  The	  proportion	  of	  primary	  NK	  cells	  expressing	  IFN-­‐γ	  after	  stimulation	  with	  3	  different	  
concentrations	  of	  MICA-­‐Fc,	  as	  in	  Figure	  3.24.	  Graph	  shows	  mean	  ±	  SEM,	  n	  >100	  per	  donor	  from	  3	  donors.	  (B)	  
Sum	  fluorescence	  staining	  for	  IFN-­‐γ	  per	  cell	  in	  NK	  cells	  stimulated	  as	  in	  (A).	  Each	  data	  point	  represents	  a	  single	  
cell	   and	   the	   red	   line	   shows	   the	  mean.	   *	   =	   p	   <0.05,	   **	   =	   p	   <0.01,	   ****	   =	   p	   <0.0001,	   one	  way	   ANOVA	  with	  
Tukey’s	  post-­‐test.	  





presence	   or	   absence	   of	   1	  µM	   lenalidomide	   and	   IFN-­‐γ	   secretion	  was	  measured	   by	   ELISA	   24	   hours	  
later.	  The	  EC50	  for	  each	  condition	  was	  calculated	  using	  nonlinear	  regression	  analysis.	  As	  expected,	  a	  
distinct	  threshold	  for	  NK	  cell	  activation	  was	  observed	  in	  DMSO-­‐treated	  cells	  (grey	  line;	  Figure	  3.26A).	  
When	  NK	   cells	  were	   also	   treated	  with	   1	  µM	   lenalidomide,	   there	  was	   a	   74%	  decrease	   in	   the	   EC50,	  
from	  1.7	  µg/ml	  to	  0.4	  µg/ml	  (Figure	  3.26A).	  The	  R2	  values	  were	  0.86	  for	  the	  DMSO	  curve	  and	  0.84	  for	  
the	   1	   µM	   lenalidomide	   curve.	   This	   indicates	   that	   lenalidomide	   treatment	   lowers	   the	   minimum	  
concentration	  of	  rituximab	  required	  to	  activate	  NK	  cells.	  	  
To	   see	   whether	   this	   effect	   was	   dose-­‐dependent,	   as	   was	   observed	   when	   ligating	   CD16	   with	   a	  
monoclonal	  antibody	  (Figure	  3.4),	  NK	  cells	  were	  stimulated	  on	  1	  µg/ml	  rituximab	  in	  the	  presence	  of	  
0.1-­‐10	  µg/ml	   lenalidomide.	  The	  results	  show	  that	  0.1	  µM	  lenalidomide	  treatment	  results	   in	  a	  two-­‐
fold	  increase	  in	  IFN-­‐γ	  production	  (from	  2300	  ±	  190	  pg/ml	  IFN-­‐γ	  without	  lenalidomide	  to	  4640	  ±	  320	  
pg/ml	  IFN-­‐γ	  with	  0.1	  µM	  lenalidomide;	  Figure	  3.26B).	  This	   is	   increased	  even	  further	  (to	  5750	  ±	  520	  
pg/ml	  IFN-­‐γ)	  with	  1	  µM	  lenalidomide	  (Figure	  3.26B).	  
Thus,	  this	  establishes	  that	  the	  combined	  use	  of	  rituximab	  and	  lenalidomide	  augments	  NK	  cell	   IFN-­‐γ	  
production	   and	   lowers	   the	   threshold	   for	   NK	   cell	   activation.	   This	   data	   therefore	   provides	   in	   vitro	  
support	   for	   testing	  the	  benefit	  of	  combining	   lenalidomide	  and	  rituximab	   in	  the	  treatment	  of	  B	  cell	  
malignancies	  in	  vivo.	  	  
	  
Figure	   3.26	   –	   Lenalidomide	   lowers	   the	   threshold	   for	   activation	   with	   rituximab.	   (A)	   Primary	   NK	   cells	   were	  
treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  for	  24	  hours	   in	  wells	  coated	  with	  0.0001-­‐100	  µg/ml	  rituximab.	   IFN-­‐γ	  
release	  was	  measured	  by	  ELISA.	  Data	  shows	  mean	  ±	  SEM	  from	  3	  donors.	  Non-­‐linear	  regression	  fit	  was	  applied	  to	  
the	   data.	   EC50	   values	   were	   calculated	   as:	   1.63	   µg/ml	   without	   lenalidomide	   (R
2	   =	   0.86)	   and	   0.44	   µg/ml	   with	  
lenalidomide	  (R2	  =	  0.84).	  (B)	  Primary	  NK	  	  cells	  were	  treated	  with	  DMSO	  or	  0.1-­‐10	  µM	  lenalidomide	  (+	  150	  U/ml	  
IL-­‐2)	  for	  24	  hours	  in	  wells	  coated	  with	  1	  µg/ml	  rituximab.	  IFN-­‐γ	  release	  was	  assessed	  by	  ELISA.	  Data	  shows	  mean	  
±	  SEM	  from	  3	  donors.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01.	  One	  way	  ANOVA	  with	  Tukey’s	  post	  test.	  
	  







3.3.1 Summary	  of	  results	  
	  
In	   this	   investigation,	   the	   main	   aim	   was	   to	   study	   the	   effect	   of	   lenalidomide	   on	   NK	   cell	   effector	  
functions	   and	   immune	   synapse	   formation.	   In	   particular,	   the	   main	   findings	   of	   this	   project	   are	   as	  
follows:	  
• Lenalidomide	  enhanced	  both	  NK	  cell	  cytotoxicity	  and	  IFN-­‐γ	  production	  in	  a	  dose-­‐dependent	  
manner,	  and	  this	  was	  dependent	  on	  the	  presence	  of	  exogenous	  IL-­‐2	  
	  
• Lenalidomide	  augmented	  IFN-­‐γ	  production	  through	  multiple	  triggers	  for	  NK	  cell	  activation.	  
	  
• Lenalidomide	   increased	   the	   proportion	   of	   cells	   producing	   IFN-­‐γ	   as	   well	   as	   the	   amount	  
produced	  per	  cell.	  
	  
• Lenalidomide	  increased	  the	  probability	  of	  immune	  synapse	  formation.	  	  
	  
• Lenalidomide	  lowered	  the	  threshold	  for	  NK	  cell	  activation	  through	  both	  CD16	  and	  NKG2D.	  
	  




To	  summarise,	   the	   immunomodulatory	  drug	   lenalidomide	  has	  a	  direct	  and	  enhancing	  effect	  on	  NK	  
cell	   effector	   functions,	   which	   can	   be	   seen	   on	   both	   a	   population	   level	   and	   a	   single	   cell	   level.	   The	  
results	  presented	  in	  this	  chapter	  clear	  up	  the	  conflict	  in	  the	  literature	  on	  the	  effect	  of	  lenalidomide	  
on	  NK	  cells	  and	  demonstrate	  that	  lenalidomide	  lowers	  the	  threshold	  for	  NK	  cell	  activation.	  This	  has	  
important	  implications	  for	  the	  use	  of	  lenalidomide	  in	  B	  cell	  malignancies	  as	  well	  as	  in	  the	  design	  of	  
new	  drugs	  in	  the	  future.	  	  
	  





3.3.2 The	  effect	  of	  lenalidomide	  on	  NK	  cell	  effector	  functions	  
	  
Lenalidomide	  enhances	  NK	  cell	  cytotoxicity	  in	  primary	  NK	  cells	  
Treatment	  of	  primary	  NK	  cells	  with	  increasing	  doses	  of	  lenalidomide	  resulted	  in	  increased	  killing	  of	  
target	  cells,	  but	  only	  in	  the	  presence	  of	  IL-­‐2.	  This	  finding	  is	  consistent	  with	  results	  shown	  in	  Wu	  et	  al	  
(2008),	  where	  lenalidomide	  treatment	  of	  primary	  NK	  cells	  alone,	  in	  the	  presence	  of	  immobilised	  IgG	  
and	  IL-­‐2,	  increased	  NK	  cell	  cytotoxicity	  against	  immortalised	  B	  cell	  lines.	  This	  finding	  is	  important	  as	  it	  
clarifies	  that	  lenalidomide	  treatment	  has	  a	  direct,	  enhancing	  effect	  on	  NK	  cell	  cytotoxicity.	  	  Previous	  
studies	  have	  suggested	  that	  CD4+	  T	  cells	  need	  to	  be	  present	  to	  observe	  an	  effect	  of	  lenalidomide	  on	  
NK	   cell-­‐mediated	   lysis	   of	   target	   cells	   (Hsu	   et	   al.,	   2011;	   Acebes-­‐Huerta	   et	   al.,	   2014).	   These	   two	  
independent	  studies	  claim	  that	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  is	  solely	  due	  to	  the	  increased	  
production	  of	  IL-­‐2	  from	  CD4+	  T	  cell	  after	  lenalidomide	  treatment,	  and	  that	  blocking	  IL-­‐2	  production	  
abrogated	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  (Hsu	  et	  al.,	  2011;	  Acebes-­‐Huerta	  et	  al.,	  2014).	  The	  
results	   shown	   here	   demonstrate	   that	   IL-­‐2	   is	   indeed	   required	   to	   see	   an	   enhancement	   of	   NK	   cell	  
cytotoxicity,	  but	   is	  not	  the	  sole	  cause	  of	   it.	  Figure	  3.1	  shows	  that	  the	  presence	  of	   IL-­‐2	  results	   in	  an	  
increase	   in	  NK	  cell-­‐mediated	   target	  cell	   lysis,	  as	  would	  be	  expected	  as	   IL-­‐2	  primes	   the	  NK	  cells	   for	  
activation.	   However,	   lenalidomide	   treatment	   further	   increases	  NK	   cell	   cytotoxicity,	   indicating	   that	  
there	  is	  a	  direct	  effect	  of	  lenalidomide	  on	  NK	  cells.	  	  	  
The	   requirement	   for	   IL-­‐2	   in	   the	   experiments	   presented	   here	   shows	   that	   concurrent	   cytokine	  
signalling	  and	  activating	  receptor	  ligation	  are	  important	  in	  order	  to	  see	  an	  effect	  with	  lenalidomide	  
treatment.	  IL-­‐2	  is	  known	  to	  boost	  NK	  cell	  responses	  and	  so	  the	  presence	  of	  IL-­‐2	  helps	  to	  increase	  the	  
activation	  state	  of	  the	  NK	  cell	  population.	  One	  explanation	  of	  the	  results	  presented	  here	  is	  that	  since	  
lenalidomide	   treatment	   augments	   NK	   cell	   activation,	   IL-­‐2-­‐activated	   NK	   cells	   therefore	   have	   a	  
stronger	  response	  to	  lenalidomide	  treatment.	  This	  is	  likely	  to	  also	  be	  true	  of	  other	  cytokines	  that	  are	  
known	  to	  activate	  NK	  cells,	  such	  as	  IL-­‐12	  and	  IL-­‐18,	  and	  this	  should	  be	  confirmed	  in	  future	  studies.	  	  
	  
Lenalidomide	  enhances	  IFN-­‐γ 	  secretion	  from	  primary	  NK	  cells	  
Treatment	  of	  primary	  NK	  cells	  with	  increasing	  concentrations	  of	  lenalidomide	  in	  the	  presence	  of	  IL-­‐2	  
also	  resulted	  in	  increased	  IFN-­‐γ	  secretion.	  This	  finding	  is	  significant	  because	  it	  contradicts	  previously	  
published	  data	  that	  shows	  that	  lenalidomide	  inhibits	  IFN-­‐γ	  production	  from	  NK	  cells	  (Dauguet	  et	  al.,	  
2010).	   In	   that	   specific	   study,	   the	   authors	   show	   that	   5	   µM	   lenalidomide	   had	   no	   effect	   on	   the	  





percentage	   of	   cells	   expressing	   IFN-­‐γ	   but	   decreased	   the	  MFI	   of	   IFN-­‐γ-­‐positive	   cells	   (Dauguet	   et	   al.,	  
2010).	  These	  results	  were	  obtained	  by	  flow	  cytometry	  of	  nine	  healthy	  donors	  and	  the	  PBMCs	  were	  
rested	  for	  7	  days	   in	   IL-­‐2	  before	  use.	  The	  results	  presented	   in	  this	  chapter	  demonstrate	  that	  0.1-­‐10	  
µM	   lenalidomide	   has	   an	   enhancing	   effect	   on	   IFN-­‐γ	   production	   by	   primary	   NK	   cells.	   The	   data	  
conclusively	  shows	  that	  lenalidomide	  increases	  both	  the	  proportion	  of	  cells	  producing	  IFN-­‐γ	  as	  well	  
as	   the	   amount	   produced	   per	   cell.	   These	   conclusions	   were	   reached	   after	   using	   three	   different	  
methods	   for	  quantifying	   the	  effect	  of	   lenalidomide	  on	   IFN-­‐γ	   production:	  ELISA	  assays,	   intracellular	  
flow	  cytometry	  and	  confocal	  microscopy.	  	  
There	   are	   a	   few	   differences	   between	   this	   study	   and	   that	   of	   Dauguet	   and	   colleagues	   that	   could	  
explain	   the	  differences	   in	   the	   results.	   First,	   the	   cells	  were	   treated	  with	   lenalidomide	   for	   7	  days	   in	  
their	   study	   compared	   to	   a	   maximum	   of	   24	   hours	   in	   this	   study.	   However,	   a	   recent	   study	   treated	  
primary	  NK	  cells	   for	  7	  days	  with	   lenalidomide	  and	  reported	  an	   increase	   in	   IFN-­‐γ	  production,	  which	  
suggests	   that	   treatment	   time	   cannot	   explain	   the	   differing	   results	   (Jungkunz-­‐Stier	   et	   al.,	   2014).	  
Second,	  NK	  cells	  were	  isolated	  prior	  to	  treatment	  with	  lenalidomide	  in	  all	  the	  experiments	  presented	  
in	  this	  chapter,	  whereas	  Dauguet	  and	  colleagues	  treated	  PBMCs	  and	  then	  gated	  on	  NK	  cells	  by	  flow	  
cytometry.	   This	   means	   that	   the	   specific	   effect	   of	   lenalidomide	   on	   NK	   cells	   is	   no	   longer	   being	  
assessed,	   as	   other	   immune	   cells	   are	   also	   being	   treated	   with	   the	   drug	   and	   their	   responses	   could	  
affect	   NK	   cell	   IFN-­‐γ	   production.	   Therefore,	   the	   results	   presented	   here	   more	   accurately	   show	   the	  
effect	  of	  lenalidomide	  on	  NK	  cells	  than	  previously	  published	  results,	  and	  it	  is	  clear	  that	  lenalidomide	  
does	  have	  an	  enhancing	  effect	  on	  IFN-­‐γ	  production	  by	  primary	  NK	  cells.	  
The	   relevance	   of	   this	   increase	   in	   IFN-­‐γ	   production	   after	   lenalidomide	   treatment	   should	   also	   be	  
noted.	   IFN-­‐γ	   is	   known	   to	   upregulate	  MHC	   class	   I	  molecules	   on	   the	   surface	   of	   tumours,	   therefore	  
aiding	   in	  the	  priming	  and	  presentation	  of	  antigens	  to	  professional	  APCs	  (Seliger	  et	  al.,	  2008).	   IFN-­‐γ	  
also	  activates	  macrophages	  and	   induces	  production	  of	  various	  chemokines,	  which	  go	  on	   to	   recruit	  
different	   effector	   cells	   to	   sites	   of	   inflammation	   (Hu	   et	   al.,	   2008).	   In	   addition,	   IFN-­‐γ	   has	   anti-­‐
proliferative,	   anti-­‐angiogenic	   and	   pro-­‐apoptotic	   activity	   in	   the	   tumour	   microenvironment,	   which	  
negatively	  impact	  the	  growth	  and	  survival	  of	  the	  tumour	  cells	  (Chin	  et	  al.,	  1996;	  Beatty	  &	  Paterson,	  
2001;	  Chawla-­‐Sarkar	  et	  al.,	  2003).	  Taken	  together,	   this	  suggests	  that	  the	   increase	   in	   IFN-­‐γ	   from	  NK	  
cells	  could	  be	  important	  in	  long-­‐term	  control	  of	  tumour	  cells.	  	  
	  
	  





Lenalidomide	  affects	  multiple	  triggers	  for	  NK	  cell	  activation	  
Previous	   research	   has	   shown	   that	   lenalidomide	   did	   not	   directly	   stimulate	   signalling	   protein	  
phosphorylation	   in	   NK	   cells	   (as	   shown	   by	   western	   blot)	   nor	   alter	   the	   expression	   of	   cell	   surface	  
receptors	   on	  NK	   cells	   (Hayashi	   et	   al.,	   2005;	  Dauguet	   et	   al.,	   2010).	   The	   results	   presented	   here	   are	  
consistent	   with	   the	   latter	   conclusion:	   lenalidomide	   does	   not	   affect	   the	   cell	   surface	   expression	   of	  
CD16,	  NKG2D	  or	   LFA-­‐1.	  This	   is	   true	   for	  unstimulated	  NK	  cells	   that	  were	   treated	  with	   lenalidomide	  
and	   for	  NK	  cells	   that	  were	   treated	  with	   lenalidomide	  whilst	  being	  stimulated	  with	  anti-­‐CD16	  mAb.	  
Thus,	   the	   mechanism	   by	   which	   lenalidomide	   influences	   NK	   cell	   responses	   remained	   unclear.	  
Crucially,	   since	   NK	   cells	   can	   be	   activated	   via	   a	   number	   of	   different	   pathways,	   it	   was	   not	   known	  
whether	   lenalidomide	  would	  augment	  only	  one	   type	  of	  NK	  cell	   receptor	   signalling	  or	  whether	   the	  
effect	  of	  lenalidomide	  would	  have	  a	  more	  global	  effect	  on	  NK	  cell	  activation.	  The	  results	  shown	  here	  
demonstrate	   that	   lenalidomide	  can	  enhance	  NK	  cell	   IFN-­‐γ	  production	   through	  multiple	   triggers	   for	  
NK	  cell	  activation.	  	  
Previously,	   it	  has	  been	  shown	  that	  ligation	  of	  CD16	  (using	  its	  ligand,	  hIgG)	  was	  required	  to	  observe	  
an	  increase	  in	  IFN-­‐γ	  secretion	  from	  primary	  NK	  cells	  (Wu	  et	  al.,	  2008).	  Here,	  anti-­‐CD16	  mAb	  was	  used	  
to	   ligate	  CD16	  and	   the	   results	   show	  that	   there	  was	  a	   significant	  enhancement	   in	   IFN-­‐γ	  production	  
after	   CD16	   ligation,	   thus	   supporting	   the	   published	   results.	   In	   addition	   to	   this,	   activation	   through	  
NKG2D	   was	   also	   investigated.	   NKG2D	   is	   an	   activating	   receptor	   that	   recognises	   stress-­‐inducible	  
ligands	  on	  the	  surface	  of	  potential	  target	  cells	  	  (e.g.	  MICA).	  MICA	  has	  been	  shown	  to	  be	  upregulated	  
on	  the	  surface	  of	  MM	  cells	  (Girlanda	  et	  al.,	  2005).	  In	  addition,	  NKG2D-­‐mediated	  recognition	  of	  MM	  
cells	   is	  known	  to	  play	  a	  role	   in	  the	  initial	  control	  of	  the	  tumour	  cells	  by	  NK	  cells	   (El-­‐Sherbiny	  et	  al.,	  
2007;	  Lu	  et	  al.,	  2012).	  	  When	  primary	  NK	  cells	  were	  activated	  through	  ligation	  of	  NKG2D	  and	  LFA-­‐1	  
simultaneously,	  in	  the	  presence	  of	  lenalidomide,	  there	  was	  a	  significant	  increase	  in	  IFN-­‐γ	  production	  
compared	  to	  stimulation	  without	  lenalidomide.	  This	  demonstrates	  that	  the	  effect	  of	  lenalidomide	  is	  
not	  restricted	  to	  NK	  cell	  activation	  through	  CD16.	  This	  result	   is	   interesting	  as	   it	  provides	  an	   insight	  
into	  how	  lenalidomide	  affects	  NK	  cells.	  The	  membrane	  proximal	  signalling	  events	  after	  CD16	  ligation	  
and	   after	   NKG2D	   and	   LFA-­‐1	   co-­‐ligation	   appear	   to	   be	   quite	   different	   (Lanier,	   2003;	   Lanier,	   2008).	  
CD16	  ligation	  is	  initiated	  by	  CD3ζ	  and	  involves	  recruitment	  of	  Syk,	  ZAP70	  and	  LAT	  (Lanier	  et	  al.,	  1989;	  
Schumann	  &	  Dasgupta,	  1994;	  Paolini	  et	  al.,	  2001).	  NKG2D,	  which	  signals	  through	  DAP10,	  recruits	  the	  
p85	  subunit	  of	  PI(3)K	  and	  the	  Grb2-­‐Vav1-­‐Sos1	  complex	  and	  does	  not	  require	  Syk	  or	  LAT	  (Billadeau	  et	  
al.,	   2003;	   Upshaw	   et	   al.,	   2006;	   Giurisato	   et	   al.,	   2007).	   Therefore,	   the	   fact	   that	   lenalidomide	  
treatment	   induces	   a	   comparable	   enhancement	   in	   IFN-­‐γ	   secretion	   after	   ligation	   of	   CD16	   and	   co-­‐
ligation	   of	   NKG2D	   and	   LFA-­‐1	   suggests	   that	   lenalidomide	   is	   acting	   downstream	   of	   membrane	  





proximal	   signalling	   events.	   This	   is	   further	   supported	   by	   the	   fact	   that	   NK	   cell	   activation	   through	  
combinations	   of	   activating	   receptors	   –	   in	   this	   case,	   NKG2D	   and	   2B4	   –	   was	   also	   enhanced	   after	  
lenalidomide	  treatment.	  Lenalidomide	  could	  be	  acting	  on	  common	  downstream	  signalling	  molecules	  
such	   as	   ERK.	   This	   hypothesis	   could	   be	   tested	   by	   assessing	   the	   levels	   of	   signalling	   molecule	  
phosphorylation	  by	  western	  blot	  in	  the	  presence	  or	  absence	  of	  lenalidomide.	  	  
	  
Lenalidomide	  lowers	  the	  threshold	  for	  NK	  cell	  activation	  
The	  main	  finding	  of	  this	  chapter	  was	  that	   lenalidomide	  lowers	  the	  threshold	  for	  activation	  through	  
multiple	   different	   activating	   receptors.	   When	   MICA	   was	   titrated	   and	   NK	   cells	   were	   imaged	   by	  
confocal	  microscopy,	  lenalidomide	  treatment	  significantly	  increased	  the	  proportion	  of	  NK	  cells	  that	  
activated	   on	   lower	   doses	   of	   MICA.	   At	   higher	   concentrations	   of	   ligand,	   however,	   no	   effect	   of	  
lenalidomide	   is	   seen,	   suggesting	   that	   the	  maximum	  proportion	  of	  NK	  cells	  were	  already	  activated.	  
This	  explains	  why	  no	  effect	  on	  lenalidomide	  was	  observed	  in	  Figure	  3.17,	  as	  the	  slides	  were	  coated	  
with	   higher	   concentrations	   of	   mAbs.	   Thus,	   lenalidomide	   treatment	   allows	   NK	   cells	   to	   activate	   in	  
response	  to	  lower	  amounts	  of	  stimuli.	  
Interestingly,	  there	  appears	  to	  be	  a	  dual	  effect	  of	  lenalidomide	  on	  IFN-­‐γ	  production	  when	  comparing	  
the	   effects	   of	   different	   concentrations	   of	  MICA:	   (i)	   lenalidomide	   increases	   the	   proportion	   of	   cells	  
producing	   IFN-­‐γ	   but	  only	   above	  a	   threshold	   concentration	  of	  MICA	  and	   (ii)	   lenalidomide	   increases	  
the	   amount	   of	   IFN-­‐γ	   produced	   per	   cell	   at	   all	   concentrations	   of	   MICA.	   The	   outcome	   is	   that	  
lenalidomide	   lowers	   the	   threshold	   for	   activation,	   suggesting	   that	   lenalidomide-­‐treated	   NK	   cells	  
would	   respond	   to	   lower	   concentrations	   of	   ligand	   on	   tumour	   cells.	   This	   explains	   the	   conjugate	  
formation	  data	  presented	   in	  this	  chapter:	  by	  reducing	  the	   level	  of	  stimuli	  needed	  to	  overcome	  the	  
minimum	   requirements	   for	   activation,	   lenalidomide	   increases	   the	   probability	   that	   contacts	   with	  
potential	   target	   cells	   will	   develop	   into	   an	   activating	   immune	   synapse.	   This	  may	   be	   important	   for	  
recognising	   tumour	   cells	   that	   have	   downregulated	   activating	   ligands	   as	   a	   mechanism	   of	   immune	  
evasion.	  	  
Similarly,	   lenalidomide	   treatment	   lowers	   the	   threshold	   for	   activation	   through	   rituximab.	   As	  
mentioned	   previously,	   rituximab	   is	   a	   humanised	   anti-­‐CD20	   antibody	   that	   is	   in	   clinical	   trials,	   in	  
combination	  with	  lenalidomide,	  for	  the	  treatment	  of	  CLL.	  The	  effectiveness	  of	  CD20	  as	  a	  therapeutic	  
target	  in	  CLL	  has	  been	  called	  into	  question,	  however,	  as	  the	  surface	  expression	  level	  of	  CD20	  on	  CLL	  
cells	  are	  relatively	  low	  compared	  to	  healthy	  B	  cells	  (Almasri	  et	  al.,	  1992;	  Prevodnik	  et	  al.,	  2011).The	  





fact	   that	   lenalidomide	   treatment	   allows	   NK	   cells	   to	   recognise	   lower	   concentrations	   of	   rituximab	  
suggests	   that	   the	   combination	   of	   the	   two	   drugs	   would	   be	   successful.	   It	   would	   be	   interesting	   to	  
investigate	  whether	  lenalidomide	  treatment	  also	  lowers	  the	  threshold	  for	  NK	  cell	  cytotoxicity	  against	  
rituximab-­‐coated	   target	   cells.	   This	   could	   be	   tested	   by	   coating	   CD20-­‐expressing	   target	   cells	   (for	  
example	  Daudi	  cells)	  with	  increasing	  concentrations	  of	  rituximab	  and	  then	  co-­‐incubating	  them	  with	  
primary	  NK	  cells.	  Target	  cell	  lysis	  could	  then	  be	  measured	  using	  a	  standard	  radioactive	  release	  assay.	  
	  
Lenalidomide	  does	  not	  result	  in	  inappropriate	  activation	  of	  NK	  cells	  
In	  T	  cells,	  lenalidomide	  results	  in	  T	  helper	  cell	  activation	  without	  the	  need	  for	  CD28	  ligation	  (LeBlanc	  
et	   al.,	   2004).	   Importantly,	   our	   results	   show	   that	   lenalidomide	   treatment	   does	   not	   affect	   NK	   cells	  
unless	  they	  have	  been	  fully	  activated.	  IFN-­‐γ	  production	  after	  partial	  NK	  cell	  activation	  –	  through	  the	  
ligation	  of	  NKG2D	  alone,	   for	  example	  –	  was	  not	  affected	  by	   lenalidomide	   treatment	  and	  no	  effect	  
was	  seen	  in	  NK	  cells	  in	  non-­‐activated	  conditions.	  This	  indicates	  that	  lenalidomide	  treatment	  does	  not	  
override	   the	   safety	   mechanisms	   in	   place	   to	   prevent	   NK	   cells	   killing	   healthy	   cells.	   Instead,	  
lenalidomide	  acts	  to	  augment	  NK	  cell	  effector	  functions	  once	  they	  have	  been	  initiated.	  	  
In	  order	  to	  prove	  this	  hypothesis	  further,	  NK	  cells	  and	  B	  cells	  could	  be	  isolated	  from	  the	  same	  donor.	  
NK	   cell	   cytotoxicity	   against	   these	   autologous	   B	   cells	   could	   then	   be	   observed	   with	   and	   without	  
lenalidomide	  treatment,	  and	  this	  could	  be	  compared	  to	  autologous	  B	  cells	  that	  had	  been	  irradiated	  
prior	  to	  co-­‐culture.	  	  
	  
3.3.3 Future	  directions	  
	  
This	   investigation	   on	   the	   effect	   of	   lenalidomide	   on	   NK	   cell	   activation	   and	   effector	   functions	   has	  
revealed	   that	   lenalidomide	   lowers	   the	   threshold	   for	   NK	   cell	   activation	   through	  multiple	   different	  
triggers.	  The	  findings	  described	   in	  this	  chapter	  give	  rise	  to	   interesting	  new	  questions,	  which	  future	  









Nanoscale	  organisation	  of	  activating	  receptors	  
Using	   single	  molecule	   localisation	  microscopy,	   it	  has	  been	   shown	   that	   some	  cell	   surface	   receptors	  
involved	   in	   lymphocyte	   activation	   and	   signalling	   exist	   in	   pre-­‐formed	   nanoscale	   protein	   clusters	  
(Lillemeier	  et	  al.,	  2010;	  Sherman	  et	  al.,	  2011;	  Pageon	  et	  al.,	  2013).	  It	  has	  been	  suggested	  that	  these	  
nanoclusters	   could	   be	   important	   in	   lymphocyte	   signalling.	   In	   particular,	   in	   NK	   cells,	   these	  
nanoclusters	   could	   be	   important	   in	   understanding	   how	   signals	   are	   integrated	   between	   activating	  
and	  inhibitory	  receptors.	  In	  the	  context	  of	  this	  study,	  it	  is	  possible	  that	  lenalidomide	  could	  alter	  the	  
nanoscale	  organisation	  of	  NK	  cell	  activating	  receptors.	  This	  could	  potentially	  explain	  how	  NK	  cells	  are	  
able	   to	   respond	   to	   lower	  concentrations	  of	  activating	   ligands.	   In	  order	   to	   test	   this	  hypothesis,	   the	  
supra-­‐molecular	  organisation	  of	  CD16	  and	  NKG2D	  could	  be	  imaged	  by	  PALM	  or	  STORM	  and	  details	  
about	   the	   size,	   shape	   and	   density	   of	   the	   nanoclusters	   could	   be	   extracted	   from	   the	   data	   using	   a	  
custom-­‐written	   MatLab	   program,	   as	   previously	   described	   (Pageon	   et	   al.,	   2013).	   This	   could	   be	  
compared	   between	   NK	   cells	   that	   were	   stimulated	   with	   or	   without	   lenalidomide	   in	   order	   to	   see	  
whether	   the	   drug	   has	   an	   effect	   on	   clusters	   in	   resting	   cells,	   or	   after	   stimulation	   with	   activating	  
ligands.	   This	   could	   also	   be	   carried	   out	   on	   different	   concentrations	   of	   activating	   ligand	   to	   observe	  
whether	  any	  differences	  could	  be	  observed	  at	  high	  or	  low	  levels	  of	  stimuli.	  
It	  would	  also	  be	  interesting	  to	  see	  whether	  lenalidomide	  has	  an	  effect	  on	  the	  nanoscale	  organisation	  
of	  membrane-­‐proximal	  signalling	  molecules.	  Some	  studies	  have	  shown	  that,	   in	  T	  cells,	   the	  adaptor	  
protein	   LAT	   pre-­‐exists	   in	   clusters	   at	   the	   membrane	   but	   these	   clusters	   are	   not	   involved	   in	   TCR	  
signalling.	   Instead,	  TCR	  activation	  results	   in	   the	   recruitment	  and	  phosphorylation	  of	  LAT	   from	  sub-­‐
synaptic	  vesicles	  (Williamson	  et	  al.,	  2011).	  The	  transport	  and	  docking	  of	  LAT-­‐containing	  vesicles	  with	  
the	  membrane	  regulates	  TCR-­‐induced	  signalling	  (Larghi	  et	  al.,	  2013).	  It	  is	  not	  yet	  known	  whether	  this	  
is	   also	   true	   in	  NK	   cells	   in	   the	   context	   of	   CD16	   signalling,	   but	   it	   is	   certainly	   possible	   since	   TCR	   and	  
CD16	   signalling	   share	   many	   of	   the	   same	   features.	   As	   lenalidomide	   augments	   CD16	   signalling,	   it	  
would	   be	   interesting	   to	   see	   whether	   there	   are	   any	   differences	   in	   LAT	   distribution,	   both	   at	   the	  
membrane	  and	  in	  vesicles,	  after	  lenalidomide	  treatment.	  	  
	  
The	  role	  of	  lymphoid	  transcription	  factors	  
It	  has	  recently	  been	  shown	  that	  lenalidomide	  causes	  the	  selective	  ubiquitination	  and	  degradation	  of	  
two	   lymphoid	   transcription	   factors,	   Ikaros	   (IKZF1)	   and	  Aiolos	   (IKZF3),	   by	   the	  CRBN	  ubiquitin	   ligase	  
complex	  in	  T	  cells.	  These	  two	  transcription	  factors	  are	  repressors	  of	  IL-­‐2	  mRNA	  expression	  and	  their	  
selective	   degradation	   results	   in	   the	   characteristic	   increase	   in	   IL-­‐2	   production	   seen	   in	   T	   cells	   after	  





lenalidomide	   treatment	   (Krönke	  et	  al.,	   2014;	  Gandhi	  et	   al.,	   2014).	   It	   is	  possible	   that	   the	  effects	  of	  
lenalidomide	  on	  NK	  cells	  could	  also	  be	  due	  to	  Ikaros	  and	  Aiolos	  protein	  degradation.	  However,	  the	  
levels	   of	   IFN-­‐γ	   mRNA	   remain	   unchanged	   after	   lenalidomide	   treatment,	   suggesting	   that	   increased	  
IFNG	   transcription	   is	   not	   the	   cause	   of	   the	   increased	   protein	   production.	   In	   order	   to	   test	  whether	  
Ikaros	  and	  Aiolos	  are	  involved	  in	  the	  effects	  of	  lenalidomide	  on	  NK	  cells,	  it	  would	  first	  be	  necessary	  
to	   observe	  whether	   the	   two	   transcription	   factors	   are	   expressed	   in	  NK	   cells	   and	  whether	   they	   are	  
degraded	   after	   the	   addition	   of	   lenalidomide.	   The	   transcription	   factors	   could	   then	   be	   transiently	  
knocked	  down	  in	  primary	  NK	  cells	  using	  siRNA	  or	  the	  CRISPR	  system.	  The	  knockdown	  cells	  could	  then	  




In	  conclusion,	  investigating	  the	  effect	  of	  lenalidomide	  on	  NK	  cells	  –	  on	  both	  a	  population	  level	  and	  a	  
single	  cell	  level	  –	  has	  revealed	  a	  dual	  effect	  of	  lenalidomide	  on	  NK	  cells	  and	  has	  shown	  for	  the	  first	  
time	   that	   lenalidomide	   lowers	   the	   threshold	   for	   NK	   cell	   activation.	   These	   results	   give	   rise	   to	  
interesting	  new	  questions	  about	  how	  lenalidomide	  augments	  NK	  cell	  signalling	  on	  a	  population	  level,	  
without	  activating	  the	  NK	  cells	   inappropriately.	   In	  the	  future,	  the	  nanoscale	  organisation	  of	  NK	  cell	  
receptors	   and	   signalling	   molecules	   after	   lenalidomide	   treatment	   should	   be	   probed	   to	   better	  









Chapter	  4	  -­‐ Imaging	  the	  actin	  meshwork	  at	  





4.1.1 The	  role	  of	  actin	  at	  the	  NK	  cell	  synapse	  
	  
NK	   cell	   effector	   functions	   largely	   depend	   on	   the	   formation	   of	   dynamic	   and	   highly	   specialised	  
intercellular	   contacts	   termed	   immune	   synapses.	   The	   processes	   involved	   in	   this,	   from	   the	  
organisation	  of	  the	   immune	  synapse	  to	  the	  release	  of	  cytokines	  and	   lytic	  granules,	   result	   from	  the	  
myriad	  indispensable	  functions	  of	  the	  cortical	  actin	  cytoskeleton	  within	  NK	  cells	  (Davis	  et	  al.,	  1999;	  
Davis,	  2002;	  Orange,	  2008;	  Lagrue	  et	  al.,	  2013).	  	  
	  
The	  spreading	  response	  
Signals	   from	   activating	   receptors	   and	   associated	   adhesion	   molecules	   lead	   to	   a	   characteristic	  
spreading	   response	   in	  NK	   cells.	   Initially,	   the	   cells	   spread	   against	   target	   cells	   or	   activating	   surfaces	  
using	  lamellipodia	  constructed	  from	  waves	  of	  F-­‐actin	  polymerisation,	  with	  the	  peak	  of	  the	  spreading	  
response	  occurring	  at	  around	  5	  minutes	  (Culley	  et	  al.,	  2009).	  This	  process	  is	  also	  observed	  in	  B	  cells	  
and	  has	  been	  well	  studied	  (Fleire	  et	  al.,	  2006;	  Weber	  et	  al.,	  2008).	  As	  the	  NK	  cell	  synapse	  matures,	  F-­‐
actin	  (along	  with	  integrins	  such	  as	  LFA-­‐1)	  form	  a	  dense	  ring	  around	  the	  central	  part	  of	  the	  synapse	  
(Vyas	   et	   al.,	   2001).	   This	   dense	   actin	   ring	   is	   very	   striking	   and	   is	   clearly	   observed	   by	   confocal	  
microscopy	  and	  so	  is	  often	  used	  as	  readout	  for	  cellular	  activation	  in	  NK	  cells.	  	  
One	  feature	  that	  distinguishes	  the	  spreading	  response	  of	  NK	  cells	  from	  that	  of	  other	  lymphocytes	  is	  
its	   seemingly	   binary	   nature.	   Previous	   results	   have	   shown	   that	   when	   stimulating	   antibodies	   were	  
diluted,	  fewer	  NK	  cells	  spread	  onto	  glass	  slides	  and	  formed	  actin	  rings,	  but	  those	  that	  did	  spread	  did	  




so	   to	   the	   same	   extent	   as	   for	   cells	   stimulated	   by	   higher	   concentrations	   of	   antibody	   (Culley	   et	   al.,	  
2009).	  This	  is	  in	  contrast	  to	  what	  is	  observed	  in	  B	  cells,	  where	  the	  extent	  of	  spreading	  is	  proportional	  
to	   the	   affinity	   of	   the	   B	   cell	   receptor	   (BCR)	   for	   its	   ligand	   (Fleire	   et	   al.,	   2006).	   This	   echoes	  what	   is	  
currently	   understood	   about	   the	  way	   these	   two	   cell	   types	   respond	   to	   their	   environment	   –	   B	   cells	  
undergo	  affinity	  maturation	  so	  responses	  that	  vary	  according	  to	  affinity	  are	  clearly	  a	  useful	  feature,	  
whereas	  NK	   cells	   have	  been	   shown	   to	   display	   a	   clear	   threshold	   for	   activation	   that,	   once	   reached,	  
results	  in	  target	  cell	  killing,	  an	  all-­‐or-­‐nothing	  response.	  	  
	  
Remodelling	  of	  the	  actin	  mesh	  
A	   long-­‐standing	   problem	   in	   NK	   cell	   biology	   is	   how	   lytic	   granule	   (and	   cytokine)	   secretion	   occurs	  
through	   the	   dense	   network	   of	   polymerised	   actin	   present	   at	   the	   NK	   cell	   immune	   synapse.	   It	   was	  
previously	  suggested	  that	  actin	  was	  cleared	  from	  the	  central	  region	  of	  the	  synapse,	  allowing	  passage	  
of	   lytic	   granules	   through.	   This	   idea	   originated	   from	   confocal	   microscopy	   and	   TIRF	   images	   which	  
showed	  a	  dense	   ring	  of	   cortical	  actin	  around	   the	  periphery	  of	   the	   synapse	  after	  NK	  cell	   activation	  
and	  no	  actin	  staining	  in	  the	  centre	  of	  the	  synapse,	  suggesting	  that	  actin	  had	  been	  cleared	  away	  (Vyas	  
et	   al.,	   2001;	   McCann	   et	   al.,	   2003;	   Orange	   et	   al.,	   2003;	   Culley	   et	   al.,	   2009).	   Recent	   advances	   in	  
microscopy	  techniques,	  however,	  have	  allowed	  the	  immune	  synapse	  to	  be	  visualised	  in	  more	  detail	  
and	  have	  shed	  new	  light	  on	  actin	  remodelling	  in	  NK	  cells.	  
Recent	   work,	   using	   the	   super-­‐resolution	   technique	   3D-­‐SIM,	   showed	   that	   actin	   is	   not	   completely	  
cleared	  from	  the	  centre	  of	  the	  synapse	  after	  NK	  cell	  activation	  as	  was	  previously	  suggested.	  Instead,	  
a	  meshwork	  of	  cortical	  actin	  was	  detected	  in	  the	  centre	  of	  the	  NK	  cell	  synapse	  both	  in	  activating	  and	  
inhibitory	  synapses	  (Brown	  et	  al.,	  2011).	  This	  meshwork	  of	  actin	  was	  not	  observed	  before	  because	  of	  
the	  diffraction	  limit	  of	  confocal	  microscopy	  –	  the	  actin	  filaments	  are	  very	  fine	  and	  require	  imaging	  at	  
the	   super-­‐resolution	   level	   to	   be	   resolved.	   The	   key	   outcome	   of	   this	   work	   was	   that,	   upon	   NK	   cell	  
activation,	   the	   actin	   mesh	   opens	   up	   in	   specific	   regions	   across	   the	   synapse,	   creating	   holes	   large	  
enough	  for	  lytic	  granules	  to	  penetrate	  (Brown	  et	  al.,	  2011;	  Brown	  et	  al.,	  2012).	  At	  the	  same	  time	  as	  
this,	   another	   research	   group	   was	   independently	   investigating	   the	   same	   phenomenon	   using	   a	  
different	   super-­‐resolution	   technique	   –	   STED	   microscopy.	   This	   technique	   allowed	   them	   to	   also	  
observe	   the	   presence	   of	   an	   actin	   meshwork	   at	   the	   NK	   cell	   synapse	   and	   they	   came	   to	   a	   similar	  
conclusion	  that	  NK	  cell	  activation	  leads	  to	  the	  presence	  of	   large	  holes	  within	  the	  actin	  mesh	  which	  
lytic	   granules	   could	   theoretically	   fit	   through	   (Rak	   et	   al.,	   2011).	   In	   both	   cases,	   however,	   the	   link	  
between	  actin	  remodelling	  and	  lytic	  granule	  secretion	  was	  suggested	  due	  to	  the	  correlative	  data,	  but	  
was	  not	  specifically	  proven.	  	  




It	   is	   important	   to	   note	   that	   these	   larger	   holes	   within	   the	   actin	   meshwork	   are	   not	   detected	   in	  
inhibitory	   synapses,	   or	  when	   cells	   have	   not	   received	   sufficient	   activating	   signals	   to	   overcome	   the	  
threshold	  for	  activation	  (Brown	  et	  al.,	  2011;	  Rak	  et	  al.,	  2011;	  Brown	  et	  al.,	  2012).	  This	  has	  led	  to	  the	  
suggestion	  that,	   in	  these	  non-­‐activating	  conditions,	  the	  actin	  mesh	  may	  act	  as	  a	  physical	  barrier	  to	  
prevent	  lytic	  granules	  from	  being	  released.	  However,	  this	  has	  yet	  to	  be	  explicitly	  shown.	  
Interestingly,	   the	   opening	   of	   the	   actin	   mesh	   under	   activating	   conditions	   appears	   to	   be	   a	   binary	  
response,	   in	   a	   similar	  manner	   to	   cell	   spreading	   (Brown	  et	   al.,	   2012).	   Titrating	  MICA	  proteins	  onto	  
glass	   slides	   before	   adding	   the	   NK	   cells	   showed	   that	   once	   the	   threshold	   for	   NK	   cell	   activation	   is	  
reached,	   the	   actin	   mesh	   opens	   up	   to	   the	   same	   extent	   at	   all	   concentrations	   of	   activating	   ligand	  
(Brown	  et	  al.,	  2012).	  This,	  again,	  suggests	  an	  all-­‐or-­‐nothing	  response	  after	  NK	  cell	  activation.	  It	  is	  also	  
important	  to	  note	  that	   the	  cortical	  actin	  mesh	  was	  also	  observed	  to	  open	  up	  at	   the	  point	  of	   IFN-­‐γ	  
secretion	   in	   NK	   cells,	   suggesting	   that	   actin	   remodelling	   also	   plays	   a	   part	   in	   directional	   cytokine	  
secretion	  (Brown	  et	  al.,	  2012).	  
	  
The	  importance	  of	  the	  actin	  mesh	  in	  NK	  cell	  biology	  
There	   is	  a	  growing	  body	  of	  work	  that	   is	  consistent	  with	  the	  theory	  that	  remodelling	  of	  the	  cortical	  
actin	  meshwork	  is	  a	  key	  step	  in	  lytic	  granule	  and	  cytokine	  secretion.	  Brown	  and	  colleagues	  showed	  
that	  the	  MTOC	  polarises	  to	  areas	  within	  the	  meshwork	  that	  have	  opened	  up	  enough	  to	  theoretically	  
allow	  the	  passage	  of	  lytic	  granules	  (Brown	  et	  al.,	  2011).	  Specifically,	  they	  showed	  that	  the	  MTOC	  was	  
consistently	   located	   in	   close	   proximity	   to	   these	   holes	   within	   the	   meshwork	   (with	   a	   mean	   lateral	  
distance	  of	  250	  nm)	  and	  so	  the	  authors	  suggest	  that	  the	  MTOC	  is	  specifically	  delivering	  granules	  to	  
these	   ‘discrete	   secretory	   domains’	   (Brown	   et	   al.,	   2011).	   In	   addition,	   Brown	   et	   al	   identified	   the	  
location	  of	  lytic	  granules	  within	  the	  cell	  and	  observed	  that	  granules	  within	  400	  nm	  of	  the	  cell	  surface	  
interface	  tended	  to	  polarise	  to	  the	  predicted	  penetrable	  areas	  (Brown	  et	  al.,	  2011).	  To	  analyse	  this,	  
an	  Odds	  Ratio	  was	  calculated	  of	  how	   likely	   it	  was	  that	  a	   lytic	  granule	  would	  be	   localised	  to	  one	  of	  
these	   penetrable	   areas,	   taking	   into	   account	   the	   granule	   location,	   number	   of	   granules	   and	   total	  
penetrable	  area/non-­‐penetrable	  area.	  The	  analysis	  revealed	  that	  lytic	  granules	  within	  400	  nm	  of	  the	  
interface	   in	   stimulated	  NK	   cells	  were	   located	  within	   regions	  of	   F-­‐actin	   that	   had	  opened	  up	   to	   the	  
greatest	  extent	   (with	  an	  odds	  ratio	  of	  between	  2.5	  and	  3.75)(Brown	  et	  al.,	  2011).	  This	   is	  a	  striking	  
result,	   as	   the	   researchers	   found	   that	   only	   approximately	   5%	   of	   the	   synapse	   was	   predicted	   to	   be	  
penetrable	  to	  lytic	  granules.	  This	  work	  is	  consistent	  with	  the	  theory	  that	  lytic	  granules	  are	  specifically	  
polarising	  to	  holes	  within	  the	  actin	  mesh,	  suggesting	  that	  they	  could	  be	  sites	  of	  secretion.	  	  




A	  study	  by	  Emily	  Mace	  and	  colleagues	  has	  provided	  additional	  results	  showing	  the	  importance	  of	  F-­‐
actin	   remodelling	   in	   lytic	   granule	   secretion	   at	   the	   NK	   cell	   synapse,	   by	   showing	   a	   defect	   in	   both	  
processes	   in	   coronin	   1A-­‐deficient	   cells	   (Mace	   &	   Orange,	   2014).	   Specifically,	   they	   showed	   that	  
coronin	   1A-­‐deficient	   cells	   had	   impaired	   F-­‐actin	   reorganisation	   (resulting	   in	   fewer	   holes	  within	   the	  
meshwork	  being	  penetrable	  to	  lytic	  granules).	  In	  addition,	  lytic	  granules	  were	  observed	  to	  sit	  within	  
hypodense	   regions	   of	   F-­‐actin	   at	   the	   NK	   cell	   synapse	   in	   coronin	   1A-­‐deficient	   cells,	   as	   opposed	   to	  
localising	   to	   holes	   within	   the	   actin	   mesh	   in	   normal	   cells.	   The	   researchers	   also	   show,	   using	   TIRF	  
microscopy,	  that	  less	  lytic	  granules	  are	  found	  within	  150	  nm	  of	  the	  interface	  in	  coronin	  1A-­‐deficient	  
cells,	  leading	  to	  the	  hypothesis	  that	  the	  granules	  are	  becoming	  trapped	  in	  the	  F-­‐actin	  dense	  regions,	  
instead	  of	  penetrating	   the	  actin	  meshwork	  as	   is	  observed	   in	   control	   cells	   (Mace	  &	  Orange,	  2014).	  	  
This	   supports	   the	   theory	   that	   F-­‐actin	   acts	   as	   a	   natural	   barrier	   to	   lytic	   granules	   and	   that	   F-­‐actin	  
remodelling	  allows	  the	  lytic	  granules	  to	  pervade	  the	  actin	  meshwork.	  
Finally,	  an	  additional	   study	  by	  Brown	  and	  colleagues	  showed	  that	   IFN-­‐γ	   vesicles	  also	  preferentially	  
localise	  to	  holes	  within	  the	  actin	  meshwork.	  Using	  an	  odds	  ratio	  calculated	  in	  a	  similar	  way	  to	  their	  
previous	  paper,	  Brown	  et	  al	   showed	   that	   vesicles	   containing	   IFN-­‐γ	  within	  250	  nm	  of	   the	   interface	  
frequently	  polarised	  to	  the	  penetrable	  areas	  in	  the	  cortical	  actin	  (with	  an	  odds	  ratio	  of	  2.8)(Brown	  et	  
al.,	  2012).	  This	   indicates	  that	  directed	  cytokine	  secretion	  at	  the	  NK	  cell	   immune	  synapse	   likely	  also	  
requires	  F-­‐actin	  remodelling.	  	  
Overall,	  despite	  the	  fact	  that	  the	  majority	  of	  this	  work	   is	  correlative	  rather	  than	  causative,	  there	   is	  
significant	  data	  to	  indicate	  that	  lytic	  granules	  and	  cytokine	  vesicles	  polarise	  to	  discrete	  regions	  in	  the	  
central	   synapse	  where	   the	  actin	  meshwork	  has	  opened	  up	  enough	   to	  allow	   these	  vesicles	   to	  pass	  
unimpeded.	   Since	   lenalidomide	   treatment	  was	   observed	   to	   both	   augment	   NK	   cell	   IFN-­‐γ	   secretion	  
and	   lower	   the	   threshold	   for	  NK	  cell	  activation	   (as	  described	   in	  Chapter	  3),	   it	   led	   to	   the	  hypothesis	  
that	  lenalidomide	  treatment	  could	  have	  an	  effect	  on	  actin	  remodelling	  at	  the	  NK	  cell	  synapse.	  This	  is	  
especially	   important	   since	   lenalidomide	  has	  already	  been	   linked	   to	  F-­‐actin	  polymerisation	   in	  other	  
cell	  types.	  
	  
4.1.2 Lenalidomide	  and	  the	  actin	  cytoskeleton	  
	  
In	  CLL	  patients,	  it	  has	  long	  been	  observed	  that	  circulating	  CLL	  tumour	  cells	  successfully	  evade	  T	  cell	  
surveillance	   in	   the	   body.	   In	   a	   series	   of	   elegant	   studies,	   Alan	   Ramsay	   and	   colleagues	   have	  
demonstrated	   that	   direct	   contact	   with	   tumour	   cells	   induces	   defective	   actin	   polymerisation	   in	  




previously	   healthy	   T	   cells	   (Ramsay	   et	   al.,	   2008;	   Ramsay	   et	   al.,	   2012).	   Functional	   T	   cell	   immune	  
synapses,	  as	  with	  NK	  cell	  activating	  synapses,	  are	  dependent	  on	  F-­‐actin	  polymerisation,	  which	  goes	  
some	  way	   to	   explaining	   how	   the	   tumour	   cells	   evade	   being	   killed.	   Ramsay	   and	   colleagues	   showed	  
that	   treatment	   of	   autologous	   T	   cells	   and	   CLL	   cells	  with	   lenalidomide	   resulted	   in	   restored	   synapse	  
formation	  (Ramsay	  et	  al.,	  2008).	  Specifically,	  they	  showed	  that	  lenalidomide	  treatment	  significantly	  
increased	   the	   number	   of	   T	   cell:CLL	   cell	   conjugates	   showing	   F-­‐actin	   polymerisation	   compared	   to	  
untreated	   cells	   from	  CLL	  patients.	   This	   increase	   resulted	   in	   synapse	   formation	   comparable	   to	   that	  
observed	  in	  healthy	  cells	  (Ramsay	  et	  al.,	  2008).	  This	  suggests	  that	  lenalidomide	  treatment	  is	  able	  to	  
fully	   restore	   F-­‐actin	   polymerisation	   after	   T	   cell	   activation,	   suggesting	   a	   link	   between	   lenalidomide	  
and	  F-­‐actin.	  	  
Given	  the	  proven	  effect	  of	   lenalidomide	  on	  F-­‐actin	  polymerisation	   in	  T	  cells,	   it	  seems	  possible	  that	  
lenalidomide	  could	  have	  an	  effect	  on	  F-­‐actin	  polymerisation	  –	  and	  possibly	  actin	  remodelling	  –	  at	  the	  
NK	   cell	   activating	   synapse.	   In	   order	   to	   investigate	   this,	   the	   nanoscale	   organisation	   of	   F-­‐actin	   was	  
visualised	  by	  super-­‐resolution	  STED	  microscopy.	  
	  
4.1.3 STED	  microscopy	  
	  
STED	  microscopy	  
STED	  microscopy	   is	   built	   on	   the	   basis	   of	   a	   confocal	   laser-­‐scanning	  microscope.	   In	   confocal	   laser-­‐
scanning	   microscopy,	   the	   objective	   lens	   focuses	   laser	   light	   onto	   a	   small	   spot	   on	   the	   sample	   and	  
fluorophores	   within	   this	   spot	   emit	   fluorescence.	   The	   resolution	   of	   a	   confocal	   microscope	   is	  
determined	   by	   the	   diffraction	   limit	   of	   light	   –	   the	   light	   intensity	   at	   the	   focal	   spot	   is	   distributed	  
according	  to	  the	  PSF	  of	  the	  microscope	  and	  this	  limits	  the	  resolution	  of	  the	  image.	  
In	   STED	  microscopy,	   a	   second	   laser	  has	  been	  added	   to	   the	  microscope	   set	  up	   (Figure	  4.1).	  During	  
image	  acquisition,	  the	  normal	  excitation	  laser	  pulse	  is	  closely	  followed	  by	  a	  doughnut-­‐shaped	  pulse	  
of	  a	   longer	  wavelength,	   termed	  the	  STED	  beam.	  The	  excited	   fluorophores	   that	  are	  exposed	  to	   the	  
STED	  beam	  are	  instantaneously	  ‘bleached’	  back	  to	  the	  ground	  state.	  In	  this	  way,	  only	  the	  molecules	  
that	   are	   in	   the	   hole	   of	   the	   doughnut	   are	   able	   to	   continue	   to	   emit	   fluorescence.	   This	   physically	  
constrains	  the	  PSF,	  thereby	  increasing	  the	  resolution	  beyond	  the	  diffraction	  limit	  (Figure	  4.1).	  
Originally,	  STED	  microscopy	  was	  demonstrated	  using	  ‘pulsed’	  lasers	  for	  both	  the	  excitation	  and	  the	  
STED	  beams.	  This	  type	  of	   laser	  works	  by	  repeatedly	  emitting	  pulses	  of	  the	  same	  duration.	   In	  order	  




for	   this	   to	  work	   in	   a	   STED	   setup,	   the	  pulses	   of	   the	   two	   lasers	   have	   to	   be	   carefully	   optimised	  –	   in	  
terms	  of	  both	  the	  exact	  arrival	  time	  at	  the	  sample	  and	  the	  duration	  of	  each	  set	  of	  pulses	  –	  in	  order	  
to	  obtain	   the	  best	   improvement	   in	   resolution.	   Simpler	   STED	   systems	  use	  a	   continuous	  wave	   (CW)	  
STED	  laser	  (where	  the	  output	  beam	  remains	  constant	  instead	  of	  pulsing).	  This	  reduces	  the	  amount	  of	  
optimisation	  required	  for	  each	  STED	  sample.	  The	  disadvantage	  of	  this	  type	  of	  system	  is	  that	  you	  lose	  
the	  ability	  to	  ensure	  that	  the	  STED	  beam	  hits	  the	  excited	  fluorophores	  at	  exactly	  the	  right	  point	  in	  
time	   to	  provide	   total	   bleaching.	   In	  CW	  STED,	   the	   fluorophores	   that	   are	   initially	   excited	  may	  begin	  
emitting	   fluorescence	   before	   being	   quenched	   by	   STED	   photons.	   This	   can	   result	   in	   residual	  




Figure	  4.1	  –	  Schematic	  diagram	  showing	  how	  STED	  microscopy	  works.	  STED	  uses	   two	   lasers,	   the	  excitation	  
laser	   (green)	   and	   the	   depletion	   laser	   (red).	   The	   depletion	   laser	   is	   a	   doughnut	   shape	   and	   so	   depletes	   the	  
fluorescence	  around	  the	  central	  point	  of	  the	  PSF,	  resulting	  in	  increased	  resolution.	  
	  
One	  solution	  to	  this	  problem	  is	  to	  include	  time-­‐gated	  detection	  for	  the	  fluorescence.	  This	  means	  that	  
you	  can	  instruct	  the	  detector	  to	  exclude	  photons	  from,	  for	  example,	  the	  first	  nanosecond	  after	  the	  
fluorophores	   have	   been	   excited.	   This	   effectively	   excludes	   the	   residual	   photons	   that	  were	   emitted	  
before	   the	   fluorophores	  were	   bleached	   and	   prevents	   reduction	   in	   the	   potential	   resolution	   of	   the	  
final	  image.	  The	  microscope	  used	  in	  this	  study	  is	  a	  gated	  CW	  STED	  microscope.	  





Applications	  of	  STED	  microscopy	  
STED	   imaging	   has	   been	   successfully	   applied	   to	   many	   fields	   of	   biology,	   including	   cell	   biology,	  
neurobiology	  and	  immunology.	  	  
In	   neurobiology,	   for	   example,	   imaging	   by	   STED	   has	   been	   used	   to	   observe	   the	   organisation	   of	  
individual	  vesicles	  at	  the	  pre-­‐synaptic	  membrane	  of	  neuronal	  synapses	  (Willig	  et	  al.,	  2006)	  as	  well	  as	  
shedding	   new	   light	   on	   spine	   morphology	   at	   the	   nanoscale	   in	   the	   context	   of	   fragile	   X	   syndrome	  
(Wijetunge	   et	   al.,	   2014).	   In	   cell	   biology,	   STED	  was	   used	   to	   investigate	   the	   organisation	   of	   SNARE	  
proteins	   in	   the	  plasma	  membrane	  (Sieber	  et	  al.,	  2006)	  and	  STED	   in	  combination	  with	   fluorescence	  
correlation	  spectroscopy	  was	  utilised	  to	  study	  the	   lipid	  membrane	  dynamics	  at	  the	  nanoscale	   level	  
(Mueller	  et	  al.,	  2013).	  	  
Live-­‐cell	  STED	  imaging	  using	  fluorescently-­‐tagged	  proteins	  has	  documented	  morphological	  nanoscale	  
changes	   of	   the	   endoplasmic	   reticulum	   over	   time	   (Hein	   et	   al.,	   2008)	   and	   movements	   of	   the	   gap	  
junction	  protein	  connexion-­‐43	  within	  the	  cell	  membrane	  (Hein	  et	  al.,	  2010).	  	  
	  
Imaging	  actin	  at	  the	  NK	  cell	  synapse	  
In	  immunology,	  STED	  microscopy	  has	  been	  used	  to	  investigate	  the	  nanoscale	  organisation	  of	  F-­‐actin	  
at	   the	  NK	  cell	   synapse,	  as	  mentioned	  previously	   (Rak	  et	  al.,	  2011;	  Mace	  &	  Orange,	  2012).	   In	   these	  
studies,	  an	  improved	  resolution	  of	  90	  nm	  was	  obtained	  (as	  measured	  by	  the	  full	  width	  half	  maximum	  
(FWHM))	   (Rak	   et	   al.,	   2011).	   To	   analyse	   the	   holes	   within	   the	   actin	   mesh,	   Rak	   and	   colleagues	  
measured	  the	  diameters	  of	  the	  clearances	  between	  the	  actin	  filaments	  and	  plotted	  the	  number	  of	  
clearance	   per	   µm2	   for	   clearances	   of	   diameters	   250-­‐499	   nm,	   500-­‐749	   nm	   and	   750	   nm+.	   The	  
clearances	  were	   identified	  by	   thresholding	   the	   images	  using	   ImageJ	   and	   then	   identifying	   the	   gaps	  
within	  the	  mesh.	  Each	  clearance	  was	  measured	  using	  the	  ‘analyse	  particles’	  tool.	  	  
In	  addition,	  super-­‐resolution	  SIM	  has	  also	  been	  used	  to	  image	  the	  nanoscale	  organisation	  of	  F-­‐actin	  
at	  the	  NK	  cell	  synapse.	  Using	  SIM,	  Brown	  and	  colleagues	  were	  able	  to	  obtain	  a	  resolution	  of	  ~100	  nm	  
(Brown	   et	   al.,	   2011).	   To	   measure	   the	   changes	   in	   the	   F-­‐actin	   structure	   observed	   after	   cellular	  
activation,	   the	   images	   were	   analysed	   using	   a	   custom-­‐written	   MatLab	   program.	   This	   program	  
automatically	  thresholds	  the	  images	  to	  create	  a	  mask	  of	  the	  actin	  filaments.	  Two	  parameters	  were	  
then	  measured:	  the	  area	  of	  the	  gaps	  between	  the	  actin	  filaments	  and	  the	  percentage	  of	  the	  central	  
synaptic	  area	  in	  which	  actin	  filaments	  were	  far	  enough	  apart	  to	  create	  gaps	  that	  a	  particle	  of	  250	  nm	  




diameter	  could	  pass	  through	  unimpeded.	  Although	  this	  program	  has	  only	  been	  used	  to	  analyse	  SIM	  
images	  before	  this	  investigation,	  it	  can	  theoretically	  also	  be	  used	  to	  analyse	  STED	  images.	  This	  would	  




Reorganisation	   of	   the	   nanoscale	   structure	   of	   F-­‐actin	   has	   been	   previously	   observed	   during	   IFN-­‐γ	  
secretion.	  Thus,	  a	  possible	  mechanism	  by	  which	  lenalidomide	  influences	  NK	  cell	  effector	  functions	  is	  
through	  cortical	  actin	  remodelling.	  	  
The	  goal	  of	  this	  project	  was	  to	  investigate	  the	  effect	  of	  lenalidomide	  on	  the	  nanoscale	  organisation	  
of	   F-­‐actin	   at	   NK	   cell	   synapses,	   using	   STED	   microscopy.	   The	   specific	   aims	   of	   this	   project	   were	   as	  
follows:	  
(i) To	  optimise	  STED	  image	  acquisition	  and	  image	  analysis	  of	  F-­‐actin	  at	  NK	  cell	  synapses.	  
	  
(ii) To	  observe	  whether	  lenalidomide	  affects	  the	  cortical	  actin	  mesh	  after	  CD16	  ligation.	  
	  
(iii) To	  determine	  whether	   IFN-­‐γ	  production	  and	  the	  presence	  of	  exogenous	   IL-­‐2	  are	   important	  
for	  lenalidomide-­‐induced	  actin	  rearrangements.	  
	  
(iv) To	   observe	   the	   effect	   of	   lenalidomide	   on	   F-­‐actin	   reorganisation	   during	   initial	   immune	  
synapse	  formation.	  
	  
(v) To	   investigate	   how	   the	   organisation	   of	   F-­‐actin	   changes	   with	   NKG2D	   ligation,	   with	   and	  








4.2 STED	  acquisition	  and	  analysis	  
	  
4.2.1 Optimisation	  of	  STED	  imaging	  
	  
Initial	  STED	  imaging	  experiments	  were	  carried	  out	  in	  order	  to	  optimise	  the	  STED	  acquisition	  settings	  
on	   the	  microscope.	   Primary	   NK	   cells	   labelled	   with	   Alexa488-­‐conjugated	   phalloidin	   (to	   visualise	   F-­‐
actin)	   were	   used	   in	   these	   preliminary	   experiments.	   The	   aim	   was	   to	   achieve	   the	   greatest	  
improvement	   in	   resolution	   in	   the	   sample	  without	   losing	  any	  of	   the	  detailed	   structure	  of	   the	  actin	  
mesh.	  As	  mentioned	  above,	  the	  microscope	  used	  in	  this	  study	  was	  a	  gated	  CW	  STED	  microscope.	  The	  
factors	   that	   could	   be	   optimised	   during	   image	   acquisition	   were	   detection	   mode,	   excitation	   laser	  
power,	   line/frame	   averaging	   and	   STED	   laser	   power.	   These	   factors	   are	   discussed	   in	   more	   detail	  
below.	  
When	   attempting	   to	   image	   the	   actin	   meshwork,	   the	   initial	   problem	   is	   that	   the	   dense	   ring	   of	  
polymerised	   F-­‐actin	   around	   the	   periphery	   of	   the	   cell	   becomes	   over-­‐exposed	   quickly.	   The	   fine	  
filaments	  of	  F-­‐actin	  within	  the	  centre	  of	  the	  actin	  ring,	  however,	  are	  prone	  to	  being	  under-­‐exposed,	  
as	   there	   is	   significantly	   less	   actin	   there	   than	   around	   the	   outside.	  When	   using	   standard	   detection	  
mode,	  it	  was	  difficult	  to	  see	  the	  filaments	  of	  actin	  because	  the	  exposure	  range	  was	  not	  wide	  enough.	  	  
This	  problem	  was	  overcome	  using	  the	  ‘Brightness	  re-­‐enforcement	  (BrightR)’	  detection	  mode,	  which	  
takes	  a	  larger	  range	  of	  exposures	  in	  one	  shot	  than	  standard	  mode.	  This	  makes	  dim	  structures	  more	  
visible,	   whilst	   not	   over-­‐exposing	   bright	   structures.	  When	   tested	   on	   the	   prepared	   NK	   cell	   sample,	  
BrightR	  was	  able	   to	  pick	  up	  the	   fine	  meshwork	  of	  F-­‐actin	  within	   the	  centre	  of	   the	  NK	  cell	   immune	  
synapse	  and	  so	  this	  detection	  mode	  was	  used	  for	  all	  STED	  image	  acquisition	  in	  this	  chapter.	  	  
The	   power	   of	   the	   two	   lasers	   and	   the	   potential	   for	   image	   averaging	   then	   had	   to	   be	   carefully	  
optimised	   in	   order	   to	   achieve	   the	   greatest	   improvement	   in	   resolution.	   The	   STED	   laser	   power	   is	  
particularly	  important	  as	  it	  controls	  the	  size	  of	  the	  PSF	  in	  the	  resulting	  image.	  High	  STED	  laser	  power	  
gives	  the	  greatest	  improvement	  in	  resolution,	  but	  a	  lower	  laser	  power	  will	  bleach	  the	  sample	  less.	  In	  
this	  way,	  a	  compromise	  has	  to	  be	  made	  on	  resolution	  improvement	  in	  order	  to	  not	  lose	  any	  of	  the	  
detail	  of	  the	  actin	  meshwork.	  In	  the	  same	  way,	  the	  excitation	  laser	  power	  and	  the	  amount	  of	  image	  
averaging	  has	  to	  be	  optimised.	  A	  higher	  excitation	  laser	  power	  will	  provide	  more	  efficient	  excitation	  
resulting	  in	  the	  fine	  actin	  filaments	  being	  more	  visible,	  however	  a	  high	  laser	  power	  will	  also	  bleach	  
the	  sample	   faster.	   Line	  averaging	  also	  gives	  a	  cleaner	   image	  as	   it	   is	   less	   likely	   to	  have	  background	  
fluorescence	   in	   the	   end	   image,	   but	   each	   time	   the	  microscope	   scans	   a	   line	   it	   bleaches	   the	   sample	  




more.	   To	   find	   the	   ideal	   balance	   of	   these	   three	   factors,	   the	   following	   conditions	  were	   tested:	   the	  
STED	  laser	  was	  tested	  for	  powers	  ranging	  from	  10-­‐100%;	  the	  excitation	  laser	  was	  tested	  for	  powers	  
ranging	   from	  5-­‐20%;	   the	   line	  averaging	  was	   tested	   from	  no	  averaging	   to	  a	   line	  average	  of	  32.	  The	  
final	   image	  acquisition	  settings	  were	  a	  STED	   laser	  power	  of	  35%,	  an	  excitation	   laser	  power	  of	  17%	  
and	  a	  line	  average	  of	  16.	  These	  settings	  generated	  the	  greatest	  improvement	  in	  resolution	  compared	  
to	  the	  confocal	  image	  (Figure	  4.2).	  
	  
	  
Figure	  4.2	  –	  Resolution	   improvement	  with	  STED.	   (A)	  Example	  of	  a	  confocal	   image	  and	  a	  STED	   image	  of	   the	  
same	  pNK	  cell	  stimulated	  on	  anti-­‐CD16	  mAb	  (stained	  with	  phalloidin-­‐Alexa488	  to	  visualise	  F-­‐actin)	  showing	  the	  
improvement	   in	   resolution	   that	   can	   be	   achieved	  with	   STED	  microscopy.	   (B)	  Overlapping	   line	   profiles	   of	   the	  
region	  shown	  in	  both	  images	  with	  a	  red	  line.	  In	  the	  STED	  image,	  three	  separate	  actin	  projections	  can	  be	  seen	  
whereas	  only	  two	  are	  visible	  in	  the	  confocal	  image.	  	  	  




4.2.2 Image	  processing	  and	  analysis	  
	  
Deconvolution	  
The	   resolution	   of	   the	   STED	   images	   was	   then	   further	   improved	   with	   image	   deconvolution.	  
Deconvolution	  is	  a	  mathematical	  operation	  designed,	  in	  this	  case,	  to	  remove	  blurring	  and	  noise	  from	  
an	   image.	   Blurring	   is	   largely	   due	   to	   the	   PSF	   of	   the	   image.	   The	   noise	   is	   caused	  by	   the	   background	  
fluorescence.	  	  
	   	  
Figure	  4.3	  –	  Further	  resolution	  improvement	  using	  image	  deconvolution.	  (A)	  Example	  of	  a	  STED	  image	  before	  
and	  after	  deconvolution.	  (B)	  Overlapping	  line	  profiles	  of	  the	  region	  shown	  in	  both	  images	  with	  a	  red	  line.	  In	  the	  
standard	   STED	   image,	   the	   grey	   value	   is	   higher	   due	   to	   background	   fluorescence.	   This	   is	   removed	   with	  
deconvolution.	  The	  dotted	  black	  lines	  show	  the	  FWHM	  for	  the	  peak	  (i.e.	  for	  the	  actin	  filament).	  




Even	  though	  STED	  microscopy	  has	  broken	  through	  the	  diffraction	  limit	  of	  confocal	  microscopy,	  the	  
resulting	  image	  –	  in	  the	  case	  of	  the	  NK	  samples	  used	  here	  –	  is	  often	  slightly	  blurred	  due	  to	  the	  fact	  
that	  the	  dense	  ring	  of	  F-­‐actin	  is	  very	  bright.	  In	  addition,	  there	  is	  always	  a	  higher	  level	  of	  background	  
fluorescence	   in	   the	   STED	   image	   relative	   to	   the	   confocal	   image,	   despite	   the	   fact	   that	   the	   first	  
nanosecond	  of	  fluorescence	  has	  been	  gated	  out.	  	  
Huygens	  deconvolution	  takes	  into	  account	  the	  type	  of	  microscopy	  used	  to	  generate	  the	  image	  and	  
calculates	  the	  theoretical	  PSF	  of	  the	  image.	  It	  then	  estimates	  what	  the	  object	  should	  look	  like	  given	  
the	  measured	  image	  and	  the	  theoretical	  PSF,	  and	  goes	  through	  multiple	  iterations	  of	  quality	  control	  
to	  remove	  noise	  (using	  the	  fact	  that	  the	  signal-­‐to-­‐noise	  ratio	  is	  determined	  by	  photon	  noise,	  and	  that	  
detected	  photons	  in	  a	  microscope	  camera	  follow	  a	  Poisson	  distribution).	  Using	  the	  Huygens	  method,	  
the	  actin	  mesh	  STED	  images	  were	  deconvolved	  to	  further	  improve	  the	  resolution	  of	  the	  images.	  An	  
example	   of	   image	   deconvolution	   is	   seen	   in	   Figure	   4.3.	   In	   the	   line	   profiles,	   the	   improvement	   in	  
resolution	  can	  be	  seen.	  In	  addition,	  image	  deconvolution	  removed	  background	  fluorescence,	  as	  can	  
be	   seen	  by	   the	   reduction	   in	   the	   grey	   value	   in	   the	   deconvolved	   image	   (Figure	   4.3B).	   This	  makes	   it	  
easier	  to	  identify	  individual	  F-­‐actin	  filaments.	  From	  the	  deconvolved	  image,	  the	  FWHM	  maximum	  for	  
one	  actin	  filament	  was	  calculated	  as	  90	  nm	  (Figure	  4.3B).	  	  
	  
Analysis	  technique	  
The	  aim	  was	  to	  use	  a	  previously	  published,	  custom-­‐written	  MatLab	  program	  (‘Actin	  Mesh	  Analyser’)	  
to	  analyse	  the	  STED	  images.	  However,	  the	  program	  was	  written	  specifically	  to	  analyse	  SIM	  images,	  
which	  were	  a	  different	  size	  and	  did	  not	  have	  as	  good	  a	  resolution	  as	  the	  STED	  images.	  Therefore,	  the	  
program	  was	  first	  tested	  to	  see	  how	  well	  it	  could	  detect	  the	  holes	  within	  the	  actin	  meshwork	  in	  the	  
STED	  images	  recorded.	  In	  order	  to	  do	  this,	  the	  results	  from	  the	  Actin	  Mesh	  Analyser	  were	  compared	  
against	  results	  generated	  using	  a	  manual	  analysis	  technique,	  described	  in	  section	  2.6.2.	  	  Briefly,	  the	  
images	   were	   imported	   into	   ImageJ	   and	   then	   thresholded.	   The	   image	   was	   then	   inverted	   and	   the	  
holes	  were	  identified	  as	  ‘objects’	  so	  that	  their	  size	  could	  be	  measured.	  	  
A	   side-­‐by-­‐side	   comparison	   of	   the	   two	   techniques	   shows	   that	   the	   two	   sets	   of	   analysis	   methods	  
provide	  similar	   results.	  Both	  of	   them	  show	  a	  similar	   increase	   in	   the	  mean	  area	  of	  holes	  within	   the	  
actin	  meshwork	  after	  CD16	  ligation	  compared	  to	  unstimulated	  conditions	  (Figure	  4.4).	  The	  average	  
hole	  size	  in	  the	  results	  from	  the	  Actin	  Mesh	  Analyser	  is	  smaller	  in	  the	  results	  provided	  by	  the	  manual	  
analysis	  technique	  as	  in	  the	  latter,	  the	  smallest	  holes	  were	  discarded	  as	  being	  below	  the	  detection	  
limit	   of	   the	   microscope.	   These	   small	   holes	   are	   still	   included	   in	   the	   results	   from	   the	   Actin	   Mesh	  




Analyser.	   The	   exclusion	   of	   this	   extra	   data	  made	   a	  minimal	   difference	   to	   the	   end	   result.	   Thus,	   the	  
Actin	   Mesh	   Analyser	   was	   chosen	   for	   the	   remainder	   of	   the	   analysis	   in	   this	   study	   as	   it	   provided	  
automated	  measurements,	  allowing	  more	  cells	  to	  be	  analysed.	  
	  
Figure	  4.4	  –	  Comparison	  of	  the	  two	  STED	  image	  analysis	  techniques.	   (A)	  Mean	  area	  of	  holes	  between	  actin	  
filaments	   in	   STED	   images	   calculated	   using	   the	   manual	   ImageJ	   analysis	   technique.	   (B)	   Mean	   area	   of	   holes	  
between	  actin	  filaments	  in	  the	  same	  STED	  images	  as	  in	  (A),	  calculated	  using	  the	  Actin	  Mesh	  Analyser	  program.	  





4.3.1 Lenalidomide	  alters	  the	  penetrability	  of	  the	  actin	  mesh	  at	  the	  NK	  cell	  ADCC	  synapse	  
	  
Cultured	   primary	   NK	   cells	   were	   treated	   with	   1	   μM	   lenalidomide	   or	   DMSO	   vehicle	   control	   and	  
incubated	  on	  surfaces	  coated	  with	   IgG1	   isotype-­‐matched	  control	  mAb	  for	  2	  hours.	  Cells	  were	  then	  
fixed	  and	  F-­‐actin	  was	  imaged	  by	  super-­‐resolution	  microscopy	  (Figure	  4.5).	  The	  ‘Actin	  Mesh	  Analyser’	  
MatLab	   program	   was	   used	   to	   analyse	   the	   molecular	   organisation	   of	   F-­‐actin	   at	   the	   contact	   point	  
between	   the	   NK	   cells	   and	   the	   slide.	   Specifically,	   the	   area	   of	   the	   gaps	   between	   individual	   actin	  
filaments	  within	  the	  central	  part	  of	  the	  synapse	  (“holes”)	  was	  calculated	  and	  false	  colour	  heat	  maps	  
were	  used	  to	  display	  the	  areas	  of	  holes	  (Figure	  4.5).	  	  




Visual	   inspection	   of	   the	   images	   suggested	   that	   NK	   cells	   did	   not	   activate	   under	   non-­‐stimulating	  
conditions,	  as	  expected,	  and	  that	  lenalidomide	  treatment	  did	  not	  change	  the	  organisation	  of	  F-­‐actin	  
(Figure	  4.5).	  This	  was	  confirmed	  with	  the	  quantitative	  results;	  the	  mean	  area	  of	  holes	  between	  actin	  
filaments	  was	  0.055	  ±	  0.009	  μm2	  in	  DMSO-­‐treated	  cells,	  and	  this	  did	  not	  change	  significantly	  in	  the	  
presence	  of	  lenalidomide	  (Figure	  4.6).	  These	  results	  support	  work	  presented	  in	  the	  previous	  chapter,	  
which	   concluded	   that	   lenalidomide	   does	   not	   affect	   NK	   cells	   in	   the	   absence	   of	   activating	   receptor	  
ligation.	   Cultured	   primary	   NK	   cells	   were	   then	   treated	   with	   1	   μM	   lenalidomide	   or	   DMSO	   and	  
incubated	   on	   surfaces	   coated	  with	   anti-­‐CD16	  mAb	   for	   2	   hours.	   F-­‐actin	  was	   then	   imaged	   by	   STED	  
microscopy	  (Figure	  4.7).	   It	   is	  clear	  from	  the	  microscopy	   images	  that	  the	  NK	  cells	  have	  activated	  on	  
anti-­‐CD16	  mAb,	  as	  the	  openings	  within	  the	  actin	  mesh	  appear	  to	  be	  larger	  (Figure	  4.7).	  Indeed,	  when	  
the	  mean	  area	  of	  holes	  between	  the	  F-­‐actin	  filaments	  were	  quantified,	  the	  mean	  hole	  size	  increased	  
to	  0.074	  ±	  0.004	  µm2	  in	  DMSO-­‐treated	  cells	  (Figure	  4.8).	  
	  
Figure	   4.5	   –	   Representative	   STED	  microscopy	   images	   for	   primary	  NK	   cells	   in	   unstimulated	   conditions.	  Top	  
row:	  example	  STED	  images	  of	  a	  primary	  NK	  cell	  treated	  with	  DMSO	  or	  1	  μM	  lenalidomide	  and	  plated	  on	  isotype	  
control	  mAb	  for	  2	  hours.	  Scale	  bars	  =	  5	  μm.	  Bottom	  row:	  holes	  between	  actin	  filaments	  in	  the	  central	  region	  of	  
the	  synapse	  shown	  as	  heat	  maps,	  with	  the	  smallest	  holes	  shown	  in	  blue	  (0.01	  μm2)	  and	  largest	  holes	  shown	  in	  
red	  (>3	  μm2).	  





Figure	  4.6	  –	  Lenalidomide	  does	  not	  affect	  the	  cortical	  actin	  mesh	  in	  unstimulated	  cells.	  Analysis	  of	  mean	  hole	  
area	  in	  cells	  stimulated	  as	  in	  Figure	  4.5.	  n	  =	  20	  from	  3	  donors.	  Each	  data	  point	  represents	  a	  single	  cell;	  red	  line	  
shows	  the	  mean.	  
	  
Figure	  4.7	  –	  Representative	  STED	  microscopy	  images	  for	  primary	  NK	  cells	  activated	  through	  CD16.	  Top	  row:	  
example	  STED	  images	  of	  primary	  NK	  cell	   treated	  with	  DMSO	  or	  1	  μM	  lenalidomide	  and	  plated	  on	  anti-­‐CD16	  
mAb	  for	  2	  hours.	  Scale	  bars	  =	  5	  μm.	  Bottom	  row:	  holes	  between	  actin	  filaments	   in	  the	  central	  region	  of	  the	  
synapse	  shown	  as	  heat	  maps,	  with	  the	  smallest	  holes	  shown	  in	  blue	  (0.01	  μm2)	  and	  largest	  holes	  shown	  in	  red	  
(>3	  μm2).	  




Treatment	  with	  lenalidomide	  caused	  a	  small,	  but	  not	  significant,	  increase	  in	  mean	  hole	  area	  to	  0.089	  
±	  0.005	  µm2	  (Figure	  4.8).	  	  To	  assess	  the	  extent	  that	  the	  actin	  meshwork	  may	  allow	  secretion	  of	  IFN-­‐γ	  
vesicles,	  the	  size	  of	  vesicles	  containing	  IFN-­‐γ	  were	  first	  assessed	  by	  deconvolved	  confocal	  microscopy	  
and	  >90%	  were	  found	  to	  be	  200−500	  nm	  diameter	  (Figure	  4.9).	  Then,	  the	  “penetrable	  area”	  of	  the	  
actin	  mesh	  was	  calculated	  and	   false	  colour	  heat	  maps	  were	  used	   to	  display	  holes	  within	   the	  actin	  
meshwork	  that	  would	  allow	  vesicles	  of	  200−500	  nm	  diameter	  to	  pass	  unimpeded.	  	  
	  
Figure	  4.8	  –	  Mean	  hole	  area	  of	  cortical	  actin	  mesh	  after	  ligation	  of	  CD16.	  Analysis	  of	  mean	  hole	  area	  in	  cells	  
stimulated	  as	  in	  Figure	  4.7.	  n	  =	  50	  from	  3	  donors.	  Each	  data	  point	  represents	  a	  single	  cell;	  red	  line	  shows	  the	  
mean.	  
	  
Figure	  4.9	  –	  Size	  of	  IFN-­‐γ 	  vesicles.	  (A)	  Vesicles	  were	  imaged	  by	  confocal	  microscopy	  at	  the	  point	  of	  contact	  with	  
the	  slide.	  Images	  were	  then	  deconvolved	  and	  the	  vesicle	  diameters	  were	  measured.	  (B)	  Frequency	  histogram	  of	  
vesicle	  diameters	  measured	  from	  4	  cells	  from	  2	  different	  donors.	  
	  





Figure	   4.10	   –	   Representative	   microscopy	   images	   showing	   proportion	   of	   the	   synapse	   predicted	   to	   be	  
penetrable	  to	  IFN-­‐γ 	  vesicles.	  Top	  row:	  example	  STED	  images	  of	  primary	  NK	  cell	  treated	  with	  DMSO	  or	  1	  μM	  
lenalidomide	  and	  plated	  on	  anti-­‐CD16	  mAb	   for	  2	  hours.	   Scale	  bars	  =	  5	  μm.	  Bottom	   row:	   regions	  are	   shown	  
through	  which	  a	  particle	  (such	  as	  an	  IFN-­‐γ	  vesicle)	  of	  diameter	  200	  nm	  (blue)	  to	  800	  nm	  (red)	  could	  fit.	  
	  
Figure	   4.11	   –	   Lenalidomide	   increases	   the	   penetrable	   area	   of	   the	   actin	   mesh	   after	   CD16	   ligation.	   The	  
proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  a	  vesicle	  of	  200−500	  nm	  diameter,	  for	  the	  same	  cells	  
as	  in	  Figure	  4.8.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  





Figure	   4.12	   –	   Lenalidomide	   increases	   the	   penetrable	   area	   of	   the	  NK	   cell	   actin	  mesh	   irrespective	   of	   IFN-­‐γ 	  
production.	  NK	  cells	  were	  treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	  stimulated	   for	  2	  hours	  on	  surfaces	  
coated	   with	   anti-­‐CD16	   mAb	   either	   without	   (A)	   or	   with	   (B)	   5	   µg/ml	   brefeldin	   A.	   Cells	   were	   then	   fixed	   and	  
stained	  with	  Alexa488-­‐conjugated	  phalloidin	  and	  Alexa647-­‐conjugated	  anti-­‐IFN-­‐γ	  mAb.	  F-­‐actin	  was	  imaged	  by	  
STED	  microscopy	  in	  cells	  that	  were	  both	  positive	  and	  negative	  for	  IFN-­‐γ	  staining.	  Graphs	  show	  the	  proportion	  
of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  vesicles	  of	  200−500	  nm	  diameter.	  n	  =	  50	  	  from	  3	  donors	  (A);	  n	  =	  
29	   from	  2	  donors	   (B).	   ns	   =	   not	   significant,*	   =	   p	   <0.05,	   **	   =	   p	   <0.01,	   ***	   =	   p	   <0.001,	   one	  way	  ANOVA	  with	  
Tukey’s	  post-­‐test.	  
	  




An	   example	   of	   this	   is	   shown	   in	   Figure	   4.10.	   For	   vehicle	   control-­‐treated	   cells	   in	   non-­‐stimulated	  
conditions,	   the	  percentage	  of	   the	  cortical	  actin	  meshwork	   that	  would	  be	  penetrable	  by	  vesicles	  of	  
200−500	  nm	  diameter	  did	  not	   significantly	   change	  with	   lenalidomide	   treatment	   (Figure	  4.11).	   The	  
penetrable	  area	  for	  vesicles	  of	  200	  nm	  diameter	  was	  <0.5%,	  which	  decreased	  with	  increasing	  vesicle	  
size	  to	  <0.0003%	  for	  a	  vesicle	  of	  500	  nm	  diameter,	  with	  no	  significant	  difference	  with	  lenalidomide	  
treatment.	   	   This	   is	   consistent	  with	   the	   findings	   reported	   in	   Chapter	   3,	   showing	   that	   lenalidomide	  
does	  not	  have	  an	  effect	  in	  the	  absence	  of	  activating	  signalling.	  When	  cells	  were	  stimulated	  by	  anti-­‐
CD16	  mAb,	   lenalidomide	   significantly	   increased	   the	   penetrable	   area	   of	   the	   synapse	   for	   the	  whole	  
range	  of	  vesicle	  sizes	  (Figure	  4.11).	  Specifically,	  the	  penetrable	  area	  for	  a	  vesicle	  of	  200	  nm	  increased	  
from	  2.1	  ±	  0.19	  %	  in	  DMSO-­‐treated	  cells	  to	  3.7	  ±	  0.23	  %	  with	  lenalidomide	  treatment.	  This	  near	  two-­‐
fold	  increase	  was	  also	  observed	  for	  vesicles	  of	  250	  and	  300	  nm	  diameter	  (from	  1	  ±	  0.12%	  and	  0.62	  ±	  
0.1%,	   respectively,	   without	   lenalidomide	   to	   2	   ±	   0.16%	   and	   1.2	   ±	   0.12%	   with	   1	   µM	   lenalidomide	  
treatment;	  Figure	  4.11).	  When	  the	  penetrable	  area	  for	  vesicles	  larger	  than	  300	  nm	  was	  assessed,	  the	  
difference	  between	  DMSO-­‐	  and	  lenalidomide-­‐treated	  cells	  became	  greater.	  For	  vesicles	  of	  350	  nm,	  
lenalidomide	   treatment	   increased	   the	   penetrable	   area	   2.5-­‐fold	   (from	   0.34	   ±	   0.06%	   without	  
lenalidomide	   to	   0.86	   ±	   0.09%	   with	   lenalidomide;	   Figure	   4.11).	   For	   vesicles	   of	   500	   nm	   diameter,	  
lenalidomide	   treatment	   increased	   the	   penetrable	   area	   nearly	   4-­‐fold	   (from	   0.07	   ±	   0.02%	   without	  
lenalidomide	  to	  0.24	  ±	  0.04%	  with	  lenalidomide;	  Figure	  4.11).	  This	  indicates	  that,	  after	  lenalidomide	  
treatment,	  a	  higher	  proportion	  of	  the	  actin	  mesh	  has	  opened	  up	  to	  create	  secretory	  domains	  of	  the	  
right	   proportions	   to	   allow	   vesicles	   of	   200−500	   nm	   through.	   However,	   as	   shown	   in	   the	   previous	  
chapter,	  lenalidomide	  treatment	  causes	  a	  higher	  proportion	  of	  NK	  cells	  to	  secrete	  IFN-­‐γ.	  Therefore,	  
this	   observation	   could	   be	   a	   result	   of	   the	   increased	   likelihood	   of	   imaging	   cells	   that	   are	   currently	  
secreting	  IFN-­‐γ,	  rather	  than	  a	  direct	  effect	  on	  the	  cortical	  actin.	  	  
In	  order	  to	  test	  this,	  STED	  imaging	  of	  the	  cortical	  actin	  was	  compared	  in	  cells	  that	  were	  positive	  or	  
negative	   for	   IFN-­‐γ	   staining.	   In	   DMSO-­‐treated	   NK	   cells,	   IFN-­‐γ	   staining	   correlated	   with	   a	   significant	  
increase	   in	   the	   penetrable	   area	   of	   the	   synapse,	   as	   expected	   (Figure	   4.12A).	   In	   contrast,	   the	  
penetrable	  area	  of	  the	  cortical	  actin	  in	  lenalidomide-­‐treated	  cells	  was	  the	  same	  (or	  higher)	  than	  the	  
IFN-­‐γ-­‐positive	   DMSO-­‐treated	   cells	   across	   the	   whole	   range	   of	   vesicle	   sizes	   (Figure	   4.12A).	   For	  
example,	  the	  predicted	  penetrable	  area	  for	  vesicles	  of	  200	  nm	  in	  IFN-­‐γ-­‐positive	  DMSO-­‐treated	  cells	  
was	  2.54%,	  whereas	  it	  was	  >3%	  in	  lenalidomide-­‐treated	  cells	  irrespective	  of	  whether	  they	  were	  IFN-­‐
γ-­‐positive	   or	   negative	   (Figure	   4.12A).	   This	   shows	   that	   lenalidomide	   treatment	   increases	   the	  
penetrable	  area	  within	  the	  actin	  mesh	  irrespective	  of	  whether	  or	  not	  the	  NK	  cells	  stained	  positively	  
for	  IFN-­‐γ.	  However,	  this	  experiment	  does	  not	  take	  into	  account	  the	  fact	  that	  lenalidomide	  treatment	  
could	   affect	   the	   rate	   of	   IFN-­‐γ	   secretion.	   This	   might	   result	   in	   some	   cells	   appearing	   IFN-­‐γ	   negative	  




because	  secretion	  has	  occurred	  at	  an	  earlier	   time	  point.	  To	  control	   for	   this,	   the	  above	  experiment	  
was	  repeated	  except	  IFN-­‐γ	  release	  was	  blocked	  with	  brefeldin	  A.	  The	  results	  show	  that	  lenalidomide	  
treatment	   increased	   the	   proportion	   of	   the	   synapse	   predicted	   to	   be	   penetrable	   by	   vesicles	   of	  
200−500	  nm	  diameter	   in	  NK	  cells	  that	  were	  positive	  for	  IFN-­‐γ,	  and	  in	  cells	  that	  were	  not	  producing	  
IFN-­‐γ	   (Figure	   4.12B).	   This	   indicates	   that	   the	   increased	   opening	   of	   the	   actin	   mesh	   caused	   by	  
lenalidomide	  does	  not	  only	  occur	  in	  cells	  that	  are	  producing	  cytokine	  –	  and	  therefore	  is	  an	  effect	  of	  
the	  drug	  independent	  of	  IFN-­‐γ	  production.	  	  
As	  the	  observed	  increase	  in	  cortical	  actin	  rearrangements	  is	  a	  separate	  effect	  of	  lenalidomide	  on	  NK	  
cells	  than	  the	  increase	  in	  IFN-­‐γ	  production,	  the	  requirement	  for	  IL-­‐2	  was	  then	  assessed.	  NK	  cells	  were	  
still	   rested	   in	   IL-­‐2	   for	   6	   days	   before	   use,	   but	   IL-­‐2	  was	   not	   given	   to	   the	   cells	   at	   the	   same	   time	   as	  
lenalidomide	  treatment	  as	  has	  been	  done	  for	  the	  previous	  experiments.	  Cells	  were	  then	  stimulated	  
on	  anti-­‐CD16	  mAb-­‐coated	  surfaces	  for	  2	  hours	  and	  then	  the	  nanoscale	  arrangement	  of	  F-­‐actin	  was	  
imaged	  by	  STED	  microscopy.	  	  Interestingly,	  lenalidomide	  treatment	  still	  resulted	  in	  an	  increase	  in	  the	  
penetrable	  area	  of	  the	  NK	  cell	  synapse	  even	  though	  IL-­‐2	  was	  not	  present	  (Figure	  4.13A).	  Specifically,	  
the	  predicted	  penetrable	  area	  for	  vesicles	  of	  200	  nm	  diameter	  increased	  from	  2.8	  ±	  0.28%	  without	  
lenalidomide	   to	  4.5	  ±	   0.4%	  with	  1	  µM	   lenalidomide	   (Figure	  4.13B).	   This	   increase	   is	   similar	   to	   that	  
observed	  when	  IL-­‐2	  was	  present	  (Figure	  4.11).	  A	  greater	  than	  4-­‐fold	  increase	  was	  also	  still	  observed	  
for	   vesicles	   of	   500	   nm	   diameter	   (from	   0.06	   ±	   0.01%	   without	   lenalidomide	   to	   0.25	   ±	   0.06%	   with	  
lenalidomide;	  Figure	  4.13B),	   indicating	   that	   lenalidomide	  does	  not	   require	   IL-­‐2	   to	  augment	  cortical	  
actin	  remodelling.	  Taken	  together,	   these	  data	  establish	  that	   lenalidomide	   influences	  the	  nanoscale	  
organisation	  of	  cortical	  actin	  at	  the	  NK	  cell	  synapse	  after	  CD16	  ligation.	  
	  
4.3.2 Lenalidomide	   treatment	   results	   in	   increased	   actin	   remodelling	   after	   ligation	   of	   CD16	  with	  
rituximab	  
	  
As	  mentioned	  previously,	  lenalidomide	  in	  combination	  with	  rituximab	  is	  currently	  in	  clinical	  trials	  for	  
the	   treatment	  of	   some	  B	  cell	   lymphomas	   (Badoux	  et	  al.,	  2013;	  Wang	  et	  al.,	  2012).	   In	   the	  previous	  
chapter,	   the	   results	   showed	   that	   lenalidomide	   lowers	   the	   threshold	   for	   activation	   through	   CD16	  
when	   rituximab	   was	   ligated.	   To	   investigate	   how	   lenalidomide	   affects	   actin	   remodelling	   in	   the	  
presence	  of	   rituximab,	   the	  optimum	   time	  point	   for	   IFN-­‐γ	   secretion	   first	   had	   to	  be	  established.	  NK	  
cells	  were	  activated	  on	  10	  µg/ml	  rituximab	  and	  fixed	  at	  different	  time	  points	  (30-­‐120	  min)	  and	  then	  
imaged	  by	  confocal	  microscopy	  to	  ascertain	  the	  optimum	  time	  point	  for	  IFN-­‐γ	  production.	  	  





Figure	  4.13	  –	  IL-­‐2	  is	  not	  required	  for	  lenalidomide-­‐induced	  F-­‐actin	  rearrangements.	  (A)	  NK	  cells	  treated	  with	  
DMSO	  or	  1	  µM	  lenalidomide	  without	  exogenous	  IL-­‐2	  and	  stimulated	  on	  anti-­‐CD16	  mAb-­‐coated	  surfaces	  for	  2	  
hours.	   Cells	   were	   then	   fixed	   and	   stained	   with	   Alexa88-­‐conjugated	   phalloidin.	   F-­‐actin	   was	   imaged	   by	   STED	  
microscopy.	  First	  column	  shows	  representative	  STED	  images.	  Second	  column	  shows	  mean	  hole	  area	  as	  a	  heat	  
map,	  with	  smallest	  holes	  in	  blue	  and	  largest	  holes	  in	  red.	  Third	  column	  shows	  penetrable	  area	  as	  a	  heat	  map	  
(B)	  The	  proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  vesicles	  of	  200−500	  nm	  diameter.	  n	  =	  53	  cells	  
from	  3	  donors.	  *	  =	  p<0.05,	  **	  =	  p<0.01,	  ***	  =	  p<0.001,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  




Interestingly,	   rituximab-­‐activated	   NK	   cells	   produced	   IFN-­‐γ	   at	   a	   much	   earlier	   time	   point	   (60	   min;	  
Figure	   4.14)	   than	  NK	   cells	   that	  were	   activated	  with	   an	   anti-­‐CD16	  mAb	   (120	  min;	   Figure	   3.12).	   To	  
observe	   whether	   lenalidomide	   alters	   the	   nanoscale	   organisation	   of	   cortical	   actin	   after	   rituximab-­‐	  
mediated	  NK	  cell	  activation,	  NK	  cells	  were	  incubated	  on	  glass	  slides	  coated	  with	  10	  µg/ml	  rituximab	  
for	  60	  min	  and	  then	  fixed	  and	  stained	  with	  Alexa488-­‐conjugated	  phalloidin.	  F-­‐actin	  was	  then	  imaged	  
by	   STED	   microscopy	   (Figure	   4.15A).	   Lenalidomide	   treatment	   led	   to	   an	   enhancement	   in	   actin	  
remodelling	  after	  CD16	  ligation	  by	  rituximab	  compared	  to	  DMSO	  alone	  (Figure	  4.15B).	  There	  was	  a	  
significant	  increase	  in	  the	  percentage	  area	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  a	  vesicle	  of	  
200-­‐300	   nm	   diameter	   after	   lenalidomide	   treatment	   (e.g.	   for	   a	   vesicle	   of	   300	   nm	   diameter,	   the	  
proportion	   increased	   from	   0.86	   ±	   0.13%	  without	   lenalidomide	   to	   1.4	   ±	   0.18%	  with	   lenalidomide;	  
Figure	  4.15B).	  Holes	  that	  would	  allow	  vesicles	  of	  a	  larger	  size	  (350-­‐500	  nm)	  were	  also	  present	  more	  
in	   lenalidomide-­‐treated	   cells	   compared	   to	   vehicle	   control,	   suggesting	   a	   greater	   degree	   of	   actin	  
remodelling	  (Figure	  4.15B).	  When	  observed	  at	  a	  later	  time	  point	  (120	  min),	  the	  penetrable	  area	  was	  
slightly	   less	   than	   that	   observed	   in	   cells	   stimulated	   for	   60	  min	   –	   for	   a	   vesicle	   size	   of	   200	   nm,	   the	  
penetrable	  area	   in	  DMSO-­‐treated	  cells	  decreased	   from	  3.5%	  at	  60	  min	   to	  2.8%	  at	  120	  min	   (Figure	  
4.15	   and	   Figure	   4.16).	   Interestingly,	   however,	   the	   increase	   in	   cortical	   actin	   after	   lenalidomide	  
treatment	  was	  still	  observed	  at	  120	  min	  when	  the	  IFN-­‐γ	  vesicles	  had	  already	  been	  released	  (Figure	  
4.16).	  This	   indicates	  a	   sustained	  effect	  of	   lenalidomide	  on	   the	  NK	  cell	   synapse.	  Thus,	   lenalidomide	  
augments	  actin	  rearrangements	  at	  the	  NK	  cell	  synapse	  triggered	  by	  rituximab.	  
	  
Figure	   4.14	   –	   Timecourse	   for	   IFN-­‐γ 	   production	   after	   stimulation	   with	   rituximab.	   The	   proportion	   of	   cells	  
expressing	   IFN-­‐γ	   after	   stimulation	   on	   anti-­‐CD16	   mAb-­‐coated	   surfaces	   in	   the	   presence	   of	   DMSO	   or	   1	   µM	  
lenalidomide	  (+	  150	  U/ml	  IL-­‐2)	  for	  30-­‐240	  min.	  Graph	  shows	  mean	  ±	  SEM,	  n	  =	  200	  from	  3	  donors.	  





Figure	   4.15	   –	   Lenalidomide	   enhances	   actin	   remodelling	   at	   the	   NK	   cell	   synapse	   after	   stimulation	   with	  
rituximab	   for	   60	  min.	   (A)	   Super-­‐resolution	   images	   obtained	   by	   STED	  microscopy	   of	  membrane	   proximal	   F-­‐
actin	  in	  primary	  NK	  cells	  incubated	  for	  60	  min	  on	  surfaces	  coated	  with	  rituximab	  (10	  µg/ml)	  in	  the	  presence	  of	  
DMSO	  or	  1	  µM	  lenalidomide.	  Scale	  bars	  =	  5	  µm.	  Second	  row:	  regions	  are	  shown	  through	  which	  a	  vesicle	  of	  
diameter	  200	  nm	  (blue)	  to	  800	  nm	  (red)	  could	  fit.	  (B)	  Proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  
a	   vesicle	   of	   200−500	   nm	  diameter	   for	   cells	   stimulated	   as	   in	   (A).	   Graph	   shows	  mean	  ±	   SEM,	   n	   =	   45	   from	  3	  
donors.	  	  





Figure	  4.16	  –	  The	  effect	  of	  lenalidomide	  on	  cortical	  actin	  remodelling	  after	  rituximab	  stimulation	  is	  sustained	  
after	  IFN-­‐γ 	  release.	  (A)	  Super-­‐resolution	  images	  obtained	  by	  STED	  microscopy	  of	  membrane	  proximal	  F-­‐actin	  
in	   primary	  NK	   cells	   incubated	   for	   120	  min	  on	   surfaces	   coated	  with	   rituximab	   (10	  µg/ml)	   in	   the	  presence	  of	  
DMSO	  or	  1	  µM	  lenalidomide.	  Scale	  bars	  =	  5	  µm.	  Second	  row:	   regions	  are	  shown	  through	  which	  a	  vesicle	  of	  
diameter	  200	  nm(blue)	  to	  800	  nm	  (red)	  could	  fit.	  (B)	  Proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  a	  
vesicle	  of	  200−500	  nm	  diameter	  for	  cells	  stimulated	  as	  in	  (A).	  Graph	  shows	  mean	  ±	  SEM,	  n	  =	  38	  from	  3	  donors.	  
	  




Lenalidomide	  augments	  cortical	  actin	  remodelling	  during	  initial	  cell	  spreading	  
	  
The	  point	  at	  which	  the	  greatest	  degree	  of	  actin	  remodelling	  occurs	   is	  during	  the	  first	  6	  minutes	  of	  
intercellular	  contact,	  when	  a	  dense	  ring	  of	  F-­‐actin	  assembles	  at	  the	  synapse	  periphery	  surrounding	  a	  
fine	  meshwork	  of	   actin	   filaments	   (Brown	  et	   al.,	   2011;	  Rak	   et	   al.,	   2011;	  Brown	  et	   al.,	   2012).	   It	   has	  
been	  suggested	  that	  this	  rearrangement	  of	  actin	  could	  be	  a	  key	  step	  in	  allowing	  lytic	  granule	  release	  
(Brown	   et	   al.,	   2011;	   Rak	   et	   al.,	   2011).	   To	   determine	   whether	   lenalidomide	   augmented	   actin	  
remodelling	  during	   initial	   cell	   spreading,	  primary	  NK	  cells	  were	   treated	  with	  1	  µM	  lenalidomide	  or	  
DMSO	  and	  stimulated	  on	  surfaces	  coated	  with	  anti-­‐CD16	  mAb	  or	  control	  isotype-­‐matched	  mAb	  for	  6	  
minutes	  before	  fixation.	  Upon	  visual	  inspection	  of	  the	  images,	  there	  were	  no	  differences	  in	  cortical	  
actin	  structure	  between	  cells	  treated	  with	  1	  µM	  lenalidomide	  or	  DMSO	  on	  isotype-­‐matched	  control	  
mAb-­‐coated	  surfaces	  (Figure	  4.17).	  This	  was	  confirmed	  when	  the	  size	  of	  the	  holes	  within	  the	  mesh	  
were	  quantified	  (Figure	  4.18).	  	  
For	   NK	   cells	   stimulated	   on	   anti-­‐CD16	   mAb,	   the	   mean	   hole	   area	   increased	   slightly,	   but	   not	  
significantly,	  after	   lenalidomide	  treatment	  (from	  0.093	  µm2	  without	   lenalidomide	  to	  0.11	  µm2	  with	  
lenalidomide;	   Figure	   4.18A).	   When	   calculating	   the	   penetrable	   area	   of	   the	   synapse,	   the	   vesicle	  
diameter	  was	   set	   to	   250	  nm,	   as	   this	  was	   previously	   defined	   as	   the	   average	   size	   of	   a	   lytic	   granule	  
(Brown	   et	   al.,	   2011).	   When	   NK	   cells	   were	   stimulated	   on	   anti-­‐CD16	   mAb,	   the	   proportion	   of	   the	  
synapse	  predicted	  to	  be	  penetrable	  by	  lytic	  granules	  was	  1.51%	  in	  DMSO-­‐treated	  cells	  and	  increased	  
to	  1.93%	  in	  lenalidomide-­‐treated	  cells	  (Figure	  4.18B).	  There	  was	  no	  change	  in	  the	  proportion	  of	  cells	  
which	  activated	  on	  anti-­‐CD16	  mAb	  after	  lenalidomide	  treatment,	  as	  measured	  by	  the	  percentage	  of	  
NK	  cells	  that	  formed	  a	  dense	  ring	  of	  peripheral	  actin	  (Figure	  4.19A).	  This	  correlates	  with	  the	  results	  
presented	   in	   the	  previous	   chapter,	  which	   found	   that	   there	  was	  no	  difference	   in	   the	  proportion	  of	  
activated	   NK	   cells	   when	   stimulated	   on	   high	   doses	   of	   activating	   ligands.	   However,	   when	   the	   cells	  
were	   stratified	   based	   on	   the	   presence	   or	   absence	   of	   a	   dense	   peripheral	   ring	   of	   F-­‐actin,	   the	  
penetrable	   area	   of	   the	   cortical	   actin	   mesh	   increased	   significantly	   between	   non-­‐activated	   and	  
activated	   cells	   (Figure	   4.19B).	   In	   activated	   NK	   cells	   (those	   displaying	   an	   actin	   ring),	   there	   was	   a	  
significant	   increase	   in	   the	   penetrable	   area	   after	   lenalidomide	   treatment	   (from	   2.1%	   without	  
lenalidomide	   to	   2.9%	   with	   1	   µM	   lenalidomide;	   Figure	   4.19B).	   	   Thus,	   lenalidomide	   treatment	  
augments	   cortical	   actin	   remodelling	   at	   an	   early	   time	   point,	   relevant	   for	   lytic	   granule	   secretion,	  
although	  to	  a	  lesser	  extent	  than	  observed	  later,	  at	  the	  point	  of	  cytokine	  secretion.	  





Figure	  4.17	  –	  Super-­‐resolution	  images	  of	  the	  actin	  mesh	  during	  initial	  cell	  spreading.	  Representative	  images	  
obtained	  by	  STED	  microscopy	  of	  membrane	  proximal	  actin	  in	  NK	  cells	  incubated	  for	  6	  min	  on	  coverslips	  coated	  
with	  isotype	  matched	  control	  mAb	  or	  anti-­‐CD16	  mAb	  (both	  3	  µg/ml)	  in	  the	  presence	  or	  absence	  of	  DMSO	  or	  1	  
µM	  lenalidomide.	  Scale	  bars	  =	  5	  µm.	  Second	  column:	  holes	  within	  the	  actin	  filaments	  in	  the	  central	  region	  of	  
the	   synapse	   shown	   as	   heat	  maps,	   with	   the	   smallest	   holes	   shown	   in	   blue	   (0.01	   µm2)	   and	   the	   largest	   holes	  
shown	   in	   red	   (>3	  µm2).	   Third	   column:	   regions	   are	   shown	   through	  which	   lytic	   granules	   of	   diameter	   200	   nm	  
(blue)	  to	  800	  nm	  (red)	  could	  fit.	  
	  





Figure	   4.18	   –	   Lenalidomide	   treatment	   and	   initial	   cell	   spreading.	   (A)	   Analysis	   of	   the	   mean	   area	   of	   holes	  
between	   actin	   filaments	   for	   cells	   activated	   as	   in	   Figure	   4.17.	   (B)	   Proportion	   of	   the	   synapse	   predicted	   to	   be	  
penetrable	  by	  a	   lytic	   granule	  of	   250	  nm	  diameter	   for	   the	   same	  cells	   as	   in	   (A).	   Each	  data	  point	   represents	   a	  
single	  cell;	  red	  line	  shows	  the	  mean,	  n	  =	  59	  from	  3	  donors.	  





Figure	  4.19	  –	  Lenalidomide	  treatment	  enhances	  opening	  of	  the	  cortical	  actin	  mesh	  in	  activated	  cells.	  (A)	  The	  
proportion	  of	  cells	  displaying	  a	  dense	  ring	  of	  F-­‐actin	  for	  same	  cells	  as	  in	  Figure	  4.17.	  (B)	  The	  proportion	  of	  the	  
synapse	   area	   predicted	   to	   be	   penetrable	   by	   a	   lytic	   granule	   of	   250	   nm	  diameter,	  with	   cells	   stratified	   by	   the	  
presence	   or	   absence	   of	   a	   peripheral	   actin	   ring.	   Each	   data	   point	   represents	   a	   single	   cell;	   red	   line	   shows	   the	  
mean	  from	  3	  donors,	  n	  =	  59	  per	  condition.	  ns	  =	  not	  significant,	  *	  =	  p	  <0.05,	  ****	  =	  p	  <0.0001,	  one	  way	  ANOVA	  
with	  Tukey’s	  post	  test.	  
	  
	  




4.3.3 Lenalidomide	  alters	  the	  periodicity	  of	  the	  actin	  mesh	  after	  NKG2D	  and	  LFA-­‐1	  co-­‐ligation	  
	  
NKG2D	  is	  a	  major	  NK	  cell	  receptor	  responsible	  for	  the	  recognition	  of	  stress-­‐inducible	  ligands	  on	  the	  
surface	   of	   tumour	   cells,	   including	   MM	   cells.	   To	   test	   whether	   or	   not	   lenalidomide	   treatment	  
augments	   actin	   rearrangements	   after	   ligation	   of	   NKG2D,	   NK	   cells	   were	   treated	   with	   1	   µM	  
lenalidomide	   or	   DMSO	   and	   stimulated	   on	   surfaces	   coated	  with	   recombinant	   ICAM-­‐1,	   anti-­‐NKG2D	  
mAb	  or	  both	  for	  90	  min	  before	  fixation.	  90	  min	  was	  chosen	  as	  this	  was	  previously	  identified	  as	  the	  
optimum	  time	  point	  for	  IFN-­‐γ	  production	  by	  primary	  NK	  cells	  following	  NKG2D	  ligation	  (Brown	  et	  al.,	  
2012).	  F-­‐actin	  was	  then	  imaged	  using	  STED	  microscopy	  (Figure	  4.20).	  When	  NK	  cells	  were	  in	  contact	  
with	   slides	   coated	   with	   ICAM-­‐1	   alone,	   the	   mean	   hole	   area	   both	   with	   and	   without	   lenalidomide	  
treatment	  was	   <0.053	  µm2	   (Figure	   4.21)	   and	   the	   percentage	   area	   of	   the	   synapse	   predicted	   to	   be	  
penetrable	   by	   IFN-­‐γ	   vesicles	   was	   <0.7%	   (Figure	   4.22).	   Ligation	   of	   NKG2D,	   with	   and	   without	   co-­‐
ligation	  of	  LFA-­‐1,	  resulted	  in	  an	  opening	  of	  the	  cortical	  actin	  mesh	  in	  DMSO-­‐treated	  cells	  compared	  
to	  unstimulated	  conditions,	  as	  expected	  (Figure	  4.20	  and	  Figure	  4.22).	  	  
When	  NKG2D	  and	  LFA-­‐1	  were	  co-­‐ligated,	  lenalidomide	  treatment	  led	  to	  a	  significant	  increase	  in	  actin	  
remodelling	  compared	   to	  DMSO	  control.	  There	  was	   little	  difference	   in	   the	  mean	  area	  of	   the	  holes	  
between	   actin	   filaments	   (Figure	   4.20).	   However	   there	   was	   a	   significant	   increase	   in	   the	   predicted	  
penetrable	   area	   across	   the	   range	   of	   vesicle	   sizes.	   Specifically,	   the	   predicted	   penetrable	   area	   for	  
vesicles	  of	  200	  nm	  increased	  from	  2.2	  ±	  0.2%	  without	  lenalidomide	  to	  3.6	  ±	  0.3%	  with	  lenalidomide	  
treatment	  (Figure	  4.22;	  p	  =	  0.0002).	  For	  vesicles	  of	  300	  nm	  diameter,	  the	  penetrable	  area	  increased	  
from	   0.4	   ±	   0.05%	  without	   lenalidomide	   to	   0.8	   ±	   0.2%	  with	   lenalidomide	   treatment	   (Figure	   4.22).	  
There	  was	  also	  a	  4-­‐fold	  increase	  in	  the	  area	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  vesicles	  of	  
500	  nm	  diameter	  (0.08	  ±	  0.01%	  without	  lenalidomide	  to	  0.38	  ±	  0.1%	  with	  lenalidomide;	  Figure	  4.22).	  
This	   suggests	   that	   lenalidomide	  augments	  actin	   remodelling	  after	   co-­‐ligation	  of	  NKG2D	  and	  LFA-­‐1.	  
When	  NKG2D	  was	   ligated	  alone,	  however,	   lenalidomide	  treatment	  had	  no	  significant	  effect	  on	  the	  
structure	   of	   the	   cortical	   actin	  mesh	   (Figure	   4.21).	   The	   proportion	   of	   the	   synapse	   predicted	   to	   be	  
penetrable	   to	   vesicles	   of	   different	   sizes	   is	   approximately	   the	   same	   between	   DMSO-­‐treated	   cells	  
stimulated	  on	  NKG2D	  mAb	  alone	  and	  NKG2D	  mAb	  plus	  ICAM-­‐1	  (Figure	  4.22).	  However,	  there	  was	  no	  
further	   increase	   in	   penetrable	   area	   after	   lenalidomide	   treatment	   (Figure	   4.22).	   These	   results	  
therefore	  corroborate	  the	  findings	  presented	  in	  the	  previous	  chapter,	  that	  lenalidomide	  requires	  full	  
cellular	  activation	  in	  order	  to	  have	  an	  effect.	  
	  









Figure	  4.20	  –	  Lenalidomide	  augments	  opening	  of	  cortical	  actin	  mesh	  after	  NKG2D	  and	  LFA-­‐1	  ligation.	  (A)	  First	  
columns:	   super-­‐resolution	   images	   obtained	   by	   STED	   microscopy	   of	   membrane	   proximal	   F-­‐actin	   in	   NK	   cells	  
incubated	   for	   90	  min	   on	   coverslips	   coated	  with	   recombinant	   human	   ICAM-­‐1	   (2.5	  µg/ml),	   anti-­‐NKG2D	  mAb	  
(3	  µg/ml)	  or	  both	   in	  the	  presence	  of	  DMSO	  or	  1	  µM	  lenalidomide.	  Scale	  bars	  =	  5	  µm.	  Second	  column:	  holes	  
between	   actin	   filaments	   in	   the	   central	   region	   of	   the	   synapse	   shown	   as	   heat	  maps,	  with	   the	   smallest	   holes	  
shown	  in	  blue	  (0.01	  µm2)	  and	  largest	  holes	  shown	  in	  red	  (>3	  µm2).	  Third	  column:	  regions	  are	  shown	  within	  the	  
actin	  mesh	  through	  which	  a	  vesicle	  of	  diameter	  200	  nm	  (blue)	  to	  800	  nm	  (red)	  could	  fit.	  
	  
4.3.4 Lenalidomide	  and	  signalling	  molecules	  
	  
In	   order	   to	   begin	   to	   dissect	   how	   lenalidomide	   treatment	   augments	   cortical	   actin	   remodelling,	   NK	  
cells	  were	  pre-­‐treated	  for	  1	  hour	  with	  1	  µM	  lenalidomide	  or	  DMSO	  and	  then	  stimulated	  on	  surfaces	  
coated	  with	   anti-­‐CD16	  mAb	  or	   isotype-­‐matched	   control	  mAb	   for	   10	  min	   and	  30	  min	  before	  being	  
lysed.	   The	   levels	   of	   three	   phosphorylated	   signalling	   proteins	   were	   then	   assessed	   by	   immunoblot	  
analysis:	  CD247,	  which	  is	  the	  adapter	  protein	  for	  CD16;	  Akt,	  which	  has	  been	  suggested	  to	  be	  further	  
downstream	  of	   CD16;	   and	  Cofilin,	  which	   is	   associated	  with	   actin	   remodelling	   (Figure	   4.23A).	   First,	  
the	  level	  of	  phosphorylated	  CD247	  (p-­‐CD247;	  also	  known	  as	  CD3ζ)	  was	  analysed.	  At	  10	  min,	  the	  level	  
of	  p-­‐CD247	   increased	  20-­‐fold	  on	  anti-­‐CD16	  mAb	  compared	  to	   isotype	  control	  mAb.	  Since	  CD247	   is	  
immediately	   downstream	   of	   CD16,	   these	   data	   indicate	   that	   the	   stimulating	   surfaces	  were	   indeed	  
activating	  the	  NK	  cells.	  	  
Treatment	   with	   lenalidomide	   had	   no	   effect	   on	   the	   level	   of	   p-­‐CD247	   in	   the	   cells,	   suggesting	   that	  
lenalidomide	  does	  not	  affect	  membrane	  proximal	  signalling	  events	  (Figure	  4.23B).	  The	  level	  of	  p-­‐Akt	  
was	   then	  assessed	  with	  and	  without	   lenalidomide	   treatment.	  Akt	   is	  downstream	  of	  PI3K,	  which	   is	  
activated	  through	  Zap70	  and	  Syk	  and	  therefore	  is	  thought	  to	  be	  downstream	  of	  CD16	  (Lanier,	  2008).	  
In	  this	  experiment,	  no	  increase	  in	  Akt	  levels	  was	  detected	  after	  CD16	  stimulation.	  Interestingly,	  after	  
30	   min	   stimulation,	   there	   appeared	   to	   be	   a	   decrease	   in	   the	   level	   of	   Akt	   phosphorylation.	  
Importantly,	   however,	   lenalidomide	   treatment	   did	   not	   affect	   the	   levels	   of	   Akt	   phosphorylation	   at	  
either	   of	   the	   time	   points	   investigated	   (Figure	   4.23B).	   Finally,	   the	   level	   of	   p-­‐Cofilin	   was	   assessed.	  
Cofilin	  is	  an	  actin	  binding	  protein	  that	  depolymerises	  and	  severs	  actin	  filaments	  and	  has	  been	  shown	  
to	  be	   important	  during	  T	  cell	  activation	  (Kueh	  et	  al.,	  2008;	  Samstag	  et	  al.,	  2013).	   It	   is	  possible	  that	  
cofilin	  is	  involved	  in	  actin	  remodelling	  at	  the	  NK	  cell	  synapse	  as	  one	  of	  its	  binding	  partners,	  Coronin	  
1A,	   has	   recently	   been	   shown	   to	   be	   important	   during	   reorganisation	   of	   the	   actin	   mesh	   (Mace	   &	  
Orange,	   2014).	   However,	   there	   was	   no	   significant	   change	   in	   the	   amount	   of	   p-­‐cofilin	   after	  
lenalidomide	  treatment,	  suggesting	  that	   lenalidomide	  does	  not	  change	  the	  activation	  status	  of	  this	  
protein	  (Figure	  4.23B).	  	  





Figure	   4.21	   –	   Lenalidomide	   does	   not	   affect	   the	  mean	   area	   of	   holes	   after	  NKG2D	   ligation.	  Average	   size	   of	  
holes	  in	  the	  actin	  mesh	  at	  the	  NK	  cell	  synapse	  for	  cells	  stimulated	  as	  in	  Figure	  4.20.	  Each	  data	  point	  represents	  
a	  single	  cell;	  red	  line	  shows	  the	  mean	  from	  3	  donors,	  n	  =	  18-­‐59	  per	  condition.	  
	  
Figure	   4.22	   –	   Lenalidomide	   increases	   the	   penetrable	   area	   of	   the	   actin	   mesh	   after	   NKG2D	   and	   LFA-­‐1	   co-­‐
ligation.	  The	  proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  a	  vesicle	  of	  200−500	  nm	  diameter	  for	  
the	  same	  cells	  as	  in	  Figure	  4.20.	  Graph	  shows	  mean	  ±	  SEM.	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001,	  one	  way	  ANOVA	  with	  
Tukey’s	  post	  test	  
	  





Figure	  4.23	  –	  No	  change	  in	  the	  levels	  of	  phosphorylated	  signalling	  proteins	  with	  lenalidomide	  treatment.	  NK	  
cells	  were	  treated	  for	  10	  or	  30	  min	  on	  slides	  coated	  with	  anti-­‐CD16	  mAb	  or	  isotype	  control	  in	  the	  presence	  of	  
DMSO	  or	  1	  µM	  lenalidomide.	  Cells	  were	  lysed	  and	  immunoblotted	  for	  phosphorylated	  CD247,	  phosphorylated	  
Akt	  and	  phosphorylated	  cofilin.	  Tubulin	  is	  shown	  as	  loading	  control.	  (A)	  Representative	  blots	  are	  shown	  and	  (B)	  
bar	  graphs	  depict	  densitometric	  analysis	  (raw	  densitometric	  values	  normalised	  to	  alpha-­‐tubulin,	  measured	  in	  
arbitrary	  units).	  Graph	  shows	  mean	  ±	  SEM	  from	  at	  least	  3	  independent	  experiments.	  These	  experiments	  were	  
carried	  out	  with	  the	  assistance	  of	  Dr	  David	  Morgan.	  





Figure	  4.24	  –	  Lenalidomide	  treatment	  enhances	  opening	  of	  cortical	  actin	  mesh	  in	  activated	  T	  cells.	  (A)	  Super-­‐
resolution	  images	  obtained	  by	  STED	  microscopy	  of	  membrane	  proximal	  F-­‐actin	  in	  T	  cells	  incubated	  for	  10	  min	  
on	  coverslips	  coated	  with	  anti-­‐CD3	  mAb	  or	  anti-­‐CD3	  mAb	  +	  anti-­‐CD28	  mAb	  in	  the	  presence	  of	  DMSO	  or	  1.0	  µM	  
lenalidomide	   (+	   150	   U/ml	   IL-­‐2).	   Scale	   bars:	   5	   µm.	   (B)	   The	   proportion	   of	   the	   synapse	   area	   predicted	   to	   be	  
penetrable	  by	  a	  vesicle	  of	  200−500	  nm	  diameter.	  Graph	  shows	  mean	  ±	  SD,	  n	  =	  20	  from	  2	  donors	  *	  =	  p	  <0.05,	  **	  
=	  p	  <0.01,	  ***	  =	  p	  <0.001,	  one	  way	  ANOVA	  with	  Tukey’s	  post-­‐test.	  
	  
Overall,	   lenalidomide	   treatment	   did	   not	   affect	   the	   levels	   of	   phosphorylated	   CD247,	   Akt	   or	   Cofilin	  
after	   CD16	   ligation.	   This	   suggests	   that	   these	   three	   signalling	   molecules	   are	   not	   altered	   after	  
lenalidomide	  treatment,	  and	  are	  therefore	  not	  involved	  in	  the	  increase	  in	  IFN-­‐γ	  production	  and	  actin	  
remodelling	  seen	  with	  lenalidomide.	  This	  work	  should	  be	  repeated	  with	  other	  proteins	  to	  determine	  
where	  lenalidomide	  acts	  in	  NK	  cell	  signalling	  pathways.	  	  




4.3.5 Lenalidomide	  also	  augments	  actin	  remodelling	  at	  the	  T	  cell	  synapse	  
	  
Finally,	   the	  effect	  of	   lenalidomide	  on	   the	   cortical	   actin	  mesh	   in	   activated	  T	   cells	  was	   investigated.	  
Until	  now,	  it	  was	  not	  known	  whether	  a	  fine	  meshwork	  of	  F-­‐actin	  was	  present	  at	  the	  T	  cell	  synapse	  
upon	   activation.	   In	   order	   to	   investigate	   this,	   primary	   human	   T	   cells	   were	   stimulated	   on	   surfaces	  
coated	  with	  anti-­‐CD3	  mAb	  or	  anti-­‐CD3	  mAb	  plus	  anti-­‐CD28	  mAb.	  Cells	  were	  fixed	  after	  10	  min	  and	  F-­‐
actin	  was	  imaged	  by	  STED	  microscopy	  (Figure	  4.24A).	  Visual	  inspection	  of	  the	  images	  showed	  that	  a	  
fine	  mesh	  of	  F-­‐actin	  was	  present	  within	  the	  dense	  peripheral	  actin	  ring	  (Figure	  4.24A).	  The	   images	  
also	   indicated	   the	   presence	   of	   larger	   holes	   within	   the	   actin	   mesh	   after	   lenalidomide	   treatment	  
(Figure	   4.24A).	   In	   order	   to	   quantify	   this,	   the	   penetrable	   area	   of	   the	   synapse	  was	   calculated.	   Even	  
though	   the	  diameter	  of	   perforin	  has	  been	  previously	   reported	   in	  NK	   cells,	   a	   range	  of	   vesicle	   sizes	  
(200−500	  nm)	  were	  used	  for	   this	  analysis	  as	   it	  gives	  a	  better	   indication	  of	   the	  extent	   to	  which	  the	  
actin	  mesh	  has	  opened	  up.	  The	  results	  show	  that	  lenalidomide	  treatment	  significantly	  enhanced	  the	  
opening	   of	   the	   actin	   mesh	   after	   stimulation	   with	   anti-­‐CD3	   mAb	   alone,	   and	   after	   combined	  
stimulation	  with	  anti-­‐CD3	  mAb	  and	  anti-­‐CD28	  mAb	   (Figure	  2.24B).	   The	  effect	  of	   lenalidomide	  was	  
stronger	   when	   the	   cells	   were	   stimulated	   with	   both	   antibodies	   compared	   to	   anti-­‐CD3	  mAb	   alone	  
(Figure	  4.24B).	  This	  indicates	  that	  the	  ability	  of	  lenalidomide	  to	  manipulate	  cortical	  actin	  remodelling	  




4.4.1 Summary	  of	  results	  
	  
In	   this	   investigation,	   the	   main	   objective	   was	   to	   investigate	   the	   effect	   of	   lenalidomide	   on	   the	  
remodelling	   of	   cortical	   F-­‐actin	   that	   occurs	   during	   NK	   cell	   immune	   synapse	   formation,	   using	   the	  
super-­‐resolution	  imaging	  technique	  STED.	  In	  particular,	  the	  key	  results	  from	  this	  investigation	  are	  as	  
follows:	  
• A	  protocol	  for	  STED	  imaging	  and	  F-­‐actin	  image	  analysis	  was	  set	  up	  and	  optimised.	  
	  




• Lenalidomide	   enhanced	   F-­‐actin	   remodelling	   after	   stimulation	   through	   CD16,	   resulting	   in	  
larger	  holes	  within	  the	  actin	  mesh,	  but	  did	  not	  affect	  F-­‐actin	  in	  unstimulated	  cells.	  
	  
• The	  effect	  of	  lenalidomide	  on	  the	  actin	  mesh	  was	  not	  dependent	  on	  IFN-­‐γ	  production	  by	  the	  
cell,	  or	  the	  presence	  of	  exogenous	  IL-­‐2.	  
	  
• Augmented	   actin	   remodelling	  was	   detected	   at	   the	   point	   of	   cytokine	   secretion	   and	  during	  
initial	  immune	  synapse	  formation.	  
	  
• Lenalidomide	   treatment	   also	   enhanced	   actin	   reorganisation	   after	   NKG2D	   and	   LFA-­‐1	   co-­‐
ligation,	  but	  did	  not	  affect	  the	  nanoscale	  organisation	  of	  actin	  after	  ligation	  of	  NKG2D	  alone.	  
	  
• Lenalidomide	  augmented	  actin	  rearrangements	  at	  the	  T	  cell	  immune	  synapse.	  
	  
	  
To	   summarise,	   the	   super-­‐resolution	  microscopy	   technique	   STED	  was	   used	   to	   study	   the	   nanoscale	  
reorganisation	  of	  F-­‐actin	  at	  the	  activating	  NK	  cell	  synapse	  with	  and	  without	  lenalidomide	  treatment.	  
The	   results	   presented	   in	   this	   chapter	   demonstrate	   that	   lenalidomide	   augments	   cortical	   actin	  
remodelling	  after	  CD16	  ligation	  and	  NKG2D	  and	  LFA-­‐1	  co-­‐ligation,	  resulting	  in	  the	  presence	  of	  larger	  
holes	  within	  the	  actin	  mesh.	  These	  results	   lead	  to	   intriguing	  new	  questions	  about	  the	  mechanisms	  
involved	  in	  actin	  remodelling	  and	  how	  lenalidomide	  manipulates	  them.	  
	  
4.4.2 STED	  microscopy	  and	  the	  actin	  mesh	  
	  
STED	   microscopy	   works	   by	   depleting	   around	   the	   central	   focal	   spot,	   thus	   limiting	   the	   PSF	   and	  
increasing	   the	   resolution	   of	   the	   image.	   The	   main	   limitation	   of	   this	   technique,	   therefore,	   is	   the	  
potential	   to	   photobleach	   the	   sample	   due	   to	   the	   high	   power	   of	   the	   depletion	   beam.	   This	   is	  
particularly	   important	  when	   imaging	   the	  actin	  meshwork,	  because	   the	   individual	  F-­‐actin	   fibres	  are	  
very	  fine	  and	  the	  structure	  of	  the	  mesh	  could	  be	  easily	  lost	  due	  to	  photobleaching.	  Thus,	  there	  is	  an	  
important	  trade-­‐off	  between	  improving	  the	  resolution	  of	  the	  image	  and	  preventing	  photobleaching.	  




This	  was	  achieved	  by	  carefully	  optimising	  the	  power	  of	  the	  STED	  laser	  along	  with	  other	  microscope	  
parameters.	  With	  the	  parameters	  used	  in	  this	  study,	  we	  obtained	  a	  FWHM	  of	  90	  nm	  for	  the	  smallest	  
actin	   filaments.	   This	   is	   the	   same	   value	   as	   that	   reported	  by	   Jordan	  Orange’s	   laboratory	  when	   they	  
imaged	  the	  actin	  meshwork	  in	  NK	  cells	  (Mace	  &	  Orange,	  2012).	  	  
One	  way	  to	  ensure	  that	  the	  results	  being	  observed	  are	  a	  correct	  representation	  of	  what	  is	  happening	  
at	  the	  immune	  synapse	  is	  to	  use	  additional	  super	  resolution	  techniques	  and	  compare	  the	  data.	  To	  an	  
extent,	   this	   is	  what	  has	  been	  done	   in	  this	  study.	  Previously,	  SIM	  has	  been	  used	  to	   image	  the	  actin	  
meshwork	   at	   the	  NK	   cell	   synapse	   (Brown	  et	   al.,	   2011;	   Brown	  et	   al.,	   2012).	   By	   imaging	  NK	   cells	   in	  
comparable	  conditions	  (activated	  vs.	  not	  activated)	  using	  STED	  microscopy,	  this	  study	  has	  confirmed	  
the	  results	  from	  previously	  published	  work	  –	  instead	  of	  clearing	  F-­‐actin	  away	  from	  the	  central	  region	  
of	  the	  synapse	  as	  was	  previously	  thought,	  the	  actin	  mesh	  is	  remodelled	  to	  create	  holes	  large	  enough	  
to	  allow	  vesicles	   through.	  However,	   it	   is	   still	   difficult	   to	  be	   sure	   that	  all	   of	   the	  details	  of	   the	  actin	  
mesh	  are	  being	  observed	  using	  these	  ensemble	  techniques.	  It	  will	  be	  important,	  therefore,	  to	  repeat	  
these	   experiments	   using	   a	   single	   molecule	   localisation	   super	   resolution	   microscopy	   technique	   in	  
order	  to	  confirm	  the	  results	  shown	  in	  this	  chapter.	  This	  is	  discussed	  further	  in	  section	  4.4.4.	  	  
Another	   issue	  with	   the	   imaging	  and	  analysis	   technique	  used	   in	   this	  study	   is	   that	   images	  were	  only	  
recorded	  at	  the	  Z	  plane	  closest	  to	  the	  coverslip,	  which	  covers	  approximately	  300-­‐400	  nm	  below	  the	  
cell	   surface.	   This	   provides	   a	   good	   idea	   of	   what	   the	   actin	  mesh	   looks	   like	   in	   any	   given	   condition,	  
however	  it	  does	  not	  take	  into	  consideration	  the	  organisation	  of	  the	  layers	  of	  F-­‐actin	  further	  into	  the	  
cell.	  Using	  STORM,	  Xu	  and	  colleagues	  showed	  that	  there	  is	  a	  three	  dimensional	  filament	  organisation	  
in	   the	  actin	  cytoskeleton	  of	   immortalised	   fibroblast	  cells	   (Xu	  et	  al.,	  2012).	  They	  colour-­‐coded	  each	  
layer	   of	   F-­‐actin	   to	   build	   up	   an	   image	   showing	  how	   the	   F-­‐actin	   layers	   overlap	   to	   create	   a	   complex	  
meshwork	  below	  the	  cell	  membrane.	  The	  implications	  of	  this	  for	  the	  NK	  cell	  synapse	  is	  that	  the	  3D	  
structure	  of	  the	  actin	  mesh	  could	  be	  an	  important	  consideration	  when	  assessing	  the	  holes	  within	  the	  
actin	  network.	  It	  would	  be	  interesting	  to	  image	  multiple	  layers	  of	  the	  actin	  cytoskeleton	  in	  activating	  
and	  non-­‐activating	  conditions	  and	   investigate	  (i)	  whether	  NK	  cells	  open	  up	  the	  actin	  mesh	   in	  the	  Z	  
plane	   as	   well	   as	   the	   X	   and	   Y	   planes	   and	   (ii)	   whether	   lenalidomide	   has	   an	   effect	   on	   the	   3D	  
organisation	  of	  F-­‐actin.	  
A	  further	  drawback	  with	  this	  method	  is	  that	  it	  is	  carried	  out	  on	  antibody-­‐	  or	  ligand-­‐coated	  coverslips	  
rather	  than	  in	  a	  more	  physiological	  setting.	  The	  next	  step	  would	  be	  to	  optimise	  a	  lipid	  bilayer	  system,	  
which	  would	  more	  accurately	   reflect	   the	  membrane	  of	   the	   target	   cell,	   and	   then	   image	  NK	  cells	   in	  
contact	   with	   the	   lipid	   bilayer	   using	   super-­‐resolution	   microscopy.	   The	   feasibility	   of	   using	   this	  
approach,	  and	  a	  protocol	  for	  setting	  up	  the	  experiment,	  has	  recently	  been	  described	  (Zheng	  et	  al.,	  




2015).	   It	   will	   be	   important	   to	   see	  whether	   the	   remodelling	   of	   the	  NK	   cell	   actin	  mesh	   can	   still	   be	  
observed	   in	  this	  system,	  to	  confirm	  that	   it	   is	  not	  an	  artefact	  arising	  from	  the	  cells	  being	   in	  contact	  
with	  glass.	  
After	   that,	   it	  would	  be	   interesting	   to	  observe	   the	  actin	  mesh	  whilst	  NK	  cells	  are	   in	  conjugate	  with	  
target	  cells.	  So	  far,	  the	  reorganisation	  of	  actin	  at	  the	  synapse	  has	  not	  been	  shown	  in	  this	  way.	  This	  is	  
due	  to	  the	  requirement	  for	  the	  mesh	  to	  be	  on	  a	  flat	  surface	  in	  order	  to	  see	  the	  whole	  synapse	  in	  a	  
two-­‐dimensional	  image.	  However,	  recent	  technological	  advances	  have	  allowed	  for	  the	  development	  
of	  3D-­‐STED.	  In	  this	  microscope	  setup,	  a	  second	  depletion	  beam	  is	  used,	  which	  acts	  to	  constrain	  the	  
PSF	   in	   the	   Z	   direction,	   thus	   reducing	   the	   size	   of	   the	   fluorescent	   spot	   in	   3	   dimensions.	   In	   this	  
arrangement,	  the	  user	  can	  choose	  between	  the	  best	  lateral	  resolution,	  the	  best	  vertical	  resolution	  or	  
a	  combination	  of	  both	  to	  obtain	  optimal	  results	  for	  the	  specific	  sample	  being	  imaged.	  This	  means	  it	  
will	  be	  possible	  to	  image	  the	  actin	  meshwork	  in	  conjugates,	  where	  the	  synapse	  is	  more	  likely	  to	  be	  
oriented	  along	  the	  Z	  direction	  (i.e.	  perpendicular	  to	  the	  image	  plane	  in	  this	  study).	  This	  will	  provide	  a	  
greater	  understanding	  of	  cortical	  actin	  rearrangements	  in	  more	  complex	  settings,	  for	  example	  when	  
NK	  cells	  are	  in	  contact	  with	  multiple	  target	  cells.	  	  
	  
4.4.3 Lenalidomide	  and	  the	  cortical	  actin	  mesh	  
	  
Lenalidomide	  augments	  actin	  remodelling	  at	  the	  NK	  cell	  synapse	  
Prior	  to	  this	  work,	  the	  nanoscale	  remodelling	  of	  actin	  at	  the	  NK	  cell	  immune	  synapse	  was	  recognised	  
as	   important	   in	   directed	   secretion	   at	   the	   synapse,	   but	   the	   specific	   effect	   of	   lenalidomide	   on	   this	  
phenomenon	   was	   unknown.	   In	   this	   chapter,	   the	   effect	   of	   lenalidomide	   on	   the	   nanoscale	  
organisation	   of	   F-­‐actin	   was	   visualised	   and	   it	   was	   shown	   that	   lenalidomide	   augments	   actin	  
remodelling	  at	  the	  NK	  cell	  synapse.	  
Previous	   work	   has	   shown	   that	   the	   actin	   meshwork	   opens	   up	   to	   a	   similar	   level	   regardless	   of	   the	  
specific	   activating	   receptor	   involved.	   	   In	   addition,	   the	   concentration	   of	   stimulating	   ligand	   did	   not	  
affect	  the	  extent	  of	  actin	  remodelling.	  This	  led	  to	  the	  assumption	  that	  actin	  remodelling	  is	  a	  binary,	  
“all-­‐or-­‐nothing”	   response.	   Here,	   it	   was	   shown	   for	   the	   first	   time	   that	   exogenous	   compounds	   can	  
manipulate	   cortical	   actin	   rearrangements,	   resulting	   in	   a	   larger	   penetrable	   area	   for	   directed	  
secretion.	   Specifically,	   lenalidomide	   treatment	   resulted	   in	   a	   two-­‐fold	   increase	   in	   the	   area	   of	   the	  
synapse	  predicted	  to	  be	  penetrable	  by	  a	  vesicle	  of	  200−500	  nm	  diameter	  after	   ligation	  of	  CD16	  or	  




co-­‐ligation	   of	   NKG2D	   and	   LFA-­‐1.	   This	   work	   is	   particularly	   interesting	   because	   it	   pinpoints	   actin	  
rearrangements	  as	  a	  druggable	  step	  in	  immune	  synapse	  assembly.	  It	  would	  be	  interesting	  to	  observe	  
whether	  the	  effect	  of	  lenalidomide	  is	  seen	  at	  multiple	  concentrations	  of	  activating	  ligand.	  The	  data	  
presented	   in	   the	   previous	   chapter	   shows	   that	   lenalidomide	   lowers	   the	   threshold	   for	   NK	   cell	  
activation	   and	   therefore	   it	   is	   possible	   that	   lenalidomide	   has	   an	   even	   greater	   effect	   on	   F-­‐actin	  
organisation	   at	   lower	   concentrations	   of	   activating	   ligand.	   This	   is	   an	   important	   question	   to	   be	  
addressed	  in	  the	  next	  stage	  of	  this	  research.	  
	  
The	  requirements	  for	  lenalidomide-­‐induced	  actin	  remodelling	  
Importantly,	   the	  effect	  of	   lenalidomide	  on	  F-­‐actin	  organisation	  was	  only	  observed	  after	  full	  NK	  cell	  
activation.	  This	   correlates	  with	   the	  data	  presented	   in	   the	  previous	  chapter,	  which	  showed	   that	  no	  
effect	  of	  lenalidomide	  was	  observed	  in	  unstimulated	  conditions.	  This	  is	  vital	  in	  the	  context	  of	  cortical	  
actin	   remodelling.	   It	   has	   been	   suggested	   that	   the	   tight	   meshwork	   of	   actin	   that	   is	   seen	   in	  
unstimulated	  conditions	  acts	  as	  a	  barrier	  to	  prevent	  lytic	  granule	  or	  cytokine	  vesicle	  release	  (Brown	  
et	  al.,	  2011;	  Rak	  et	  al.,	  2011;	  Brown	  et	  al.,	  2012).	  If	  this	  were	  the	  case,	  actin	  remodelling	  would	  be	  an	  
important	  step	  in	  allowing	  the	  vesicles	  to	  transverse	  the	  mesh.	  If	  lenalidomide	  disrupted	  this	  barrier	  
without	   appropriate	   signals	   for	   cellular	   activation,	   it	   could	   result	   in	   unnecessary	   activation	   of	   the	  
immune	  system	  and	  death	  of	  bystander	  cells.	   Importantly,	  our	  results	  are	  consistent	  with	  the	   idea	  
that	   lenalidomide	  does	  not	  override	   the	  safety	  mechanisms	   in	  place	   to	  prevent	  NK	  cells	  damaging	  
healthy	  cells.	  
Especially	  interesting	  is	  the	  fact	  that	  lenalidomide	  does	  not	  augment	  actin	  remodelling	  after	  ligation	  
of	  NKG2D	  alone.	  Previous	  work	  has	  shown	  that,	  even	  though	  NKG2D	  ligation	  alone	  cannot	  elicit	  NK	  
cell	   effector	   functions,	   it	   can	   induce	   actin	   remodelling	   (Brown	   et	   al.,	   2012).	   These	   results	   are	  
confirmed	  here,	  as	  the	  penetrable	  area	  of	  the	  synapse	  is	  comparable	  when	  NKG2D	  and	  LFA-­‐1	  were	  
co-­‐ligated	  and	  when	  NKG2D	  was	   ligated	  alone.	  However,	   lenalidomide	  treatment	  had	  no	  effect	  on	  
the	   penetrable	   area	   of	   the	   synapse	   when	   surfaces	   were	   coated	   with	   only	   anti-­‐NKG2D	  mAb.	   This	  
provides	  an	   interesting	   insight	   into	  how	   lenalidomide	  affects	  NK	  cells.	  Activation	  of	   the	  machinery	  
involved	  in	  actin	  remodelling	  (which	  has	  yet	  to	  be	  fully	  understood)	  is	  not	  enough	  for	  lenalidomide	  
to	  have	  an	  effect;	  full	  NK	  cell	  activation	  has	  to	  take	  place.	  This	  correlates	  with	  the	  increase	  in	  IFN-­‐γ	  
production	   after	   lenalidomide	   treatment	   presented	   in	   the	   previous	   chapter.	   However,	   unlike	   the	  
enhancement	   in	   cytokine	   production,	   the	   presence	   of	   exogenous	   IL-­‐2	   was	   not	   important	   for	  
lenalidomide-­‐enhanced	   actin	   rearrangements.	   In	   addition,	   the	   cells	   do	   not	   have	   to	   be	   producing	  
cytokine	  in	  order	  for	  lenalidomide	  to	  induce	  actin	  rearrangements.	  	  




Therefore,	  full	  cellular	  activation	  is	  required	  for	  lenalidomide	  to	  augment	  actin	  rearrangements,	  but	  
the	  cells	  do	  not	  have	  to	  be	  producing	  cytokine.	  Many	  studies	  have	  observed	  that	  IFN-­‐γ	  secretion	  and	  
perforin	  secretion	  occur	  in	  different	  subsets	  of	  cells	  (Brown	  et	  al.,	  2012).	  It	  is	  possible	  that	  these	  IFN-­‐
γ-­‐negative	   cells	   are	   instead	   producing	   perforin,	   but	   this	   was	   not	   confirmed	   because	   perforin	  
secretion	  was	  not	  imaged	  in	  this	  study.	  Perforin	  secretion	  usually	  occurs	  at	  an	  earlier	  time	  point	  to	  
IFN-­‐γ	   secretion,	   however	   it	   is	   possible	   that	   lenalidomide	   treatment	   results	   in	   prolonged	   perforin	  
secretion,	   thus	   explaining	  why	   actin	   rearrangements	   are	   still	   occurring	   in	   IFN-­‐γ-­‐negative	   cells	   at	   2	  
hours	   post-­‐stimulation.	   This	   could	   be	   tested	   by	   imaging	   perforin	   alongside	   IFN-­‐γ	   using	   super-­‐
resolution	  microscopy.	  
This	  work	  has	  provided	   a	  more	  detailed	   set	   of	   requirements	   for	   the	   effect	   of	   lenalidomide	  on	  NK	  
cells	   than	  has	  been	  shown	  previously.	  However,	   the	  mechanisms	  governing	  this	  effect	  are	  still	  not	  
known.	   Here,	   the	   levels	   of	   three	   different	   phosphorylated	   proteins	   within	   NK	   cell	   activating	  
pathways	   were	   assessed	   by	   western	   blot,	   both	   with	   and	   without	   lenalidomide	   treatment.	  
Specifically,	  p-­‐CD3ζ,	  p-­‐Akt	  and	  p-­‐cofilin	  were	  tested	  and	  lenalidomide	  had	  no	  effect	  on	  the	  levels	  of	  
any	   of	   them.	   These	   three	  proteins	  were	   chosen	   as	   examples	   of	   different	   aspects	   of	   the	   signalling	  
pathway	  (membrane-­‐proximal	  signalling,	  downstream	  signalling	  and	  actin-­‐associated,	  respectively).	  
The	  fact	  that	  p-­‐CD3ζ	  levels	  did	  not	  change	  after	  lenalidomide	  treatment	  is	  consistent	  with	  the	  idea	  
that	  lenalidomide	  does	  not	  affect	  membrane-­‐proximal	  signalling	  events,	  as	  suggested	  in	  the	  previous	  
chapter.	   However,	   this	   work	   only	   represents	   the	   first	   attempt	   at	   investigating	   how	   lenalidomide	  
affects	  NK	  cell	  signalling	  pathways.	  There	  are	  many	  other	  proteins	  that	  play	  an	  important	  role	  in	  NK	  
cell	  signalling	  and	  these	  need	  to	  be	  investigated	  in	  order	  to	  find	  out	  where	  lenalidomide	  acts	  within	  
the	  signalling	  pathways.	  	  
	  
Lenalidomide	  and	  the	  T	  cell	  actin	  mesh	  
The	  link	  between	  lenalidomide	  and	  the	  cytoskeleton	  in	  lymphocytes	  has	  been	  previously	  explored	  in	  
T	  cells	  by	  Alan	  Ramsay	  and	  colleagues	  (Ramsay	  et	  al.,	  2008;	  Ramsay	  et	  al.,	  2009;	  Ramsay	  et	  al.,	  2012;	  
Ramsay	  et	  al.,	  2013).	  They	  imaged	  actin	  at	  the	  T	  cell	  synapse	  using	  confocal	  microscopy	  and	  showed	  
that	  lenalidomide	  restored	  synapse	  formation	  in	  follicular	  T	  cells	  from	  CLL	  patients.	  Specifically,	  the	  
authors	  scored	  T	  cell	  conjugates	  based	  on	  whether	  they	  had	  a	  distinct	  band	  of	  polymerised	  actin	  at	  
the	   intercellular	   contact	   based	  on	   increased	   fluorescence	   intensity	   of	   actin	   staining.	   They	   showed	  
that	  follicular	  T	  cells	  from	  CLL	  patients	  had	  reduced	  F-­‐actin	  polymerisation	  compared	  to	  healthy	  cells	  
(Ramsay	  et	  al.,	  2009).	  In	  addition,	  lenalidomide	  treatment	  dramatically	  increased	  the	  proportion	  of	  




follicular	  T	  cell	  conjugates	  that	  scored	  positive	  for	  F-­‐actin	  polymerisation,	  restoring	  the	  proportion	  of	  
observed	  synapses	  back	  to	  the	  level	  seen	  in	  healthy	  cells	  (Ramsay	  et	  al.,	  2009).	  Here,	  primary	  human	  
T	   cells	   were	   imaged	   by	   STED	  microscopy	   and	   the	   results	   show	   that	   lenalidomide	   augments	   actin	  
remodelling	  after	  T	  cell	  activation.	  This	  suggests	  that	  the	  mechanisms	  governing	  T	  cell	  activation	  are	  
similar	  to	  those	  involved	  in	  NK	  cell	  activation,	  and	  that	  lenalidomide	  is	  affecting	  an	  actin-­‐associated	  
protein	  (or	  proteins),	  which	  is	  important	  in	  both	  cell	  types.	  This	  is	   interesting	  because	  the	  effect	  of	  
lenalidomide	   on	   T	   cells	   and	  NK	   cells	   is	   thought	   to	   be	   very	   different,	   and	   so	   this	   conserved	   effect	  
warrants	  further	  investigation.	  
Of	   note,	   this	   is	   also	   the	   first	   time	   that	   actin	   remodelling	  has	  been	   shown	   in	   T	   cells.	   In	   contrast,	   a	  
recent	  study	  has	  suggested	  that	  actin	  is	  completely	  cleared	  from	  the	  centre	  of	  the	  T	  cell	  synapse	  and	  
that	   this	   is	   where	   degranulation	   occurs	   (Ritter	   et	   al.,	   2015).	   However,	   there	   are	   a	   number	   of	  
important	   differences	   between	   the	   study	   presented	   in	   this	   chapter	   and	   the	   work	   of	   Ritter	   and	  
colleagues.	   Firstly,	   the	   work	   presented	   here	   was	   carried	   out	   in	   primary	   human	   T	   cells,	   whereas	  
Ritter’s	  work	  was	  in	  T	  cells	  from	  mice.	  Secondly,	  the	  authors	  utilise	  TIRF	  microscopy	  and	  lattice	  light-­‐
sheet	  microscopy,	  which	  have	  too	  low	  a	  resolution	  to	  clearly	  observe	  the	  fine	  meshwork	  of	  F-­‐actin	  
filaments.	  Specifically,	  the	  resolution	  of	   lattice	  light	  sheet	  microscopy	  is	  230	  nm	  and	  that	  of	  TIRF	  is	  
approximately	  100	  nm,	  whereas	  the	  FWHM	  of	  the	  actin	  filaments	  observed	  by	  STED	  microscopy	  was	  
90	  nm	  (Chen	  et	  al.,	  2014;	  Rak	  et	  al.,	  2011).	  More	  work	  is	  needed	  to	  confirm	  the	  presence	  of	  a	  fine	  
network	   of	   actin	   in	   T	   cell	   synapses,	   however	   the	  work	   presented	   here	   suggests	   that	   this	  mesh	   is	  
present	  and	  that	  it	  can	  be	  manipulated	  by	  lenalidomide.	  
	  
4.4.4 Future	  directions	  
	  
This	  investigation	  on	  the	  effect	  of	  lenalidomide	  on	  the	  cortical	  actin	  mesh	  at	  the	  NK	  cell	  synapse	  has	  
revealed	   that	   lenalidomide	   augments	   actin	   remodelling	   after	   NK	   cell	   activation.	   In	   addition,	  
lenalidomide	  enhances	  actin	  reorganisation	  at	  the	  T	  cell	  synapse.	  These	  results	  raise	  interesting	  new	  
questions	  that	  future	  experiments	  should	  aim	  to	  address.	  
	  
Imaging	  the	  actin	  meshwork	  using	  single-­‐molecule	  localisation	  microscopy	  techniques	  
In	   order	   to	   further	   confirm	   the	   results	   presented	   in	   this	   chapter,	   it	   is	   important	   to	   repeat	   the	  
experiments	  using	  single-­‐molecule	  localisation	  microscopy	  techniques	  such	  as	  STORM.	  As	  mentioned	  




previously,	   it	   is	   possible	   that	   some	   of	   the	   detail	   of	   the	   actin	   meshwork	   is	   being	   lost	   due	   to	  
photobleaching	  of	   the	   sample.	  As	   STORM	  works	  by	   theoretically	  pinpointing	   the	   location	  of	   every	  
fluorophore,	   every	   actin	   filament	  within	   the	  mesh	  will	   be	   identified.	   Also,	   because	   STORM	  uses	   a	  
TIRF	  illumination	  geometry,	  the	  background	  fluorescence	  from	  F-­‐actin	  further	  within	  the	  cell	  will	  be	  
limited.	   This	   will	   prevent	   background	   fluorescence	   from	   interfering	   with	   the	   detection	   of	   the	  
meshwork,	  as	  was	   sometimes	   the	  case	   in	  STED	   images.	  Xu	  and	  colleagues	  published	  an	  optimised	  
protocol	   for	   imaging	   F-­‐actin	   within	   cells	   using	   STORM	   that	   involves	   staining	   with	   higher	  
concentrations	   of	   fluorophore-­‐conjugated	   phalloidin	   (Xu	   et	   al.,	   2012).	   This	   protocol	   could	   be	  
optimised	   for	   imaging	   primary	   NK	   cells	   and	   then	   used	   to	   repeat	   the	   experiments	   shown	   in	   this	  
chapter.	  One	  limiting	  step	  will	  be	  that	  the	  resulting	  STORM	  image	  will	  show	  the	  filaments	  as	  a	  line	  of	  
dots,	  rather	  than	  as	  a	  solid	  line.	  This	  will	  mean	  that	  the	  Actin	  Mesh	  Analyser	  program	  in	  its	  current	  
form	   will	   find	   it	   difficult	   to	   identify	   the	   filaments.	   To	   overcome	   this,	   a	   MatLab	   program	   will	   be	  
written	  to	  create	  a	  mask	  over	  the	  STORM	  image,	  essentially	   joining	  up	  the	  dots	  in	  the	  filaments	  to	  
create	   an	   impression	  of	   the	  meshwork.	   This	  mask	  may	   then	  be	   analysed	  using	   the	  Actin	  Analyser	  
program.	  These	  experiments	  will	  not	  only	  provide	  confirmation	  of	  the	  effect	  of	  lenalidomide	  on	  the	  
actin	  mesh,	  but	  will	  also	  provide	  the	  most	  detailed	  images	  of	  the	  actin	  mesh	  in	  NK	  cells	  seen	  to	  date.	  
Two-­‐colour	  STORM	  imaging	  of	  the	  actin	  meshwork	  and	  IFN-­‐γ	  vesicles	  can	  also	  be	  carried	  out,	  which	  




It	  has	  been	  previously	  reported	  that	   the	  effect	  of	   lenalidomide	   in	  T	  cells	   in	  dependent	  on	  CRBN,	  a	  
substrate	  receptor	  of	  the	  cullin	  4	  ring	  E3	  ubiquitin	   ligase	  complex	  (Ito	  et	  al.,	  2010;	  Lopez-­‐Girona	  et	  
al.,	   2012).	   	   Specifically,	   it	   has	   been	   shown	   that	   depleting	   CRBN	   using	   shRNA	   abrogates	   the	   drug-­‐
induced	   IL-­‐2	   expression	   (Lopez-­‐Girona	   et	   al.,	   2012).	   In	   order	   to	   clarify	   that	   the	   augmented	   actin	  
remodelling	   at	   the	   NK	   cells	   synapse	   reported	   in	   this	   chapter	   is	   a	   direct	   result	   of	   lenalidomide	  
treatment,	  CRBN	  could	  be	  knocked	  down	  in	  primary	  NK	  cells.	  Specifically,	  CRBN	  could	  be	  transiently	  
depleted	  using	   siRNA	  or	   shRNA.	  Previous	   studies	  have	  depleted	  CRBN	   in	  primary	  T	   cells	   using	   the	  
Amaxa	   system	   and	   obtained	   knockdown	   efficiencies	   of	   approximately	   70%	   (Lopez-­‐Girona	   et	   al.,	  
2012).	   A	   similar	   knockdown	   efficiency	   would	   be	   required	   in	   order	   to	   perform	   experiments	   using	  
primary	   NK	   cells,	   and	   this	   could	   be	   tested	   by	   qRT-­‐PCR.	   The	   CRBN	   knockdown	   NK	   cells	   would	   be	  
compared	  against	  NK	  cells	  that	  have	  been	  transfected	  with	  a	  scramble	  siRNA	  or	  shRNA	  sequence	  to	  
control	   for	   cellular	   stress	   resulting	   from	   the	   transfection.	   In	   previous	   studies,	   the	   primary	   T	   cells	  




were	  used	  72	  hours	  after	  transfection.	  In	  future	  experiments	  using	  primary	  NK	  cells,	  the	  efficiency	  of	  
the	   knockdown	   would	   be	   tested	   every	   24	   hours	   from	   1	   day	   post-­‐transfection	   to	   5	   days	   post-­‐
transfection	  in	  order	  to	  determine	  the	  optimum	  time	  point	  to	  use	  the	  cells,	  and	  to	  see	  how	  long	  the	  
knockdown	   lasts.	  The	  CRBN-­‐deficient	  NK	  cells	   could	   then	  be	  used	   in	  STED	   imaging	  experiments	   to	  
observe	  actin	  remodelling	  after	  activation.	  CRBN	  knockdown	  should	  result	  in	  the	  NK	  cells	  becoming	  
resistant	  to	  lenalidomide,	  and	  therefore	  could	  lead	  to	  an	  abrogation	  of	  the	  effect	  of	  lenalidomide	  on	  
NK	   cells.	   Or,	   if	   CRBN	   is	   naturally	   repressing	   proteins	   involved	   in	   actin	   remodelling	   (through	  
ubiquitination)	   and	   lenalidomide	   binding	   results	   in	   the	   activation	   of	   these	   proteins,	   then	   CRBN	  
knockdown	   could	   result	   in	   an	   increase	   in	   actin	   remodelling	   without	   the	   need	   for	   lenalidomide	  
treatment.	   Either	   way,	   this	   would	   prove	   that	   lenalidomide	   binding	   to	   CRBN	   is	   necessary	   for	   the	  
effect	  of	  lenalidomide	  on	  NK	  cells	  that	  is	  reported	  in	  this	  thesis.	  	  
In	   addition,	   lenalidomide-­‐induced	   actin	   rearrangements	   could	   be	   linked	   to	   the	   Ikaros	   and	   Aiolos	  
transcription	   factors.	   Lenalidomide	   treatment	   results	   in	   the	   CRBN-­‐dependent	   ubiquitination	   and	  
degradation	  of	   Ikaros	  and	  Aiolos	  and	  this	  causes	  the	   increase	   in	   IL-­‐2	  observed	  in	  T	  cells	   (Gandhi	  et	  
al.,	  2014).	   	   In	  B	  cells,	  deletion	  of	   the	   Ikaros	  gene	   led	   to	  upregulation	  of	  genes	   that	  are	   involved	   in	  
focal	   adhesion	   and	   remodelling	   of	   the	   actin	   cytoskeleton.	   These	   include	   myosin	   genes,	   vinculin,	  
laminin,	   actinin	   and	   rap1b	   (a	   small	   GTPase	   that	   interacts	   with	   the	   actin	   cytoskeleton).	   Ikaros	  
depletion	   also	   affected	   genes	   involved	   in	   Rho	   and	   Rac	   GTPase	   signalling	   (Joshi	   et	   al.,	   2014).	   This	  
suggests	   that	   Ikaros	   depletion	   could	   be	   important	   for	   actin	   remodelling,	  which	   could	   explain	   how	  
lenalidomide	   is	   acting.	   In	   order	   to	   test	   this,	   the	   effect	   of	   lenalidomide	   on	   Ikaros	   protein	   levels	   in	  
primary	  NK	  cells	  would	  have	  to	  be	  measured	  to	  observe	  whether	  lenalidomide	  treatment	  results	  in	  
the	   degradation	   of	   Ikaros	   proteins	   as	   is	   seen	   in	   primary	   T	   cells.	   This	   could	   be	   achieved	   using	  
immunoblot	   analysis.	   Then	   Ikaros	   could	   be	   knocked	   down	   in	   primary	   NK	   cells	   using	   siRNA	   and	  
knockdown	  efficiency	  can	  be	  checked	  by	  qRT-­‐PCR.	  These	  knockdown	  cells	  could	  then	  be	  imaged	  by	  
super-­‐resolution	   microscopy	   to	   determine	   whether	   increased	   actin	   remodelling	   is	   observed.	   This	  
would	  provide	   the	   first	   link	  between	   lenalidomide-­‐induced	  actin	   rearrangements	   and	   Ikaros	   in	  NK	  
cells.	  	  
	  
Lenalidomide	  and	  Rho/Rac	  GTPases	  
Recently,	   it	   was	   shown	   that	   follicular	   T	   cells	   in	   CLL	   patients	   have	   impaired	   immune	   synapse	  
formation	  due	  to	  defective	  signalling	  through	  RhoA	  and	  Rac1	  and	  that	  these	  defects	  can	  be	  restored	  
through	   lenalidomide	   treatment	   (Ramsay	   et	   al.,	   2013).	   The	   authors	   show	   that	   lenalidomide	  
upregulates	   RhoA	   and	   Rac1	   and	   downregulates	   Cdc42	   (Ramsay	   et	   al.,	   2013).	   There	   have	   been	  




multiple	   studies	   that	   have	   linked	   these	   small	   GTPases	   to	   remodelling	   of	   the	   actin	   cytoskeleton	  
(Silbert	   et	   al.,	   2008;	   Sit	  &	  Manser,	   2011).	   For	   example,	   Rac1	   and	  Cdc42	  bind	  WASP	   and	  WAVE	   to	  
drive	   Arp2/3-­‐mediated	   F-­‐actin	   branching	   and	   therefore	   rapid	   actin	   polymerisation	   (Kurisu	   &	  
Takenawa,	  2009).	   	  Notably,	  one	  study	  showed	  that	  IFN-­‐γ	  secretion	  by	  CD4+	  T	  cells	  required	  Cdc42-­‐
dependent	   local	   actin	   remodelling	   (Chemin	  et	   al.,	   2012).	   It	   is	   therefore	  possible	   that	   the	  effect	  of	  
lenalidomide	   on	   actin	   remodelling	   (and	   possibly	   the	   effect	   on	   IFN-­‐γ	   secretion)	   could	   be	   due	   to	  
manipulated	   Rho/Rac	   signalling.	   This	   could	   be	   tested	   by	   treating	   NK	   cells	   with	   lenalidomide	   and	  
assessing	   the	   levels	   of	   GTP-­‐bound	   RhoA,	   Rac1	   and	   Cdc42	   using	   PAK	   pulldown	   assays	   and	  
immunoblot	  analysis.	  This	  can	  be	  assessed	  with	  and	  without	  stimulation	  through	  CD16	  and	  NKG2D	  
plus	   ICAM-­‐1;	   the	   hypothesis	   being	   that	   lenalidomide	   treatment	   results	   in	   a	   change	   in	   GTP-­‐bound	  
RhoA,	  Rac1	  and/or	  Cdc42	  but	  only	  after	  NK	  cell	  activation.	  A	  more	  quantitative	  method	  of	  assessing	  
Rho	  GTPase	  signalling	  is	  using	  G-­‐LISA	  kits,	  available	  from	  Cytoskeleton,	  Inc.	  (Denver,	  CO).	  These	  kits	  
work	  by	  using	  plates	  coated	  with	  the	  binding	  domain	  of	  the	  Rho-­‐family	  protein	  of	  interest.	  When	  cell	  
lysates	   are	   added	   to	   the	   plate,	   the	   active	   GTP-­‐bound	   form	   of	   the	   protein	   will	   bind	   to	   the	   plate	  
whereas	  the	  inactive	  GDP-­‐bound	  form	  will	  not.	  The	  bound	  proteins	  are	  detected	  by	  incubation	  with	  
specific	   primary	   antibodies	   followed	   by	   HRP-­‐conjugated	   secondary	   antibody,	   and	   the	   signal	   is	  
developed	   using	   chemiluminescent	   reagents.	   This	   method,	   which	   is	   similar	   to	   the	   ELISA	   method	  
described	   in	   Chapter	   2,	   therefore	   yields	   quantitative	   results,	   and	   is	   more	   likely	   to	   reveal	   smaller	  
changes	  in	  Rho	  family	  protein	  activation.	  	  	  
	  
4.4.5 Conclusions	  
In	  conclusion,	  imaging	  the	  nanoscale	  organisation	  of	  F-­‐actin	  at	  the	  NK	  cell	  synapse	  has	  revealed	  that	  
lenalidomide	  treatment	  augments	  actin	  remodelling,	  thus	  increasing	  the	  proportion	  of	  the	  synapse	  
predicted	  to	  be	  penetrable	  to	  IFN-­‐γ	  vesicles.	  These	  results	  have	  given	  rise	  to	  many	  new	  interesting	  
questions	   regarding	   the	   mechanisms	   involved	   in	   actin	   remodelling	   and	   how	   lenalidomide	  
manipulates	   them.	   In	   the	   future,	   dissection	   of	   the	   signalling	   components	   involved	   in	   actin	  










Chapter	  5	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NK	  cells	  have	  been	  shown	  to	  be	   important	   in	   the	  context	  of	  MM,	  but	   there	   is	  a	  decline	   in	  NK	  cell	  
surveillance	  and	  cytotoxicity	  against	  MM	  cells	  as	  the	  disease	  progresses	  (Godfrey	  &	  Benson,	  2012).	  It	  
has	   been	   suggested	   that	   immunomodulatory	   drugs	   such	   as	   lenalidomide	   could	   be	   important	   in	  
rescuing	  the	  anti-­‐tumour	  effect	  of	  NK	  cells	  in	  MM	  patients	  (Godfrey	  &	  Benson,	  2012).	  To	  investigate	  
this,	   the	  effect	  of	   lenalidomide	  on	  NK	  cells	   from	  MM	  patients	  was	  assessed,	  both	  on	  a	  population	  
level	  and	  a	  single	  cell	  level.	  	  
	  
5.1.1 NK	  cell	  versus	  MM	  effect	  
	  
A	  role	  for	  NK	  cell	  immunity	  in	  the	  clinical	  context	  of	  MM	  was	  first	  suggested	  over	  30	  years	  (Uchida	  et	  
al.,	   1984).	   Many	   studies	   have	   shown	   that	   patients	   with	   MGUS	   and	   newly	   diagnosed	   MM	   have	  
increased	  numbers	  of	  NK	  cells	  compared	  to	  healthy	  controls	  (Osterborg	  et	  al.,	  1990;	  Famularo	  et	  al.,	  
1992;	  Gonzalez	  et	  al.,	  1992;	  Sawanobori	  et	  al.,	  1997;	  Jurisic	  et	  al.,	  2007).	  Alongside	  this,	   it	  has	  also	  
been	   reported	   that	  NK	   cells	   function	   normally	   in	   the	   context	   of	  MGUS	   and	   newly	   diagnosed	  MM	  
(Uchida	  et	  al.,	   1984;	  De	  Rossi	  et	  al.,	   1987;	  Osterborg	  et	  al.,	   1990;	   Frohn	  et	  al.,	   2002;	   Jurisic	  et	  al.,	  
2007).	  For	  example,	  NK	  cells	   from	  patients	  with	  MGUS	  and	  newly	  diagnosed,	  untreated	  MM	  were	  
able	   to	   lyse	   antibody-­‐coated	   target	   cells	   to	   a	   similar	   extent	   (approximately	   60%	   lysis)	   as	   NK	   cells	  
from	  healthy	  controls	  (De	  Rossi	  et	  al.,	  1987).	  However,	  as	  the	  disease	  progresses	  to	  the	  latter	  stages,	  
there	  is	  a	  decline	  in	  NK	  cell	  activity	  against	  MM	  cells	  (Ogmundsdóttir,	  1988;	  García-­‐Sanz	  et	  al.,	  1996;	  
King	  &	  Radicchi-­‐Mastroianni,	  1996).	  There	  is	  also	  a	  decline	   in	  the	  number	  of	  NK	  cells;	  for	  example,	  
higher	   numbers	   of	   CD16+	   NK	   cells	   were	   observed	   in	   patients	   with	   early	   stage	  MM	   compared	   to	  





patients	  with	   late	   stage	  MM	   (Gonzalez	   et	   al.,	   1992).	  One	   study	   showed	   that	   high	   numbers	   of	  NK	  
cells,	   which	   elicited	   strong	   lytic	   capability	   against	   K562	   cells	   in	   vitro	   correlated	   with	   low	   tumour	  
burdens,	   whereas	   low	   numbers	   of	   NK	   cells	   (with	   low	   lytic	   capability)	   correlated	   with	   advanced	  
disease	  states	  (Osterborg	  et	  al.,	  1990).	  This	  data	  has	  given	  rise	  to	  the	  idea	  that	  NK	  cells	  may	  initially	  
contribute	   to	   control	   of	   malignant	   plasma	   cells,	   but	   this	   effect	   is	   diminished	   as	   the	   disease	  
progresses.	  
	  
NK	  cell	  dysfunction	  in	  MM	  
The	   decline	   in	   NK	   cell	   surveillance	   against	  MM	   cells	   has	   been	   attributed	   to	   a	  mixture	   of	   general	  
humoral	   mechanisms	   and	   mechanisms	   that	   are	   specific	   to	   NK	   cells.	   The	   humoral	   factors	   mainly	  
involve	  altered	  cytokine	  production,	  which	  often	  has	  a	  direct	  effect	  on	  NK	  cell	  function.	  For	  example,	  
MM	  cells	  produce	  TGF-­‐β,	  which	  leads	  to	  suppression	  of	  CD16-­‐mediated	  IFN-­‐γ	  production	  and	  ADCC	  
in	   NK	   cells	   (Trotta	   et	   al.,	   2008).	   Also,	   there	   are	   high	   levels	   of	   IL-­‐10	   in	   the	   MM	   tumour	  
microenvironment,	  which	  could	  impair	  NK	  cell	  IFN-­‐γ	  production	  (D’Andrea	  et	  al.,	  1993).	  	  
There	  are	  also	  a	  number	  of	  processes	  in	  MM	  that	  directly	  attenuate	  NK	  cell	  function.	  First,	  there	  are	  
high	  amounts	  of	  immunoglobulin	  present	  in	  the	  serum	  of	  MM	  patients.	  Treatment	  of	  NK	  cells	  with	  
purified	   IgA	   led	  to	  a	  decrease	   in	  NK	  cell	  cytotoxicity	  that	  was	  partially	  caused	  by	  a	  decrease	   in	  the	  
number	  of	  cytolytic	  granules	  (Komiyama	  et	  al.,	  1986).	  Purified	  IgG	  has	  been	  shown	  to	  elicit	  a	  similar	  
negative	  effect	  on	  NK	  cell	   function	   (Gherman	  et	  al.,	  1987).	  This	   suggests	   that	  high	   levels	  of	   serum	  
immunoglobulin	   could	   directly	   diminish	   NK	   cell	   function.	   Second,	   there	   is	   a	   dysregulation	   of	   the	  
cytokines	  that	  are	  important	  for	  NK	  cell	  activation,	  proliferation	  and	  effector	  function.	  For	  example,	  
high	   levels	   of	   soluble	   IL-­‐2	   receptors	   have	   been	   found	   in	   the	   serum	   of	  MM	   patients,	   which	   could	  
inhibit	  T	  cell-­‐mediated	  NK	  cell	  activation	  via	  IL-­‐2	  (Nielsen	  et	  al.,	  1991).	  Third,	  MM	  progression	  from	  
MGUS	  to	  advanced	  levels	  of	  MM	  is	  associated	  with	  loss	  of	  surface	  expression	  of	  MICA	  (Carbone	  et	  
al.,	  2005;	  Jinushi	  et	  al.,	  2008;	  Bedel	  et	  al.,	  2011).	  NKG2D-­‐mediated	  recognition	  of	  MM	  cells	  has	  been	  
shown	   to	   be	  one	  of	   the	   key	  ways	   that	  NK	   cells	   kill	  MM	  cells,	   so	   loss	   of	  MICA	  would	   have	   a	   clear	  
detrimental	  effect	  on	  NK	  cell	  function	  (El-­‐Sherbiny	  et	  al.,	  2007).	  In	  addition,	  this	  loss	  of	  MICA	  could	  
be	   due	   to	   shedding	   of	   the	   protein	   into	   a	   soluble	   form,	   which	   has	   been	   shown	   to	   trigger	   down-­‐
regulation	  of	  NKG2D	  on	  NK	  cells	  (Jinushi	  et	  al.,	  2008).	  Also,	  the	  expression	  of	  MHC	  Class	  I	  proteins	  on	  
the	  surface	  of	  MM	  cells	  is	  very	  low	  in	  early	  MM,	  but	  high	  in	  the	  latter	  stages	  of	  the	  disease	  (Carbone	  
et	  al.,	  2005).	  This	  is	  relevant	  to	  NK	  cells	  as	  binding	  of	  MHC	  proteins	  to	  KIR	  receptors	  on	  the	  surface	  of	  
NK	  cells	   leads	   to	   inhibition	  of	  NK	  cell	   activation.	   	  However,	   little	   is	   known	  about	  whether	  NK	  cells	  





from	  MM	   patients	   have	   any	   intrinsic	   defects,	   such	   as	   impaired	   immune	   synapse	   formation,	   and	  
whether	  this	  changes	  as	  the	  disease	  progresses.	  This	  will	  be	  investigated	  in	  this	  study.	  
In	   addition,	   the	   data	   presented	   in	   the	   previous	   two	   chapters	   shows	   that	   lenalidomide	   is	   able	   to	  
augment	   IFN-­‐γ	  production	  and	   increase	  cortical	  actin	   remodelling	   in	  NK	  cells	   from	  healthy	  donors.	  
However,	  it	  is	  not	  yet	  known	  whether	  these	  effects	  are	  also	  observed	  in	  NK	  cells	  from	  MM	  patients.	  
Further	   data	   on	   the	   effect	   of	   lenalidomide	   on	   NK	   cells	   from	  MM	  patients	   is	   required	   in	   order	   to	  
provide	  a	  greater	  understanding	  of	  how	  lenalidomide	  works	  in	  a	  clinical	  setting.	  	  
	  
5.1.2 Aims	  
The	  goal	  of	   this	  project	  was	   to	   investigate	  whether	   lenalidomide	  augmented	   IFN-­‐γ	  production	  and	  
cortical	  actin	  remodelling	  in	  NK	  cells	  from	  MM	  patients.	  In	  addition,	  the	  role	  of	  disease	  progression	  
status	   on	  NK	   cell	   phenotype	   and	   function	  was	   analysed.	   The	   specific	   aims	   of	   this	   project	  were	   as	  
follows:	  
(i) To	  phenotype	  NK	  cells	  from	  MM	  patients.	  	  
	  
(ii) To	   investigate	   IFN-­‐γ	   production	   from	   MM	   NK	   cells,	   with	   and	   without	   lenalidomide	  
treatment.	  
	  
(iii) To	  assess	  the	  effect	  of	  MM	  disease	  status	  in	  NK	  cell	  function.	  
	  













5.2.1 Phenotyping	  of	  samples	  from	  MM	  patients	  
	  
NK	   cells	   from	   MM	   patients	   were	   obtained	   from	   by	   the	   Myeloma	   clinic	   at	   Christie	   Hospital,	   in	  
collaboration	   with	   the	   MCRC	   Biobank	   and	   in	   accordance	   with	   the	   declaration	   of	   Helsinki.	  
Information	  provided	  by	   the	  clinic	   included	  whether	   the	  patient	  was	   in	   remission	  or	   relapsing	  and	  
whether	  they	  were	  on	  any	  current	  treatment	  (Table	  5.1).	  The	  criteria	  for	  sample	  collection	  included	  
that	  the	  patient	  had	  not	  been	  on	  lenalidomide	  (or	  any	  thalidomide	  analogue)	  within	  the	  last	  2	  years.	  
40	  ml	  of	  blood	  was	  collected	  from	  each	  patient	  and	  NK	  cells	  were	  isolated	  within	  8	  hours	  of	  sample	  
collection.	  1-­‐4	  million	  NK	  cells	  were	  isolated	  from	  each	  sample.	  Due	  to	  the	  limited	  number	  of	  cells,	  
only	   a	   few	   cellular	   assays	   could	   be	   carried	   out.	   Flow	   cytometry	   (to	   phenotype	   the	   cells)	   and	  
microscopy	   (to	   look	   for	   IFN-­‐γ	  production	  and	  cortical	  actin	   rearrangements)	  were	  deemed	  the	   top	  
priority	  experiments	  as	  they	  required	  fewer	  cells	  than	  other	  functional	  assays.	  ELISAs	  to	  assess	  IFN-­‐γ	  
Patient	  ID	   Remission	  status	   Current	  treatment	  (if	  any)	  
P001M	   1st	  remission	   Biophosphonate	  
P002M	   Asymptomatic	   -­‐	  
P003M	   1st	  remission	   Biophosphonate	  
P004M	   1st	  relapse	   -­‐	  
P005M	   1st	  relapse	   -­‐	  
P006M	   Partial	  remission	  2	   -­‐	  
P007M	   1st	  relapse	   Proteasome	  inhibitor	  
P008M	   CNS	  relapse	   Steroid	  
P009M	   Complete	  remission	  1	   -­‐	  
P010M	   3rd	  partial	  remission	   -­‐	  
P011M	   Partial	  remission	   -­‐	  
P012M	   Relapse	  1	   -­‐	  
P013M	   2nd	  remission	   Proteasome	  inhibitor	  
P014M	   Gradually	  relapsing	   -­‐	  
Table	  5.1	  –	  Diagnostic	  information	  for	  the	  14	  patients’	  samples	  that	  were	  used	  in	  this	  study.	  Samples	  in	  grey	  
gave	  too	  few	  NK	  cells	  to	  carry	  out	  any	  experiments	  with.	  





secretion	  were	  carried	  out	  if	  enough	  cells	  were	  isolated.	  Of	  the	  14	  MM	  patients’	  samples	  that	  were	  
obtained	   from	   the	  Biobank,	  12	  gave	   sufficient	  numbers	  of	  NK	  cells	   to	   carry	  out	  experiments	  with.	  
Less	  than	  1	  million	  NK	  cells	  were	  isolated	  from	  P003M	  and	  P005M	  and	  so	  they	  were	  not	  used	  for	  the	  
remainder	  of	  the	  study.	  	  
	  
Figure	   5.1	   –	   CD16	   and	  NKG2D	   expression	   on	  MM	  NK	   cells.	  Representative	   histograms	   of	   CD16	   expression	  
(right	  panel)	  and	  NKG2D	  expression	  (left	  panel)	  in	  healthy	  donor	  NK	  cells	  (purple	  line	  histogram)	  and	  NK	  cells	  










Patient	  ID	   CD56	   CD16	   NKG2D	  
P001M	   98.6	   97.7	   35.5	  
P002M	   93.8	   97.3	   35.2	  
P004M	   98.9	   95.5	   -­‐	  
P006M	   96.8	   87.3	   -­‐	  
P007M	   97.9	   92.8	   -­‐	  
P008M	   99.1	   82.7	   37.6	  
P009M	   98.7	   89.9	   23.2	  
P010M	   88.1	   97.5	   18.5	  
P011M	   99.4	   91.6	   30.1	  
P012M	   98.5	   88	   14.2	  
P013M	   98.6	   96.3	   24.2	  
P014M	   99.8	   91.5	   37.9	  
Table	  5.2	  –	  Percentage	  expression	  levels	  of	  NK	  cell	  receptors	  on	  MM	  patients’	  NK	  cells.	  Expression	  level	  was	  
assessed	   by	   flow	   cytometry	   based	   on	   isotype	   control	   mAb	   staining.	   P004M,	   P006M	   and	   P007M	   were	   not	  
assessed	  for	  NKG2D	  expression.	  Grey	  sample	  was	  not	  used	  in	  any	  further	  experiments.	  








First,	  NK	  cells	  from	  MM	  patients	  were	  analysed	  by	  flow	  cytometry	  for	  their	  expression	  of	  CD56,	  CD16	  and	  
NKG2D	   (Table	   5.2,
	  
Figure	  5.1).	  The	  percentage	  of	  cells	  positive	  for	  CD56	  staining	  did	  not	  significantly	  change	  between	  
the	  12	  samples,	  and	  this	  was	  comparable	  to	  the	  results	  from	  two	  healthy	  donors	  (Table	  5.2).	  There	  
was	   also	  no	   significant	  difference	   in	   the	  proportion	  of	   cells	   positive	   for	  CD16	   staining.	   The	   lowest	  
recorded	   was	   82.7%	   and	   the	   highest	   was	   97.7%	   (Table	   5.2).	   Again,	   this	   was	   comparable	   to	   the	  
results	   from	  the	  two	  healthy	  donors	  who	  were	  90.4%	  and	  95.6%	  CD16-­‐positive	  respectively	   (Table	  
5.2).	   This	   suggests	   that	   there	   is	   no	   loss	   of	   CD16	   expression	   in	   NK	   cells	   from	   MM	   patients.	   To	  
investigate	  whether	   disease	   progression	   plays	   a	   role	   in	   CD16	   expression,	   the	   cells	   were	   stratified	  
based	  on	  whether	  the	  patient	  was	  classified	  as	  being	  in	  remission	  or	  relapsing.	  CD16	  expression	  was	  
assessed	  based	  on	  both	  percentage	  of	  cells	  expressing	  CD16	  and	  the	  gMFI.	  
The	  results	  show	  that	  there	  is	  no	  difference	  in	  CD16	  expression	  between	  NK	  cells	  from	  patients	  who	  were	  in	  
remission	  or	  relapsing	  (Figure	  5.2).	  Interestingly,	  however,	  there	  was	  a	  dramatic	  reduction	  in	  the	  amount	  of	  
	   CD56	   CD16	   NKG2D	  
Healthy	  
donor	  1	   99.5	   90.4	   87	  
Healthy	  
donor	  2	   93.1	   95.6	   80	  
Table	  5.3	  –	  Percentage	  expression	  levels	  of	  NK	  cell	  receptors	  on	  healthy	  donor	  NK	  cells.	  Expression	  level	  was	  
assessed	  by	  flow	  cytometry	  based	  on	  isotype	  control	  mAb	  staining.	  





cells	   expressing	   NKG2D	   (Table	   5.2,
	  
Figure	  5.1).	  	  This	  indicates	  that	  NK	  cell	  activation	  through	  CD16	  would	  be	  the	  best	  system	  to	  look	  at	  
to	  check	  for	   intrinsic	  NK	  cell	  defects	  –	  as	  any	  defects	  observed	  would	  not	  be	  due	  to	  reduced	  CD16	  
ligation	  –	  and	  to	  observe	  the	  effect	  of	  lenalidomide.	  






Figure	   5.2	   –	   CD16	   expression	   on	   NK	   cells	   from	  MM	   patients	   who	   are	   in	   remission	   or	   are	   relapsing.	   (A)	  
Representative	  histograms	  of	  CD16	  receptor	  expression	  (grey	  filled	  histograms)	  compared	  to	  isotype-­‐matched	  
control	  (grey	  line	  histograms)	  on	  fresh	  healthy	  NK	  cells	  and	  NK	  cells	  from	  MM	  patients	  who	  were	  in	  remission	  
and	  who	  were	  relapsing.	  (B)	  The	  percentage	  of	  NK	  cells	  in	  each	  population	  who	  are	  positive	  for	  CD16	  staining.	  
(C)	  The	  geometric	  mean	  fluorescence	   intensity	  (gMFI)	  of	  CD16	  fluorescence	  of	  the	  3	  populations	  of	  NK	  cells.	  
Graphs	  show	  mean	  ±	  SEM	  from	  2	  healthy	  donors	  and	  4	  different	  MM	  patients	  for	  each	  clinical	  condition.	  ns	  =	  
not	  significant.	  






Figure	  5.3	  –	  Lenalidomide	  enhances	  IFN-­‐γ 	  secretion	  after	  CD16	  ligation	  in	  NK	  cells	  from	  MM	  patients.	  	  (A)	  NK	  
cells	  from	  MM	  patients	  were	  treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	  stimulated	  on	  anti-­‐CD16	  mAb	  or	  
isotype-­‐matched	   control	   mAb	   for	   24	   hours	   and	   then	   the	   supernatants	   were	   assessed	   by	   ELISA	   for	   IFN-­‐γ	  
secretion.	  Data	  from	  9	  MM	  samples.	  Graph	  shows	  mean	  ±	  SEM.	  (B)	  ELISA	  results	  from	  the	  9	  MM	  patients’	  NK	  
cells	   presented	   as	   individual	   results.	   One-­‐way	   ANOVA	   was	   used	   to	   test	   if	   observed	   differences	   were	  
statistically	  significant.	  *	  =	  p	  <0.05,	  **	  =	  p	  <0.01,	  ***	  =	  p	  <0.001.	  
	  
5.2.2 Lenalidomide	  augments	  IFN-­‐γ 	  production	  from	  MM	  NK	  cells	  
	  
NK	  cells	  from	  MM	  patients	  were	  then	  assessed	  for	  their	  ability	  to	  produce	  IFN-­‐γ	  after	  CD16	  ligation.	  
Specifically,	   NK	   cells	   were	   treated	   with	   DMSO	   or	   1	  µM	   lenalidomide	   and	   stimulated	   on	   surfaces	  





coated	  with	  anti-­‐CD16	  mAb	  or	  isotype-­‐matched	  control	  mAb.	  Supernatants	  were	  harvested	  24	  hours	  
later	  and	  tested	  for	  the	  presence	  of	  IFN-­‐γ.	  	  
The	  results	  show	  that	  overall,	  NK	  cells	  from	  MM	  patients	  secreted	  IFN-­‐γ	  in	  response	  to	  CD16	  and	  this	  
was	   significantly	   increased	   with	   lenalidomide	   treatment	   (Figure	   5.3A).	   No	   secretion	   of	   IFN-­‐γ	   was	  
detected	  in	  the	  unstimulated	  control	  conditions,	  either	  with	  or	  without	   lenalidomide	  (Figure	  5.3A).	  
The	  results	  from	  each	  patient’s	  samples	  were	  then	  plotted	  separately	  to	  see	  whether	  lenalidomide	  
had	  a	  significant	  effect	  on	  each	  one.	  The	  results	  show	  that	  lenalidomide	  had	  an	  enhancing	  effect	  on	  
IFN-­‐γ	  production	  in	  7	  out	  of	  the	  9	  samples	  that	  were	  tested	  (Figure	  5.3B).	  P002M	  and	  P004M	  did	  not	  
show	  a	  notable	  increase	  in	  IFN-­‐γ	  secretion	  with	  lenalidomide	  treatment.	  Interestingly,	  the	  effect	  of	  
lenalidomide	  was	  not	  dependent	  on	  how	  responsive	  the	  cells	  were	  to	  start	  with	  (i.e.	  on	  the	  amount	  
of	  IFN-­‐γ	  secreted	  when	  lenalidomide	  was	  not	  added;	  Figure	  5.3B).	  
	  
Figure	  5.4	  –	  Lenalidomide	  increases	  the	  proportion	  of	  MM	  NK	  cells	  producing	  IFN-­‐γ 	  after	  CD16	  ligation.	  NK	  
cells	  were	  stimulated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	  stimulated	  on	  slides	  coated	  with	  anti-­‐CD16	  mAb	  or	  
isotype-­‐matched	   control	   mAb	   for	   2	   hours.	   Cells	   were	   then	   fixed	   and	   stained	   for	   IFN-­‐γ	   and	   F-­‐actin.	   The	  
proportion	  of	  NK	  cells	  that	  stained	  positive	  for	  IFN-­‐γ	  was	  then	  quantified.	  Graph	  shows	  mean	  ±	  SEM	  for	  9	  MM	  
patients.	  One	  way	  ANOVA	  with	   Tukey’s	   post-­‐test	  was	   used	   to	   test	   if	   observed	   differences	  were	   statistically	  
significant.	  ***	  =	  p	  <0.001.	  
	  
In	  addition,	  IFN-­‐γ	  production	  was	  assessed	  on	  a	  single	  cell	  level	  by	  imaging	  MM	  NK	  cells	  by	  confocal	  
microscopy.	  MM	  NK	  cells	  were	   treated	  with	  DMSO	  or	  1	  µM	  lenalidomide	  and	   stimulated	  on	  glass	  





slides	  coated	  with	  anti-­‐CD16	  mAb	  or	   isotype-­‐matched	  control	   for	  2	  hours	  at	  37°C.	  Cells	  were	  then	  
fixed	   and	   stained	  with	   Alexa488-­‐conjugated	   anti-­‐IFN-­‐γ	  mAb	   and	   Atto590-­‐conjugated	   phalloidin	   to	  
visualise	  F-­‐actin.	  The	  proportion	  of	  cells	  expressing	  IFN-­‐γ	  in	  unstimulated	  conditions	  was	  <17%,	  with	  
or	  without	  lenalidomide	  (Figure	  5.4).	  When	  MM	  NK	  cells	  were	  stimulated	  with	  anti-­‐CD16	  mAb,	  the	  
proportion	   of	   cells	   expressing	   IFN-­‐γ	   rose	   to	   35	   ±	   4%	   in	   DMSO-­‐treated	   conditions	   (Figure	   5.4).	  
Treatment	  with	   lenalidomide	   increased	  the	  proportion	  of	  cells	  expressing	   IFN-­‐γ	   to	  52	  ±	  3%	  (Figure	  
5.4).	  This	  indicates	  that	  the	  increase	  in	  IFN-­‐γ	  produced	  by	  MM	  NK	  cells	  after	  lenalidomide	  treatment	  
is	  at	  least	  in	  part	  due	  to	  an	  increase	  in	  the	  proportion	  of	  cells	  expressing	  IFN-­‐γ.	  	  
	  
	  
Figure	   5.5	   –	  NK	   cells	   from	   relapsing	   patients	   have	  defective	   IFN-­‐γ 	   secretion	   in	   response	   to	   CD16	   ligation.	  	  
IFN-­‐γ	  secretion	  by	  MM	  NK	  cells	  stratified	  by	  whether	  the	  patients	  were	  in	  remission	  or	  were	  relapsing.	  Graph	  
shows	  mean	  ±	  SEM	  for	  5	  remission	  patients	  and	  4	  relapsing	  patients.	  One	  way	  ANOVA	  with	  Tukey’s	  post-­‐test	  
was	  used	  to	  test	  if	  observed	  differences	  were	  statistically	  significant.	  *	  =	  p	  <0.05,	  ***	  =	  p	  <0.001.	  
	  





5.2.3 NK	  cells	  from	  relapsing	  MM	  patients	  show	  defective	  IFN-­‐γ 	  production	  
	  
One	  observation	  from	  looking	  each	  ELISA	  result	  separately	  is	  that	  there	  is	  a	  large	  amount	  of	  patient	  
variability	   in	   IFN-­‐γ	   production	   from	   DMSO-­‐treated	   NK	   cells	   (Figure	   5.3B).	   Patients	   differed	   in	   the	  
amount	   of	   IFN-­‐γ	   produced	   after	   ligation	   of	   CD16;	   some	   patients	   responded	  well	   (e.g.	   P001M	  and	  
P013M)	   whereas	   others	   responded	   very	   poorly	   (e.g.	   P007M,	   P012M	   and	   P014M)(Figure	   5.3B).	  	  
Patients	   also	   differed	   in	   how	   they	   responded	   to	   lenalidomide	   treatment,	   with	   some	   patients	  
showing	   a	   4-­‐fold	   increase	   in	   IFN-­‐γ	   production	   and	   others	   showing	   no	   effect	   at	   all	   (Figure	   5.3B).	  
Interestingly,	  this	  variability	  seemed	  to	  correlate	  with	  the	  disease	  progression	  status	  of	  the	  patient	  
(Table	  5.1).	  In	  order	  to	  visualise	  this	  more	  clearly,	  the	  ELISA	  results	  were	  re-­‐plotted	  with	  the	  patients’	  
sample	  data	   stratified	  based	  on	  whether	   the	  patients	  were	   in	   remission	  or	  were	   relapsing	   (Figure	  
5.5).	  	  
	   	  
Figure	   5.6	   –	   Disease	   progression	   status	   does	   not	   affect	   the	   proportion	   of	  MM	  NK	   cells	   expressing	   IFN-­‐γ .	  
Proportion	  of	   IFN-­‐γ	   positive	  MM	  NK	  cells	   stratified	  by	  whether	   the	  MM	  patients	  were	   in	   remission	  or	  were	  
relapsing.	  Graph	  shows	  mean	  ±	  SEM	  for	  5	  remission	  patients	  and	  4	  relapsing	  patients.	  One	  way	  ANOVA	  with	  
Tukey’s	  post-­‐test	  was	  used	  to	  test	  if	  observed	  differences	  were	  statistically	  significant.	  **	  =	  p	  <0.01,	  ns	  =	  not	  
significant.	  





The	  results	  show	  that	  NK	  cells	  from	  patients	  in	  remission	  secreted	  5-­‐fold	  more	  IFN-­‐γ	  compared	  to	  NK	  
cells	   from	  patients	  who	  were	   relapsing	   (3259	  ±	  562	  pg/ml	   from	  remission	  samples	  and	  636	  ±	  187	  
pg/ml	   from	   relapsing	   samples;	   Figure	   5.5).	   In	   both	   cases,	   however,	   lenalidomide	   treatment	  
augmented	   IFN-­‐γ	   production	   from	  MM	   NK	   cells	   (Figure	   5.5).	   In	   NK	   cells	   from	   relapsing	   patients,	  
lenalidomide	  treatment	   resulted	   in	  a	  3-­‐fold	   increase	   in	   IFN-­‐γ	   secretion,	   resulting	   in	   IFN-­‐γ	   secretion	  
being	  near	  the	  level	  secreted	  from	  NK	  cells	  from	  MM	  patients	  were	  in	  remission	  (Figure	  5.5).	  
Then	  the	  results	  from	  the	  analysis	  of	  the	  proportion	  of	  cells	  producing	  IFN-­‐γ	  were	  stratified	  based	  on	  
whether	   the	  patients	  were	   relapsing	  or	  were	   in	   remission.	   Intriguingly,	   there	  was	  no	  difference	   in	  
the	  number	  of	  IFN-­‐γ-­‐positive	  cells	  between	  these	  two	  groups	  of	  patients	  (32	  ±	  0.3%	  in	  NK	  cells	  from	  
MM	  patients	   in	   remission	   compared	   to	  37	  ±	   2%	   in	  NK	   cells	   from	  MM	  patients	  who	  are	   relapsing;	  
Figure	  5.6).	   This	   suggests	   that	  disease	   status	  does	  not	   affect	   the	  number	  of	  NK	   cells	   that	   activate	  
after	  CD16	  ligation,	  but	  instead	  influences	  IFN-­‐γ	  secretion.	  
	  
5.2.4 Lenalidomide	  augments	  cortical	  actin	  remodelling	  in	  NK	  cells	  from	  MM	  patients	  
	  
As	   mentioned	   previously,	   one	   of	   the	   proposed	   barriers	   to	   IFN-­‐γ	   secretion	   is	   cortical	   actin	  
remodelling.	   Therefore,	   the	   nanoscale	   organisation	   of	   the	   actin	  meshwork	   at	   the	  NK	   cell	   synapse	  
was	   observed	   in	   NK	   cells	   from	   MM	   patients.	   MM	   NK	   cells	   were	   treated	   with	   DMSO	   or	   1	   µM	  
lenalidomide	  and	  stimulated	  on	  slides	  coated	  with	  anti-­‐CD16	  mAb	  for	  2	  hours.	  Cells	  were	  then	  fixed	  
and	  F-­‐actin	  was	  imaged	  by	  STED	  microscopy	  (Figure	  5.7).	  Visual	  inspection	  of	  the	  images	  suggested	  
that	   lenalidomide	   augments	   cortical	   actin	   remodelling	   in	   NK	   cells	   from	  MM	   patients.	   To	   quantify	  
this,	   the	  mean	   area	   of	   holes	   between	   the	   actin	   filaments	  was	   first	  measured.	   The	   results	   show	   a	  
small	  but	  not	  significant	  increase	  in	  mean	  hole	  area	  after	  lenalidomide	  treatment	  (Figure	  5.8).	  This	  is	  
similar	  to	  the	  results	  observed	  in	  healthy	  cells,	  which	  was	  presented	  in	  the	  previous	  chapter.	  There	  
was	  no	  change	  in	  the	  mean	  hole	  area	  of	  the	  actin	  mesh	  in	  NK	  cells	  under	  non-­‐stimulating	  conditions	  
(Figure	  5.8).	  
The	   proportion	   of	   the	   synapse	   predicted	   to	   be	   penetrable	   to	   vesicles	   of	   200−500	   nm	   diameter	  
significantly	  increased	  with	  lenalidomide	  treatment.	  Specifically,	  the	  penetrable	  area	  for	  vesicles	  of	  
200	  nm	  diameter	  increased	  from	  1.0	  ±	  0.17%	  without	  lenalidomide	  to	  1.7	  ±	  0.22%	  with	  lenalidomide	  
(Figure	  5.9).	  For	  vesicles	  of	  250	  nm	  diameter,	  the	  penetrable	  area	  increased	  2-­‐fold	  from	  0.4	  ±	  0.1%	  
without	   lenalidomide	   to	   0.82	   ±	   0.16%	   with	   lenalidomide	   (Figure	   5.9).	   This	   2-­‐fold	   increase	   was	  





observed	   at	   all	   diameters	   of	   vesicles	   that	   were	   tested,	   indicating	   that	   lenalidomide	   significantly	  
augments	  cortical	  actin	  remodelling	  (Figure	  5.9).	  In	  order	  to	  determine	  whether	  disease	  progression	  
status	   affects	   F-­‐actin	   reorganisation	   at	   the	  NK	   cell	   synapse,	   the	   patient’s	  NK	   cells	  were	   separated	  
based	  on	  whether	  the	  patients	  were	  in	  remission	  or	  were	  relapsing.	  The	  results	  show	  that	  NK	  cells	  
from	  relapsing	  patients	  have	  a	  smaller	  penetrable	  area	  for	  vesicles	  of	  200−300	  nm	  diameter	  (1.1	  ±	  
0.40%	   in	   NK	   cells	   from	   relapsing	   patients	   compared	   to	   2.1	   ±	   0.38%	   in	   NK	   cells	   from	   patients	   in	  
remission;	  Figure	  5.10)	  
	  
Figure	  5.7	  –	  Lenalidomide	  augments	  cortical	  actin	  remodelling	  in	  NK	  cells	  from	  MM	  patients.	  Representative	  
images	  obtained	  by	  STED	  microscopy	  of	  membrane	  proximal	  actin	   in	  MM	  NK	  cells	   incubated	  for	  120	  min	  on	  
coverslips	   coated	   with	   isotype	  matched	   control	   mAb	   or	   anti-­‐CD16	  mAb	   (both	   3	  µg/ml)	   in	   the	   presence	   or	  
absence	  of	  DMSO	  or	  1	  µM	  lenalidomide.	  Second	  row:	  holes	  within	  the	  actin	  filaments	  in	  the	  central	  region	  of	  
the	   synapse	   shown	   as	   heat	  maps,	   with	   the	   smallest	   holes	   shown	   in	   blue	   (0.01	   µm2)	   and	   the	   largest	   holes	  
shown	  in	  red	  (>3	  µm2).	  Third	  row:	  regions	  are	  shown	  through	  which	  lytic	  granules	  of	  diameter	  200	  nm	  (blue)	  to	  
800	  nm	  (red)	  could	  fit.	  
	  






Figure	  5.8	  –	  Mean	  hole	  area	  of	  cortical	  actin	  mesh	  after	  ligation	  of	  CD16.	  Analysis	  of	  mean	  hole	  area	  in	  cells	  
stimulated	   as	   in	   Figure	   5.6.	   n	   =	   20	   from	  each	   patient’s	   sample.	   Each	   data	   point	   represents	  mean	   from	  one	  
patient’s	  NK	  cells;	  black	  line	  shows	  the	  overall	  mean.	  
Figure	   5.9	   –	   Lenalidomide	   augments	   cortical	   actin	   remodelling	   in	   NK	   cells	   from	  MM	  patients.	  Analysis	   of	  
proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  vesicles	  of	  200−500	  nm	  diameter	  in	  cells	  stimulated	  as	  
in	  Figure	  5.7.	  n	  =	  20	  from	  each	  patient’s	  sample.	  Graph	  shows	  mean	  ±	  SEM	  from	  9	  patients.	  One	  way	  ANOVA	  
with	  Tukey’s	  post	  test	  was	  used	  to	  determine	  if	  the	  observed	  differences	  were	  statistically	  significant.	  ***	  =	  p	  
<0.001,	  **	  =	  p	  <0.01.	  






Figure	   5.10	   –	   Relapsing	   patients	   show	  defective	   actin	   remodelling	   after	   ligation	   of	   CD16.	  Penetrable	   area	  
data	  was	  stratified	  based	  on	  whether	  the	  patients	  were	   in	  remission	  or	  were	  relapsing.	  Penetrable	  area	  was	  
grouped	  into	  vesicles	  of	  200−300	  nm	  diameter	  and	  301−500	  nm	  diameter.	  Graph	  shows	  mean	  ±	  SEM	  from	  9	  
patients	  (5	  in	  remission	  and	  4	  who	  were	  relapsing).	  One	  way	  ANOVA	  with	  Tukey’s	  post	  test	  was	  used	  to	  test	  if	  
observed	  differences	  were	  statistically	  significant.	  	  *	  	  =	  p	  <0.05.	  
	  
For	   vesicles	   of	   larger	   diameter,	   there	   was	   a	   significant	   decrease	   in	   the	   penetrable	   area	   of	   the	  
synapse	  in	  NK	  cells	  from	  patients	  who	  were	  relapsing	  (0.04	  ±	  0.01%	  compared	  to	  0.29	  ±	  0.08%	  in	  NK	  
cells	  from	  patients	  in	  remission;	  Figure	  5.10).	  This	  indicates	  that	  there	  are	  far	  fewer	  holes	  within	  the	  
actin	  mesh	  in	  NK	  cells	  from	  relapsing	  patients	  that	  are	  predicted	  to	  be	  penetrable	  to	  IFN-­‐γ	  vesicles.	  
This	   suggests	   that	  NK	  cells	   from	  relapsing	  patients	  have	  defective	  actin	   remodelling	  during	  NK	  cell	  
activation.	  
	  






Figure	  5.11	  –	  Lenalidomide	  does	  not	  affect	  the	  proportion	  of	  cells	  that	  become	  activated.	  MM	  NK	  cells	  were	  
treated	   with	   DMSO	   or	   1	   µM	   lenalidomide	   for	   1	   hour	   prior	   to	   6	   min	   stimulation	   on	   (A)	   anti-­‐CD16	  mAb	   or	  
isotype	   matched	   control	   mAb	   or	   (B)	   recombinant	   ICAM-­‐1,	   anti-­‐NKG2D	   mAb	   or	   both.	   Cells	   were	   fixed	   and	  
stained	  for	  F-­‐actin	  and	  the	  proportion	  of	  cells	  displaying	  actin	  rings	  was	  measured.	  Graph	  shows	  mean	  ±	  SEM	  
in	  50	  cells	  from	  (A)	  3	  MM	  patients	  and	  (B)	  2	  MM	  patients.	  
	  
5.2.5 Lenalidomide	  affects	  initial	  synapse	  formation	  in	  NK	  cells	  from	  MM	  patients	  
	  
The	   final	   experiments	   that	   were	   carried	   out	   with	   NK	   cells	   from	  MM	   patients	   investigated	   initial	  
immune	  synapse	  formation	  with	  different	  stimuli.	   	  First,	  NK	  cells	  were	  treated	  with	  DMSO	  or	  1	  µM	  
lenalidomide	  for	  one	  hour	  before	  being	  transferred	  to	  glass	  slides	  coated	  with	  either	  anti-­‐CD16	  mAb	  





or	  anti-­‐NKG2D	  mAb	  with	  and	  without	  recombinant	  ICAM-­‐1.	  Cells	  were	  fixed	  after	  6	  min	  stimulation	  
and	   imaged	  by	  confocal	  microscopy	  to	   look	   for	   the	   formation	  of	  actin	  rings.	  The	  results	  show	  that	  
MM	   NK	   cells	   activated	   well	   on	   anti-­‐CD16	   mAb,	   however	   lenalidomide	   had	   no	   effect	   on	   the	  
proportion	  of	  cells	  that	  activated	  (with	  58%	  of	  DMSO-­‐treated	  cells	  having	  a	  dense	  peripheral	  ring	  of	  
F-­‐actin	   compared	   to	   60%	   of	   lenalidomide-­‐treated	   cells;	   Figure	   5.11).	   These	   results	   reflect	   those	  
observed	  in	  healthy	  cells,	  which	  were	  presented	  in	  Chapter	  4	  in	  Figure	  4.18.	  Conversely,	  when	  MM	  
NK	   cells	   were	   stimulated	   through	   NKG2D	   ligation,	   fewer	   than	   30%	   of	   cells	   became	   activated	  
regardless	  of	  whether	  LFA-­‐1	  was	  co-­‐ligated	  using	  ICAM-­‐1	  (Figure	  5.11).	  	  	  
	  
Figure	   5.12	   –	   Lenalidomide	   augments	   actin	   remodelling	   during	   initial	   cell	   spreading.	   First	   row:	  
Representative	   images	  obtained	  by	  STED	  microscopy	  of	  membrane	  proximal	  actin	   in	  MM	  NK	  cells	   incubated	  
for	  6	  min	  on	  coverslips	  coated	  with	  anti-­‐CD16	  mAb	  in	  the	  presence	  or	  absence	  of	  DMSO	  or	  1	  µM	  lenalidomide.	  
Second	  row:	  holes	  within	  the	  actin	  filaments	  in	  the	  central	  region	  of	  the	  synapse	  shown	  as	  heat	  maps,	  with	  the	  
smallest	  holes	  shown	  in	  blue	  (0.01	  µm2)	  and	  the	  largest	  holes	  shown	  in	  red	  (>3	  µm2).	  Third	  row:	  regions	  are	  
shown	  through	  which	  lytic	  granules	  of	  diameter	  200	  nm	  (blue)	  to	  800	  nm	  (red)	  could	  fit.	  





This	   is	   2-­‐fold	   less	   than	  would	  be	  expected	  based	  on	   the	  data	   from	  healthy	   cells	   (Figure	  3.17B).	   In	  
addition,	   lenalidomide	   treatment	   had	   no	   effect	   on	   the	   proportion	   of	   activated	   cells	   (Figure	   5.11).	  
This	  can	  be	  explained	  by	  the	   fact	   that	  MM	  NK	  cells	  appear	   to	  have	  reduced	  NKG2D	  expression	  on	  
their	  surface	  (Table	  5.2).	  Because	  of	  this,	  only	  cells	  that	  were	  stimulated	  with	  anti-­‐CD16	  mAb	  were	  
assessed	  using	  STED	  microscopy.	  
To	  observe	  initial	  cell	  spreading	  in	  MM	  NK	  cells,	  and	  to	  see	  whether	  lenalidomide	  augments	  cortical	  
actin	  remodelling	  during	  immune	  synapse	  formation,	  NK	  cells	  were	  activated	  on	  anti-­‐CD16	  mAb	  and	  
imaged	  by	  STED	  microscopy	  (Figure	  5.12).	  Cortical	  actin	  remodelling	  was	  analysed	  by	  measuring	  the	  
penetrable	  area	  of	  the	  actin	  mesh.	  The	  diameter	  of	  lytic	  granules	  has	  been	  previously	  measured	  as	  
around	  250	  nm.	  However,	  in	  this	  analysis	  a	  range	  of	  vesicle	  sizes	  (200−500	  nm)	  was	  used	  in	  order	  to	  
get	   a	   better	   idea	   of	   how	   the	   actin	   mesh	   has	   opened	   up.	   The	   results	   show	   that	   lenalidomide	  
treatment	  significantly	  increases	  F-­‐actin	  remodelling,	  with	  the	  penetrable	  area	  increasing	  from	  1.3	  ±	  
0.09%	  without	  lenalidomide	  to	  2	  ±	  0.1%	  with	  lenalidomide	  treatment	  for	  a	  vesicle	  of	  200	  nm	  (Figure	  
5.13).	  	  
	  
Figure	   5.13	   –	   Lenalidomide	   increases	   the	   penetrable	   area	   of	   the	   actin	   mesh	   during	   immune	   synapse	  
formation	  after	  CD16	  ligation.	  Analysis	  of	  proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  vesicles	  of	  
200−500	  nm	  diameter	   in	  cells	  stimulated	  as	   in	  Figure	  5.12.	  n	  =	  20	   from	  each	  patient’s	  sample.	  Graph	  shows	  
mean	  ±	   SEM	   from	   9	   patients.	   One	  way	   ANOVA	  with	   Tukey’s	   post	   test	   was	   used	   to	   determine	   is	   observed	  
differences	  were	  statistically	  significant.	  ***	  =	  p	  <0.001.	  
	  





For	  vesicles	  of	  larger	  diameters,	  however,	  there	  was	  no	  significant	  difference	  in	  the	  penetrable	  area	  
after	   lenalidomide	   treatment	   (Figure	   5.13).	   This	   suggests	   that	   lenalidomide	   affects	   cortical	   actin	  





5.3.1 Summary	  of	  results	  
	  
In	  this	  investigation,	  the	  main	  aim	  was	  to	  investigate	  the	  effect	  of	  lenalidomide	  on	  IFN-­‐γ	  production	  
and	   cortical	   actin	   remodelling	   in	   NK	   cells	   from	   MM	   patients.	   In	   addition,	   the	   effect	   of	   disease	  
progression	  status	  on	  NK	  cell	   function	  was	  assessed.	  The	  key	   results	   from	  this	   investigation	  are	  as	  
follows:	  
• NK	  cells	   from	  MM	  patients	  have	  similar	  expression	  of	  CD16	  compared	  to	  healthy	  cells	  but	  
have	  decreased	  expression	  of	  NKG2D	  	  
	  
• Lenalidomide	  augments	  IFN-­‐γ	  secretion	  from	  MM	  NK	  cells	  after	  ligation	  of	  CD16	  
	  
• NK	  cells	   from	  relapsing	  MM	  patients	  have	  decreased	  IFN-­‐γ	  secretion	  compared	  to	  NK	  cells	  
from	   patients	   that	   are	   in	   remission.	   However,	   the	   proportion	   of	   cells	   producing	   IFN-­‐γ	  
remains	  the	  same.	  
	  
• Lenalidomide	  augments	  cortical	  actin	  remodelling	  after	  CD16	  ligation	  in	  MM	  NK	  cells	  
	  
• NK	  cells	  from	  relapsing	  MM	  patients	  have	  defective	  cortical	  actin	  remodelling	  compared	  to	  
NK	  cells	  from	  patients	  that	  are	  in	  remission.	  
	  





To	   summarise,	   lenalidomide	   augments	   IFN-­‐γ	   production	   and	   cortical	   actin	   remodelling	   in	  NK	   cells	  
from	  MM	  patients,	   indicating	  that	  the	  drug	  manipulates	  NK	  cell	   function	   in	  the	  context	  of	  disease.	  
The	   results	   presented	   in	   this	   chapter	   also	   demonstrate	   that	   NK	   cells	   from	  MM	   patients	   who	   are	  
relapsing	  show	  defective	  actin	  reorganisation	  at	  the	  immune	  synapse	  and	  decreased	  IFN-­‐γ	  secretion.	  
This	   is	   consistent	   with	   the	   fact	   that	   NK-­‐mediated	   surveillance	   and	   cytotoxicity	   against	   MM	   cells	  
declines	  as	  the	  disease	  progresses.	  
	  
5.3.2 NK	  cells	  from	  MM	  patients	  and	  the	  effect	  of	  lenalidomide	  
	  
The	  phenotype	  of	  NK	  cells	  from	  MM	  patients	  
Previous	  work	  has	   reported	  a	  number	  of	  different	   features	  of	  NK	  cells	   from	  MM	  patients.	  Studies	  
have	   shown	   that	   significantly	   fewer	   NK	   cells	   from	   MM	   patients	   expressed	   NKG2D	   compared	   to	  
healthy	  controls	  (von	  Lilienfeld-­‐Toal	  et	  al.,	  2010;	  Costello	  et	  al.,	  2013).	  Here,	  we	  also	  show	  reduced	  
expression	   of	   NKG2D	   on	   all	   patients’	   samples	   that	   were	   analysed.	   This	   reduced	   cell	   surface	  
expression	  is	  thought	  to	  be	  contact-­‐dependent,	  as	  co-­‐culture	  of	  NK	  cells	  with	  myeloma	  cells	  resulted	  
in	   reduced	   NKG2D	   expression	   (von	   Lilienfeld-­‐Toal	   et	   al.,	   2010).	   Both	   2B4	   and	   DNAM-­‐1	   have	   also	  
been	  found	  to	  have	  reduced	  surface	  expression	  in	  NK	  cells	  from	  MM	  patients	  (Fauriat	  et	  al.,	  2006;	  El-­‐
Sherbiny	   et	   al.,	   2007;	   Costello	   et	   al.,	   2013).	   This	   is	   interesting,	   as	  DNAM-­‐1	   and	  NKG2D	  have	   both	  
been	   shown	   to	   be	   crucial	   in	   the	   NK	   cell-­‐mediated	   killing	   of	   myeloma	   cells,	   reflecting	   possible	  
immune	  selection	  during	  disease	  progression	  (Carbone	  et	  al.,	  2005;	  El-­‐Sherbiny	  et	  al.,	  2007).	  	  
Our	   results	   also	   showed	   that	   expression	   of	   CD16	   remained	   at	   a	   similar	   level	   to	   that	   observed	   in	  
healthy	  NK	  cells.	  	  This	  is	  in	  contrast	  to	  results	  presented	  by	  Fauriat	  and	  colleagues,	  who	  showed	  that	  
whilst	  the	  proportion	  of	  patients	  expressing	  CD16	  remained	  the	  same,	  the	  MFI	  was	  reduced	  in	  MM	  
patients	   compared	   to	   healthy	   donors	   (Fauriat	   et	   al.,	   2006).	   It	   is	   worth	   noting,	   however,	   that	   the	  
results	   from	   that	   study	  were	  obtained	   from	   fewer	  MM	  patients	   than	   the	   results	  presented	   in	   this	  
chapter	  (6	  patients	  and	  12	  patients,	  respectively).	  Also,	  all	  6	  of	  the	  patients	  were	  newly	  diagnosed,	  
whereas	  the	  12	  patients	  who	  gave	  samples	  for	  this	  study	  represent	  a	  broader	  range	  of	  disease	  states	  
(Fauriat	  et	  al.,	  2006).	  Specifically,	  the	  patients	  whose	  NK	  cells	  were	  used	  in	  this	  study	  were	  a	  mixture	  
of	  untreated	  patients,	  relapsing	  patients	  and	  patients	   in	  remission.	  The	  results	  shown	  in	  this	  study	  
show	  that	  CD16	  expression	  is	  not	  affected	  in	  MM	  NK	  cells,	  even	  in	  patients	  who	  are	  relapsing.	  This	  





indicates	   that	   the	   use	   of	   exogenous	   antibodies	   to	   trigger	   ADCC	   has	   potential	   in	   the	   treatment	   of	  
MM.	  
Interestingly,	  there	  are	  some	  studies	  that	  suggest	  that	  there	  may	  be	  a	  difference	  in	  the	  phenotype	  of	  
NK	   cells	   from	  peripheral	   blood	  and	   from	   the	  bone	  marrow	  of	  patients.	   The	   few	   studies	   that	  have	  
investigated	  bone	  marrow	  NK	  cells	   in	  MM	  demonstrate	  an	   increased	  proportion	  of	  NK	  cells	   in	   the	  
bone	  marrow	  of	  MM	  patients,	  which	  have	   little	  cytotoxic	  activity	  against	  MM	  cells	   (García-­‐Sanz	  et	  
al.,	  1996;	  Scheper	  et	  al.,	  2014).	  	  It	  is	  possible	  that	  there	  is	  a	  great	  impairment	  of	  NK	  cell	  function	  in	  
cells	   from	   the	   bone	   marrow	   microenvironment.	   In	   order	   to	   test	   this	   further,	   immune	   synapse	  
formation	  in	  bone	  marrow	  NK	  cells	  from	  MM	  patients	  should	  be	  investigated	  in	  the	  future.	  
	  In	  order	  to	  better	  understand	  the	  phenotype	  of	  MM	  NK	  cells,	  other	  cell	  surface	  markers	  should	  be	  
investigated	   in	   future	   experiments.	   CD57	   is	   an	   activation	   marker,	   and	   is	   considered	   to	   be	   an	  
indicator	   of	   memory	   NK	   cells	   (Lopez-­‐Vergès	   et	   al.,	   2010).	   One	   study	   has	   shown	   that	   there	   is	   an	  
increase	  in	  the	  proportion	  of	  CD57+	  NK	  cells	  in	  the	  peripheral	  blood	  and	  in	  the	  bone	  marrow	  of	  MM	  
patients	  (Hsu	  et	  al.,	  2013).	  It	  would	  be	  interesting	  to	  see	  whether	  the	  proportion	  of	  CD57+	  NK	  cells	  
differs	  between	  relapsing	  patients	  and	  patients	  in	  remission,	  and	  whether	  it	  correlates	  with	  effector	  
function	  in	  these	  patients.	  In	  addition,	  CD25	  indicates	  proliferative	  potential	  in	  NK	  cells	  and	  CD69	  is	  a	  
useful	  marker	  for	  cytotoxic	  activity.	  Both	  markers	  could	  be	  interesting	  to	  investigate	  in	  MM	  NK	  cells	  
to	  see	  whether	  certain	  subsets	  of	  activated	  NK	  cells	  are	  affected	  by	  disease	  state	  and	  by	  treatment	  
with	  lenalidomide	  (Clausen	  et	  al.,	  2003).	  
	  
Lenalidomide	  and	  MM	  NK	  cells	  
The	  results	  presented	  in	  this	  chapter	  show	  that	  lenalidomide	  has	  the	  same	  effect	  on	  MM	  NK	  cells	  as	  
was	  observed	  in	  NK	  cells	  from	  healthy	  donors.	  Specifically,	   lenalidomide	  treatment	  resulted	  in	  a	  2-­‐
fold	   increase	   in	   IFN-­‐γ	   secretion	   and	   a	   significant	   increase	   in	   the	   proportion	   of	   MM	   NK	   cells	  
expressing	  IFN-­‐γ.	   In	  addition,	   lenalidomide	  increases	  the	  proportion	  of	  the	  synapse	  predicted	  to	  be	  
penetrable	   to	   IFN-­‐γ	   vesicles	   and	   to	   lytic	   granules.	   This	   provides	   a	   clearer	   picture	   of	   the	   specific	  
immunomodulatory	  effects	  of	  lenalidomide	  when	  it	  comes	  to	  NK	  cell	  function.	  	  
One	   effect	   of	   lenalidomide	   that	   was	   not	   investigated	   in	   this	   chapter	   was	   its	   ability	   to	   lower	   the	  
threshold	   for	  activation	   in	  healthy	  NK	  cells.	   This	  was	  not	  assessed	   in	   this	   study	  due	   to	   the	   limited	  
numbers	  of	  NK	  cells.	   In	  the	  future,	  this	  should	  be	  assessed	  in	  MM	  NK	  cells	   in	  the	  context	  of	  CD16-­‐
mediated	   activation.	   It	   is	   possible	   that	   the	   effect	   of	   lenalidomide	   could	   be	   different	   between	  





patients	  who	  are	  in	  remission	  and	  those	  that	  are	  relapsing.	  The	  ability	  of	  lenalidomide	  to	  trigger	  NK	  
cells	  to	  respond	  to	  lower	  concentrations	  of	  activating	  ligand	  is	  crucial	  in	  the	  context	  of	  MM,	  where	  
the	  tumour	  cells	  are	  known	  to	  downregulate	  potential	  NK	  cell	  ligands.	  	  
	  
Defective	  immune	  synapse	  formation	  in	  NK	  cells	  from	  relapsing	  MM	  patients	  
As	  mentioned	  previously,	  NK	  cells	  are	  thought	  to	  be	  important	  in	  the	  control	  of	  early	  stage	  MM,	  but	  
NK	  cell	  surveillance	  and	  cytotoxicity	  against	  MM	  cells	  declines	  as	  the	  disease	  progresses.	  Previously,	  
this	  has	  been	  attributed	  to	  immune	  evasion	  tactics	  by	  the	  MM	  cells,	  such	  as	  downregulation	  of	  MICA	  
and	   upregulation	   of	   HLA	   Class	   I	   molecules,	   rather	   than	   any	   inherent	   defect	   in	   the	   NK	   cells	  
themselves.	  Here,	  the	  results	  show	  that	  NK	  cells	  from	  MM	  patients	  who	  are	  relapsing	  have	  reduced	  
secretion	  of	  IFN-­‐γ	  compared	  to	  NK	  cells	  from	  patients	  who	  are	  in	  remission.	  Importantly,	  this	  is	  not	  
due	  to	  a	  change	  in	  the	  proportion	  of	  cells	  expressing	  IFN-­‐γ,	  suggesting	  that	  the	  amount	  released	  per	  
cell	  is	  being	  affected.	  Furthermore,	  NK	  cells	  from	  relapsing	  patients	  do	  not	  open	  up	  the	  actin	  mesh	  
to	  the	  same	  extent.	  One	  hypothesis	  to	  explain	  these	  results	   is	  that	  fewer	  IFN-­‐γ	  vesicles	  are	  able	  to	  
pervade	  the	  actin	  network	  as	  less	  cortical	  actin	  remodelling	  has	  taken	  place.	  	  
In	  order	  to	  test	  this	  hypothesis,	  it	  should	  first	  be	  established	  whether	  the	  amount	  of	  IFN-­‐γ	  expressed	  
per	  cell	  is	  lower	  in	  NK	  cells	  from	  patients	  who	  are	  relapsing	  compared	  to	  NK	  cells	  from	  patients	  who	  
are	   in	   remission.	  This	  can	  be	   imaged	  by	  confocal	  microscopy	  and	  then	  the	  sum	   IFN-­‐γ	   fluorescence	  
per	   cell	   can	   be	   measured	   using	   Imaris	   analysis	   (as	   described	   in	   section	   2.6.1).	   In	   addition,	   IFN-­‐γ	  
fluorescence	  can	  be	  assessed	  by	   flow	  cytometry	  analysis	   (as	  described	   in	  section	  2.4.3).	   If	  NK	  cells	  
from	  patients	  who	  are	  relapsing	  are	  found	  to	  be	  producing	   less	   IFN-­‐γ,	   then	  that	  could	  explain	  why	  
less	   IFN-­‐γ	   is	   secreted.	  However,	   if	   the	  NK	  cells	  are	  expressing	  comparable	  amounts	  of	   IFN-­‐γ	   to	  NK	  
cells	  from	  patients	  in	  remission,	  then	  that	  would	  suggest	  that	  IFN-­‐γ	  secretion	  is	  being	  interfered	  with	  
in	   some	   way.	   To	   investigate	   this,	   dual-­‐colour	   super-­‐resolution	   microscopy	   can	   be	   used	   to	   image	  
vesicle	  secretion.	  Specifically,	  the	  localisation	  of	  IFN-­‐γ	  vesicles	  can	  be	  compared	  to	  holes	  within	  the	  
actin	  mesh	  and	  this	  will	  give	  a	  greater	  understanding	  of	  whether	  the	  vesicles	  are	  able	  to	  pervade	  the	  
actin	  meshwork.	  	  
The	  results	  presented	  in	  this	  chapter	  imply	  that	  there	  is	  a	  clear	  defect	  in	  NK	  cells	  that	  is	  only	  present	  
in	   more	   advanced	   stages	   of	   MM,	   and	   goes	   some	   way	   towards	   explaining	   why	   NK	   cells	   are	   less	  
functional	   as	   the	   disease	   progresses.	   Defects	   such	   as	   these	   are	   not	   uncommon	   in	   haematological	  
malignancies.	   NK	   cells	   from	   patients	   with	   MDS	   show	   reduced	   cytolytic	   function	   against	   tumour	  





target	  cells	  compared	  to	  healthy	  controls,	  although	  this	  is	  at	  least	  in	  part	  due	  to	  down-­‐regulation	  of	  
NK	  cell	  activating	  receptors	  on	  these	  cells	  (Epling-­‐Burnette	  et	  al.,	  2007).	   	   Importantly,	  the	  defect	  in	  
MM	  NK	  cells	   from	   relapsing	  patients	   shown	  here	   is	  not	  due	   to	  a	  down-­‐regulation	  of	  CD16	  on	   the	  
surface	   of	   the	   cells.	   Another	   example	   of	   a	   similar	   defect	   is	   the	   impairment	   of	   immune	   synapse	  
formation	  in	  follicular	  T	  cells	  from	  CLL	  patients	  (Ramsay	  et	  al.,	  2008).	  In	  this	  case,	  the	  follicular	  T	  cells	  
were	  not	  able	  to	  polymerise	  F-­‐actin	  at	  the	  immune	  synapse,	  and	  this	  is	  in	  part	  due	  to	  malfunctioning	  
Rho	   GTPase	   signalling	   (Ramsay	   et	   al.,	   2008;	   Ramsay	   et	   al.,	   2013).	   Understanding	  which	   signalling	  
pathways	   are	   functioning	   differently	   in	   NK	   cells	   from	   relapsing	   patients	   compared	   to	   patients	   in	  
remission	  is	  an	  important	  next	  step	  in	  understanding	  how	  to	  treat	  this	  deficiency.	  
One	  important	  conclusion	  that	  can	  be	  drawn	  from	  this	  work	  is	  that	  treatment	  with	  lenalidomide	  is	  
able	  to	  partially	  restore	  NK	  cell	  activity.	  There	  is	  a	  5-­‐fold	  decrease	  in	  the	  amount	  of	  IFN-­‐γ	  secreted	  by	  
NK	  cells	   from	  MM	  patients	  who	  are	  relapsing,	  compared	  to	  those	   in	  remission.	  After	   lenalidomide	  
treatment,	   there	   is	   a	   2.5-­‐fold	   increase	   in	   the	   amount	   of	   IFN-­‐γ	   secreted,	   which	   restores	   IFN-­‐γ	  
secretion	  to	  over	  half	  of	  that	  observed	  in	  NK	  cells	  from	  patients	  in	  remission.	  This	  increase	  in	  IFN-­‐γ	  
secretion	   could	  have	  a	   significant	   effect	  when	   it	   comes	   to	   activating	  bystander	   immune	   cells.	   The	  
effect	  of	  lenalidomide	  on	  cortical	  actin	  remodelling	  is	  even	  greater.	  There	  is	  a	  7-­‐fold	  decrease	  in	  the	  
proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  by	  vesicles	  of	  301-­‐500	  nm	  diameter	  in	  NK	  cells	  
from	   relapsing	   patients	   compared	   to	   those	   in	   remission.	   Treatment	  with	   lenalidomide	   completely	  
restores	   cortical	   actin	   remodelling	   in	   NK	   cells	   from	   relapsing	   MM	   patients.	   This	   indicates	   that	  
lenalidomide	  treatment	  is	  sufficient	  to	  rescue	  NK	  cells	  from	  this	  defect	  in	  actin	  reorganisation.	  
	  
5.3.3 Future	  directions	  
	  
This	   investigation	   on	   the	   effect	   of	   lenalidomide	   on	   NK	   cells	   from	  MM	   patients	   has	   revealed	   that	  
lenalidomide	   augments	   IFN-­‐γ	   production	   and	   cortical	   actin	   remodelling.	   In	   addition,	   these	   results	  
have	  shown	  that	  there	  is	  a	  defect	  in	  IFN-­‐γ	  secretion	  and	  in	  F-­‐actin	  rearrangements	  in	  NK	  cells	  from	  
relapsing	  patients	  that	  can	  be	  partially	  rescued	  with	  lenalidomide	  treatment.	  This	  raises	  interesting	  
new	  questions	  that	  future	  experiments	  should	  aim	  to	  address.	  
The	  most	   important	  question	   that	  needs	   to	  be	  considered	   is	  what	   is	   causing	   this	  defect	   in	  NK	  cell	  
activation	   after	   CD16	   ligation.	   The	   results	   have	   shown	   that	   it	   is	   not	   due	   to	   a	   reduction	   in	   CD16	  
surface	  expression	  suggesting	  that	   initial	  membrane	  proximal	  signalling	   is	  still	   functioning.	  This	  can	  





be	   confirmed	  by	   looking	   at	   the	   levels	   of	   phosphorylated	   CD3ζ,	   Syk	   and	   ZAP70	   after	   CD16	   ligation	  
using	  immunoblot	  analysis	   in	  NK	  cells	  from	  patients	  who	  are	  in	  remission	  and	  who	  are	  relapsing.	  If	  
membrane	  proximal	  signalling	  is	  functioning	  normally,	  it	  is	  possible	  that	  there	  is	  impairment	  in	  one	  
of	   the	   tightly	   regulated	   stages	   of	   immune	   synapse	   formation.	   These	   stages	   include	   initial	   contact	  
with	  target	  cell,	   receptor	  clustering,	  MTOC	  polarisation,	  actin	  mesh	  opening	  and	  then	   lytic	  granule	  
docking	  and	  release	  (Orange,	  2008).	  The	  results	  shown	  in	  this	  chapter	  suggest	  that	  there	  is	  a	  defect	  
in	   actin	   mesh	   opening,	   however	   immune	   synapse	   formation	   could	   have	   been	   halted	   before	   this	  
point	  due	  to	  a	   fault	  at	  an	  earlier	  stage.	   In	  order	  to	   investigate	  this,	  each	  stage	   in	   immune	  synapse	  
formation	   can	   be	   observed	   using	  MM	   NK	   cells	   from	   relapsing	   patients	   (and	   NK	   from	   patients	   in	  
remission	   as	   a	   control)	   in	   conjugate	   with	   target	   cells.	   Conjugate	   formation	   can	   be	   assessed	   by	  
confocal	   microscopy	   and	   by	   flow	   cytometry.	   MTOC	   polarisation	   can	   be	   imaged	   by	   confocal	  
microscopy,	   by	   staining	   the	  MTOC	  with	   an	   antibody	   against	   tubulin	   as	   has	   been	   done	   previously	  
(Banerjee	  et	  al.,	  2007;	  Rudnicka	  et	  al.,	  2013).	  Another	  way	  to	  image	  MTOC	  polarisation	  is	  to	  use	  TIRF	  
microscopy	  and	  observe	  whether	  the	  MTOC	  is	  polarising	  to	  within	  100	  nm	  of	  the	  coverslip,	  as	  would	  
be	  expected	  if	  the	  MTOC	  were	  docking	  at	  the	  synapse.	  	  
In	   addition,	   receptor	   clustering	   can	   be	   imaged	   using	   single-­‐molecule	   localisation	   microscopy	  
techniques	  such	  as	  STORM.	  CD16	  and	  associated	  signalling	  molecules	  could	  be	  imaged	  by	  STORM	  to	  
see	   whether	   clustering	   patterns	   at	   the	   cell	   surface	   change	   during	   MM	   disease	   progression.	  
Increasing	   the	  distance	  between	   ligands	  on	  a	   slide	  has	  been	   shown	   to	  decrease	  NK	  cell	   activation	  
through	  CD16	  (Delcassian	  et	  al.,	  2013).	  This	  suggests	  that	  the	  size	  and	  number	  of	  clusters	  of	  CD16	  on	  
the	  surface	  of	  NK	  cells	  could	  contribute	  to	  NK	  cell	  activation.	  The	  motility	  of	  receptor	  clusters	  have	  
also	  been	  shown	  to	  be	  important	  during	  T	  cell	  activation,	  although	  this	  has	  not	  been	  studied	  in	  detail	  
in	  NK	  cells	  (Beemiller	  et	  al.,	  2012).	  The	  motility	  of	  CD16	  clusters	  could	  be	  imaged	  using	  live	  cell	  TIRF	  
microscopy	   and	   then	   compared	   between	   NK	   cells	   from	   different	   stages	   of	   the	   disease	   to	   see	  
whether	  there	  is	  a	  difference.	  
Finally,	  it	  would	  be	  interesting	  to	  carry	  out	  a	  long-­‐term	  study	  on	  NK	  cells	  from	  MM	  patients.	  In	  the	  
study	   presented	   here,	   the	   patients	   have	   been	   diagnosed	   at	   different	   times	   and	   have	   had	   varying	  
rounds	  of	  different	  drug	  treatments.	  Although	  none	  of	  the	  patients	  were	  currently	  on	  lenalidomide,	  
it	   is	  difficult	   to	  control	   for	   the	  effect	  of	  other	  drugs	  and	   for	   time	  since	  diagnosis	  using	   the	  current	  
data.	  It	  would	  be	  useful	  to	  follow	  one	  cohort	  of	  MM	  patients	  from	  diagnosis	  and	  study	  NK	  cells	  from	  
the	  same	  patients	  as	  the	  disease	  progresses.	  In	  one	  17-­‐year	  study	  of	  95	  asymptomatic	  MM	  patients,	  
it	   was	   reported	   that	   the	   median	   time	   of	   progression	   to	   symptomatic	   disease	   was	   26	   months	  
(Dimopoulos	   et	   al.,	   1993).	   However,	   individuals	   with	   lytic	   bone	   disease	   and	   high	   levels	   of	   serum	  





markers	   (designated	   ‘high-­‐risk’)	   had	   a	   much	   shorter	   time	   to	   progression	   (approximately	   10	  
months)(Dimopoulos	  et	   al.,	   1993).	  With	   this	   in	  mind,	   the	   study	  would	   take	   samples	   from	  patients	  
every	  3	  or	  4	  months	  and	  assess	  NK	  cell	  activation	  and	  function	  as	  the	  disease	  progresses.	  Alongside	  
this,	  it	  would	  be	  interesting	  to	  study	  NK	  cells	  before	  and	  after	  lenalidomide	  treatment	  in	  the	  clinic,	  




In	  conclusion,	  observing	  NK	  cells	   from	  MM	  patients	  at	  different	  stages	  of	  the	  disease	  has	  revealed	  
that	   lenalidomide	   augments	   cortical	   actin	   remodelling	   and	   IFN-­‐γ	   secretion	   in	   the	   context	   of	  MM.	  
These	   results	   also	   show	   that	  NK	   cells	   from	  MM	  patients	  who	   are	   relapsing	   secrete	   less	   IFN-­‐γ	   and	  
open	  up	  the	  actin	  mesh	  to	  a	   lesser	  extent	   than	  cells	   from	  patients	  who	  are	   in	  remission,	  although	  
this	  can	  be	  partially	  restored	  with	  lenalidomide	  treatment.	  The	  data	  presented	  in	  this	  chapter	  gives	  
rise	  to	  many	  new	  questions	  regarding	  the	  cause	  of	  the	  intrinsic	  NK	  cell	  defect	  in	  MM	  patients	  who	  
are	   relapsing	   and	   how	   lenalidomide	   can	   rescue	   NK	   cell	   activity.	   For	   example,	   what	   role	   does	   the	  
nanoscale	  organisation	  of	  actin	  play	  in	  the	  defective	  IFN-­‐γ	  secretion?	  Is	  the	  denser	  actin	  meshwork	  
directly	  blocking	  IFN-­‐γ	  secretion	  or	  is	  it	  a	  secondary	  effect	  brought	  on	  by	  a	  defect	  in	  a	  different	  stage	  
of	   immune	   synapse	   formation?	   In	   the	   future,	   further	   dissection	   of	   immune	   synapse	   formation	   in	  
MM	   NK	   cells	   will	   provide	   a	   more	   detailed	   understanding	   of	   how	   NK	   cell	   function	   becomes	  
attenuated	  as	  the	  disease	  progresses.	  	  









The	  immunomodulatory	  drug	  lenalidomide	  is	  FDA	  approved	  for	  the	  treatment	  of	  MM,	  and	  has	  the	  
potential	  to	  be	  clinically	  useful	  in	  a	  variety	  of	  diseases	  due	  to	  its	  ability	  to	  activate	  different	  arms	  of	  
the	   immune	   system.	   The	   cell	   types	   altered	   after	   lenalidomide	   treatment	   include	  members	   of	   the	  
adaptive	   immune	   system,	   for	   example	   T	   cells,	   and	   the	   innate	   immune	   system,	   including	  
macrophages	  and	  NK	  cells.	  Despite	  the	  large	  breadth	  of	  research	  undertaken	  over	  the	  last	  ten	  years,	  
it	   is	   still	   unclear	  whether	   lenalidomide	  has	   a	  direct	   effect	  on	  NK	   cells.	  NK	   cells	   directly	   lyse	   target	  
cells	   and	   secrete	   inflammatory	   cytokines	   such	   as	   IFN-­‐γ	   following	   the	   formation	   of	   structured	  
intercellular	  contacts	  called	  immune	  synapses.	  Recent	  advances	  in	  imaging	  techniques	  have	  revealed	  
that	   the	   dynamics	   of	   the	   actin	   cytoskeleton	   could	   play	   a	   key	   role	   in	   the	   function	   of	   the	   immune	  
synapse.	  	  
A	   major	   gap	   in	   the	   knowledge	   is	   whether	   lenalidomide	   treatment	   has	   a	   direct	   effect	   on	   NK	   cell	  
activation	   and	   effector	   function.	   In	   addition,	   it	   is	   unknown	   whether	   lenalidomide	   affects	   the	  
nanoscale	   structure	   of	   F-­‐actin	   at	   the	   NK	   cell	   immune	   synapse.	   Using	   functional	   assays	   alongside	  
state-­‐of-­‐the-­‐art	   imaging	   techniques,	   this	   investigation	   has	   revealed	   that	   lenalidomide	   has	   a	   direct	  
effect	  on	  NK	  cell	  effector	  function,	  and	  on	  the	  structure	  of	  the	  immune	  synapse.	  The	  research	  was	  
split	   into	   three	   separate	   but	   related	   studies,	   presented	   in	   chapters	   3−5	   of	   this	   thesis.	   Chapter	   3	  
investigated	   the	   effect	   of	   lenalidomide	   on	   NK	   cell	   activation	   and	   IFN-­‐γ	   production.	   The	   results	  
showed	  that	   lenalidomide	  augmented	  NK	  cell	  effector	   functions	  and	   lowered	  the	  threshold	   for	  NK	  
cell	   activation.	  Chapter	  4	   focussed	  on	   the	  effect	  of	   lenalidomide	  on	   the	  nanoscale	  organisation	  of	  
cortical	   actin	   at	   the	   NK	   cell	   synapse.	   Lenalidomide	   increased	   actin	   remodelling	   after	   NK	   cell	  
activation	  resulting	  in	  a	  larger	  proportion	  of	  the	  synapse	  predicted	  to	  be	  penetrable	  to	  lytic	  granules	  
and	   IFN-­‐γ	   vesicles.	   Chapter	   5	   examined	   the	   effect	   of	   lenalidomide	   on	   NK	   cells	   isolated	   from	   the	  
blood	  of	  MM	  patients	  and	  showed	  that	  lenalidomide	  augmented	  NK	  cell	  activation	  in	  cells	  from	  MM	  
patients.	  In	  addition,	  MM	  NK	  cells	  from	  patients	  who	  were	  relapsing	  had	  defective	  IFN-­‐γ	  production	  
and	  F-­‐actin	  rearrangements	  compared	  to	  NK	  cells	  from	  patients	  who	  were	  in	  remission.	  This	  defect	  
in	  NK	  cell	  activation	  was	  able	  to	  be	  rescued	  with	  lenalidomide	  treatment.	  	  





6.2 Investigation	   into	   the	   effect	   of	   lenalidomide	   on	   NK	   cell	  
activation	  
	  
Chapter	  3	  discussed	  the	  effect	  of	  lenalidomide	  treatment	  on	  NK	  cell	  effector	  functions	  –	  focussing	  on	  
IFN-­‐γ	  production	  –	  and	  on	  the	  threshold	  for	  NK	  cell	  activation.	  This	  study	  utilised	  functional	  assays,	  
such	  as	  ELISAs,	  and	  confocal	  microscopy	  to	  determine	  whether	   lenalidomide	  has	  a	  direct	  effect	  on	  
NK	   cell	   function.	   This	   question	  was	   identified	   as	   important	   as	   there	   is	   considerable	   conflict	   in	   the	  
literature	   about	   whether	   NK	   cells	   are	   directly	   affected	   by	   lenalidomide,	   or	   whether	   the	   effect	   is	  
indirect	  due	  to	  the	  presence	  of	  T	  helper	  cells	  (Hayashi	  et	  al.,	  2005;	  Wu	  et	  al.,	  2008;	  Hsu	  et	  al.,	  2011;	  
Acebes-­‐Huerta	  et	  al.,	  2014).	  The	  results	  from	  this	  study	  showed	  that	  lenalidomide	  directly	  affected	  
NK	   cell	   function	   without	   the	   need	   for	   T	   helper	   cells	   to	   be	   present.	   Specifically,	   lenalidomide	  
treatment	  significantly	  enhanced	  IFN-­‐γ	  production	  after	  NK	  cell	  activation	  through	  multiple	  different	  
triggers.	  The	  results	  showed	  that	  lenalidomide	  treatment	  resulted	  in	  a	  near	  two-­‐fold	  increase	  in	  the	  
proportion	  of	  NK	  cells	  producing	  IFN-­‐γ	  and	  a	  20-­‐fold	   increase	  in	  the	  amount	  of	   IFN-­‐γ	  produced	  per	  
cell.	  This	  indicates	  that	  lenalidomide	  has	  an	  effect	  on	  both	  the	  NK	  cell	  population	  level	  –	  altering	  the	  
proportion	  of	  cytokine-­‐producing	  cells	  –	  and	  on	  a	  single	  cell	  level.	  	  
One	  important	  outcome	  of	  this	  work	  was	  that	  lenalidomide	  alone	  was	  not	  able	  to	  activate	  resting	  NK	  
cells.	   Instead,	   lenalidomide	   increased	   NK	   cell	   effector	   functions	   after	   the	   cells	   had	   become	   fully	  
activated	   (through	   ligation	  of	   activating	   receptors).	  No	  effect	   of	   lenalidomide	  was	  observed	   in	  NK	  
cells	  in	  non-­‐activated	  conditions,	  or	  after	  partial	  NK	  cell	  activation	  (from	  example	  through	  ligation	  of	  
NKG2D	  alone).	  This	  indicates	  that	  the	  safety	  mechanisms	  in	  place	  to	  prevent	  NK	  cells	  killing	  healthy	  
cells	  are	  preserved	  after	  treatment	  with	  lenalidomide.	  	  
Regarding	   the	   threshold	   for	   NK	   cell	   activation,	   this	   study	   showed	   that	   lenalidomide	   treatment	  
enabled	   NK	   cells	   to	   respond	   to	   lower	   concentrations	   of	   activating	   ligand.	   This	   resulted	   in	   the	  
threshold	  for	  NK	  cell	  activation	  being	  shifted	  to	  the	  left,	  and	  was	  shown	  using	  the	  ligands	  for	  CD16	  
and	  for	  NKG2D.	  This	  may	  be	  important	  in	  recognising	  tumour	  cells	  that	  have	  downregulated	  ligands	  
for	   NK	   cell	   activating	   receptors	   as	   a	   mechanism	   of	   immune	   avoidance.	   Similarly,	   lenalidomide	  
treatment	  also	   lowered	   the	   threshold	   for	  activation	   through	   the	   therapeutic	  humanised	  anti-­‐CD20	  
antibody	   rituximab.	   This	   indicates	   that	   lenalidomide	   treatment	  would	   allow	  NK	   cells	   to	   recognise	  
lower	   concentrations	   of	   rituximab	  on	  potential	   target	   cells.	   This	   suggests	   that	   the	   combination	  of	  
lenalidomide	  and	  rituximab	  in	  a	  clinical	  setting	  might	  be	  successful.	  	  	  	  





Overall,	   this	   study	  has	   revealed	   that	   lenalidomide	  augments	  NK	   cell	   effector	   functions	   and	   lowers	  
the	  threshold	  for	  activation.	  Immediate	  future	  work	  should	  now	  be	  focussed	  on	  determining	  what	  is	  
causing	   this	   effect	   of	   lenalidomide.	   This	   could	   involve	   identifying	   signalling	   pathway	   components	  
and/or	  transcription	  factors	  that	  are	  upregulated	  or	  downregulated	  after	  lenalidomide	  treatment.	  In	  
addition,	   the	   effect	   of	   lenalidomide	   on	   the	   nanoscale	   organisation	   of	   receptors	   at	   the	   NK	   cell	  
synapse	   should	   be	   investigated.	   This	   will	   involve	   imaging	   specific	   receptors	   using	   single-­‐molecule	  
localisation	  microscopy	  techniques	  such	  as	  STORM	  and	  will	  provide	  clues	  as	  to	  whether	  clustering	  of	  
receptors	  on	  the	  nanometre	  scale	  is	  important	  in	  determining	  NK	  cell	  activating	  thresholds.	  
	  
6.3 The	   effect	   of	   lenalidomide	   on	   cortical	   actin	   at	   the	   NK	   cell	  
synapse	  
	  
Chapter	  4	  used	  super-­‐resolution	  STED	  microscopy	  to	  image	  the	  meshwork	  of	  cortical	  actin	  at	  the	  NK	  
cell	  synapse.	  After	  optimising	  STED	  image	  acquisition	  and	  F-­‐actin	  mesh	  analysis,	  the	  aim	  of	  this	  study	  
was	  to	  assess	  whether	  lenalidomide	  treatment	  affected	  F-­‐actin	  remodelling	  after	  NK	  cell	  activation.	  
The	   results	   of	   this	   investigation	   showed	   that	   lenalidomide	   enhances	   actin	   rearrangements	   after	  
stimulation	  through	  CD16	  or	  stimulation	  through	  NKG2D	  and	  LFA-­‐1,	  resulting	  in	  larger	  holes	  within	  
the	  actin	  mesh.	  Specifically,	  there	  was	  a	  two-­‐fold	  increase	  in	  the	  area	  of	  the	  synapse	  predicted	  to	  be	  
penetrable	   by	   a	   vesicle	   of	   200−500	   nm	   diameter.	   This	   showed	   for	   the	   first	   time	   that	   exogenous	  
compounds	  can	  manipulate	  actin	  rearrangements.	  
Importantly,	   the	  effect	  of	   lenalidomide	  on	  F-­‐actin	  organisation	  was	  only	  observed	  after	  full	  NK	  cell	  
activation,	   in	  line	  with	  the	  results	  from	  chapter	  3.	  NKG2D	  alone	  is	  able	  to	  induce	  actin	  remodelling	  
(although	  it	  cannot	  induce	  effector	  function)	  however	  lenalidomide	  had	  no	  effect	  on	  the	  penetrable	  
area	   of	   the	   synapse	   when	   only	   NKG2D	   was	   ligated.	   This	   indicates	   that	   activation	   of	   the	   actin	  
remodelling	  signalling	  pathways	  (which	  remain	  to	  be	  fully	  understood)	  is	  not	  sufficient	  to	  observe	  an	  
effect	  with	  lenalidomide.	  Interestingly,	  however,	  the	  NK	  cells	  did	  not	  have	  to	  be	  producing	  cytokine	  
in	  order	  for	  lenalidomide	  to	  induce	  actin	  rearrangements.	  These	  observations	  underline	  the	  need	  to	  
further	  understand	  the	  mechanisms	  governing	  F-­‐actin	  rearrangements	  as	  well	  as	  how	  lenalidomide	  
manipulates	  them.	  





Overall,	   this	   investigation	   showed	   that	   lenalidomide	   treatment	   enhances	   cortical	   actin	  
rearrangements	   after	   NK	   cell	   activation.	   The	   next	   stage	   in	   this	   investigation	   should	   focus	   on	  
understanding	  what	   governs	   actin	   remodelling	   and	  how	   lenalidomide	  manipulates	   this.	   This	   could	  
include	  observing	  whether	  Rho	  or	  Rac	  GTPases	  are	  involved	  in	  F-­‐actin	  rearrangements	  at	  the	  NK	  cell	  
synapse	  and	  whether	  lenalidomide	  treatment	  affects	  the	  amount	  of	  GTP-­‐bound	  RhoA	  or	  Rac1	  after	  
activating	   receptor	   ligation.	   In	   addition,	   the	   role	   of	   the	   E3	   ubiquitin	   ligase	   CRBN	   could	   be	  
investigated	   by	   knocking	   down	   this	   protein	   in	   primary	   NK	   cells.	   Together,	   these	   experiments	   will	  
improve	  understanding	  of	  the	  mechanisms	  involved	  in	  actin	  remodelling	  as	  well	  as	   identifying	  new	  
downstream	  targets	  of	  lenalidomide.	  	  
	  
6.4 Studying	  NK	  cells	  from	  MM	  patients	  
	  
The	   final	   investigation	   presented	   in	   this	   thesis,	   described	   in	   chapter	   5,	   explored	   the	   effect	   of	  
lenalidomide	  on	  NK	  cells	  from	  MM	  patients.	  This	  study	  applied	  the	  techniques	  used	  in	  the	  previous	  
two	   chapters	   to	   freshly	   isolated	   NK	   cells	   from	  MM	   patients	  who	  were	   in	   remission	   or	  who	  were	  
relapsing.	  The	  aim	  was	  to	  observe	  whether	  lenalidomide	  had	  the	  same	  effect	  on	  MM	  NK	  cells	  as	  was	  
seen	   in	   NK	   cells	   from	   healthy	   donors.	   The	   results	   from	   this	   study	   showed	   that	   lenalidomide	  
treatment	  resulted	  in	  a	  2-­‐fold	  increase	  in	  IFN-­‐γ	  secretion	  and	  a	  significant	  increase	  in	  the	  proportion	  
of	  MM	  NK	  cells	  expressing	  IFN-­‐γ.	  In	  addition,	  lenalidomide	  increased	  the	  proportion	  of	  the	  synapse	  
predicted	  to	  be	  penetrable	  to	  IFN-­‐γ	  vesicles	  and	  to	  lytic	  granules.	  This	  shows	  that	  lenalidomide	  has	  a	  
significant	  effect	  on	  NK	  cell	  effector	  function	  and	  F-­‐actin	  remodelling	  in	  NK	  cells	  from	  MM	  patients,	  
indicating	  that	  the	  results	  described	  in	  the	  previous	  two	  chapters	  are	  relevant	  in	  a	  clinical	  context.	  
Regarding	  disease	  status,	  this	  study	  showed	  that	  NK	  cells	  from	  MM	  patients	  who	  were	  relapsing	  had	  
reduced	  secretion	  of	   IFN-­‐γ	   after	   ligation	  of	  CD16	  compared	   to	  NK	  cells	   from	  patients	  who	  were	   in	  
remission.	  This	  was	  not	  due	  to	  a	  change	  in	  the	  proportion	  of	  cells	  expressing	  IFN-­‐γ,	  suggesting	  that	  
the	   amount	   of	   IFN-­‐γ	   secreted	   per	   cell	   is	   reduced.	   Consistent	   with	   this,	   NK	   cells	   from	   relapsing	  
patients	   had	   reduced	   F-­‐actin	   remodelling.	   This	   resulted	   in	   a	   smaller	   proportion	   of	   the	  meshwork	  
being	  penetrable	  to	  IFN-­‐γ	  vesicles	  compared	  to	  NK	  cells	  from	  MM	  patients	  who	  were	  in	  remission.	  
This	   defect	   in	   NK	   cell	   function	   present	   in	  more	   advanced	   stages	   of	   the	   disease	   could	   be	   partially	  
restored	   by	   lenalidomide	   treatment.	   Specifically,	   lenalidomide	   caused	   a	   7-­‐fold	   increase	   in	   the	  





proportion	   of	   the	   synapse	   predicted	   to	   be	   penetrable	   to	   larger	   vesicles,	   thereby	   restoring	   actin	  
remodelling	  to	  the	  level	  observed	  in	  NK	  cells	  from	  MM	  patients	  who	  were	  in	  remission.	  	  
Overall,	   this	   investigation	   has	   revealed	   that	   lenalidomide	   augments	   IFN-­‐γ	   production	   and	   cortical	  
actin	   remodelling	   in	  NK	   cells	   from	  MM	  patients.	   In	   addition,	   the	   study	   has	   shown	   that	   there	   is	   a	  
defect	  in	  IFN-­‐γ	  secretion	  and	  in	  F-­‐actin	  rearrangements	  in	  NK	  cells	  from	  relapsing	  patients	  that	  can	  
be	   partially	   rescued	   with	   lenalidomide	   treatment.	   Immediate	   future	   work	   should	   focus	   on	   what	  
causes	  this	  defect	  in	  NK	  cell	  activation	  after	  CD16	  ligation.	  This	  should	  involve	  analysis	  of	  membrane	  
proximal	   signalling	   in	   NK	   cells	   from	   relapsing	  MM	   patients	   to	   observe	   whether	   early	   signalling	   is	  
functioning	   normally.	   The	   stages	   in	   NK	   cell	   immune	   synapse	   formation	   could	   also	   be	   analysed,	  
including	  conjugate	  formation,	  receptor	  clustering	  and	  MTOC	  polarisation.	  In	  the	  long	  term,	  it	  would	  
be	   interesting	   to	   carry	   out	   a	   long	   term	   study	   on	   NK	   cells	   from	  MM	   patients.	   This	   could	   involve	  
following	  one	  cohort	  of	  MM	  patients	  through	  lenalidomide	  treatment	  to	  observe	  how	  lenalidomide	  
affects	  NK	  cells	  after	  long	  term	  exposure	  and	  how	  NK	  cells	  respond	  through	  different	  disease	  stages.	  
This	  will	  provide	  a	  more	   in-­‐depth	  understanding	  of	  how	  NK	  cell	   function	  attenuates	  as	  the	  disease	  
progresses.	  
	  
6.5 Closing	  remarks	  
	  
The	  work	  reported	  in	  this	  thesis	  demonstrates	  a	  significant	  direct	  effect	  of	  lenalidomide	  on	  NK	  cells,	  
on	  a	  population	  level,	  a	  single	  cell	  level	  and	  on	  the	  nanoscale	  organisation	  of	  the	  immune	  synapse.	  
The	   investigation	   showed	   in	   detail	   that	   lenalidomide	   augments	   NK	   cell	   activation	   and	   effector	  
functions	   in	   healthy	   NK	   cells	   without	   activating	   NK	   cells	   inappropriately.	   These	   results	   were	  
confirmed	   in	   the	   context	   of	   MM	   using	   NK	   cells	   from	   the	   blood	   of	   patients.	   The	   work	   on	   the	  
nanoscale	  organisation	  of	  F-­‐actin	  has	  provided	  the	  first	  evidence	  that	  the	  actin	  meshwork	  at	  the	  NK	  
cell	   synapse	   can	   be	   manipulated	   by	   immunomodulatory	   drugs.	   This	   opens	   up	   the	   idea	   that	  
compounds	  could	  be	  screened	  for	  an	  effect	  on	  synaptic	  cortical	  actin	  to	  augment	  NK	  cell-­‐mediated	  
responses.	  Perhaps	  most	   importantly,	   these	  data	  establish	   that	   lenalidomide	   lowers	   the	   threshold	  
for	  activation	  of	  human	  NK	  cells,	  indicating	  that	  the	  drug	  may	  be	  useful	  in	  other	  medical	  conditions	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